<SEC-DOCUMENT>0001179929-22-000080.txt : 20220428
<SEC-HEADER>0001179929-22-000080.hdr.sgml : 20220428
<ACCEPTANCE-DATETIME>20220428120320
ACCESSION NUMBER:		0001179929-22-000080
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220428
DATE AS OF CHANGE:		20220428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLINA HEALTHCARE, INC.
		CENTRAL INDEX KEY:			0001179929
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				134204626
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31719
		FILM NUMBER:		22864059

	BUSINESS ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
		BUSINESS PHONE:		5624353666

	MAIL ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOLINA HEALTHCARE INC
		DATE OF NAME CHANGE:	20020812
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>moh-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6096143c-bea0-4d64-8a46-ebe0e276f797,g:2f020790-0dbf-4089-8da8-8ebe5a4cb586,d:d73f22483d2c490396b597725038007f--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:moh="http://www.molinahealthcare.com/20220331" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>moh-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl8zLTEtMS0xLTQxOTI1_b2296ba7-4ecf-4092-9438-d7b8f8729b39">0001179929</ix:nonNumeric><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl80LTEtMS0xLTQxOTI1_4ce06493-a6c5-40d8-98d1-e728de56a479">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl81LTEtMS0xLTQxOTI1_5e67a796-f06c-4982-a4fd-bd4fb4df9438">2022</ix:nonNumeric><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl82LTEtMS0xLTQxOTI1_d2e37668-da95-4e05-8014-71caeea3acf8">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl83LTEtMS0xLTQxOTI1_16d1bd90-490b-4a4f-9faf-8ea00a8adf06">false</ix:nonNumeric><ix:nonNumeric contextRef="i8851606cc612421ab07daae70b687796_D20220101-20220331" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMy_742266a5-3364-47ae-b977-fd809341826f">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="moh-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5088f3c4c0b64cf3a6113fcf094799c3_I20220422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a364e3f02f45059e7d588902f74a7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d495bb1496443bf84bdb17358ef9e27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfbbdfebf5e0417db5c15c1f2203e943_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210479d51b0949d4b306fa898f8ab68e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a791bedc8c497a9b951c0a54286c99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9197f15ee9d540a0993914efdd5e51cd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4a419317fc4c44910821bd8c61e989_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e97722ed58740a3af7cda41b611b9c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fa7fde4814471db3810635d40bdbdc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e78bf8f50943f1aa07fa55e4049d43_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45bf3fe8b354f538d45f5c9cbfd0225_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b8c89c2c664032b3e7c570dd406ef5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id82c487ce2bc462599459c0507d1ca62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i995ada66e7f14440b7cfd0a914ac8acf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff011ca48c834fabbfb52d9e98555c1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0199bf3103774fb5b433a7b2f787c39d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdcb8a23a1fc4ae8a13e0ed56f15658f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e99d1b775642728d269200485a7951_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e7d8195295e452a9c89b318b1b39b4b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1fa8ff9f704dc4a9aafd83714c7904_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb68bdab10a46ea8ce7f8f06b183910_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3691bc168b04f23adb9b834865b296d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84780b904fcb43cf980043acfdf85931_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c66fd9d79140e89e5a2167138c066a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6201f33888046d1a89c449d69d0e023_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6768c723a834132a8dff21a78dbcbc9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2550091eda44588baae1b353781d6f9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>moh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2a15fbb627e648a9b3cfcb7d23c86eb5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="member"><xbrli:measure>moh:member</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>moh:position</xbrli:measure></xbrli:unit><xbrli:context id="i8851606cc612421ab07daae70b687796_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71bef60ed3804c7b985e0a7f9eb18119_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb5e9c9ed8a4e7a8212fec43122957e_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b6fd4fee764ab083cdc892e2c0c076_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83542a544914da9a096018bb51d522d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if33590d339e94d2d901dd2dd40d1f5ad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i756495c112ec486ca365574f64977791_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced25630f7f04a17b0750b5a726c2fdf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6984c064c12462fac6706daa823e721_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b0a19236ea419588cf999ba5003db3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16fa21da2b342b1b9b512fecc011c4a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d5b3e94914400d9df6eef34274142b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:StructuredSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df831b90dca48389c4a46065aa0e36b_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4224640832fc459a976f07601ca3b865_D20211025-20211025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-25</xbrli:startDate><xbrli:endDate>2021-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c70e6d3865429ab8c21490e9d52463_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9841f89feb4b6f833b989726c603b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d24f62cc41249a59883cfafb9f90a0b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d6f584300eb4da4b4a6f02de502ee05_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd269fb2ad24963b173ecee97871066_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8f3df78577405d89b78540630ab85b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib601f7ea9e1544bba2449d05dd7b52fb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6c43599fc843d0829a435fbdc90272_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e5991e34f746b4a7de6f87d9b23770_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57bf75d7d2d40ce88df34d243fb7161_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80581b9110ec4a21aad1d72ab421ff09_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i914e26952f0846cbab0b1ae7d986cd2f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb15836aa8ef41a0ab9a6005c565e6af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i611e6b094ace4fdb8726ca8580b06107_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a014ebcaec4257afdea4362d4f7dcd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53a531742ed4dd185794ef0fece2924_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc43d4329cfd4c3da7fcc8ab7fc08335_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ec83ce9f514a99ba56f61ebd1703d2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2530162568594c229e21427834758000_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i385070469b464b4c8f16f134196230a2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8232d132f78246a9b19395e9881b3b9e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a461815e0cd4109af3d6157d9306450_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2599f46d545f4a9694a18ef8b64edd24_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2566bfad24064edcb4c6f1cc871fe634_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66eb009ac1814de594979994b70ed488_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6d9575386442c88a03e9392c8d4680_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45dcb81690184808b8b2e4355d718016_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc3230becc0c4828baf9d10e3a700d76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa407138475458aaaef37293a812835_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7278ef49c004479caacda424a824f532_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb6f235c56e4125932f967ec4150a5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8a92024a5dd4f20a93bb06874c6c09f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief0d79f965424c5688f2b4927964c092_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568adc428eb44729bae4b7054ca3ecf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54ceccf75bcd408a9bf4399875c3a587_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6246e151bd44c8ea675865e0681f3e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2814ecb054554ae0ac8032339ced6fc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3dcacd3393d4b038db393a7e50dcb86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5bf030bb894331af4cc030aaf8955d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1727e43bcce4e9f99238725b4368289_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3215d158f874704ae5a909e76a9ffef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8096af143794d6ba663925f6c296688_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd80b1629894491abd8c97b39181c6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1308b34078d94ba9a442e2340bb7d947_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75af6a9d0fe3485ea6fb3e7b00fc7df8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id47adc9834a74a3abd37340b07640e50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic15681f11c644b1fb6bc25282ff28394_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib12dbc47902b42e7bd4cd39167f525fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30977d23049a41d78ef8f2e721e78cae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6aa324dfe249378a208c3b0ce83c03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5e3d221ec54558b758b1d1fa20008d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c52f1b8250479b8972444c6c5e8a60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3145ece7ff6a499db53f8fe074c21db2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740cf33bc2fe44aa91439e45ae7070d5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ba2b9f8f70480582002fca729cdf80_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9e413d250b1c4d62b2a2ce56ec990ee3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e17e3d8ee2e4532b2cedd534f9c43c7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d82ade78bd740c5a619b23a903384cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e68e13a919f45a69729166fad740cce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59df97eaf2b1410da01b135ea8df9e67_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16fb8f79f27a4ba1975a3c0080fac1f1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416b558733524b4eb313dc3fd149027e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc71c1998d340b785d6c9e22719d163_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531b1272dc854f2d96ea4aaa8c7ac85b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db08fccd6a24dd4923b782282695b76_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3cfafe3e344d1c81dc96f60ad4e0b6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc601537972b46fe9d996ede277d82de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd44300529054baab8274cb4fdd4c646_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i571d57dd721148bcba35827581b9aab2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35e7bbcc8d91489a9ac9423421979dce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3510f01da59140459a2feaa5c20cc72f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb73d2285af40bb99c52adb7201908c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eca5b1af11a4d5592dd3ab9138e6d87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i137c985bf2b84d7284fe720707605375_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64fd06cf9ff3480e80700431d359cc79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>moh:security</xbrli:measure></xbrli:unit><xbrli:context id="i860bf70640a44ea9b73b26a8d15aba5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if190d4db77c042b58e04f6bd35da403b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf71eb3d9cc444083f1b2554c284e40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0826354779264443891d6a415136b373_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7174960f5b134c548aa4d81b816b31fb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea26c2873f4475288eeedd9a1ca9042_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27309968abdf4262bb2205ee58ad5acc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib37da93f7f23442d8e258fd0d8326698_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaebf3329ac42485e9cb9a16f9bd00f59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib653e5e8294241fb8b57acb7b6fc82ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa7e42e08294660a93554586f9e98e6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358fe90d0eb44486b61c0746c2230690_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib11ad222d0b546dd9ac72ba5f96d48c9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id580a7d8949142a485d23eb67d12db45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb8113f4fdf46a6a6d5465c3af10b83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id84833fac2b9441da5a93a848c1d7ae7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7656849cc94666be3e0a7a222c0a01_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e05d493b2494afe9d2924b87d069e98_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a498059fcf4606b716a944ac2ec8b6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba47bf9899884717ab70af9ee14f9c2c_D20220427-20220427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-27</xbrli:startDate><xbrli:endDate>2022-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8119dbb6aa8f4209831488917ed525c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72ca4bc7ef0408bbf17ce916c1f6509_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e316ab4ba32437c958ac31c5508c0b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9d80104f1b540928f8ac1ddc8014d3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65b5ad20d89f472cad8dfcd21eda5886_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07ce4db9efe048acac76f18d5fa8a4e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb923c3c38347a98af734e4bc95e64b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e922a7c4de84239b28fe388eb3877de_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da7d7575ad342f2b9348f4fc572b689_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f4e15da99f48ff99edb0138e60332a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bebfc17f52c4711b46e9ec3c87538ce_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503f2f6a1ef14912910191aaf1ea287a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9508779f4b0c40619e8754cfbb98b602_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f137a107044827823d5b3929276fde_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id73f22483d2c490396b597725038007f_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:385.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk3_cf270ac3-28e1-491f-8337-243220a37cbf">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:506.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:384.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6YzdlNzgyZGY2MDkwNDc1ODlkOThmYmQ5ZWIwOGU5NWEvdGFibGVyYW5nZTpjN2U3ODJkZjYwOTA0NzU4OWQ5OGZiZDllYjA4ZTk1YV8wLTAtMS0xLTQxOTI1_091ce782-e722-4d8c-b7b9-ed9403f5980c">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8xMzc_b7292708-6758-40de-a7d2-f2b7138e7fb1">March 31, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMyMjY4ODQ1MzBkNDE3ZWJmNDk1M2M2YWI5ODM2MDUvdGFibGVyYW5nZTo1MzIyNjg4NDUzMGQ0MTdlYmY0OTUzYzZhYjk4MzYwNV8wLTAtMS0xLTQxOTI1_d5145005-27fa-4313-afdf-04617d1953fa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ________&#160;to&#160;________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAz_c37666fb-af6c-4599-9d93-b0e1073dcad2">001-31719</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="moh-20220331_g1.jpg" alt="moh-20220331_g1.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTA0_d18369e4-442c-4208-93cd-b32f74bedbfc">MOLINA HEALTHCARE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8wLTAtMS0xLTQxOTI1_8ee437e6-3076-4034-8c1a-37c0b4307a15">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8wLTMtMS0xLTQxOTI1_1d76ad20-27f1-46bd-9e71-d3c53872e2f8">13-4204626</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8zLTAtMS0xLTQxOTI1L3RleHRyZWdpb246ODMzNDY1ZWI4MWM2NDc1YWJiZTYzMGY1OGFhYWQ0NWJfNA_e205b282-87e0-4aed-bcbf-d1c9275ca202">200 Oceangate</ix:nonNumeric>, <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8zLTAtMS0xLTQxOTI1L3RleHRyZWdpb246ODMzNDY1ZWI4MWM2NDc1YWJiZTYzMGY1OGFhYWQ0NWJfOA_45b050c6-32ed-47bc-a964-f12966e4566a">Suite 100</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV80LTAtMS0xLTQxOTI1_f97637de-867d-481c-9870-3bd82a70221a">Long Beach,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV80LTEtMS0xLTQxOTI1_464b63f9-f9f1-4b25-984a-fe22c5fa38fd">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV80LTMtMS0xLTQxOTI1_d9fe1a02-2850-486a-b068-6b3ee334c9f5">90802</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk4_ab44b1fe-3517-4b20-863c-d85868bf4a88">562</ix:nonNumeric>) <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk5_5173c3f7-394e-46e9-87d5-5fab8f6145f9">435-3666</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:390.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:199.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:115.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:199.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMwMzNjYWUyZjIxNGU3OWE3MWUwZWNkODczMGYwNWIvdGFibGVyYW5nZTo1MzAzM2NhZTJmMjE0ZTc5YTcxZTBlY2Q4NzMwZjA1Yl8xLTAtMS0xLTQxOTI1_26065fac-638f-4f80-bf26-f5512fc702f8">Common Stock, $0.001 Par Value</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMwMzNjYWUyZjIxNGU3OWE3MWUwZWNkODczMGYwNWIvdGFibGVyYW5nZTo1MzAzM2NhZTJmMjE0ZTc5YTcxZTBlY2Q4NzMwZjA1Yl8xLTEtMS0xLTQxOTI1_a31db9f3-64c4-4d40-aabc-940abb19b724">MOH</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMwMzNjYWUyZjIxNGU3OWE3MWUwZWNkODczMGYwNWIvdGFibGVyYW5nZTo1MzAzM2NhZTJmMjE0ZTc5YTcxZTBlY2Q4NzMwZjA1Yl8xLTItMS0xLTQxOTI1_fbd62aac-645a-4af9-b179-600d16b622bb">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk0_cb82bf12-5e84-48bc-859d-26a2b3b40bb6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk1_2a5dcda5-4081-4892-9e89-a7c227d454d0">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF81NDk3NTU4MTQxMDIy_1e3cbc3f-45fd-4471-a87f-8adf74d42362" continuedAt="ib4d9b4b7290f43fda9ada4b7b757efe7">L</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ib4d9b4b7290f43fda9ada4b7b757efe7">arge Accelerated Filer</ix:continuation> &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAw_e3135d05-952b-43b0-875d-ab3008677a55">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAx_def02d58-fa7b-47af-be9f-e22994e5f555">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   &#9744;</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;   Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAy_f7314a0c-da1e-4dd3-93c7-f9ec411bca52">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.001 par value, outstanding as of April&#160;22, 2022, was approximately <ix:nonFraction unitRef="shares" contextRef="i5088f3c4c0b64cf3a6113fcf094799c3_I20220422" decimals="-5" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDky_9d79818e-0e45-40b6-9707-b049418266f4">58,700,000</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id73f22483d2c490396b597725038007f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MOLINA HEALTHCARE, INC. FORM 10-Q</span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 </span></div><div><span><br/></span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ITEM NUMBER</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_10">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_79">19</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_121">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_124">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_124">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_127">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_130">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_133">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_136">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_139">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id73f22483d2c490396b597725038007f_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_13"></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNS0xLTEtMS00MTkyNQ_5dbf4135-2010-45d3-912f-321693aeb9a0">7,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNS0zLTEtMS00MTkyNQ_df390563-a786-49fa-8fd1-4a70017c4a98">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNi0xLTEtMS00MTkyNQ_3bc3fcaa-4354-498c-8709-0292dbbb7b51">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNi0zLTEtMS00MTkyNQ_23d90c04-2956-46aa-b936-85eb54e17a23">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOC0xLTEtMS00MTkyNQ_ed14f852-a4ab-475c-bc27-e0a21d45d914">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOC0zLTEtMS00MTkyNQ_8a61adbf-58a1-4a50-af95-6e988ccc9102">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOS0xLTEtMS00MTkyNQ_ebfa9c1e-3431-480a-8a0b-2c9f9b8e5fc2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOS0zLTEtMS00MTkyNQ_93c7adfb-c3dd-4a01-ae55-73eef239153f">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTAtMS0xLTEtNDE5MjU_d035d567-6d01-4aee-8e25-03bc06f95873">7,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTAtMy0xLTEtNDE5MjU_931a39da-6987-4b90-99b4-954c2c3eb9b9">6,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical care costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTItMS0xLTEtNDE5MjU_a05e355b-36b6-4b70-8689-c38ac359e393">6,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTItMy0xLTEtNDE5MjU_e4deeda0-b966-45f0-9e24-2c66243797c1">5,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTMtMS0xLTEtNDE5MjU_ab801fa6-acf5-4759-b2dd-a44518bd8fea">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTMtMy0xLTEtNDE5MjU_c3f5e546-77cd-4e84-900a-07f0d7d308bf">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTQtMS0xLTEtNDE5MjU_f60d4c4e-4bd0-432d-b109-bd1de9dda84a">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTQtMy0xLTEtNDE5MjU_4f8b1fac-016b-49cf-a171-9bd74ebed72c">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTYtMS0xLTEtNDE5MjU_be499acc-f302-476c-be55-dd5608dba7b2">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTYtMy0xLTEtNDE5MjU_4b92331a-d098-45d1-aa96-7298cb1d308f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTctMS0xLTEtNDE5MjU_7903c74e-0eb1-410a-8d23-8810e58ebbfd">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTctMy0xLTEtNDE5MjU_58579eec-6ec8-4931-8f93-4aa4bb2d2c48">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTgtMS0xLTEtNDE5MjU_f9d2f5a8-34a3-4827-90b6-7edf6b3a4d5a">7,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTgtMy0xLTEtNDE5MjU_452f75b1-5437-4ede-90ea-855282adf987">6,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTktMS0xLTEtNDE5MjU_24aec44f-5b09-40b7-bd36-2241ae982a91">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTktMy0xLTEtNDE5MjU_b53dc0ff-06ad-42f5-bd93-3eaea0baa2c5">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjEtMS0xLTEtNDE5MjU_a42c0828-270e-4cc1-97af-c3ec2d1da89c">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjEtMy0xLTEtNDE5MjU_c2f57e75-d262-46aa-a1ef-1a28c4ed269e">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjMtMS0xLTEtNDE5MjU_fedf7469-6e4f-43ad-9c87-1b73405c3b06">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjMtMy0xLTEtNDE5MjU_d6914f04-0a45-4922-8601-a4c22f0d5bce">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjQtMS0xLTEtNDE5MjU_4c1f44af-5e7d-4baa-baac-bca8a94983f6">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjQtMy0xLTEtNDE5MjU_aa00929e-3ef3-4a56-a2da-6904dcb85e00">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjUtMS0xLTEtNDE5MjU_7587f837-bbfa-44fb-9f70-f335063ead98">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjUtMy0xLTEtNDE5MjU_947037a9-88f9-4c1c-8c1e-e3194e0ab9b0">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjYtMS0xLTEtNDE5MjU_3c915a28-52d0-4977-a429-8687a78a584d">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjYtMy0xLTEtNDE5MjU_385e0c0c-503a-4bfb-af7f-dc9b773960b2">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjgtMS0xLTEtNDE5MjU_5320cb19-0abe-4d20-a29f-a9fa30e05bdb">4.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjgtMy0xLTEtNDE5MjU_ee6c2bfe-9273-4eef-b774-dc3238885f05">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjktMS0xLTEtNDE5MjU_c0844af2-23f0-4902-963e-0806794614ea">4.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjktMy0xLTEtNDE5MjU_f416eec0-7f2a-4268-bb43-005798070794">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNC0xLTEtMS00MTkyNQ_01b9fbe6-f6a9-45e8-948f-3ac51e30bf3a">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNC0zLTEtMS00MTkyNQ_04352930-8481-4e0a-8dde-465bb90f1fb6">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNi0xLTEtMS00MTkyNQ_25319112-6581-4495-b95f-b262836e74bb">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNi0zLTEtMS00MTkyNQ_3c792a0d-42aa-48dd-b386-48907e052419">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNy0xLTEtMS00MTkyNQ_c0e1e760-bf85-431f-a9d4-598653456503">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNy0zLTEtMS00MTkyNQ_8099c27f-c7e1-4ba9-b473-5d092f7ac54d">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOC0xLTEtMS00MTkyNQ_1df7a77d-4d06-46ce-b18b-cb1ba37bf5c6">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOC0zLTEtMS00MTkyNQ_badbb3c0-bf73-4202-8b9d-e4bfd402aca8">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOS0xLTEtMS00MTkyNQ_d9a8c235-ae26-4c14-a075-aaf02bbb910c">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOS0zLTEtMS00MTkyNQ_dee91e33-3072-401b-94ef-1747c9dbdc40">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 3</span></div></div></div><div id="id73f22483d2c490396b597725038007f_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions,<br/>except per-share amounts)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNi0xLTEtMS00MTkyNQ_116231ad-cdd5-41bc-8d1a-87f169f3493e">4,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNi0zLTEtMS00MTkyNQ_d2420aeb-093c-44cd-ba38-f1d982ad2259">4,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNy0xLTEtMS00MTkyNQ_d839a372-9ee8-4762-9295-96ccd7ee0d24">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNy0zLTEtMS00MTkyNQ_76f5578b-d01b-4cdb-9e1f-b39afac90d33">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOC0xLTEtMS00MTkyNQ_14ccb453-55de-43e8-afe2-b3184be663b7">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOC0zLTEtMS00MTkyNQ_a4fe39e9-3e5f-43b3-b11c-5206d65a4b49">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOS0xLTEtMS00MTkyNQ_14360b4a-a47f-405f-ad22-08a2879d769c">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOS0zLTEtMS00MTkyNQ_80aa63d2-7f3d-4a72-977e-7b17195e72d9">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTAtMS0xLTEtNDE5MjU_db873b86-29d7-40a5-9de0-915894825026">10,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTAtMy0xLTEtNDE5MjU_3364ee0c-78e1-4162-ad0d-87360360c015">10,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTEtMS0xLTEtNDE5MjU_8bbdc46c-f467-4921-a5f1-4a6789fc7020">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTEtMy0xLTEtNDE5MjU_631edce7-f540-4a27-a1c7-87144ada160e">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill, and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTItMS0xLTEtNDE5MjU_a142a60a-5c92-44fe-ad27-b3feeeff04a0">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTItMy0xLTEtNDE5MjU_49a661a7-8b9d-4e4c-ab64-afe28cebd53b">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTMtMS0xLTEtNDE5MjU_702b62be-ed38-4f08-bda1-39e7ca7cb1e6">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTMtMy0xLTEtNDE5MjU_83e8445a-3475-488c-afb3-0d92edad107a">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTQtMS0xLTEtNDE5MjU_64768bb1-2d36-44b7-b768-932e388274b0">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTQtMy0xLTEtNDE5MjU_19c6208b-17a7-4e1f-bdaa-2928f011996c">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTUtMS0xLTEtNDE5MjU_a2a1d884-e17d-4c71-bc95-5b92309936d6">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTUtMy0xLTEtNDE5MjU_88b3a193-12ca-4d64-bb5c-95172f8365b2">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTYtMS0xLTEtNDE5MjU_8871a6f3-bb20-48b2-820b-41b846341850">12,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTYtMy0xLTEtNDE5MjU_3759067a-af2b-426e-a5d2-6c58ac37d4e3">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjAtMS0xLTEtNDE5MjU_652063d9-57da-458b-82dc-453f2891ca0b">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjAtMy0xLTEtNDE5MjU_db2d7efd-b903-47df-9e84-3e30e717f98a">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjEtMS0xLTEtNDE5MjU_cf4d8f52-a8ac-4015-83fb-6cae704d159c">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjEtMy0xLTEtNDE5MjU_d2a1cf5c-6b3b-4bcd-81a4-c768b7f96022">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjItMS0xLTEtNDE5MjU_4e972244-42ae-4db9-a0f1-0ba201020145">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjItMy0xLTEtNDE5MjU_9e51257c-30b8-4588-a08d-b85371d11e70">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjMtMS0xLTEtNDE5MjU_c309f5c3-59d1-4a4b-88dc-a633e7402e55">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjMtMy0xLTEtNDE5MjU_e328fe0f-e562-479e-baf5-1b81959cf8d4">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjQtMS0xLTEtNDE5MjU_f0a88e92-a37c-4c0b-86bd-035a59d9233b">7,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjQtMy0xLTEtNDE5MjU_108d0574-e647-4cff-b870-b3c0bff8494d">7,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjUtMS0xLTEtNDE5MjU_2de1b7ff-3d96-4a77-a0cc-aa62c63d1fb5">2,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjUtMy0xLTEtNDE5MjU_5f6c9b4d-625c-48a1-896a-83a53beeb57b">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjYtMS0xLTEtNDE5MjU_5977cf69-6301-46b5-a26b-d50bd47dcdac">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjYtMy0xLTEtNDE5MjU_2411ac95-5d40-44fd-81fb-5520ffea808f">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjctMS0xLTEtNDE5MjU_2a6284a9-1857-43bd-bb6d-3d246bececad">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjctMy0xLTEtNDE5MjU_f9cd4b47-a7cd-4fa7-9da6-30a8f49761c0">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjgtMS0xLTEtNDE5MjU_064a113f-9f61-463e-8652-b23b25534da9">9,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjgtMy0xLTEtNDE5MjU_0fca9a13-4316-448a-89e0-3062648c6f8b">9,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18xOQ_50a58f93-17a6-43f3-b9f7-9afd42e0b83b"><ix:nonFraction unitRef="usdPerShare" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18xOQ_bed5e657-a523-4470-b62a-49cd82a70958">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18zMw_c2bf3665-8de3-44bd-8c31-0ad416ada7d7"><ix:nonFraction unitRef="shares" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18zMw_fbfd6646-d742-4bb4-826b-1b8b78a62c30">150</ix:nonFraction></ix:nonFraction> million shares authorized; outstanding: <ix:nonFraction unitRef="shares" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N182OA_46c5f5e7-eae5-4821-aa94-705cf34ed4ea">59</ix:nonFraction> million shares at March&#160;31, 2022, and <ix:nonFraction unitRef="shares" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N184OQ_328c0fc2-99c6-4be9-b04f-bd525178e2e0">58</ix:nonFraction> million shares at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMS0xLTEtNDE5MjU_510e506b-fe6e-42ca-8af8-f7158ea13439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMy0xLTEtNDE5MjU_c80e0ac4-ab14-47a9-9298-1ec14e5d9f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8yMg_2631d387-fcb6-4a2e-a667-63e3f4c6510d"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8yMg_4fc9b716-b5df-46c5-84e1-6c4e787690f8">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8zNg_8e37d505-0e8c-47eb-92a0-833058014f1d"><ix:nonFraction unitRef="shares" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8zNg_bec920d4-9d65-4776-9b79-4c6ec4778554">20</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_41514d74-16e0-42ca-ae18-d2e09c150b05"><ix:nonFraction unitRef="shares" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_5a6620c7-41d9-49db-8a00-e6ca69b3d07d"><ix:nonFraction unitRef="shares" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_dddee989-a408-441e-8449-e1be50176b62"><ix:nonFraction unitRef="shares" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_f220d742-9765-402a-b09f-a7c80278a200">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMS0xLTEtNDE5MjU_ef1bac42-59d4-4f0e-9126-51014784d7d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMy0xLTEtNDE5MjU_3f3aafb6-d877-4ada-973b-8631a0fb9ef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzItMS0xLTEtNDE5MjU_ab301366-3e88-4bea-b717-baa639c88f67">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzItMy0xLTEtNDE5MjU_ec3fd03c-f413-4668-a312-6cdc92fa1737">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzMtMS0xLTEtNDE5MjU_4c76f2fb-4c80-4cd8-9a77-6cb15c5c653b">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzMtMy0xLTEtNDE5MjU_de86c31d-54a2-4792-92af-ad67732861f6">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzQtMS0xLTEtNDE5MjU_1534c1cf-7ad9-4426-a080-267eb7b40229">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzQtMy0xLTEtNDE5MjU_7c6d473c-dedc-47d9-aa14-083ac2f2c9ff">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzUtMS0xLTEtNDE5MjU_b464d6eb-bbda-4484-ac4f-9ac93db03fef">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzUtMy0xLTEtNDE5MjU_478734f5-1960-4601-bb85-41154e65b466">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzYtMS0xLTEtNDE5MjU_a4b62da2-2620-48b2-811a-379d1070b2aa">12,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzYtMy0xLTEtNDE5MjU_903a39ce-de67-472d-97ec-4bef021f41a1">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 4</span></div></div></div><div id="id73f22483d2c490396b597725038007f_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d495bb1496443bf84bdb17358ef9e27_I20211231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS0xLTEtMS00MTkyNQ_41148aa6-557f-48e7-8103-cd429e6efc97">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d495bb1496443bf84bdb17358ef9e27_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS0zLTEtMS00MTkyNQ_4a0420c2-528b-41c4-bdf1-f633015fc462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbbdfebf5e0417db5c15c1f2203e943_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS01LTEtMS00MTkyNQ_5179271c-3c03-4b79-8108-f9ecd48737b3">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i210479d51b0949d4b306fa898f8ab68e_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS03LTEtMS00MTkyNQ_f36a42f8-5445-4627-acb8-150de7358b72">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a791bedc8c497a9b951c0a54286c99_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS05LTEtMS00MTkyNQ_93bca112-4bb4-47ae-9a49-d03432204653">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS0xMS0xLTEtNDE5MjU_6e68d91c-2de6-4988-b758-85f78a850ce6">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9197f15ee9d540a0993914efdd5e51cd_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNi05LTEtMS00MTkyNQ_b0ee8fc7-5a6d-4620-9110-d1a0578b7d3c">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNi0xMS0xLTEtNDE5MjU_bfba73ec-90e1-45a4-9ea1-2c5fc58d4167">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd4a419317fc4c44910821bd8c61e989_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTYtNy0xLTEtNDE5MjU_3c1ddd4f-5c28-49ca-b98e-1ce2bbeae66e">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTYtMTEtMS0xLTQxOTI1_3fc6b632-e482-46cc-8ce0-8b2f8879ac6e">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e97722ed58740a3af7cda41b611b9c1_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTctMS0xLTEtNDE5MjU_75742506-6225-4b8f-9242-1062bd2f10b4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1fa7fde4814471db3810635d40bdbdc_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTctNS0xLTEtNDE5MjU_731cc2c7-af11-49e7-93ee-fc8efd572e78">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTctMTEtMS0xLTQxOTI1_68a51aa1-2c87-47bc-b526-649ecaff57d2">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67e78bf8f50943f1aa07fa55e4049d43_I20220331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtMS0xLTEtNDE5MjU_a9eb5c38-55d2-4a4d-973c-d104bbaecd44">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e78bf8f50943f1aa07fa55e4049d43_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtMy0xLTEtNDE5MjU_b045c54f-4fef-4b58-9f91-145ed9e5c19e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib45bf3fe8b354f538d45f5c9cbfd0225_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtNS0xLTEtNDE5MjU_0240f41c-ddd7-4711-98c7-3ba7a19841f6">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97b8c89c2c664032b3e7c570dd406ef5_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtNy0xLTEtNDE5MjU_91addf92-64f2-4423-9228-300521841349">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82c487ce2bc462599459c0507d1ca62_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtOS0xLTEtNDE5MjU_bfc3cf18-58af-41ae-9163-910f5351cc6a">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtMTEtMS0xLTQxOTI1_c4591611-c7c7-4d89-a22c-8d2252806ef3">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i995ada66e7f14440b7cfd0a914ac8acf_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS0xLTEtMS00MTkyNQ_01fc285c-a879-4924-b02e-444937caacda">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995ada66e7f14440b7cfd0a914ac8acf_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS0zLTEtMS00MTkyNQ_5bc7acea-d51c-47e5-8aba-3a2d39e6aaf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff011ca48c834fabbfb52d9e98555c1c_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS01LTEtMS00MTkyNQ_6ffeed3d-7f61-4b0b-abd3-c1fec0a392db">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0199bf3103774fb5b433a7b2f787c39d_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS03LTEtMS00MTkyNQ_55accc4a-a597-4642-8f11-2f47cd156d5b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdcb8a23a1fc4ae8a13e0ed56f15658f_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS05LTEtMS00MTkyNQ_9b05f5ed-c9fd-4ae1-be35-4892a01f4257">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e99d1b775642728d269200485a7951_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS0xMS0xLTEtNDE5MjU_2b5b43dc-c30d-4540-bd9b-19066bed5cf4">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e7d8195295e452a9c89b318b1b39b4b_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNi05LTEtMS00MTkyNQ_447693aa-ad40-4660-822c-3f8f3fad1af4">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNi0xMS0xLTEtNDE5MjU_43edcd18-e897-4ebd-be4d-c9d2bd13b774">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4c1fa8ff9f704dc4a9aafd83714c7904_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy0xLTEtMS00MTkyNQ_cfcbc9ce-d584-40fc-80f5-6d30692747e4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb68bdab10a46ea8ce7f8f06b183910_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy01LTEtMS00MTkyNQ_3dbbe64f-e7c1-4d7a-804e-bba6c55b9a8c">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e7d8195295e452a9c89b318b1b39b4b_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy05LTEtMS00MTkyNQ_e27893fe-b7d1-40f8-a680-b7229d5ed671">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy0xMS0xLTEtNDE5MjU_b66f4d69-ea47-40c6-bb48-d70703ff20a0">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3691bc168b04f23adb9b834865b296d_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTYtNy0xLTEtNDE5MjU_89695fec-4ddd-4f47-910f-90b00e5b71cd">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTYtMTEtMS0xLTQxOTI1_0f6bbc93-6c13-4309-a541-804724968cdd">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb68bdab10a46ea8ce7f8f06b183910_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTctNS0xLTEtNDE5MjU_e6dccdeb-9fce-4c6d-b28c-7ebba31dcfcd">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTctMTEtMS0xLTQxOTI1_a11327d8-6e41-49bd-a80d-26298c8f0b75">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84780b904fcb43cf980043acfdf85931_I20210331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtMS0xLTEtNDE5MjU_589e473f-2fa1-4ee5-bd63-ab10616e7b55">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84780b904fcb43cf980043acfdf85931_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtMy0xLTEtNDE5MjU_5f888e79-75f2-4371-b315-9150db2de8dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c66fd9d79140e89e5a2167138c066a_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtNS0xLTEtNDE5MjU_0e793471-b039-4b39-a819-1ca6c6b5c69a">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6201f33888046d1a89c449d69d0e023_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtNy0xLTEtNDE5MjU_0cd07c51-7edd-478c-9b14-d12d9dbc0701">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6768c723a834132a8dff21a78dbcbc9_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtOS0xLTEtNDE5MjU_bcfec61a-de1b-4a65-a07a-8ee501b0e5c4">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2550091eda44588baae1b353781d6f9_I20210331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtMTEtMS0xLTQxOTI1_fd01e6cf-364f-4175-bc36-e9a9f2da7857">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 5</span></div></div></div><div id="id73f22483d2c490396b597725038007f_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNS0xLTEtMS00MTkyNQ_d49f59de-3282-447a-ba11-6229319084c1">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNS0zLTEtMS00MTkyNQ_5b5d48f7-b5f2-4a72-bde4-951939532f88">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNy0xLTEtMS00MTkyNQ_cc6fb692-2e55-47dc-8b82-9f4afdadafc5">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNy0zLTEtMS00MTkyNQ_42cbcc45-b26a-4700-b2d6-51ad17296401">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOC0xLTEtMS00MTkyNQ_b9a0b8e5-4ff4-4141-bf76-b67c2b05d8c4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOC0zLTEtMS00MTkyNQ_27aac6a0-9a7a-4910-bc17-784d4e79abb3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOS0xLTEtMS00MTkyNQ_210123ca-3ddc-4bb2-8c1d-356570db823a">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOS0zLTEtMS00MTkyNQ_8e5d585f-0d4f-451c-83bd-610e91f45405">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTEtMS0xLTEtNDE5MjU_da3c9114-596f-44c4-8629-4e5125410332">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTEtMy0xLTEtNDE5MjU_78a69990-5059-4775-8622-f73f610f5d21">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTMtMS0xLTEtNDE5MjU_a27ada32-5790-4a49-8844-f79bcc1482e3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTMtMy0xLTEtNDE5MjU_b290097f-812e-418c-b007-98fbfe58afc1">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTQtMS0xLTEtNDE5MjU_cb5489de-755c-415a-9874-fa4c92cbde8f">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTQtMy0xLTEtNDE5MjU_b9bb788c-80ab-49b6-9979-8d38c44b8d52">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTUtMS0xLTEtNDE5MjU_d40a46ce-2173-4c61-8f96-ba5b7b0c135b">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTUtMy0xLTEtNDE5MjU_308249cf-0e4f-4c1f-bccd-b886c92a14da">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTYtMS0xLTEtNDE5MjU_5ae7de7b-8c58-41ed-b2fe-e4233c7aeb52">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTYtMy0xLTEtNDE5MjU_b39672b4-7cc6-4390-bebe-638b57a85381">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTctMS0xLTEtNDE5MjU_9a902882-fadd-450d-86f8-f2dda6fcf802">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTctMy0xLTEtNDE5MjU_39fafd7f-0734-4d59-ae19-eefedb60c666">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTgtMS0xLTEtNDE5MjU_d3375e83-20ae-40bb-990f-803f4d72301a">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTgtMy0xLTEtNDE5MjU_04e9fed3-d37b-4b04-994d-25610ef7af41">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTktMS0xLTEtNDE5MjU_1fa80a27-d611-41d4-b876-587b8db06e5c">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTktMy0xLTEtNDE5MjU_0e91ec68-7e3e-4c4d-b8b6-55655e7f2bd3">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjAtMS0xLTEtNDE5MjU_469527f1-8a3a-43c3-9f1a-7d860c08db0e">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjAtMy0xLTEtNDE5MjU_bd3acc4b-510e-4ab4-8e34-10b8fcac90c6">568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjItMS0xLTEtNDE5MjU_a97ca345-fc33-4f47-a767-1a3d0406c2ef">403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjItMy0xLTEtNDE5MjU_f9910f91-e1ac-4a8c-a336-eed4821134df">388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjMtMS0xLTEtNDE5MjU_27054653-5b1a-4ced-958d-eeb00318895a">513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjMtMy0xLTEtNDE5MjU_8daebfee-3c69-45e0-b96e-3d24f546938d">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjQtMS0xLTEtNDE5MjU_3812e177-b68c-4486-a1e8-69c7e4f65e60">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjQtMy0xLTEtNDE5MjU_7022e7bf-0959-4cfc-bd2c-ce02d83a2559">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjYtMS0xLTEtNDE5MjU_f07d6d8b-0bc0-45cd-9415-05c9bf269858">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjYtMy0xLTEtNDE5MjU_c6c37564-33d9-4dbc-a369-feaacd9c0ef7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjctMS0xLTEtNDE5MjU_b42fd6a0-959f-42e1-b5fa-b033e4f86b4c">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjctMy0xLTEtNDE5MjU_dd791810-e3bd-4ba5-8602-4b72ca327281">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld to settle employee tax obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzAtMS0xLTEtNDE5MjU_cf17dc42-f2da-4084-8047-923113da9d74">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzAtMy0xLTEtNDE5MjU_b407060d-8707-4c94-a534-dc68aeada45d">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzEtMS0xLTEtNDE5MjU_9ab97f11-02d5-41ff-86f1-6c66aa8d1aba">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzEtMy0xLTEtNDE5MjU_5c6fb2a7-6a5c-4545-a50c-eb77a55e7cf3">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzItMS0xLTEtNDc3OTM_dd5d694c-aad3-4061-8e47-a955620fcc30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzItMy0xLTEtNDc3OTM_b81e2565-7c39-4c85-87bc-859267ee0759">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDAtMS0xLTEtNDE5MjU_d9a2137e-7478-4a53-8dc1-9592be2cd1b0">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDAtMy0xLTEtNDE5MjU_55fb4851-5f50-4306-b420-b73ee093a8e9">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDEtMS0xLTEtNDE5MjU_b31ea7cf-580b-4802-8cec-054875387e88">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDEtMy0xLTEtNDE5MjU_59228f10-41d8-4b23-9942-a2389f73470e">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDItMS0xLTEtNDE5MjU_f53642eb-d7b1-4a59-a5c9-28842c8593db">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDItMy0xLTEtNDE5MjU_47f4cec1-b46e-4a3b-a144-5295a1540beb">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDMtMS0xLTEtNDE5MjU_d39d20e8-4dbe-49b8-b608-d182f17528b6">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e99d1b775642728d269200485a7951_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDMtMy0xLTEtNDE5MjU_275184c1-a808-4fb0-acad-e5fe905f31b1">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDQtMS0xLTEtNDE5MjU_b7ea3421-168c-4cf9-a21d-b2789d9e9e6f">4,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2550091eda44588baae1b353781d6f9_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDQtMy0xLTEtNDE5MjU_0c60c7e6-5640-4385-b251-cd20643f9cc4">4,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 6</span></div></div></div><div id="id73f22483d2c490396b597725038007f_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MARCH&#160;31, 2022 </span></div><div><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_31"></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMwOQ_2e9e9368-dfcd-4534-90fb-2c9a27516d19" continuedAt="i04ca0dd297d24966a38adb0171793cd2" escape="true">Organization and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="i04ca0dd297d24966a38adb0171793cd2" continuedAt="i2f6c9bc8862a4dc1a795e08dcdf9d984"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We currently have <ix:nonFraction unitRef="segment" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="moh:NumberOfReportableSegment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfMTA5OTUxMTY0MDc0NA_49c96d44-a6a4-4f5f-ba20-c1c1d4d199cc">four</ix:nonFraction> reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we served approximately <ix:nonFraction unitRef="member" contextRef="i2a15fbb627e648a9b3cfcb7d23c86eb5_I20220331" decimals="-5" name="moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNTg3_670180d5-6521-4db1-88b2-e765aea34de8">5.1</ix:nonFraction>&#160;million members eligible for government-sponsored healthcare programs, located across <ix:nonFraction unitRef="position" contextRef="i2a15fbb627e648a9b3cfcb7d23c86eb5_I20220331" decimals="INF" name="moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNjY4_7ff86fc5-b86a-4aea-8ce7-ba05a1118c9b">19</ix:nonFraction> states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMy_742266a5-3364-47ae-b977-fd809341826f">three</span>&#160;to&#160;<ix:nonNumeric contextRef="i71bef60ed3804c7b985e0a7f9eb18119_D20220101-20220331" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzM4_29ae773a-bb91-440e-aa40-32876d58a2ad">five years</ix:nonNumeric>, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we submitted our RFP response. We expect the award to be announced in early August 2022, with an effective date of January 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP, with awards estimated to be announced in the fourth quarter of 2022, and start of operations in September 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The <ix:nonNumeric contextRef="i3fb5e9c9ed8a4e7a8212fec43122957e_D20210901-20210930" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfODI0NjMzNzIyMTEwMw_cc58b790-7307-4deb-9757-8a7c87d113c4">four year</ix:nonNumeric> contract with a possible <ix:nonNumeric contextRef="i3fb5e9c9ed8a4e7a8212fec43122957e_D20210901-20210930" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfODI0NjMzNzIyMTEwNA_138a3056-90d2-4715-8720-adf4a1afce09">two-year</ix:nonNumeric> extension was ratified in September 2021.</span></div><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMwMg_a8193228-c50e-468c-a1ab-da8ec1259f2c" continuedAt="ic17434588e7b40948a6e19251fd384d9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic17434588e7b40948a6e19251fd384d9">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzI5OQ_ed66eeb4-8dd8-4c58-b9ec-e76c01fb4da5" continuedAt="i2ce8ff0fe41f4013b234c146f9571444" escape="true">Use of Estimates</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f6c9bc8862a4dc1a795e08dcdf9d984"><ix:continuation id="i2ce8ff0fe41f4013b234c146f9571444">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</ix:continuation></ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc3Ng_d481e446-af66-43a5-9698-523f9704af91" continuedAt="i1e84ded8f8e94a05a406164701d3ce6c" escape="true">Significant Accounting Policies</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i1e84ded8f8e94a05a406164701d3ce6c" continuedAt="i97720224bd9f45948b72373faf918a19"> </ix:continuation></span></div><ix:continuation id="i97720224bd9f45948b72373faf918a19" continuedAt="i81923239f46944139fca843024cc565d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzczNQ_f52f7bc5-d88e-4000-b998-044559103164" continuedAt="ief5c81c72788406ca994bdad99a59199" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ief5c81c72788406ca994bdad99a59199">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase.</ix:continuation> <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc2NQ_f515bf59-d915-45c4-8fb7-b1f7dead58d2" continuedAt="ia065b76c560e44f88108c6d23c96a442" escape="true"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc2OA_ed67e3dc-70ab-48a6-8f68-9bab7ca09a65" continuedAt="ic2c1083fd9134f64af99ccf67e850ce8" escape="true">The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="ia065b76c560e44f88108c6d23c96a442"><ix:continuation id="ic2c1083fd9134f64af99ccf67e850ce8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNC0xLTEtMS00MTkyNQ_61d71ac9-2dab-4c30-a5db-fef8aed2969b">4,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2550091eda44588baae1b353781d6f9_I20210331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNC0zLTEtMS00MTkyNQ_b232e9d8-44bc-4f33-a587-76a88388f867">4,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNS0xLTEtMS00MTkyNQ_9e8b9017-edc8-4d09-adc0-e3b42b1ed7e6">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2550091eda44588baae1b353781d6f9_I20210331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNS0zLTEtMS00MTkyNQ_fe73b1af-ac3a-44b2-b0d0-b354681edab0">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNi0xLTEtMS00MTkyNQ_701dc28f-6e03-4774-b92f-b26ad27a2542">4,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2550091eda44588baae1b353781d6f9_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNi0zLTEtMS00MTkyNQ_2173c886-e59c-4765-bbfe-7258f59b2e6e">4,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc4OA_1cf82b24-9be4-4851-ae99-8e9b77001f90" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div></ix:nonNumeric><div><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc0Ng_4718a2b0-4f50-4671-b4eb-f48bc3586f83" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b6fd4fee764ab083cdc892e2c0c076_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfMy0xLTEtMS00MTkyNQ_f7a5393b-f55d-4647-b4ea-faf0bb72a085">1,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83542a544914da9a096018bb51d522d_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfMy0zLTEtMS00MTkyNQ_271fa9fc-09b2-4451-97a3-f8d56000b1bf">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if33590d339e94d2d901dd2dd40d1f5ad_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNC0xLTEtMS00MTkyNQ_f852148c-14bb-42f0-aaf1-2cb5dbb04e11">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756495c112ec486ca365574f64977791_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNC0zLTEtMS00MTkyNQ_97c2430a-0476-4a43-8177-f6278ae1b41a">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced25630f7f04a17b0750b5a726c2fdf_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNi0xLTEtMS00MTkyNQ_131afd22-3589-45ab-b7a3-bf5dc3bce792">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6984c064c12462fac6706daa823e721_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNi0zLTEtMS00MTkyNQ_2a862445-417c-4d2f-b751-b7c98098326c">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfOC0xLTEtMS00MTkyNQ_0f2fcc99-3fd6-4e8b-8250-ee46aaa14a4b">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfOC0zLTEtMS00MTkyNQ_ecbe0a74-7312-4d73-86dd-36e64d4540d6">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc4OQ_60d7c0ea-abbe-4d00-87b1-046c86d35f22" continuedAt="i193bbfcf7efb4740805108051e9bafbf" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><ix:continuation id="i81923239f46944139fca843024cc565d" continuedAt="i7dc5d764b709482884713ed5a70aece8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i193bbfcf7efb4740805108051e9bafbf" continuedAt="i1438baaf095a498bbf5d36dadf441f07">Contractual Provisions That May Adjust or Limit Revenue or Profit</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1438baaf095a498bbf5d36dadf441f07" continuedAt="i3b1e123c6dd64728879bad98b6ae48ad">Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.</ix:continuation> <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ReservesReportedToOtherAgenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc0MQ_99c39e3c-002c-43a4-8ece-e551f00a5558" continuedAt="i31c029d6c9da4043af7a31cf2b308872" escape="true">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. </ix:nonNumeric></span></div><ix:continuation id="i31c029d6c9da4043af7a31cf2b308872"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth amounts due government agencies, categorized by program:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNC0xLTEtMS00MTkyNQ_c69c1fdb-facb-4043-b138-953f8baaf4c6">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNC0zLTEtMS00MTkyNQ_342ae047-8ac7-45e7-8b06-ac7d19fdc4e1">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNS0xLTEtMS00MTkyNQ_506110d0-5a5d-4711-834b-8f22c828d904">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNS0zLTEtMS00MTkyNQ_941f5fdc-9a18-498e-b687-3ede4430d100">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNy0xLTEtMS00MTkyNQ_75e54ba6-6a0b-4b6d-aff5-61461628a644">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNy0zLTEtMS00MTkyNQ_e0a1d4e9-f22d-401c-b2ef-8a0ebef6082d">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOC0xLTEtMS00MTkyNQ_af6a4a26-f9d4-472e-937e-7f10be052a22">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOC0zLTEtMS00MTkyNQ_903bc611-2e0a-40df-ae51-8ce3d70029ec">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOS0xLTEtMS00MTkyNQ_6e90b706-2fda-49fa-a055-4edbbeba2515">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOS0zLTEtMS00MTkyNQ_3944ca43-4532-4c02-8fb3-e6cf29680cdc">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTEtMS0xLTEtNDE5MjU_e5b28047-4ad0-4475-b8d3-e9d1c9791949">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTEtMy0xLTEtNDE5MjU_6ac42bb5-4597-412d-8529-ce89a84cbab1">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTItMS0xLTEtNDE5MjU_48a2866b-19f6-47c8-b777-5d977b5c8f5e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTItMy0xLTEtNDE5MjU_08bb5bac-52c3-4352-b55d-958ed30f4292">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTMtMS0xLTEtNDE5MjU_eb8a3525-7b82-41c3-9334-d2717abee7da">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTMtMy0xLTEtNDE5MjU_f73d6274-c730-4b62-b5c2-4a52b9757521">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTUtMS0xLTEtNDE5MjU_033b8f9b-2780-44e2-a8c4-1bcceb9d5d67">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTUtMy0xLTEtNDE5MjU_478edaa4-445d-455b-8f9f-d10e31abf8be">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation><ix:continuation id="i3b1e123c6dd64728879bad98b6ae48ad" continuedAt="iaa7c78c6bb7c4de5a905927e7eefdd4d"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three months ended March 31, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i42b0a19236ea419588cf999ba5003db3_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfMzY1NA_279b301b-565f-45d3-894a-d43848da7b9f">28</ix:nonFraction> million related to such risk corridors, primarily in the Medicaid segment, compared to $<ix:nonFraction unitRef="usd" contextRef="ib16fa21da2b342b1b9b512fecc011c4a_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfMTA5OTUxMTYzNjMyMA_98150e94-007e-4d62-8483-a23db576b653">110</ix:nonFraction>&#160;million recognized in the three months ended March 31, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="iaa7c78c6bb7c4de5a905927e7eefdd4d" continuedAt="i95d6f3c6e4b94bc4855b8b1c3dd6722f">Risk Adjustment.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i95d6f3c6e4b94bc4855b8b1c3dd6722f"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</ix:continuation> As of March&#160;31, 2022, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" sign="-" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNDk3NA_805ac04f-8150-4abd-b11d-c578720ed9d2">949</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTAxMw_0b4c5c16-5760-4e4d-97c2-9a2013e4fa21">33</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTAzOA_1ce5fbae-9771-447d-855e-41569fd9209d">916</ix:nonFraction> million. As of December&#160;31, 2021, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTE2MA_1eaee581-959b-4e82-a0ed-fa566cf2971e">902</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTE5OQ_4d0f471d-afb1-4b29-99f5-636dece1a160">7</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTIyNA_475ce609-2964-499e-87bf-b493584962d9">895</ix:nonFraction> million. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><ix:continuation id="i7dc5d764b709482884713ed5a70aece8"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc4NQ_25c2c8c8-42bc-43d7-a6b0-7f74cf34c679" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="moh:InvestmentsMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTg1MA_2229aa53-3b74-40eb-9b34-24c28fb123a2">15</ix:nonNumeric> years, or less than <ix:nonNumeric contextRef="i60d5b3e94914400d9df6eef34274142b_D20220101-20220331" name="moh:InvestmentsAverageMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTg2Nw_6dc76ec8-2e81-4f48-8ee5-a840cc209caf">15</ix:nonNumeric> years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc3Mw_6abcb3a4-cc66-488a-acf4-33a73e2cbdce" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc3NA_be0f0195-c7da-43b3-b972-28e471301171" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_37"></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RleHRyZWdpb246OGQzNmUwODc3MjhhNDkyYzlhNmNkY2U1MmZjNzk3MTNfMjg4_a206de2a-06fa-4021-a6d9-cfe9c9b131a1" continuedAt="i31f37737bf0e4370a26fbccf0f8d4bea" escape="true">Net Income Per Share </ix:nonNumeric></span></div><ix:continuation id="i31f37737bf0e4370a26fbccf0f8d4bea" continuedAt="ie3e84d3c8fc649a7b894470bc8b3133b"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RleHRyZWdpb246OGQzNmUwODc3MjhhNDkyYzlhNmNkY2U1MmZjNzk3MTNfMjk2_005cdf22-6265-469e-a53c-7f46c462e349" continuedAt="i311b1ec25c7c413e927bc41cfb4a2ff6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNS0xLTEtMS00MTkyNQ_3a7c9f46-5cad-48f5-a408-d82c4fe5d46b">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNS0zLTEtMS00MTkyNQ_f8b1bae0-c504-4de7-bf35-48a72505cdf9">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNy0xLTEtMS00MTkyNQ_fa401802-ff41-4f82-8bc7-513c8f54fc47">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63e99d1b775642728d269200485a7951_I20201231" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNy0zLTEtMS00MTkyNQ_234c3f7b-c30d-47ab-ad0a-241228211ae2">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0xLTEtMS00NzU4MQ_c72b8fdc-acb0-443d-b49e-4c55e3a6c8b9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0zLTEtMS00NzU4MQ_99898b62-d207-4b03-aaac-93cdc8e09b27">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0xLTEtMS00MTkyNQ_b604d912-37d9-4338-a984-69a6cfcab9f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0zLTEtMS00MTkyNQ_e14caf3d-9c42-4306-978d-6620fd4b08c2">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTEtMS0xLTEtNDE5MjU_e2757c4e-bd72-4f8c-b733-55bc9b1c8a9c">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTEtMy0xLTEtNDE5MjU_67d9c995-f1a4-4ba7-90e9-1c93c48ba0d3">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTMtMS0xLTEtNDE5MjU_7051ad27-6d5d-4d81-a8d4-68671f5a552f">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTMtMy0xLTEtNDE5MjU_d063fb57-297b-4539-ba08-19991b677818">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTUtMS0xLTEtNDE5MjU_a99b5fda-e419-4ee5-849d-cc06ed58267b">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTUtMy0xLTEtNDE5MjU_85a87cf4-b444-4f44-895e-9ff2a3444985">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTctMS0xLTEtNDE5MjU_42363ac3-f538-4922-b367-bb6b4e24df33">4.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTctMy0xLTEtNDE5MjU_968e0a06-9a9d-484b-996d-1746bdb43b05">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTgtMS0xLTEtNDE5MjU_0955baee-d7ee-4b0c-b024-5d403870d448">4.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTgtMy0xLTEtNDE5MjU_38531f97-7de8-4b33-b395-67b6ef09d623">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ie3e84d3c8fc649a7b894470bc8b3133b"><ix:continuation id="i311b1ec25c7c413e927bc41cfb4a2ff6">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</ix:continuation></ix:continuation></span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </span></div><div id="id73f22483d2c490396b597725038007f_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfNzM3_87f31299-19de-4d7d-9b74-36d93c1969a6" continuedAt="ic0dc55fb532649059bd7e561c74eb323" escape="true">Business Combinations</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ic0dc55fb532649059bd7e561c74eb323" continuedAt="ibd690a43277c47349dcd1c4044fce744"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cigna. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMTA5OTUxMTYzNDE0NQ_5e5a8b4b-dffc-47ff-b206-9d7e33a1699e">60</ix:nonFraction>&#160;million. We acquired membership and a provider network with a preliminary fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i0df831b90dca48389c4a46065aa0e36b_D20220101-20220101" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMjE5OTAyMzI2MjU1OA_466f2007-2ffe-429e-aaf2-98d860c7ab00">36</ix:nonFraction> million. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfODI0NjMzNzIxNDcwMQ_c564e3d1-e1f1-4943-ae1e-2d29eef551aa">24</ix:nonFraction> million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. </span></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ibd690a43277c47349dcd1c4044fce744" continuedAt="i66cd6a666e9c49a98d9051d9040da256">Affinity. </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i66cd6a666e9c49a98d9051d9040da256">On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for initial purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i4224640832fc459a976f07601ca3b865_D20211025-20211025" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfOTM0NTg0ODg0MjUyOQ_1871eb0d-1581-4a67-8ec8-0bb8b27ffd45">176</ix:nonFraction>&#160;million. In the three months ended March&#160;31, 2022, we recorded various measurement period adjustments, including a decrease of $<ix:nonFraction unitRef="usd" contextRef="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331" decimals="-6" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMTA5OTUxMTYzNDYyOQ_16d4be13-61de-4635-b50c-1a7ed5b82203">25</ix:nonFraction>&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $<ix:nonFraction unitRef="usd" contextRef="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331" decimals="-6" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMTA5OTUxMTYzNDYxNw_b7689033-20fb-4be8-ae36-d4e4ca0cdba2">4</ix:nonFraction>&#160;million to &#8220;Amounts due government agencies.&#8221; In the aggregate, we recorded a net increase of $<ix:nonFraction unitRef="usd" contextRef="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfNzY5NjU4MTQwMTEwMQ_ccde1337-66ce-4180-8039-73f3ee6d8976">11</ix:nonFraction>&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_43"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjQ5Ng_d5292e12-0da1-4f52-baec-306b850a9d1a" continuedAt="id23190d3b98b49bc9dff854bb5416524" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="id23190d3b98b49bc9dff854bb5416524" continuedAt="i380c7d411ec34fa4a92cabf8021e1d3e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2021 Annual Report on Form 10-K, Note 5, &#8220;Fair Value Measurements.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the three months ended March 31, 2022 and 2021, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjE5OTAyMzI1OTg0Nw_da4b6839-8309-4db1-b600-ec12ea6d3428">4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTA5OTUxMTYzMjA1NA_d5a77f4a-bc9b-4dc6-a67c-5c280765ae48">8</ix:nonFraction>&#160;million, respectively, for the increase in the fair value of the contingent consideration liabilities described below.</span></div><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjQ5OA_df84bd3d-aaeb-4a83-82ee-182145191d52" continuedAt="i33dd1d2ecbca4466881ad1d09c4124ee" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC0xLTEtMS00MTkyNQ_8885a75e-af5f-4917-aa26-efed7f3d8a26">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9841f89feb4b6f833b989726c603b7_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC0zLTEtMS00MTkyNQ_99cb6fff-44ec-4c16-b02f-f0b57dd75540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d24f62cc41249a59883cfafb9f90a0b_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC01LTEtMS00MTkyNQ_9140066f-19df-426e-9542-5310bac22a8a">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6f584300eb4da4b4a6f02de502ee05_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC03LTEtMS00MTkyNQ_cf4d0259-3a44-4c21-a610-4379d952b68a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd269fb2ad24963b173ecee97871066_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS0xLTEtMS00MTkyNQ_4d64a429-c097-4fe5-b9ab-7eeb692c748f">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8f3df78577405d89b78540630ab85b_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS0zLTEtMS00MTkyNQ_87c69da1-f7e9-490f-bbaa-cace5f8ab7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib601f7ea9e1544bba2449d05dd7b52fb_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS01LTEtMS00MTkyNQ_b0cfc19b-67f1-4f53-850d-06d16779ae3b">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6c43599fc843d0829a435fbdc90272_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS03LTEtMS00MTkyNQ_f176af6c-4acc-4038-9cb0-44f519bbf6a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0xLTEtMS00OTMwOA_e2d14328-ee65-49dc-9456-64c95a3f0e25">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12e5991e34f746b4a7de6f87d9b23770_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0zLTEtMS00OTMwOA_617c6f67-17a0-4682-872c-aaa5b6fe2c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57bf75d7d2d40ce88df34d243fb7161_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi01LTEtMS00OTMwOA_9134ac15-12cc-4e0f-9451-6acea7ca631a">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80581b9110ec4a21aad1d72ab421ff09_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi03LTEtMS00OTMwOA_cdbf5d7f-5032-4584-a0c2-0a6b4f9a40e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0xLTEtMS00MTkyNQ_7175afca-056f-41dc-9944-ca7d6d127f6a">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb15836aa8ef41a0ab9a6005c565e6af_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0zLTEtMS00MTkyNQ_999ef367-130f-4d08-af6e-9345ebd332fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611e6b094ace4fdb8726ca8580b06107_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi01LTEtMS00MTkyNQ_ee79ecd9-4aa1-4db4-9c78-cb953d374404">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a014ebcaec4257afdea4362d4f7dcd_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi03LTEtMS00MTkyNQ_0fdf7665-a210-4dd5-98d9-785624e1ceaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC0xLTEtMS00MTkyNQ_e45577ab-a050-4e03-bed8-1dd91a986147">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc43d4329cfd4c3da7fcc8ab7fc08335_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC0zLTEtMS00MTkyNQ_43f7861d-f3bd-4b68-b357-2bfd914796a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ec83ce9f514a99ba56f61ebd1703d2_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC01LTEtMS00MTkyNQ_953a9edd-54ef-4321-ae52-54902524142c">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2530162568594c229e21427834758000_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC03LTEtMS00MTkyNQ_308c3c09-5b57-4919-bfe4-94c148bd83be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItMS0xLTEtNDE5MjU_66651d8e-8d1f-4053-874c-d57e82d170b4">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8232d132f78246a9b19395e9881b3b9e_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItMy0xLTEtNDE5MjU_b3a22412-f3a0-4624-8af8-d878be3e5d17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a461815e0cd4109af3d6157d9306450_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItNS0xLTEtNDE5MjU_8d719568-d278-4874-b28e-bde394b3c29c">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2599f46d545f4a9694a18ef8b64edd24_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItNy0xLTEtNDE5MjU_82deb29b-fc88-42dd-9c5e-a290a58948c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtMS0xLTEtNDE5MjU_16b9307b-2f1c-47a1-af2c-a47ed4592db5">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtMy0xLTEtNDE5MjU_6aafb9f8-216e-40ff-b27c-f857a9817644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2566bfad24064edcb4c6f1cc871fe634_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtNS0xLTEtNDE5MjU_62c69b5d-9aab-464a-b8a8-0463d6892fdd">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66eb009ac1814de594979994b70ed488_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtNy0xLTEtNDE5MjU_f130354e-62d8-471a-b10d-94aaf50da97b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtMS0xLTEtNDE5MjU_207af0e5-6f92-49e0-b398-333c956e4990">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtMy0xLTEtNDE5MjU_12cb9273-24d1-4b0e-bc56-acab50953f4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2566bfad24064edcb4c6f1cc871fe634_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtNS0xLTEtNDE5MjU_9aee4289-7567-43c4-bb31-562e4608e379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6d9575386442c88a03e9392c8d4680_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtNy0xLTEtNDE5MjU_5542b10d-2b0b-40a5-93a0-d31bae9210a0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtMS0xLTEtNDE5MjU_34202721-b65a-40db-9229-c244181bede5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtMy0xLTEtNDE5MjU_2ff698f6-5b1c-4453-92a5-f8235df67ec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2566bfad24064edcb4c6f1cc871fe634_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtNS0xLTEtNDE5MjU_fff749be-efce-4565-9186-5dbc20a1e910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66eb009ac1814de594979994b70ed488_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtNy0xLTEtNDE5MjU_f9c85d8b-ed49-4ff9-9903-b715d1e9db3e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><ix:continuation id="i380c7d411ec34fa4a92cabf8021e1d3e"><ix:continuation id="i33dd1d2ecbca4466881ad1d09c4124ee"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC0xLTEtMS00MTkyNQ_a1b27d33-3e59-486d-85ee-36971634507c">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3230becc0c4828baf9d10e3a700d76_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC0zLTEtMS00MTkyNQ_ed71ad61-d393-4fc2-a9e6-f51e98518b71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa407138475458aaaef37293a812835_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC01LTEtMS00MTkyNQ_3905b644-87ef-4f63-b8a3-1918331b5c11">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7278ef49c004479caacda424a824f532_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC03LTEtMS00MTkyNQ_64741ae8-7019-4ecb-be55-308fdffc3bb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb6f235c56e4125932f967ec4150a5a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS0xLTEtMS00MTkyNQ_fdd2cfca-4069-454d-886b-15141a0e9c0b">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8a92024a5dd4f20a93bb06874c6c09f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS0zLTEtMS00MTkyNQ_06305f42-654e-4ec4-aae4-c6d6fc08b356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0d79f965424c5688f2b4927964c092_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS01LTEtMS00MTkyNQ_3ddec9db-53ed-4311-8b37-3760a5f8420a">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568adc428eb44729bae4b7054ca3ecf0_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS03LTEtMS00MTkyNQ_992efaaf-4d46-496d-88ce-f85309884a76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0xLTEtMS00OTMxMw_61efff9b-1023-40b5-9f7a-90f71df12c35">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6246e151bd44c8ea675865e0681f3e6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0zLTEtMS00OTMxMw_17ff6462-9f09-4aec-9329-504590c0b952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2814ecb054554ae0ac8032339ced6fc3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi01LTEtMS00OTMxMw_832e156b-2f8a-41eb-be80-bc076eed7460">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3dcacd3393d4b038db393a7e50dcb86_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi03LTEtMS00OTMxMw_b164ccf9-bdaf-4330-a3a2-64488d043f55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0xLTEtMS00MTkyNQ_367fab4f-63d9-4d8c-869a-d0f81d857de3">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1727e43bcce4e9f99238725b4368289_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0zLTEtMS00MTkyNQ_57635d8a-868f-4c35-af93-10313bd7e11f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3215d158f874704ae5a909e76a9ffef_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi01LTEtMS00MTkyNQ_21a08f94-b120-4828-99b1-1951e234693f">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8096af143794d6ba663925f6c296688_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi03LTEtMS00MTkyNQ_2e230ab3-d0a9-45a7-9e04-f7c5fe061ae7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC0xLTEtMS00MTkyNQ_3b652136-3796-4167-b02f-d86954ec1160">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1308b34078d94ba9a442e2340bb7d947_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC0zLTEtMS00MTkyNQ_1db632d4-a682-4fe8-9932-8a3f0969c625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75af6a9d0fe3485ea6fb3e7b00fc7df8_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC01LTEtMS00MTkyNQ_91f46796-f4e6-41bb-b5dd-94667120186e">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47adc9834a74a3abd37340b07640e50_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC03LTEtMS00MTkyNQ_27717d4c-ba9d-4c7b-a9cc-e3df9d9d4860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtMS0xLTEtNDE5MjU_803a73f8-bda6-4275-bc8c-f27d16e7e08d">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12dbc47902b42e7bd4cd39167f525fd_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtMy0xLTEtNDE5MjU_cfcc79b2-8a54-4031-80d4-98e88fcdd5a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30977d23049a41d78ef8f2e721e78cae_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtNS0xLTEtNDE5MjU_e46620ca-bd21-46ac-9b32-9bee8b357743">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d6aa324dfe249378a208c3b0ce83c03_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtNy0xLTEtNDE5MjU_70bea3be-0186-4794-b8c6-9ba65c90a166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItMS0xLTEtNDE5MjU_1ab8e8c1-2c8a-42de-bf8a-eb0fe039ffdc">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5e3d221ec54558b758b1d1fa20008d_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItMy0xLTEtNDE5MjU_10f937f9-6528-4c36-92bb-af0919a2ce70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c52f1b8250479b8972444c6c5e8a60_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItNS0xLTEtNDE5MjU_1172951b-1f96-4e15-8f59-14649d34d9e3">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItNy0xLTEtNDE5MjU_46ba4825-6dda-4e19-a966-73c1e66b509c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtMS0xLTEtNDE5MjU_3b3edfac-397b-4096-87ea-7b91d5a180cf">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5e3d221ec54558b758b1d1fa20008d_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtMy0xLTEtNDE5MjU_7fdeb1ee-310e-4dac-97c8-bf6fc090519a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c52f1b8250479b8972444c6c5e8a60_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtNS0xLTEtNDE5MjU_3620ee3e-a055-4cac-8815-668f24c4f979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtNy0xLTEtNDE5MjU_190c5d83-1c28-47f3-8507-95569f57eb0f">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtMS0xLTEtNDE5MjU_3dfb7928-aad4-49cd-8c5e-b5a43668a3ad">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5e3d221ec54558b758b1d1fa20008d_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtMy0xLTEtNDE5MjU_b501f99e-af10-4c4f-9405-f674088a724a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c52f1b8250479b8972444c6c5e8a60_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtNS0xLTEtNDE5MjU_9fc2b83f-dd83-41fd-9ba2-0323f13b8ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtNy0xLTEtNDE5MjU_2b4a3dec-3ec4-46e5-a7d0-d813c63c4d21">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 financial instruments at March&#160;31, 2022 are comprised solely of contingent consideration liabilities of $<ix:nonFraction unitRef="usd" contextRef="i0f6d9575386442c88a03e9392c8d4680_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTM0Mw_5542b10d-2b0b-40a5-93a0-d31bae9210a0">8</ix:nonFraction> million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Such liabilities are recorded at fair value on a recurring basis. In the three months ended March 31, 2022, the estimated fair value of contingent purchase consideration increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTA5OTUxMTYzMTAzMA_da4b6839-8309-4db1-b600-ec12ea6d3428">4</ix:nonFraction> million, relating to an operating income guarantee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2022 we paid the seller $<ix:nonFraction unitRef="usd" contextRef="i3145ece7ff6a499db53f8fe074c21db2_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTA5OTUxMTYzNDI1MA_cd13ac56-85b4-44c2-8994-59255a1b77f1">43</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i3145ece7ff6a499db53f8fe074c21db2_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTYyNA_61a2f5f3-54fb-4a91-8539-ccdc7f2d0665">23</ix:nonFraction>&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $<ix:nonFraction unitRef="usd" contextRef="i740cf33bc2fe44aa91439e45ae7070d5_D20220101-20220331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjE5OTAyMzI2MDQyNA_c5202855-e527-485d-968d-02ea1c24bb98">20</ix:nonFraction>&#160;million was for the first payment of the consideration due for the operating income guarantee. For the amounts paid in the three months ended March 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjE5OTAyMzI2MTE2NA_9ab97f11-02d5-41ff-86f1-6c66aa8d1aba">20</ix:nonFraction> million has been presented in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221; The remaining balance of the liabilities is reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjUyMA_6e077cca-6321-45f0-9366-8f607050181b" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC0wLTEtMS00MTkyNS90ZXh0cmVnaW9uOmRiZDk4MTVmNDkzNTQ1OTRhYmQyYTYwMmY1ZTQ4ZTJlXzQ_d3659b07-b12a-4436-b6b1-c884b1b68ae5">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e413d250b1c4d62b2a2ce56ec990ee3_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC0xLTEtMS00MTkyNQ_468d3e19-5a59-4921-b869-b29d5e48ea8f">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e17e3d8ee2e4532b2cedd534f9c43c7_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC0zLTEtMS00MTkyNQ_d6ff3605-3d25-41b2-9800-a03d7a31fd27">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d82ade78bd740c5a619b23a903384cd_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC01LTEtMS00MTkyNQ_68587951-e9be-4a07-b44f-081e7d12e964">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e68e13a919f45a69729166fad740cce_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC03LTEtMS00MTkyNQ_0cd7d97a-7990-412b-aeb3-e00f730e5e7a">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0wLTEtMS00MTkyNS90ZXh0cmVnaW9uOjEzZThmMDk5YzllYjRhOTNhMTU1OTBmMzRjZWFlYzkyXzQ_022c73e4-7acb-4b50-8b07-28c62d184a37">3.875</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fb8f79f27a4ba1975a3c0080fac1f1_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0xLTEtMS00MTkyNQ_a0dc7817-df09-47a0-a3f7-b629cf0ae823">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416b558733524b4eb313dc3fd149027e_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0zLTEtMS00MTkyNQ_537faca5-8565-4a52-80e2-e79c3eb54a2b">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc71c1998d340b785d6c9e22719d163_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi01LTEtMS00MTkyNQ_d47626e9-3a97-42bf-ac1e-db9d3809f2cd">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531b1272dc854f2d96ea4aaa8c7ac85b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi03LTEtMS00MTkyNQ_5465e969-3c68-4ff6-ba08-2d4c55e0ce98">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0wLTEtMS00NjYzOS90ZXh0cmVnaW9uOjJjYWM1ZmM2YmE3OTRhOWY4ZjExNDc2MmE4YmY3MWFmXzEwOTk1MTE2Mjc4MDc_4e837c9c-61ad-4104-b466-30e5d32c4fc2">3.875</ix:nonFraction>% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3cfafe3e344d1c81dc96f60ad4e0b6_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0xLTEtMS00NDU5Mw_f52da29b-9019-4187-9641-999a6921e270">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc601537972b46fe9d996ede277d82de_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0zLTEtMS00NDU5Mw_c3f29cc6-1bb0-4494-bf9e-23fe7af8165b">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd44300529054baab8274cb4fdd4c646_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi01LTEtMS00NDU5MA_c930cf1f-3d83-44a7-91f3-1fd5a0859f5b">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i571d57dd721148bcba35827581b9aab2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi03LTEtMS00NDU5MA_81ba82c3-f230-451a-ba76-22fa8b1e36f4">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e7bbcc8d91489a9ac9423421979dce_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy0xLTEtMS00MTkyNQ_f01be3c4-b421-4975-a155-d67b592f9332">2,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3510f01da59140459a2feaa5c20cc72f_I20220331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy0zLTEtMS00MTkyNQ_3e4c3c39-1c05-4b27-a58b-94199599b0e0">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb73d2285af40bb99c52adb7201908c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy01LTEtMS00MTkyNQ_4de91d05-98aa-4519-95a2-66f70b67e6ac">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eca5b1af11a4d5592dd3ab9138e6d87_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy03LTEtMS00MTkyNQ_99c9b145-92fe-4ab3-afd0-ac2107c47d0e">2,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 12</span></div></div></div><div id="id73f22483d2c490396b597725038007f_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RleHRyZWdpb246NjI4ODAxYmQ1ZmMxNDI4MzgxMzI5MDkzY2EwMTZiMzJfNzY5NjU4MTM5NTc3Mw_e18ec03e-6c97-41a2-9b08-fe21ba9388e7" continuedAt="ief6c3dfe1081415d80c72d367bc404a5" escape="true">Investments </ix:nonNumeric></span></div><ix:continuation id="ief6c3dfe1081415d80c72d367bc404a5" continuedAt="i7c9bc99fc98149648909692b372a4fe5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all of our investments classified as current assets to be available-for-sale. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RleHRyZWdpb246NjI4ODAxYmQ1ZmMxNDI4MzgxMzI5MDkzY2EwMTZiMzJfMTI2Mg_f17f7321-0b13-4601-9496-6be71e5cbac1" continuedAt="i12e7024c0457480d8c21b9276f0b3763" escape="true">The following tables summarize our current investments as of the dates indicated:</ix:nonNumeric></span></div><ix:continuation id="i12e7024c0457480d8c21b9276f0b3763"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS0xLTEtMS00MTkyNQ_35f4a8ba-1e2e-4602-a1ca-4be68672fde3">1,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS0zLTEtMS00MTkyNQ_88e2bc0b-48ff-424d-883b-8e265ec35435">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS01LTEtMS00MTkyNQ_274ce038-d479-4027-9a4f-9462973ae7ea">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS03LTEtMS00MTkyNQ_1eb5f4f4-5d37-4644-a48a-0d86430d9e0d">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi0xLTEtMS00MTkyNQ_b2c45655-9235-4f92-b747-93c051dc6d45">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi0zLTEtMS00MTkyNQ_db84477b-091c-40c5-beab-5f9cc898dda7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi01LTEtMS00MTkyNQ_7bd21fe3-1ebb-40fe-8674-a4638d14ad65">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi03LTEtMS00MTkyNQ_0c0b0b6d-180c-4457-9f19-685e1c6d0029">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0xLTEtMS00OTMxOA_c2fd0fb0-c11d-4528-a263-ab4fcba42385">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0zLTEtMS00OTMxOA_aecc3e8d-0d28-4646-b967-37aaad04a29c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy01LTEtMS00OTMxOA_c973af68-36ec-41b2-881b-0ab4f363a253">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy03LTEtMS00OTMxOA_9e3b6f59-3fa7-42b0-b448-22af4c018715">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0xLTEtMS00MTkyNQ_bd2059a4-a171-494b-a809-39249bd62a96">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0zLTEtMS00MTkyNQ_afcd310e-7c05-4160-a5eb-019df20ac68f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy01LTEtMS00MTkyNQ_b7697e09-810c-4e33-a938-bfd08191f945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy03LTEtMS00MTkyNQ_20d39557-a2f4-4ad1-95aa-8703b8dda93c">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS0xLTEtMS00MTkyNQ_2e21f198-e8e5-4669-b35f-951d3992051f">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS0zLTEtMS00MTkyNQ_d05856ef-0a77-4b50-9f04-beee08afda2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS01LTEtMS00MTkyNQ_dcd7d12e-a8a3-4c5d-a48b-fd2e8aa93c6f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS03LTEtMS00MTkyNQ_8b3c29f5-473e-4d92-8e3a-0e3d673ebd29">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtMS0xLTEtNDE5MjU_6150c5a7-9ff3-48c9-91f4-6128e55f1d73">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtMy0xLTEtNDE5MjU_8b30b258-ef36-4442-85b2-b97ec567a1de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtNS0xLTEtNDE5MjU_8c6ae669-8134-4636-ac72-f5861aab50c2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtNy0xLTEtNDE5MjU_e56c37d3-58a0-4a65-8c65-bcc4e4878ff7">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtMS0xLTEtNDE5MjU_e3b7ec91-e9e9-42e4-9650-5768f28ec8ee">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtMy0xLTEtNDE5MjU_1d0ceeff-7091-40f0-9814-55a777aef35b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtNS0xLTEtNDE5MjU_4659f9e0-ef69-4c08-8b51-40dae7a6447d">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtNy0xLTEtNDE5MjU_e3e8f6a9-f944-4600-8440-84d3cdf6f8e1">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS0xLTEtMS00MTkyNQ_d8a2715e-be91-40c2-aea7-f5e36cdd6272">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS0zLTEtMS00MTkyNQ_5d58e870-796e-4a61-b817-4f800c38d3fd">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS01LTEtMS00MTkyNQ_d98f131e-6f1b-46ef-94dc-f0398b84ceca">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS03LTEtMS00MTkyNQ_efd317e9-1986-478c-8b12-7cf2e5a3fa84">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi0xLTEtMS00MTkyNQ_2bc86d55-c4ce-4e04-9982-7f99706421af">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi0zLTEtMS00MTkyNQ_df8a85e7-1f89-434a-abda-26aa493f8bed">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi01LTEtMS00MTkyNQ_e73ca7ba-fae9-495c-8913-6c978e24871b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi03LTEtMS00MTkyNQ_36cf4f8e-0952-4fd2-8c56-2c38035b1c61">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0xLTEtMS00OTMyMw_584371ac-2399-480b-9004-03ec0f86e81d">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0zLTEtMS00OTMyMw_7da5ab54-e708-4f0c-8051-7b32cbc707f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy01LTEtMS00OTMyMw_b3df01a7-8d49-48d0-a889-4f578b1f2cdd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy03LTEtMS00OTMyMw_3ae5ec95-8a7e-4e05-9391-e10956db0d5a">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0xLTEtMS00MTkyNQ_45cc06b3-7228-47cc-8e6b-7d825dbac03a">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0zLTEtMS00MTkyNQ_0167ebef-1380-4ded-8b24-11483652d10d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy01LTEtMS00MTkyNQ_50b4dec2-ada0-4661-9242-a7ca586b0c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy03LTEtMS00MTkyNQ_918c6637-ae9f-4105-8309-2160476a92f6">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS0xLTEtMS00MTkyNQ_1afff04d-1f5d-4380-96ca-70a5cb3947c4">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS0zLTEtMS00MTkyNQ_752a9887-d8a7-4e67-bb54-9d34139b1240">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS01LTEtMS00MTkyNQ_615c636d-4f4a-44ca-8144-e566d17d8f17">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS03LTEtMS00MTkyNQ_2b8eddf7-df27-4ac5-a69e-0a4e6e68f991">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItMS0xLTEtNDE5MjU_df9a2212-4e59-4765-b4df-53cd4ed57a2c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItMy0xLTEtNDE5MjU_930855fd-0593-4594-83d8-c1cd772d2bd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItNS0xLTEtNDE5MjU_86c4928b-fb56-441e-b075-4794306ba09c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItNy0xLTEtNDE5MjU_e9bffb94-218f-4c1e-93ac-4436a3a9e782">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtMS0xLTEtNDE5MjU_4d86ff88-8b29-4163-82e4-a3ba33d7c8e1">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtMy0xLTEtNDE5MjU_d454e8e6-3730-4cbf-86d5-d46769b795d4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtNS0xLTEtNDE5MjU_7d152edb-7c0e-453b-862f-2ad7dd167b17">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtNy0xLTEtNDE5MjU_27bd4040-9130-4e26-9360-1ec721b6080b">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RleHRyZWdpb246NjI4ODAxYmQ1ZmMxNDI4MzgxMzI5MDkzY2EwMTZiMzJfMTI0NQ_5be0c3d7-e056-4d51-8d6e-c23be1114e23" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of March&#160;31, 2022 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfMy0xLTEtMS00MTkyNQ_a53d4b6c-4672-40ea-a88d-eb08d4265187">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfMy0zLTEtMS00MTkyNQ_7268d036-7cf2-4211-b520-de2574eb73b3">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNC0xLTEtMS00MTkyNQ_0524fc5e-5ff6-47bd-971e-dbaa884165be">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNC0zLTEtMS00MTkyNQ_e735fe68-cfb6-4c87-b1a9-70dffbc828b7">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNS0xLTEtMS00MTkyNQ_10f5a1bc-eef0-4931-a000-38382ad0b283">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNS0zLTEtMS00MTkyNQ_e6aa24da-9b4e-4845-9354-0c8597b1df8f">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNi0xLTEtMS00MTkyNQ_66dbc9c6-6328-4067-bce2-c1ad078a817e">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNi0zLTEtMS00MTkyNQ_b7e38e10-53be-4671-ba19-9c57a8d7aa27">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNy0xLTEtMS00MTkyNQ_6c97e5c0-612a-4952-a0ba-57af03851a53">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNy0zLTEtMS00MTkyNQ_5f1e009a-330c-4049-974e-80347e2d35c8">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains and losses were insignificant for the three months ended March 31, 2022, and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at March&#160;31, 2022, and December&#160;31, 2021, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 13</span></div></div></div><div id="id73f22483d2c490396b597725038007f_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><ix:continuation id="i7c9bc99fc98149648909692b372a4fe5" continuedAt="i9b4fc1c90fe54e88acc9d8c094a5f373"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RleHRyZWdpb246NGY3NDQyNjAyZDlmNDljMmJhNzI5YzkyYmNkZjRjZjdfMjQw_b8053ebb-0c3f-4af9-a6ba-b24b5ac83256" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2022, and December&#160;31, 2021.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0xLTEtMS00MTkyNQ_f9cfc33b-3cd5-42bd-83ad-379d944ea8b8">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0zLTEtMS00MTkyNQ_394533bf-0a35-4fea-a293-f59f446a87ed"><ix:nonFraction unitRef="usd" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0zLTEtMS00MTkyNQ_c51bffca-17ac-4807-809d-6e01e8ab659f">67</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC01LTEtMS00MTkyNQ_d66e33eb-2c2b-47be-a0b2-e331ff5ed4b6">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC03LTEtMS00MTkyNQ_26b24672-be04-4a5a-b1ed-da7e05bbf413">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC05LTEtMS00MTkyNQ_36e51b84-01ba-4343-9fd6-6b5b1e9bd1d1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i45dcb81690184808b8b2e4355d718016_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0xMS0xLTEtNDE5MjU_8b8684ee-c69f-4891-a5d7-afbfbc5091cd">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0xLTEtMS00MTkyNQ_bb778413-70ca-4039-90c5-29145b2e40f9">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0zLTEtMS00MTkyNQ_00e371ce-c5de-4f1e-9169-fe6a03bf43f7"><ix:nonFraction unitRef="usd" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0zLTEtMS00MTkyNQ_8b12d7ae-4882-4b35-bfa8-96373365bf70">24</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i137c985bf2b84d7284fe720707605375_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS01LTEtMS00MTkyNQ_85e66bf3-e9b2-4bd8-93f2-bfe6fa003ff8">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS03LTEtMS00MTkyNQ_687d503f-03fc-4dbf-8037-5e6b85dccc2c">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS05LTEtMS00MTkyNQ_a5fb7757-e7e9-4aca-a5b6-015a62932cd1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0xMS0xLTEtNDE5MjU_da8a5085-0b34-4612-a336-1a3aaef6b7da">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi0xLTEtMS00MTkyNQ_032483e1-b6e3-49af-aec4-715f86de98b5">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi0zLTEtMS00MTkyNQ_db3b56a9-f4a9-4f28-9aea-2e08d8166937">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi01LTEtMS00MTkyNQ_0922e180-12e4-43c1-96c8-902700e58ad6">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi03LTEtMS00MTkyNQ_9aae9c6b-bcb4-4159-8af5-7565a9ae1176">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi05LTEtMS00MTkyNQ_74fb3d51-456e-4b1f-b208-7b203f50c394">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi0xMS0xLTEtNDE5MjU_27ef0858-7f75-4028-99e9-89800d27dcd1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC0xLTEtMS00MTkyNQ_04b4aa45-2527-4230-9804-54ff0571f35c">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC0zLTEtMS00MTkyNQ_503af639-4b1b-41a2-b971-0d81d488cd6e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC01LTEtMS00MTkyNQ_8e8dabb0-55f2-49a5-ad4d-30d728e92c7e">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC03LTEtMS00MTkyNQ_f363c18b-62dc-4497-9891-80e40e495b0c">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC05LTEtMS00MTkyNQ_aff29cfd-e03e-4eba-a26a-8ad1bc61e63b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC0xMS0xLTEtNDE5MjU_88b97f94-10bc-44c0-b215-e1c4d373c6f9">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS0xLTEtMS00OTI1NQ_af1f2724-00a2-437c-b4ef-c79ce18d4620">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS0zLTEtMS00OTI1NQ_0ded89b9-051a-43b3-b46f-dd85bab61a87">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i385070469b464b4c8f16f134196230a2_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS01LTEtMS00OTI1NQ_77bdf9a3-d8d0-45d2-a3e5-72da335f0513">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS03LTEtMS00OTc3OQ_a2145b14-effb-4b7d-a5ca-effd2a2143b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS05LTEtMS00OTc3OQ_a7327378-dc47-445f-9288-59db46317557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS0xMS0xLTEtNDk3Nzk_40efd2bc-7f41-4d67-a6d9-194dce443658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMS0xLTEtNDE5MjU_e9b9950d-53e9-4f46-acdf-01c87b9bbf31">2,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMy0xLTEtNDE5MjU_6524a3c9-4435-4078-a609-27d352409a1c"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMy0xLTEtNDE5MjU_bedcb40f-f805-465e-a371-cd18aa97b146">107</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItNS0xLTEtNDE5MjU_5cfbd4c8-2f83-43c7-832c-d6262a81ce2c">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItNy0xLTEtNDE5MjU_4914c0af-5241-46ea-a186-5dc4a6287440">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItOS0xLTEtNDE5MjU_20c39548-b18e-44b7-9110-4465a7e0dd9a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMTEtMS0xLTQxOTI1_c8f20511-916a-4d39-b89d-1e7aaf830bf1">677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_58"></div><ix:continuation id="i9b4fc1c90fe54e88acc9d8c094a5f373"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Investments Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81OC9mcmFnOmNiMmVjNGRjYTAwMzQwODJiZjViNzQ3YmFlOWQ2MDYwL3RleHRyZWdpb246Y2IyZWM0ZGNhMDAzNDA4MmJmNWI3NDdiYWU5ZDYwNjBfOTg3_d4eb6b16-e945-4b65-a397-a53bc0acd9cf">221</ix:nonFraction> million at March&#160;31, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81OC9mcmFnOmNiMmVjNGRjYTAwMzQwODJiZjViNzQ3YmFlOWQ2MDYwL3RleHRyZWdpb246Y2IyZWM0ZGNhMDAzNDA4MmJmNWI3NDdiYWU5ZDYwNjBfMTAwNg_39d0ec61-181c-4a19-87b1-c99fd5dfabbf">190</ix:nonFraction> million will mature in one year or less, and $<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81OC9mcmFnOmNiMmVjNGRjYTAwMzQwODJiZjViNzQ3YmFlOWQ2MDYwL3RleHRyZWdpb246Y2IyZWM0ZGNhMDAzNDA4MmJmNWI3NDdiYWU5ZDYwNjBfMTA0Ng_52d09fe4-46df-43c0-804d-606f934b2862">31</ix:nonFraction>&#160;million will mature in one through five years.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="moh:MedicalClaimsAndBenefitsPayableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTQxMg_4dbf6c7d-eb3f-4a8f-b300-cc66376ea518" continuedAt="i8376c560383247789bd18d805eb91343" escape="true">Medical Claims and Benefits Payable</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i8376c560383247789bd18d805eb91343" continuedAt="i4454c8a4a2f04cf89e99f64f4a4ee400"> </ix:continuation></span></div><ix:continuation id="i4454c8a4a2f04cf89e99f64f4a4ee400" continuedAt="i2ca656fab0354091895fae46ebab4cb8"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTQxMw_7f40ce0e-eb20-454a-a86e-5999ebd75587" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfMy0xLTEtMS00MTkyNQ_74825bb3-828e-4f81-a285-9558e1835e33">2,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfMy0zLTEtMS00MTkyNQ_3332c654-267f-491d-9d73-822d40a0d8d1">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNC0xLTEtMS00MTkyNQ_3b6ed2d6-056b-422b-bd4b-68b47725965e">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNC0zLTEtMS00MTkyNQ_7f6c6789-f04c-461e-a38e-be797f94b9f5">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNS0xLTEtMS00MTkyNQ_2f2b5bdc-13fa-4054-b7f6-618d16660af8">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNS0zLTEtMS00MTkyNQ_0ca64ba7-dbd9-4b58-8932-00001bbdcbc5">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNi0xLTEtMS00MTkyNQ_ddaa5e0c-c554-48e7-8c93-5cc8048499f1">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNi0zLTEtMS00MTkyNQ_469b191e-ed5f-4214-a5d6-be36032f2bda">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfOC0xLTEtMS00MTkyNQ_e409c3cc-d4e7-41e0-a240-713a0c2e6a51">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfOC0zLTEtMS00MTkyNQ_a0aaea61-2e14-495b-8f8e-479f3c6add30">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfNDQ1_afd896ed-e5f7-4202-8f5d-58b3e548d5c1">322</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfNDUy_18a9f83f-3157-46d7-b974-aa36af52fbaa">226</ix:nonFraction> million as of March&#160;31, 2022, and December&#160;31, 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTQyOQ_00ff22f3-11a3-4b6f-b5e3-31226a7d4d20" continuedAt="iddfb5d9fc368427eb0f74917ee9581a0" escape="true">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><ix:continuation id="i2ca656fab0354091895fae46ebab4cb8"><ix:continuation id="iddfb5d9fc368427eb0f74917ee9581a0"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860bf70640a44ea9b73b26a8d15aba5b_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC0xLTEtMS00MTkyNQ_7c512453-1a89-45d9-9c92-ac979147a09e">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if190d4db77c042b58e04f6bd35da403b_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC0zLTEtMS00MTkyNQ_7c308fd6-010d-4d2f-bad2-d5eaf2fd1cc8">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf71eb3d9cc444083f1b2554c284e40_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC01LTEtMS00MTkyNQ_0d2eca9b-efaf-4fac-80be-b29b0dbb8626">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC03LTEtMS00MTkyNQ_29f13ae3-26a7-40d3-bfa5-4d60317ef433">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi0xLTEtMS00MTkyNQ_604be576-4294-4cb9-8516-b887170c1894">5,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi0zLTEtMS00MTkyNQ_960fb8c8-3fc7-442e-8c68-7a38e7fd75f4">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi01LTEtMS00MTkyNQ_bc69a424-d288-4286-a6c0-9502ebfbe54a">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi03LTEtMS00MTkyNQ_bbefb26e-b1e7-4416-86f8-1f67cbb704ca">6,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy0xLTEtMS00MTkyNQ_537b7e82-59a1-42b1-b5d6-e2d150e1a60f">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy0zLTEtMS00MTkyNQ_13fc9383-18d4-4221-bc04-e6a5e6783ab1">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy01LTEtMS00MTkyNQ_715613a9-b541-4ca9-a61b-f9c8b95c0af4">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy03LTEtMS00MTkyNQ_af91632b-0447-4f6a-b578-5e1e3447e0f7">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC0xLTEtMS00MTkyNQ_c13a23d8-40ff-4102-8110-662b6762f4e1">5,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC0zLTEtMS00MTkyNQ_1a3b06f3-633c-498c-b4aa-4cd3e8dbaae9">815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC01LTEtMS00MTkyNQ_768f3e8b-75a0-4d65-81cc-61c108fbf0d2">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC03LTEtMS00MTkyNQ_a5dff92e-1e9c-4045-badf-f5f72606e77a">6,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtMS0xLTEtNDE5MjU_f8ea0cbd-a71b-42b5-acc5-9c6109e7f46c">3,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtMy0xLTEtNDE5MjU_acad6cf0-afaf-4727-b4fa-8fc1d450bec4">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtNS0xLTEtNDE5MjU_44339427-2230-4613-9ea1-6b019d455027">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtNy0xLTEtNDE5MjU_eb2d6c21-8fec-4113-89d9-10543528813f">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtMS0xLTEtNDE5MjU_00525a12-be4d-49f2-9b4c-356ddcecfd9b">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtMy0xLTEtNDE5MjU_fd0af921-7150-4ca4-b328-f29aea1fa67b">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtNS0xLTEtNDE5MjU_75ea090b-6766-4a05-9191-9fb34c1c8e50">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtNy0xLTEtNDE5MjU_39dd1b4c-7adb-481f-99b5-c9f52d8c69cb">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItMS0xLTEtNDE5MjU_4c1afb6f-5b41-4137-8a0c-bb3af23678c2">5,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItMy0xLTEtNDE5MjU_03d80694-3e70-4310-9c37-4bff38ef7378">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItNS0xLTEtNDE5MjU_972e8a69-3398-48c1-88ad-c09dfc50ac8a">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItNy0xLTEtNDE5MjU_42e043f6-fa52-427d-96ee-8b2ea17d8be3">6,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtMS0xLTEtNDE5MjU_f8db2116-4e2c-4dea-a638-dce374a8aeb1">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtMy0xLTEtNDE5MjU_fcb9cac5-a15c-49b7-8a8d-8ce23ab65433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtNS0xLTEtNDE5MjU_fcf6833a-b819-4a5e-8ea1-36b09da3d2ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtNy0xLTEtNDE5MjU_278ee324-c06f-4a4d-aad8-f5381acad1c6">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtMS0xLTEtNDE5MjU_baeb23ee-75d3-42b1-8ed8-2730b6f63ea8">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtMy0xLTEtNDE5MjU_2396c2ae-97da-4ec1-981a-886fe701593f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtNS0xLTEtNDE5MjU_3bdbe976-f37f-4225-8b54-15aaac878e57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtNy0xLTEtNDE5MjU_14f61eaf-2fcf-47f8-bb56-56ffde9e8ba0">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174960f5b134c548aa4d81b816b31fb_I20220331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtMS0xLTEtNDE5MjU_3bdd3969-a7c2-4663-9fc5-76efc1944b27">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea26c2873f4475288eeedd9a1ca9042_I20220331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtMy0xLTEtNDE5MjU_5fe7a6c8-6d18-46cc-bd26-1c7eba9841dd">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27309968abdf4262bb2205ee58ad5acc_I20220331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtNS0xLTEtNDE5MjU_94468130-1467-4c85-9529-a545ef565b1b">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtNy0xLTEtNDE5MjU_3ccd13c3-53ba-4377-80fc-e10a018fcfff">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib37da93f7f23442d8e258fd0d8326698_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC0xLTEtMS00MTkyNQ_150adf5b-f152-41eb-800e-1bdfc1d0809e">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaebf3329ac42485e9cb9a16f9bd00f59_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC0zLTEtMS00MTkyNQ_5368a299-9b73-42dd-9eb9-afbc82f05e3e">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib653e5e8294241fb8b57acb7b6fc82ec_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC01LTEtMS00MTkyNQ_84eb22ea-3b7d-45d0-9cdf-40e16bc92e56">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e99d1b775642728d269200485a7951_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC03LTEtMS00MTkyNQ_3db145cb-9352-45e2-b432-e83aa123b054">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi0xLTEtMS00MTkyNQ_89d80af0-71e0-483c-ac7a-721c6435d427">4,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi0zLTEtMS00MTkyNQ_fca4aae6-d935-4923-a871-32890be77480">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi01LTEtMS00MTkyNQ_7861e0d2-bcd4-4b3a-909c-ed0af9a78816">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi03LTEtMS00MTkyNQ_a7961df9-e2b2-4849-b295-c679bb6811a6">5,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy0xLTEtMS00MTkyNQ_ee18c57f-3ec0-4398-8f58-c117c6c1acdb">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy0zLTEtMS00MTkyNQ_de6fbc91-0180-4a4b-abf5-9661ad20f703">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy01LTEtMS00MTkyNQ_c6a70c6d-2de1-4ae5-b63e-395149caf072">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy03LTEtMS00MTkyNQ_5c413a34-8762-400d-b299-9a3650e46c24">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC0xLTEtMS00MTkyNQ_dafa2575-6040-45c5-aaed-6b6a1eef50a4">4,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC0zLTEtMS00MTkyNQ_e41f73f7-7ed2-4063-acfe-dda3af801a78">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC01LTEtMS00MTkyNQ_0c68a7f8-748d-4911-92d2-dfa47b30b3ef">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC03LTEtMS00MTkyNQ_e59d91bf-53fd-4ad7-98f7-0dbe9e8143d5">5,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtMS0xLTEtNDE5MjU_aab4da9a-d95e-4e97-9043-78ee49b8a1ce">2,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtMy0xLTEtNDE5MjU_117ac91c-c5cc-48a5-8a82-fa3a64044cc3">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtNS0xLTEtNDE5MjU_8170aac8-cd34-4dbc-9455-8dc5dfeb4688">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtNy0xLTEtNDE5MjU_1c7ed189-2352-4946-bfc4-4f5309ceae0e">3,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtMS0xLTEtNDE5MjU_aa816df8-c088-4896-9428-57260e5f1b9d">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtMy0xLTEtNDE5MjU_735f6fe2-7cbe-465d-aeaf-9e35e09529ff">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtNS0xLTEtNDE5MjU_747c5855-f16c-4efb-8e7c-4a45d402896c">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtNy0xLTEtNDE5MjU_a74865b2-d70c-4a54-a703-c21fd2f4f9f3">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItMS0xLTEtNDE5MjU_462960c4-f690-4ec4-aabb-74ad591a58b6">4,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItMy0xLTEtNDE5MjU_17f29c0f-64a0-4b35-947d-ef0a9a268320">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItNS0xLTEtNDE5MjU_db15991f-5f9b-427f-9329-84c025377067">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItNy0xLTEtNDE5MjU_8f62ada5-248a-452c-a10a-b119440499e4">5,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMS0xLTEtNDQ4MTg_d383a0ea-0fa5-482f-9f4d-0c90131a0b1d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMy0xLTEtNDQ4MzI_7d4180fe-ad59-4fc1-9ab0-cf2d7da4c1dc">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNS0xLTEtNDQ4Mzg_995e1ced-4333-4703-ab84-bc8eba1699ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNy0xLTEtNDQ4NDQ_7216a82b-02f9-4cd6-9bda-0ac35f0f48d8">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMS0xLTEtNDE5MjU_9e99ef60-b3fc-453c-8771-729e2ba52deb">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMy0xLTEtNDE5MjU_bf3a8aec-f5c1-4253-b544-21f44d5d8698">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNS0xLTEtNDE5MjU_853fbf2b-0f66-472c-b3a2-79cb50138504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNy0xLTEtNDE5MjU_166c9186-66ea-4649-8907-494503563ae8">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa7e42e08294660a93554586f9e98e6_I20210331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtMS0xLTEtNDE5MjU_b4574d41-e3fb-4e9f-88fb-a058d1381350">2,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358fe90d0eb44486b61c0746c2230690_I20210331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtMy0xLTEtNDE5MjU_ff971fc8-fbf0-4f30-aa30-9f2bb1468737">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11ad222d0b546dd9ac72ba5f96d48c9_I20210331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtNS0xLTEtNDE5MjU_de3560c3-beb6-41be-bae6-9f82137057a4">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2550091eda44588baae1b353781d6f9_I20210331" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtNy0xLTEtNDE5MjU_7f4ef71c-1ec4-498c-9d96-999a04a05002">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2021, and 2020 developed favorably by approximately $<ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTA0Nw_af91632b-0447-4f6a-b578-5e1e3447e0f7">206</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTA1NA_5c413a34-8762-400d-b299-9a3650e46c24">194</ix:nonFraction> million as of March&#160;31, 2022, and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in the three months ended March 31, 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our  estimates in 2021.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 15</span></div></div></div><div id="id73f22483d2c490396b597725038007f_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjU4MQ_c011b713-3afd-468f-836c-b17f603cef93" continuedAt="i9db8817f50e743d5b3bef0ea3091290d" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="i9db8817f50e743d5b3bef0ea3091290d" continuedAt="i3048aae04c884706bb2586a70e691dda"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent, which is reported in the Other segment. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjU3NQ_89b4b017-7218-4454-b091-88d1b3d6ae19" continuedAt="id5ea99efd4d7400eb1194d1461df0f46" escape="true">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="id5ea99efd4d7400eb1194d1461df0f46"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfOC0wLTEtMS00MTkyNS90ZXh0cmVnaW9uOjk2ZGM5OTg5MjYxMzQ4NjRiYTAyY2NiOTI2ZDM0NjJmXzQ_d3659b07-b12a-4436-b6b1-c884b1b68ae5">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfOC0xLTEtMS00MTkyNQ_854b16ae-9578-4e62-8e13-a1abf7a35073">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id580a7d8949142a485d23eb67d12db45_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfOC0zLTEtMS00MTkyNQ_b03b6e73-06e9-4d88-999c-8b2a97951c15">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiY2EyYmJkYjRjMDQ0MzU5OTliMGYwY2MzNzk4ZGZmZl80_022c73e4-7acb-4b50-8b07-28c62d184a37">3.875</ix:nonFraction>% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMS0xLTEtNDE5MjU_0051640e-ea08-4c48-91c7-855526d9d40b">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb8113f4fdf46a6a6d5465c3af10b83_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMy0xLTEtNDE5MjU_39a2ad8c-8848-4cab-a6f0-4d6b6c783f68">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMC0xLTEtNDM2NDgvdGV4dHJlZ2lvbjowYmJiMWVhMDk3Y2U0MmRkODg4YWQ3MTQ1NzI2NDQyNl80_522708cd-e63b-440e-97d6-e746ad7b9dd6">3.875</ix:nonFraction>% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMS0xLTEtNDM2NzI_e34ec4ae-5e89-4457-be71-73ef3aafabed">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84833fac2b9441da5a93a848c1d7ae7_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMy0xLTEtNDM2NzI_1c0a0323-feb8-4dc6-ac03-e2669e7202cb">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTEtMS0xLTEtNDE5MjU_978f41a2-4756-4394-b469-1668b5faa100">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTEtMy0xLTEtNDE5MjU_99921f3e-9d06-428b-84f9-9d2673774701">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTItMS0xLTEtNDE5MjU_52ad453e-a90e-4a91-9820-69bb47732b9b">2,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTItMy0xLTEtNDE5MjU_7d925767-4d30-47e5-9c64-1217a5a30018">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (the &#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="ifc7656849cc94666be3e0a7a222c0a01_I20220331" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMzYy_e493a59e-fa0b-47e9-aeec-95432ddb07c3">1.0</ix:nonFraction> billion, among other provisions. The Credit Agreement has a term of <ix:nonNumeric contextRef="i1e05d493b2494afe9d2924b87d069e98_D20220101-20220331" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfNDI1_998066d5-0b89-4b90-bc75-b50cc50cdd2b">five years</ix:nonNumeric>, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of March&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of March&#160;31, 2022, <ix:nonFraction unitRef="usd" contextRef="ifc7656849cc94666be3e0a7a222c0a01_I20220331" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA1Ng_29d72fb0-80f6-4223-af33-6e90314334b7">no</ix:nonFraction> amounts were outstanding under the Credit Facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTc2MA_d3659b07-b12a-4436-b6b1-c884b1b68ae5">4.375</ix:nonFraction>% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTc4Ng_c601efd4-0e65-47da-b19d-aab54973ff4e">800</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTgzOA_d3659b07-b12a-4436-b6b1-c884b1b68ae5">4.375</ix:nonFraction>% Notes&#8221;) outstanding as of March&#160;31, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTk0OA_d3659b07-b12a-4436-b6b1-c884b1b68ae5">4.375</ix:nonFraction>% per annum, is payable semiannually in arrears on June 15 and December 15.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjI5NA_022c73e4-7acb-4b50-8b07-28c62d184a37">3.875</ix:nonFraction>% Notes due 2030. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjMyMA_6bc0c671-01ee-4c34-90f2-d34eaeefa475">650</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjM3Mg_022c73e4-7acb-4b50-8b07-28c62d184a37">3.875</ix:nonFraction>% Notes due 2030&#8221;) outstanding as of March&#160;31, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjQ4Ng_022c73e4-7acb-4b50-8b07-28c62d184a37">3.875</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i3048aae04c884706bb2586a70e691dda" continuedAt="if35d79e2b8e642ac9e50e613485b2497"><ix:nonFraction unitRef="number" contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTAxMg_4e837c9c-61ad-4104-b466-30e5d32c4fc2">3.875</ix:nonFraction>% Notes due 2032.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if35d79e2b8e642ac9e50e613485b2497"> We had $<ix:nonFraction unitRef="usd" contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTA0OA_7a995503-777c-4662-8d69-afbd9b68dbee">750</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTAyMQ_4e837c9c-61ad-4104-b466-30e5d32c4fc2">3.875</ix:nonFraction>% Notes due 2032&#8221;) outstanding as of March&#160;31, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTAzMA_4e837c9c-61ad-4104-b466-30e5d32c4fc2">3.875</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15.</ix:continuation> </span></div><div><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82Ny9mcmFnOjg2OTQ4ODY1NzAwYTRjMmNiYjEwOTY0MGE3MTQwYTdlL3RleHRyZWdpb246ODY5NDg4NjU3MDBhNGMyY2JiMTA5NjQwYTcxNDBhN2VfMTIxNw_3a4d3c2d-511a-45e3-a13e-7d265b2ce9f4" continuedAt="i57d3a79e38f84f4f99e989dcf484b24d" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i57d3a79e38f84f4f99e989dcf484b24d">In September 2021, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="i90a498059fcf4606b716a944ac2ec8b6_I20210930" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82Ny9mcmFnOjg2OTQ4ODY1NzAwYTRjMmNiYjEwOTY0MGE3MTQwYTdlL3RleHRyZWdpb246ODY5NDg4NjU3MDBhNGMyY2JiMTA5NjQwYTcxNDBhN2VfOTM0NTg0ODgzNzg1NQ_3f54cafb-6024-4184-bf78-1915d59539c6">500</ix:nonFraction>&#160;million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  As of April&#160;27, 2022, we have purchased <ix:nonFraction unitRef="shares" contextRef="iba47bf9899884717ab70af9ee14f9c2c_D20220427-20220427" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82Ny9mcmFnOjg2OTQ4ODY1NzAwYTRjMmNiYjEwOTY0MGE3MTQwYTdlL3RleHRyZWdpb246ODY5NDg4NjU3MDBhNGMyY2JiMTA5NjQwYTcxNDBhN2VfOTM0NTg0ODgzNzg2OA_6d453b9c-8850-4c17-b824-bde3354f17a3">85,000</ix:nonFraction> shares under the stock purchase program approved in 2021.</ix:continuation></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 16</span></div></div></div><div id="id73f22483d2c490396b597725038007f_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RleHRyZWdpb246ZDJlNDMwNjUwODBlNDNlZDk2OWViNDhmYjg4MDllYjhfMzAyMA_df165ae6-6b4b-4d1e-a788-22caeeef82d8" continuedAt="ic82b946b9b1b4c749db73c94b6aec252" escape="true">Segments </ix:nonNumeric></span></div><ix:continuation id="ic82b946b9b1b4c749db73c94b6aec252"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have <ix:nonFraction unitRef="segment" contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331" decimals="INF" name="moh:NumberOfReportableSegment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RleHRyZWdpb246ZDJlNDMwNjUwODBlNDNlZDk2OWViNDhmYjg4MDllYjhfMTA5OTUxMTYzMjQwNA_49c96d44-a6a4-4f5f-ba20-c1c1d4d199cc">four</ix:nonFraction> reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#8220;MCR&#8221;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.</span></div><ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RleHRyZWdpb246ZDJlNDMwNjUwODBlNDNlZDk2OWViNDhmYjg4MDllYjhfMzAyOQ_7614a9d2-8936-44e9-8c79-eb4d8a6a88c7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNS0xLTEtMS00MTkyNQ_c859dea8-9e82-4e6e-9f1d-d6317e956336">6,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNS0zLTEtMS00MTkyNQ_64386e63-7ba1-40fe-b213-8ee2c4ff6e1e">5,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNi0xLTEtMS00MTkyNQ_5978bbb2-e3b9-4fde-8362-d982b4370471">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNi0zLTEtMS00MTkyNQ_ecfd4fdb-9b69-45e7-9a6e-9a56e3053078">805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0826354779264443891d6a415136b373_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNy0xLTEtMS00MTkyNQ_ecaae174-2854-4a25-9aba-65b59f16d88a">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNy0zLTEtMS00MTkyNQ_c75fbc3b-30cd-4715-ace8-5d03db608acf">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8119dbb6aa8f4209831488917ed525c3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOC0xLTEtMS00MTkyNQ_13729aa4-7e1f-440b-b102-c5b765cec365">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72ca4bc7ef0408bbf17ce916c1f6509_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOC0zLTEtMS00MTkyNQ_1bc726ea-dd72-496d-bc52-86a678cdc4c0">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOS0xLTEtMS00MTkyNQ_be266fc4-7cc8-46a1-bb0c-3de1200e2a25">7,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOS0zLTEtMS00MTkyNQ_15d413ce-3e36-48ff-a919-05a4f50d0791">6,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e316ab4ba32437c958ac31c5508c0b5_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNS0xLTEtMS00MTkyNQ_2f81d446-165f-4aa6-bcdb-0059a13edc68">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d80104f1b540928f8ac1ddc8014d3e_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNS0zLTEtMS00MTkyNQ_106cf550-75a8-4e85-afaf-254d549ab069">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b5ad20d89f472cad8dfcd21eda5886_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNi0xLTEtMS00MTkyNQ_b2760ae8-667e-4a2c-959f-d51f8f281f14">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07ce4db9efe048acac76f18d5fa8a4e5_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNi0zLTEtMS00MTkyNQ_bf00bbf1-0eb7-4fa8-85a4-aaceaa9f0ba1">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb923c3c38347a98af734e4bc95e64b_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNy0xLTEtMS00MTkyNQ_9d67aa65-61e7-4604-8406-9deac39819a4">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e922a7c4de84239b28fe388eb3877de_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNy0zLTEtMS00MTkyNQ_a5d50f4f-6db6-404d-a7e9-3f997bee2d24">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da7d7575ad342f2b9348f4fc572b689_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOC0xLTEtMS00MTkyNQ_ba1712c5-2bbd-489d-89a5-4bef5cde6642">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f4e15da99f48ff99edb0138e60332a_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOC0zLTEtMS00MTkyNQ_bb653fee-9c77-432c-9790-e90af2d538b4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bebfc17f52c4711b46e9ec3c87538ce_D20220101-20220331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOS0xLTEtMS00MTkyNQ_62e4fbda-04ac-4c9d-8aeb-cb6443304a5e">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i503f2f6a1ef14912910191aaf1ea287a_D20210101-20210331" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOS0zLTEtMS00MTkyNQ_f58fc068-c3f1-47d4-a87d-6538b515aa73">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9508779f4b0c40619e8754cfbb98b602_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTAtMS0xLTEtNDE5MjU_ef68bf27-d3b3-4e99-a748-0f4a9bc71af0">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f137a107044827823d5b3929276fde_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTAtMy0xLTEtNDE5MjU_40be0a6d-88bb-45bc-bdfd-b4daa4c40502">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9508779f4b0c40619e8754cfbb98b602_D20220101-20220331" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTEtMS0xLTEtNDE5MjU_ac1a6e65-4759-4271-b89d-8f20458904d4">820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72f137a107044827823d5b3929276fde_D20210101-20210331" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTEtMy0xLTEtNDE5MjU_79e75447-822e-4d7d-9cc1-dbfb68e7afdc">700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTItMS0xLTEtNDE5MjU_afb8fedf-cf96-4596-9a75-5817e3bb5945">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTItMy0xLTEtNDE5MjU_be35cc69-10d9-49ed-9514-02467c30c8e7">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTMtMS0xLTEtNDE5MjU_1c2d705c-2b59-43aa-b6f1-2fbd137c0e93">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTMtMy0xLTEtNDE5MjU_c3cd4acc-b840-41b0-8dfc-a00338fa8288">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTQtMS0xLTEtNDE5MjU_1b70badf-e00c-4558-babd-40ceca51521d">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTQtMy0xLTEtNDE5MjU_05d528f0-8121-4eb9-93df-bb8357b98192">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.</span></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 17</span></div></div></div><div id="id73f22483d2c490396b597725038007f_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11. <ix:nonNumeric contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83My9mcmFnOjYzM2YxNjg3ZjY1MTRhM2JhYWVmYmZhYzk4MjY0OGMzL3RleHRyZWdpb246NjMzZjE2ODdmNjUxNGEzYmFhZWZiZmFjOTgyNjQ4YzNfNDA5OA_3e78b58d-1c6f-4316-82c5-6f4d0b6265de" continuedAt="i26cc9b7018094980b465a658e8613867" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i26cc9b7018094980b465a658e8613867"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, the repayment of previously billed and collected revenues and reputational damage.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. The appellate briefing has concluded and no assurances can be given regarding the ultimate outcome. Under the Court&#8217;s June 16, 2021 final Order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#8220;MHPR&#8221;) filed a complaint asserting, among other claims, breach of contract against the Puerto Rico Health Insurance Administration (&#8220;ASES&#8221;). On September 13, 2021, in addition to filing its answer to MHPR&#8217;s complaint, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. The counterclaim alleges that MHPR and the Company breached contractual obligations by failing to pay providers, and seeks damages and various equitable remedies. On October 8, 2021, MHPR filed its reply to the counterclaim, denying all the allegations, and on November 1, 2021, the Company filed its answer to the third-party complaint. On December 3, 2021, MHPR filed a request for disbursement of illegally withheld funds, and ASES filed its opposition. At a status hearing on January 19, 2022, the Court heard MHPR&#8217;s request for disbursement. The Court has not ruled on the request. On March 23, 2022, the Court informed the parties that it will appoint a Special Commissioner to review the merits of the entire case, with the assigned judge retaining final authority over any resolution. The parties are negotiating the engagement of the Special Commissioner. This matter is in its early stages and remains subject to significant additional proceedings, and no prediction can be made as to the outcome. No gain or loss is probable and reasonably estimable with regard to either MHPR&#8217;s complaint or the counterclaim of ASES.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 18</span></div></div></div><div id="id73f22483d2c490396b597725038007f_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (&#8220;MD&amp;A&#8221;)</span></div><div id="id73f22483d2c490396b597725038007f_82"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, and results of operations within the meaning of Section&#160;27A of the Securities Act of 1933, or Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, or Securities Exchange Act. Many of the forward-looking statements are located under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as &#8220;guidance,&#8221; &#8220;future,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;growth,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; and similar terms. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company&#8217;s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled &#8220;Risk Factors&#8221; in our 2021 Annual Report on Form 10-K, including without limitation the following:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic and its associated or indirect effects on our business, operations, and financial results, including without limitation the duration of the Public Health Emergency Declaration (&#8220;PHE&#8221;) and associated suspension in redeterminations, and the potential impact on our workforce or contractors of federal or state vaccine mandates;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">significant budget pressures on state governments from diminished tax revenues incidental to the COVID-19 pandemic and their efforts to reduce rates or limit rate increases, to impose profit caps or risk corridors, or to recoup previously paid premium amounts on a retroactive basis; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the numerous political, judicial, and market-based uncertainties associated with the Affordable Care Act (the &#8220;ACA&#8221;);  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the market dynamics surrounding the ACA Marketplaces, including issues impacting enrollment, risk adjustment estimates and results, the potential for disproportionate enrollment of higher acuity members, and the discontinuation of premium tax credits;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the legal proceedings in Kentucky with regard to the Medicaid contract award to our Kentucky health plan and our acquisition of certain assets of Passport;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to retain existing or awarded government contracts, and the success of any bid submissions in response to requests for proposal, including our contracts in California and Texas; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consummate, integrate, and realize benefits from acquisitions, including the completed acquisitions of Magellan Complete Care, Passport, Affinity, and the Medicaid assets of Cigna in Texas, and the announced acquisition of AgeWell New York;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">effective management of our medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with COVID-19; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">cyber-attacks, ransomware attacks, or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected information;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success and renewal of our duals demonstration programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the accurate estimation of incurred but not reported or paid medical costs across our health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">efforts by states to recoup previously paid and recognized premium amounts; </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">changes in our annual effective tax rate, due to federal and/or state legislation, or changes in our mix of earnings and other factors;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">complications, member confusion, eligibility redeterminations, or enrollment backlogs related to the renewal of Medicaid coverage;   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">fraud, waste and abuse matters, government audits or reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, corrective action plan, monitoring program, or premium recovery that may result therefrom;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">our exit from Puerto Rico, including the payment in full of our outstanding accounts receivable, the effective run-out of claims, the return of our capital, and the outcome of the claims filed against our Puerto Rico health plan and us by the Puerto Rico Health Insurance Administration, or ASES;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes with respect to our provider contracts and the loss of providers; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">approval by state regulators of dividends and distributions by our health plan subsidiaries;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">high dollar claims related to catastrophic illness; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the resolution, favorable or unfavorable, of litigation, arbitration, or administrative proceedings;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the relatively small number of states in which we operate health plans, including the greater scale and revenues of our California, Ohio, Texas, and Washington health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to comply with the financial or other covenants in our credit agreement or the indentures governing our outstanding notes;  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity, and meet our general liquidity needs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of funds on hand to pay the amounts due upon maturity of our outstanding notes;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of a state in which we operate to renew its federal Medicaid waiver;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes generally affecting the managed care industry; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increases in government surcharges, taxes, and assessments;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the unexpected loss of the leadership of one or more of our senior executives; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increasing competition and consolidation in the Medicaid industry.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the terms &#8220;Molina Healthcare, Inc.&#8221; &#8220;Molina Healthcare,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us,&#8221; as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Readers should refer to the section entitled &#8220;Risk Factors&#8221; in our 2021 Annual Report on Form 10-K, for a discussion of certain risk factors that could materially affect our business, financial condition, cash flows, or results of operations. Given these risks and uncertainties, we can give no assurance that any results or events projected or contemplated by our forward-looking statements will in fact occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the following discussion of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the notes to those statements appearing elsewhere in this report, and the audited financial statements and Management&#8217;s Discussion and Analysis appearing in our 2021 Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 20</span></div></div></div><div id="id73f22483d2c490396b597725038007f_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 155), provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We served approximately 5.1&#160;million members as of March&#160;31, 2022, located across 19 states.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FIRST QUARTER 2022 HIGHLIGHTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net income of $258 million, or $4.39 per diluted share, for the first quarter of 2022, which reflected the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Membership increase of 480,000, or 10%, compared with March&#160;31, 2021, and a 114,000 sequential decrease compared to December&#160;31, 2021;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Premium revenue of $7.5 billion increased 19% compared with the first quarter of 2021, reflecting increased organic membership in Medicaid and Medicare, along with the impact of acquisitions, partially offset by the decline in Marketplace membership;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated medical care ratio (&#8220;MCR&#8221;) was 87.1%, compared with 86.8% for the first quarter of 2021, and increased due to the net effect of COVID, which increased the MCR by 50 basis points in the first quarter of 2022, but was negligible in the first quarter of 2021;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expense (&#8220;G&amp;A&#8221;) ratio of 7.4%, which compared with 7.3% in the first quarter of 2021, reflecting temporary labor costs challenges, certain non-recurring costs and appropriate investments to accommodate growth, partially offset by the benefits of scale produced by our increase in revenue; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After-tax margin of 3.3%, which was in line with our expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We note the following factors impacting the 2022 first quarter financial results:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We estimate that the net effect of COVID decreased net income by approximately $0.57 per diluted share in the first quarter of 2022. The net effect of COVID had a negligible impact on the first quarter of 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The net effect of COVID reflects higher COVID inpatient costs, lower COVID-related utilization curtailment and the impact of the COVID risk-sharing corridors, and impacted all of our segments during the first quarter of 2022.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL SUMMARY</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: medical care costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MCR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">G&amp;A ratio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Net income per share &#8211; Diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Statistics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After-tax margin </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;MCR represents medical care costs as a percentage of premium revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;G&amp;A ratio represents general and administrative expenses as a percentage of total revenue. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;After-tax margin represents net income as a percentage of total revenue.</span></div><div><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_88"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED RESULTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NET INCOME AND OPERATING INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income in the first quarter of 2022 amounted to $258 million, or $4.39 per diluted share, compared with $228 million, or $3.89 per diluted share, in the first quarter of 2021. The 13% increase in net income is consistent with the improvement in operating income, which increased to $372 million in the first quarter of 2022, compared with $335 million in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The improvement in operating income was mainly due to membership growth and higher premium revenues, partially offset by an increase in the MCR. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PREMIUM REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue increased $1.2 billion, or 19%, in the first quarter of 2022, when compared with the first quarter of 2021. The higher premium revenue reflects increased organic membership in the Medicaid and Medicare segments and the impact of acquisitions, partially offset by a decline in the Marketplace segment. The increase in premium </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue was partially attributable to a reduced impact of COVID-related risk corridors that were enacted in several states beginning in the second quarter of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MEDICAL CARE RATIO</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated MCR in the first quarter of 2022 was 87.1%, compared with 86.8% in the first quarter of 2021. The Medicaid and Marketplace MCRs increased in the first quarter of 2022, while the Medicare MCR decreased. The net effect of COVID increased the consolidated MCR in the first quarter of 2022 by approximately 50 basis points and impacted all segments in the first quarter of 2022. The net effect of COVID had a negligible impact on the first quarter of 2021. The impacts were varied by segment in both periods. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year reserve development in the first quarter of 2022 was modestly favorable, but its impact on earnings was absorbed by the COVID-related risk corridors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PREMIUM TAX REVENUE AND EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) was 2.7% and 2.9% for the first quarter of 2022 and 2021, respectively. The current year ratio decrease was mainly due to changes in business mix.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INVESTMENT INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income increased to $11 million in the first quarter of 2022, compared with $9 million in the first quarter of 2021, mainly due to an increase in interest rates and higher levels of invested assets. Investment yields were lower in the first quarter of 2021 due to a temporary allocation in shorter-term invested assets due to the COVID-19 pandemic, until it was rescinded in the second quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue was consistent at $20 million in the first quarter of 2022 and 2021. Other revenue mainly includes service revenue associated with long-term services and supports consultative services we provide in Wisconsin. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G&amp;A EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G&amp;A expense ratio was 7.4% in the first quarter of 2022, compared with 7.3% in the first quarter of 2021, mainly reflecting temporary labor cost challenges, certain non-recurring costs and appropriate investments to accommodate growth, partially offset by the benefits of scale produced by our increase in revenue. We expect our full year 2022 G&amp;A ratio to be consistent with our long term targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEPRECIATION AND AMORTIZATION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization increased to $40 million in the first quarter of 2022, compared with $33 million in the first quarter of 2021, due primarily to amortization associated with recent acquisitions completed in the fourth quarter of 2021 and the first quarter of 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER OPERATING EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses totaled $16 million in the first quarter of 2022, compared with $20 million in the first quarter of 2021. Other operating expenses mainly includes service costs associated with long-term services and supports consultative services we provide in Wisconsin, as noted above. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INTEREST EXPENSE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased to $28 million in the first quarter of 2022, compared with $30 million in the first quarter of 2021. The decrease resulted from our early redemption of $700 million aggregate principal amount of our 5.375% senior notes due 2022 in the fourth quarter of 2021, partially offset by interest related to the private offering of the 3.875% Notes due 2032 in the same period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INCOME TAXES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense amounted to $86 million in the first quarter of 2022, or 25.0% of pretax income, compared with income tax expense of $77 million, or 25.2% of pretax income in the first quarter of 2021. The difference in the effective tax rate is primarily due to the impact of certain discrete tax benefits recognized in the three months ended March 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 23</span></div></div></div><div id="id73f22483d2c490396b597725038007f_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRENDS AND UNCERTAINTIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COVID-19 PANDEMIC</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, its ongoing impact to our business, results of operations, financial condition, and cash flows is uncertain and difficult to predict. Specific trends and uncertainties related to our Medicaid, Medicare, and Marketplace segments follow. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Economic Stabilization and Other Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 16, 2022, the Biden Administration extended the COVID-19 related PHE, which, among other things, continued the suspension in state Medicaid eligibility redeterminations for 90 days until April 16, 2022. Effective April 17, 2022, the Biden Administration extended the PHE for another 90 days and it will remain in effect until July 15, 2022, unless extended. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty as to the duration and breadth of the pandemic, we are unable to reasonably estimate the ultimate impact of the economic stabilization and other programs to our business, financial condition, and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enrollment and Premium Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding acquisitions and our exit from Puerto Rico, we added over 750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through mid-July 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. The current rate environment is stable and rational. We continue to believe that the risk-sharing corridors previously introduced are related to the declared PHE and will likely be eliminated as the COVID pandemic subsides. However, the risk corridors continue to contribute an added level of variability to our results of operations. In the three months ended March 31, 2022, we recognized approximately $28 million, for the impact of these risk corridors, compared to $110 million recognized in the three months ended March 31, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Care Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect continued uncertainty regarding utilization trends as the pandemic continues. The speed and extent to which utilization rebounds will be greatly impacted by the economy and consumer behavior, provider capacity, and the potential resurgence of COVID-19 infection rates. We believe that some portion of the utilization curtailment experienced in the three months ended March 31, 2022 is likely the result of service deferrals, and so these services will likely be provided to members over the remainder of the year.   </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capital and Financial Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future. Refer to &#8220;Liquidity and Financial Condition&#8221; below for further discussion of our capital and financial resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER RECENT DEVELOPMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we submitted our RFP response. We expect the award to be announced in early August 2022, with an effective date of January 2024. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP, with awards estimated to be announced in the fourth quarter of 2022, and start of operations in September 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible two-year extension was ratified in September 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketplace Enrollment. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We now expect to end 2022 with approximately 270,000 members, reflecting normal attrition over the remainder of the year and limited special enrollment period growth based on revised eligibility rules and our product design and distribution strategy. This represents an increase compared to our previous estimate of 250,000 members by the end of 2022, resulting from stronger final enrollment and grace period membership.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional segment trends, uncertainties and other developments, refer to our 2021 Annual Report on Form 10-K, &#8220;Item 1. Business&#8212;Our Business,&#8221; and &#8220;&#8212;Legislative and Political Environment.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_97"></div><div style="margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORTABLE SEGMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we served approximately 5.1 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have 4 reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HOW WE ASSESS PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#8220;MCR&#8221;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of the change in medical margin is discussed below under &#8220;Segment Financial Performance.&#8221; For more information, see Notes to Consolidated Financial Statements, Note 10, &#8220;Segments.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SEGMENT MEMBERSHIP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our membership by segment as of the dates indicated:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,566,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,329,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,859,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">620,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,085,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,199,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,605,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SEGMENT FINANCIAL PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes premium revenue, medical margin, and MCR by segment for the periods indicated (dollars in millions):</span></div><div style="margin-bottom:1pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium<br/>Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical<br/>Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,531&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid premium revenue increased $1.1 billion, or 24%, in the first quarter of 2022, when compared with the first quarter of 2021. The increase was mainly due to organic membership growth, including Nevada, and the impact from the Affinity and Cigna acquisitions that closed in the fourth quarter of 2021 and in January 2022, respectively. Excluding the acquisitions, membership growth was across several states and was mainly driven by the extension of the PHE period and the associated suspension of membership redeterminations due to COVID-19. The increase was partially attributable to a reduced impact of state risk corridors stemming from COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above in &#8220;Trends and Uncertainties,&#8221; we recognized approximately $28 million in the first quarter of 2022, for the impact of risk corridors enacted in several states beginning in the second quarter of 2020, in response to the lower utilization of medical services resulting from COVID-19. We recognized approximately $110 million for the impact of such risk corridors in the first quarter of 2021. The decrease is due to the elimination of most of the COVID-19 risk corridors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical margin in our Medicaid program increased $106 million, or 18%, in the first quarter of 2022 when compared with the first quarter of 2021. The increase was driven by increased premium revenues and margin associated with the membership growth discussed above, partially offset by an increase in the MCR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid MCR increased to 88.1% in the first quarter of 2022, from 87.5% in the first quarter of 2021, or 60 basis points. The increase was mainly attributable to a year-over-year increase in the net effect of COVID, partially offset by improved operations, including medical cost management. The year-over-year change in the net effect of COVID reflects an increase in COVID-related inpatient costs, and lower COVID-related utilization curtailment, partially offset by the decrease in COVID-related risk corridors. The Medicaid MCR is consistent with our long-term target despite the net effect of COVID.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare premium revenue increased $144&#160;million, or 18%, in the first quarter of 2022, primarily due to the impact of product expansion and organic membership growth in existing states, partially offset by lower premium revenue PMPM from the change in business mix. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical margin for Medicare increased $51&#160;million, in the first quarter of 2022, when compared with the first quarter of 2021, mainly due to the increase in premium revenues and the improvement in the MCR discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare MCR decreased to 86.5% in the first quarter of 2022, from 90.3% in the first quarter of 2021, or 380 basis points. The improvement was primarily driven by a lower net effect of COVID, improved operating performance, including higher risk scores that more closely reflect the acuity of our membership, and the change in business mix. The Medicare MCR is lower than our long-term target.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketplace</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketplace premium revenue in the first quarter of 2022 decreased $59&#160;million, compared with the first quarter of 2021, mainly due to a reduction in membership, partially offset by an increase in premium revenue PMPM. Our Marketplace membership as of March&#160;31, 2022 amounted to 371,000 members, representing a decline of 357,000 members compared to December 31, 2021, which is in line with our product and pricing strategy to achieve our target margins in this business. The increase in premium revenue PMPM is consistent with the product and pricing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategy, reflecting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an increase of members in the silver metal tier and a decrease of members in the bronze metal tier.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace medical margin decreased $21 million in the first quarter of 2022, when compared with the first quarter of 2021, primarily due to the decrease in membership and premiums, and the increase in the MCR described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace MCR increased to 78.6% in the first quarter of 2022, from 77.3% in the first quarter of 2021, or 130 basis points. The increase resulted mainly from changes in membership mix discussed above. Silver metal tier products incur less MCR seasonality than bronze metal tier products due to lower deductibles. The Marketplace MCR is in line within our long-term target. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other segment includes service revenues and costs associated with long-term services and supports consultative services we provide in Wisconsin, and also includes certain corporate amounts not allocated to the Medicaid, Medicare, or Marketplace segments. Such amounts were immaterial to our consolidated results of operations in the first quarters of 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIQUIDITY AND FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LIQUIDITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity. In the first quarter of 2022, we did not experience noticeable delays to, or changes in, the timing or level of premium receipts as a result of the COVID-19 pandemic, but there can be no assurances that we will not experience such delays in the future. See further discussion below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Uses&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of the assets held by our regulated health plan subsidiaries is in the form of cash, cash equivalents, and investments. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for general corporate purposes. In the three months ended March 31, 2022, the parent company received $115&#160;million, in dividends and return of capital from the regulated health plan subsidiaries. See further discussion of dividends below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parent company may also contribute capital to the regulated health plan subsidiaries to satisfy minimum statutory net worth requirements, including funding for newer health plans. In the three months ended March 31, 2022, the parent company contributed capital of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $19&#160;million,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the regulated health plan subsidiaries. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments at the parent company amounted to $250&#160;million and $348&#160;million as of March&#160;31, 2022, and December&#160;31, 2021, respectively. The decrease as of March&#160;31, 2022, was primarily due to the timing of corporate payments and capital contributions to regulated health plan subsidiaries, partially offset by dividends received from regulated health plan subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After considering expected cash flows from operating activities, we generally invest cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies which conform to applicable state laws and regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 15 years, or less than 15 years average life for structured securities. Professional portfolio managers operating under </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the risks of the COVID-19 pandemic, as they relate to our investments, are minimal. The overall rating of our portfolio remains strong and is rated AA. Our investment policy has directives in conjunction with state guidelines to minimize risks and exposures in volatile markets. Additionally, our portfolio managers assist us in navigating the current volatility in the capital markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets.</span></div><div id="id73f22483d2c490396b597725038007f_106"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows are summarized as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically receive capitation payments monthly, in advance of payments for medical claims; however, government payors may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government payors may delay our premium payments, or they may prepay the following month&#8217;s premium payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operations for the three months ended March 31, 2022 was $363 million, compared with $568 million in the three months ended March 31, 2021. The $205 million decrease in cash flow was due to the net impact of timing differences in government receivables and payables and partially offset by an increase in net earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $74 million in the three months ended March 31, 2022, compared with $87 million used in investing activities in the three months ended March 31, 2021, an increase in cash flow of $161 million. This increase in cash flow was primarily due to the net activity of proceeds and purchases of investments in the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $77 million in the three months ended March 31, 2022, compared with $207 million used in the three months ended March 31, 2021, an increase in cash flow of $130 million. In the three months ended March 31, 2022, cash outflow included $52 million for common stock withheld to settle employee tax obligations. In the three months ended March 31, 2021, financing cash outflows included common stock purchases of $128 million and $51 million for common stock withheld to settle employee tax obligations.  Additionally, we paid $20 million each in the first quarters of 2022 and 2021 to settle contingent consideration liabilities relating to our Kentucky Passport acquisition that closed in 2020. </span></div><div><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_109"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash resources, borrowing capacity available under the Credit Agreement as discussed further below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources,&#8221; and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, at March&#160;31, 2022, our working capital was $3.1 billion, compared with $3.0 billion at December&#160;31, 2021. At March&#160;31, 2022, our cash and investments amounted to $8.0 billion, compared with $7.9 billion at December&#160;31, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Capital and Dividend Restrictions </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our regulated, wholly owned subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement for these subsidiaries was estimated to be approximately $2.1 billion at both March&#160;31, 2022 and December&#160;31, 2021. The aggregate capital and surplus of our wholly owned subsidiaries was in excess of these minimum capital requirements as of both dates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable regulatory requirements, the amount of dividends that may be paid by our wholly owned subsidiaries without prior approval by regulatory authorities as of March&#160;31, 2022, was approximately $229&#160;million in the aggregate. The subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our cash and investments balances as of March&#160;31, 2022, management believes that our regulated, wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Ratings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our senior notes is rated &#8220;BB-&#8221; by Standard &amp; Poor&#8217;s, and &#8220;Ba3&#8221; by Moody&#8217;s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our future borrowing costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Covenants</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios are computed as defined by the terms of the Credit Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the indentures governing each of our outstanding senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As of March&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt.</span></div><div><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_112"></div><div style="margin-bottom:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FUTURE SOURCES AND USES OF LIQUIDITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Excluding acquisitions and our exit from Puerto Rico, we added over 750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through mid-July 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends from Subsidiaries.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. As a result of the COVID-19 pandemic, state regulators could further restrict the ability of our regulated health plan subsidiaries to pay dividends to the parent company, which would reduce the liquidity of the parent company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement Borrowing Capacity. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had available borrowing capacity of $1&#160;billion under the revolving credit facility of our Credit Agreement. In addition, the Credit Agreement provides for a $15&#160;million swingline sub-facility and a $100&#160;million letter of credit sub-facility, as well as incremental term loans available to finance certain acquisitions up to $500&#160;million, plus an unlimited amount of such term loans as long as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our consolidated net leverage ratio is not greater than a defined maximum. See further discussion in the Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Uses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Purchases. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  As of April&#160;27, 2022, $472 million remained available to purchase our common stock under this program through December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. The purchase price for the transaction is approximately $106&#160;million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described above in &#8220;Trends and Uncertainties,&#8221; we have been subject to Medicaid risk corridors as a result of the pandemic. Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three months ended March 31, 2022, we recognized approximately $28 million related to such risk corridors, primarily in the Medicaid segment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Capital Requirements.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_115"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of future obligations under our various contractual obligations and commitments as of December&#160;31, 2021, was disclosed in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our contractual obligations and commitments outside the ordinary course of business during the three months ended March 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_118"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures; actual results could differ from these estimates. Our critical accounting estimates relate to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medical claims and benefits payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Notes to Consolidated Financial Statements, Note 7, &#8220;Medical Claims and Benefits Payable,&#8221; for a table that presents the components of the change in medical claims and benefits payable, and for additional information regarding the factors used to determine our changes in estimates for all periods presented in the accompanying consolidated financial statements. Other than the discussion as noted above, in the three months ended March 31, 2022 there were no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may adjust or limit revenue or profit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies.&#8221; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the three months ended March 31, 2022, there were no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business combinations, goodwill, and intangible assets, net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the three months ended March 31, 2022, there were no significant changes to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our 2021 Annual Report on Form 10-K. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_121"></div><div style="margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at March&#160;31, 2022, the fair value of our fixed income investments would decrease by approximately $69 million. Declines in interest rates over time will reduce our investment income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on fair value measurements and our investment portfolio, please refer to Notes to Consolidated Financial Statements, Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. For further information, see Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_124"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management, with the participation of our chief executive officer and our chief financial officer, has concluded, based upon its evaluation as of the end of the period covered by this report, that the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), are effective to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no changes in our internal control over financial reporting during the three months ended March 31, 2022, that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_127"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding legal proceedings, see Notes to Consolidated Financial Statements, Note 11, &#8220;Commitments and Contingencies.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="id73f22483d2c490396b597725038007f_130"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain risks may have a material adverse effect on our business, financial condition, cash flows, results of operations, or stock price, and you should carefully consider them before making an investment decision with respect to our securities. In addition to the other information set forth in this report, you should carefully consider the risk factors discussed under the caption &#8220;Risk Factors,&#8221; in our 2021 Annual Report on Form 10-K. The risk factors described in our 2021 Annual Report on Form 10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows, results of operations, or stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 31</span></div></div></div><div id="id73f22483d2c490396b597725038007f_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of common stock made by us, or on our behalf, during the first quarter of 2022, including shares withheld by us to satisfy our employees&#8217; income tax obligations, are set forth below:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchased&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of&#160;Shares<br/>Purchased as Part of<br/>Publicly&#160;<br/>Announced&#160;<br/>Plans or <br/>Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate&#160;Dollar&#160;Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares that May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January  1 - January 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1 - February 28</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1 - March 31 </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">During the first quarter of 2022, we withheld approximately 166,000 shares of common stock, to settle employee income tax obligations, for releases of awards granted under the Molina Healthcare, Inc. 2019 Equity Incentive Plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">For further information on our stock repurchase programs, refer to Note 9, &#8220;Stockholders' Equity.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 32</span></div></div></div><div id="id73f22483d2c490396b597725038007f_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of Filing</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992922000028/exhibit101_amendedemployme.htm">Amendment of Employment Agreement, date</a><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992922000028/exhibit101_amendedemployme.htm">d February 16, 2022, by and between Jos</a><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992922000028/exhibit101_amendedemployme.htm">eph M. Zubretsky and Molina Healthcare, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed as Exhibit 10.1 to registrant&#8217;s Form 8-K filed February 16, 2022.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh1q22_ex311.htm">Section 302 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh1q22_ex312.htm">Section 302 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh1q22_ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh1q22_ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data file (formatted as Inline XBRL and embedded within Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 33</span></div></div></div><div id="id73f22483d2c490396b597725038007f_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id73f22483d2c490396b597725038007f_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MOLINA HEALTHCARE, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 28, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JOSEPH M. ZUBRETSKY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 28, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ MARK L. KEIM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mark L. Keim</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. March&#160;31, 2022 Form 10-Q | 34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>moh1q22_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2324e343e113447c98e4f86263f6a001_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph M. Zubretsky, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended March&#160;31, 2022, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>moh1q22_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icd666c8c91144199a38e83d8b0e51a03_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark L. Keim, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended March&#160;31, 2022, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>moh1q22_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i14603e145ede455f8158adf67083f3e5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 (the &#8220;Report&#8221;), I, Joseph M. Zubretsky, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>moh1q22_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i96b9f38ef9a3420f88c59a247256f28e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022 (the &#8220;Report&#8221;), I, Mark L. Keim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>moh-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6096143c-bea0-4d64-8a46-ebe0e276f797,g:2f020790-0dbf-4089-8da8-8ebe5a4cb586-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:moh="http://www.molinahealthcare.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.molinahealthcare.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.molinahealthcare.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesReceivablesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails">
        <link:definition>2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails">
        <link:definition>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShare">
        <link:definition>2110103 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareTables">
        <link:definition>2311302 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareDetails" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails">
        <link:definition>2412406 - Disclosure - Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.molinahealthcare.com/role/BusinessCombinations">
        <link:definition>2113104 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsDetails" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsDetails">
        <link:definition>2414407 - Disclosure - Business Combinations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements">
        <link:definition>2115105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables">
        <link:definition>2316303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
        <link:definition>2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.molinahealthcare.com/role/Investments">
        <link:definition>2120106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.molinahealthcare.com/role/InvestmentsTables">
        <link:definition>2321304 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails">
        <link:definition>2422411 - Disclosure - Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails">
        <link:definition>2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails">
        <link:definition>2424413 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails">
        <link:definition>2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayable" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable">
        <link:definition>2126107 - Disclosure - Medical Claims and Benefits Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableTables" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables">
        <link:definition>2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails">
        <link:definition>2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.molinahealthcare.com/role/Debt">
        <link:definition>2131108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.molinahealthcare.com/role/DebtTables">
        <link:definition>2332306 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails">
        <link:definition>2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails">
        <link:definition>2434419 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.molinahealthcare.com/role/StockholdersEquity">
        <link:definition>2135109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityDetails">
        <link:definition>2436420 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.molinahealthcare.com/role/Segments">
        <link:definition>2137110 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.molinahealthcare.com/role/SegmentsTables">
        <link:definition>2338307 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails">
        <link:definition>2439421 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsScheduleofOperatingSegmentInformationDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails">
        <link:definition>2440422 - Disclosure - Segments - Schedule of Operating Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
        <link:definition>2441423 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies">
        <link:definition>2142111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" abstract="false" name="MedicalPremiumsLiabilityMedicalCareCostsThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableTextBlock" abstract="false" name="MedicalClaimsAndBenefitsPayableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MagellanCompleteCareMember" abstract="true" name="MagellanCompleteCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MarketplaceMember" abstract="true" name="MarketplaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" abstract="false" name="AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PharmacyRebateReceivablesMember" abstract="true" name="PharmacyRebateReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_OtherMedicareProgram" abstract="false" name="OtherMedicareProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" abstract="false" name="AmountsDuetoGovernmentAgenciesRiskAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" abstract="false" name="MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_WeightedAverageNumberofSharesShareBasedCompensation" abstract="false" name="WeightedAverageNumberofSharesShareBasedCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moh_GovernmentReceivablesMember" abstract="true" name="GovernmentReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" abstract="false" name="ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_InvestmentsAverageMaturityPeriod" abstract="false" name="InvestmentsAverageMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_ThreePointEightSevenFivePercentSeniorNotesMember" abstract="true" name="ThreePointEightSevenFivePercentSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayable" abstract="false" name="MedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherProgramMember" abstract="true" name="OtherProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidOther" abstract="false" name="AmountsDueToGovernmentAgenciesMedicaidOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_StructuredSecuritiesMember" abstract="true" name="StructuredSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_NumberOfReportableSegment" abstract="false" name="NumberOfReportableSegment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_HealthPlanContractTerm" abstract="false" name="HealthPlanContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_ComponentsOfMedicalCareCostsAbstract" abstract="true" name="ComponentsOfMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicalPremiumLiabilityDueToAgency" abstract="false" name="MedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlanExtensionOptionPeriod" abstract="false" name="HealthPlanExtensionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_OtherSecuritiesMember" abstract="true" name="OtherSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" abstract="false" name="NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_SharesOutstandingExcludingRestrictedStockAwards" abstract="false" name="SharesOutstandingExcludingRestrictedStockAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" abstract="false" name="LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PremiumTaxExpenses" abstract="false" name="PremiumTaxExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" abstract="false" name="LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_A4375SeniorNotesMember" abstract="true" name="A4375SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" abstract="false" name="IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MunicipalSecuritiesMember" abstract="true" name="MunicipalSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" abstract="false" name="BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_MemberListsMember" abstract="true" name="MemberListsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_AffinityHealthPlanIncMember" abstract="true" name="AffinityHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_InvestmentsMaturityPeriod" abstract="false" name="InvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_HealthCareOrganizationPremiumTaxRevenue" abstract="false" name="HealthCareOrganizationPremiumTaxRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CapitationClaimsPayable" abstract="false" name="CapitationClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PassportHealthPlanIncMember" abstract="true" name="PassportHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_HealthPlansMember" abstract="true" name="HealthPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_A3875SeniorNotesMember" abstract="true" name="A3875SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesOther" abstract="false" name="AmountsDuetoGovernmentAgenciesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicareProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_CommonStockWithheldToSettleEmployeeTaxObligations" abstract="false" name="CommonStockWithheldToSettleEmployeeTaxObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherClaimsPayable" abstract="false" name="OtherClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherReceivablesMember" abstract="true" name="OtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_PharmacyClaimsPayable" abstract="false" name="PharmacyClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>moh-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6096143c-bea0-4d64-8a46-ebe0e276f797,g:2f020790-0dbf-4089-8da8-8ebe5a4cb586-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_500a0483-6baf-4502-a090-38067fab5e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cc33da5d-ca63-4931-8dbb-283a8906a3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_500a0483-6baf-4502-a090-38067fab5e14" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cc33da5d-ca63-4931-8dbb-283a8906a3a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_344a0497-f585-4c14-bfc0-16882e4d7826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_500a0483-6baf-4502-a090-38067fab5e14" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_344a0497-f585-4c14-bfc0-16882e4d7826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_5a69d25e-55d8-4391-9984-7b61f1384ed3" xlink:href="moh-20220331.xsd#moh_PremiumTaxExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_500a0483-6baf-4502-a090-38067fab5e14" xlink:to="loc_moh_PremiumTaxExpenses_5a69d25e-55d8-4391-9984-7b61f1384ed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f340ab4d-cd72-4060-bcd5-9547a576c0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_500a0483-6baf-4502-a090-38067fab5e14" xlink:to="loc_us-gaap_DepreciationAndAmortization_f340ab4d-cd72-4060-bcd5-9547a576c0be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_fb383769-c358-4a22-8390-ebba3d1dfb71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_500a0483-6baf-4502-a090-38067fab5e14" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_fb383769-c358-4a22-8390-ebba3d1dfb71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_443f1e58-f224-4243-aef8-8f03588ff5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_99d4efcf-5ac0-4e8d-a660-59c87bda20ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_443f1e58-f224-4243-aef8-8f03588ff5cb" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_99d4efcf-5ac0-4e8d-a660-59c87bda20ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_c4a063b9-4bbe-49b0-9d46-eaa945cd41b2" xlink:href="moh-20220331.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_443f1e58-f224-4243-aef8-8f03588ff5cb" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_c4a063b9-4bbe-49b0-9d46-eaa945cd41b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_9e60b34f-81a5-4fde-b401-026377366688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_443f1e58-f224-4243-aef8-8f03588ff5cb" xlink:to="loc_us-gaap_NetInvestmentIncome_9e60b34f-81a5-4fde-b401-026377366688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_98c3667c-15e3-41f9-acfb-5a08b1b8fa64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_443f1e58-f224-4243-aef8-8f03588ff5cb" xlink:to="loc_us-gaap_PremiumsEarnedNet_98c3667c-15e3-41f9-acfb-5a08b1b8fa64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e5bdd71-09f2-4b65-9d66-4d9d0e5a5531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_194ae956-262f-4728-b0ae-64700110f8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5e5bdd71-09f2-4b65-9d66-4d9d0e5a5531" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_194ae956-262f-4728-b0ae-64700110f8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1d945852-8b81-42d6-84ca-da4b6272962d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5e5bdd71-09f2-4b65-9d66-4d9d0e5a5531" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1d945852-8b81-42d6-84ca-da4b6272962d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a2273992-0e12-41f2-8314-65efecec3e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7ba2039b-2fe8-4f9c-b32f-efca5ea3c721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a2273992-0e12-41f2-8314-65efecec3e28" xlink:to="loc_us-gaap_InterestExpense_7ba2039b-2fe8-4f9c-b32f-efca5ea3c721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f7787c3e-e28d-4433-9f6b-9eba73da36b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_88b0146a-7c0e-45d7-91fa-5124f50a12da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f7787c3e-e28d-4433-9f6b-9eba73da36b2" xlink:to="loc_us-gaap_Revenues_88b0146a-7c0e-45d7-91fa-5124f50a12da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8e0a32b6-88dd-465a-b3ec-9e181cb557ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f7787c3e-e28d-4433-9f6b-9eba73da36b2" xlink:to="loc_us-gaap_CostsAndExpenses_8e0a32b6-88dd-465a-b3ec-9e181cb557ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85dda2ba-9424-41a7-9891-3a38c51b3851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fae4fe05-d02c-45ad-9461-7fcbfb77f55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85dda2ba-9424-41a7-9891-3a38c51b3851" xlink:to="loc_us-gaap_OperatingIncomeLoss_fae4fe05-d02c-45ad-9461-7fcbfb77f55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d7ba781b-0069-4b38-aa8b-2a035fe09fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85dda2ba-9424-41a7-9891-3a38c51b3851" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d7ba781b-0069-4b38-aa8b-2a035fe09fab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d727b5a-770c-426d-8551-253cfa51ecf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e43047d6-31d0-4266-b711-a41146d3c130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d727b5a-770c-426d-8551-253cfa51ecf2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e43047d6-31d0-4266-b711-a41146d3c130" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e89fc543-736a-4d85-93ac-271015375f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d727b5a-770c-426d-8551-253cfa51ecf2" xlink:to="loc_us-gaap_NetIncomeLoss_e89fc543-736a-4d85-93ac-271015375f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c016c091-5403-466e-a51f-642a97d7f5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_60d60b39-854a-4e41-b6e5-8db1fb982afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c016c091-5403-466e-a51f-642a97d7f5cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_60d60b39-854a-4e41-b6e5-8db1fb982afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_048481a9-0c46-4144-b0e6-2b3e1b26008d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c016c091-5403-466e-a51f-642a97d7f5cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_048481a9-0c46-4144-b0e6-2b3e1b26008d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1a7b82b7-b17c-46bf-a2a0-cb26d4cfed92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_19b5c2ad-b638-4b8b-9bdc-b8c37cd0bb30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1a7b82b7-b17c-46bf-a2a0-cb26d4cfed92" xlink:to="loc_us-gaap_Liabilities_19b5c2ad-b638-4b8b-9bdc-b8c37cd0bb30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_703ba3b9-4bdd-4d74-ba81-cd757713a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1a7b82b7-b17c-46bf-a2a0-cb26d4cfed92" xlink:to="loc_us-gaap_StockholdersEquity_703ba3b9-4bdd-4d74-ba81-cd757713a91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_54cfd5c9-ce0b-4e99-9049-9883d287cfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b8d9a54c-77ba-4f3c-aaa4-7f904b861824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_54cfd5c9-ce0b-4e99-9049-9883d287cfc7" xlink:to="loc_us-gaap_LiabilitiesCurrent_b8d9a54c-77ba-4f3c-aaa4-7f904b861824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ce22dde0-ab6d-4b68-871b-f1b3e0602a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_54cfd5c9-ce0b-4e99-9049-9883d287cfc7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ce22dde0-ab6d-4b68-871b-f1b3e0602a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8a5ead5d-c218-4a9a-affd-4833a8962744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_54cfd5c9-ce0b-4e99-9049-9883d287cfc7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8a5ead5d-c218-4a9a-affd-4833a8962744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2a5204c0-8bd9-4d68-9b10-747cdd8cf6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_54cfd5c9-ce0b-4e99-9049-9883d287cfc7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2a5204c0-8bd9-4d68-9b10-747cdd8cf6a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_478378c3-2cb7-4f0c-90db-bc969895d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_15e8fac7-9481-4491-811f-08a8a03d374c" xlink:href="moh-20220331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_478378c3-2cb7-4f0c-90db-bc969895d18f" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_15e8fac7-9481-4491-811f-08a8a03d374c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_57c7e2f6-fa1a-4832-8736-b97c73b259d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_478378c3-2cb7-4f0c-90db-bc969895d18f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_57c7e2f6-fa1a-4832-8736-b97c73b259d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9619a4d1-b5b2-4016-806a-49a836f0cbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_478378c3-2cb7-4f0c-90db-bc969895d18f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9619a4d1-b5b2-4016-806a-49a836f0cbe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_074d8625-6e50-4b18-a905-bf65ee8cec0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_478378c3-2cb7-4f0c-90db-bc969895d18f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_074d8625-6e50-4b18-a905-bf65ee8cec0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_03576297-53cc-4a7c-9a46-62b8851a20a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_a8b01839-26c2-4885-b52d-6c081940aeca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03576297-53cc-4a7c-9a46-62b8851a20a5" xlink:to="loc_us-gaap_ReceivablesNetCurrent_a8b01839-26c2-4885-b52d-6c081940aeca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64262555-10ba-4d21-a2cc-0d11ab22b755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03576297-53cc-4a7c-9a46-62b8851a20a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64262555-10ba-4d21-a2cc-0d11ab22b755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_9a5c5708-a992-4051-aefc-275bcb8204aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03576297-53cc-4a7c-9a46-62b8851a20a5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_9a5c5708-a992-4051-aefc-275bcb8204aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_79903000-8f22-4445-9601-6bc6a513e6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03576297-53cc-4a7c-9a46-62b8851a20a5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_79903000-8f22-4445-9601-6bc6a513e6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2451b239-3f70-46e8-ba7f-6a68cf89a550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5c649cee-9953-4e82-88cf-3f23cf460945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2451b239-3f70-46e8-ba7f-6a68cf89a550" xlink:to="loc_us-gaap_AssetsCurrent_5c649cee-9953-4e82-88cf-3f23cf460945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8ccaa491-11fb-4d2a-b4e1-667382a0f227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2451b239-3f70-46e8-ba7f-6a68cf89a550" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8ccaa491-11fb-4d2a-b4e1-667382a0f227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_13f8ba08-1964-43c1-b225-f4eddd11b099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2451b239-3f70-46e8-ba7f-6a68cf89a550" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_13f8ba08-1964-43c1-b225-f4eddd11b099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_b2e0ea48-2d73-4781-b164-b350e8027a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2451b239-3f70-46e8-ba7f-6a68cf89a550" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_b2e0ea48-2d73-4781-b164-b350e8027a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_928f275e-f56b-4914-aad2-5e31455317f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2451b239-3f70-46e8-ba7f-6a68cf89a550" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_928f275e-f56b-4914-aad2-5e31455317f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b921954c-0fe6-4925-b758-3ff0b80721a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2451b239-3f70-46e8-ba7f-6a68cf89a550" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b921954c-0fe6-4925-b758-3ff0b80721a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a6deb910-185c-46a8-bcba-f997ef21fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_0e9ffdf8-a8a6-4b04-b8e1-c712b392c79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6deb910-185c-46a8-bcba-f997ef21fe43" xlink:to="loc_us-gaap_CommonStockValueOutstanding_0e9ffdf8-a8a6-4b04-b8e1-c712b392c79e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4192feca-3126-4e0e-9790-8f2a9c293818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6deb910-185c-46a8-bcba-f997ef21fe43" xlink:to="loc_us-gaap_PreferredStockValue_4192feca-3126-4e0e-9790-8f2a9c293818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8055f25c-bb61-4702-a96c-23c83276b442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6deb910-185c-46a8-bcba-f997ef21fe43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8055f25c-bb61-4702-a96c-23c83276b442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ab0c5bc-a1b2-4269-9be0-28854c317f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6deb910-185c-46a8-bcba-f997ef21fe43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ab0c5bc-a1b2-4269-9be0-28854c317f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_95ffec9a-4c5c-4b7b-8247-f542db7345b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a6deb910-185c-46a8-bcba-f997ef21fe43" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_95ffec9a-4c5c-4b7b-8247-f542db7345b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_733840ce-00d6-4d15-a651-9c29cfdfcac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_733840ce-00d6-4d15-a651-9c29cfdfcac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_af3b7a1a-e103-4dad-a557-a6e2bad2dab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_ShareBasedCompensation_af3b7a1a-e103-4dad-a557-a6e2bad2dab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_310a036c-ac43-44d5-9b8a-2337dda79826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_310a036c-ac43-44d5-9b8a-2337dda79826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_d75c07bd-a83e-46a5-be8a-4a371c4aa8f1" xlink:href="moh-20220331.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_d75c07bd-a83e-46a5-be8a-4a371c4aa8f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_cefb7d68-e62d-4c9b-81c4-641926f8ef94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_cefb7d68-e62d-4c9b-81c4-641926f8ef94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e671208-a09c-4daf-a8d8-c4eaa1611c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_NetIncomeLoss_7e671208-a09c-4daf-a8d8-c4eaa1611c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_9f0517a1-4fd8-443d-a328-76b0953f9efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_9f0517a1-4fd8-443d-a328-76b0953f9efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_fc50bbcf-b5aa-44f0-9a9e-bf70f02bd45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_fc50bbcf-b5aa-44f0-9a9e-bf70f02bd45d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f2d642db-7b7a-4a9c-bb5e-8671172dfcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f2d642db-7b7a-4a9c-bb5e-8671172dfcc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3644070c-1e87-483d-b3ad-22fbb24a2051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3644070c-1e87-483d-b3ad-22fbb24a2051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0437c19c-9133-445a-b965-afcdf8d35424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0437c19c-9133-445a-b965-afcdf8d35424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_595a9a7b-594a-4b47-ba77-7db3c6a7c0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1634b10-12a4-47af-9627-8ce7bb523ce9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_595a9a7b-594a-4b47-ba77-7db3c6a7c0a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_382d58d9-d53d-450f-a87c-19a9c7d90c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0cd41031-f93b-430a-aac4-dd9b379cd129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_382d58d9-d53d-450f-a87c-19a9c7d90c64" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0cd41031-f93b-430a-aac4-dd9b379cd129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c65b0f23-047b-4ab1-a7e3-044a8673649c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_382d58d9-d53d-450f-a87c-19a9c7d90c64" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c65b0f23-047b-4ab1-a7e3-044a8673649c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_883c081f-7f7f-4385-96ce-a04afa039aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_382d58d9-d53d-450f-a87c-19a9c7d90c64" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_883c081f-7f7f-4385-96ce-a04afa039aca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_afaa99fe-1a71-47f0-8a87-f0f3db832978" xlink:href="moh-20220331.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_382d58d9-d53d-450f-a87c-19a9c7d90c64" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_afaa99fe-1a71-47f0-8a87-f0f3db832978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e048d280-538b-4823-a1a7-85b41defb005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ec49038d-a0e7-4e59-98dd-02ab6f829fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e048d280-538b-4823-a1a7-85b41defb005" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ec49038d-a0e7-4e59-98dd-02ab6f829fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1948884f-7c4c-4bd1-90a3-3b452548a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e048d280-538b-4823-a1a7-85b41defb005" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1948884f-7c4c-4bd1-90a3-3b452548a1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0514359c-53bc-4374-b446-b805a89b846a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e048d280-538b-4823-a1a7-85b41defb005" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0514359c-53bc-4374-b446-b805a89b846a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9a2b040a-8568-459e-9a6e-2a46b4474c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e048d280-538b-4823-a1a7-85b41defb005" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9a2b040a-8568-459e-9a6e-2a46b4474c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eac8378e-04be-41f3-9b49-a6e745b4c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_222d8223-8038-40c8-b992-a9ac3d12791d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eac8378e-04be-41f3-9b49-a6e745b4c74e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_222d8223-8038-40c8-b992-a9ac3d12791d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2da29bba-7d7b-425a-84b0-71166d28a7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eac8378e-04be-41f3-9b49-a6e745b4c74e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2da29bba-7d7b-425a-84b0-71166d28a7a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d965d763-a588-4386-b420-2ed48c685e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eac8378e-04be-41f3-9b49-a6e745b4c74e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d965d763-a588-4386-b420-2ed48c685e83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d65d16e9-9458-40fa-b0ba-cd0b47273f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04874af0-c363-4272-abb0-5a3c12c816d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d65d16e9-9458-40fa-b0ba-cd0b47273f07" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04874af0-c363-4272-abb0-5a3c12c816d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_144c7a4f-e4a9-47f4-80de-194a992307cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d65d16e9-9458-40fa-b0ba-cd0b47273f07" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_144c7a4f-e4a9-47f4-80de-194a992307cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:href="moh-20220331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_13576f71-a927-4775-a0c2-ea53ac97c02e" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_13576f71-a927-4775-a0c2-ea53ac97c02e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_fd9e9a41-fad5-42bf-9681-06f20a73aec3" xlink:href="moh-20220331.xsd#moh_OtherMedicareProgram"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_OtherMedicareProgram_fd9e9a41-fad5-42bf-9681-06f20a73aec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_bb3dcb9d-b9bf-4069-9fdc-4bf272fc0e6b" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_bb3dcb9d-b9bf-4069-9fdc-4bf272fc0e6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_bb50a399-87f6-4a85-b489-daa5d55deeb3" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_bb50a399-87f6-4a85-b489-daa5d55deeb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_5d506244-1275-46d8-99d5-fa1ad9cf9d4f" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_5d506244-1275-46d8-99d5-fa1ad9cf9d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_921a7563-427b-497b-bd87-aab784d55054" xlink:href="moh-20220331.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_921a7563-427b-497b-bd87-aab784d55054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_49194cf0-7328-475c-8c9a-362ddef0c178" xlink:href="moh-20220331.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_49194cf0-7328-475c-8c9a-362ddef0c178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_cc14a659-dca5-4bd0-97b3-c2e472a087e2" xlink:href="moh-20220331.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_38396a61-16b6-49f9-8c30-3d443e1ea1e1" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_cc14a659-dca5-4bd0-97b3-c2e472a087e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#NetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0efd9d22-5077-4e90-bbe3-c252ad852e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e796b43f-3054-4e2b-a985-75e0d7c9f400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0efd9d22-5077-4e90-bbe3-c252ad852e30" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e796b43f-3054-4e2b-a985-75e0d7c9f400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_59493263-4848-4a50-9f6d-9f21b5739fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0efd9d22-5077-4e90-bbe3-c252ad852e30" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_59493263-4848-4a50-9f6d-9f21b5739fa2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_be846c9f-1d7d-4342-a19e-9a17af3432f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ef085f34-e3b8-4561-9357-866e93ada04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_be846c9f-1d7d-4342-a19e-9a17af3432f8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ef085f34-e3b8-4561-9357-866e93ada04f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ab496373-4c2e-4607-b2eb-b332d3504b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b066cb63-1ac9-47d7-8a0f-15df6a47aac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ab496373-4c2e-4607-b2eb-b332d3504b1e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b066cb63-1ac9-47d7-8a0f-15df6a47aac2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_bff42f65-7181-410d-a098-895e00955064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed3060c3-b25f-4770-9186-8a791953dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_bff42f65-7181-410d-a098-895e00955064" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed3060c3-b25f-4770-9186-8a791953dd5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_022fd0eb-31ab-4be4-a7c0-9ea7afe76e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_bff42f65-7181-410d-a098-895e00955064" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_022fd0eb-31ab-4be4-a7c0-9ea7afe76e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da62e4a0-e717-4e85-8be5-9212919c789b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_bff42f65-7181-410d-a098-895e00955064" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da62e4a0-e717-4e85-8be5-9212919c789b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4caaf23e-7807-4f1b-a33d-00a834490914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f4704f5f-31ea-4957-9613-4830d63ffa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4caaf23e-7807-4f1b-a33d-00a834490914" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f4704f5f-31ea-4957-9613-4830d63ffa8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a707df0f-b15c-4639-9f5e-a82c3b0173e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4caaf23e-7807-4f1b-a33d-00a834490914" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_a707df0f-b15c-4639-9f5e-a82c3b0173e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_0c982508-c9a5-46ed-bfff-1993d0df5c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4caaf23e-7807-4f1b-a33d-00a834490914" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_0c982508-c9a5-46ed-bfff-1993d0df5c26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_036aa4e0-fd73-489f-8c61-ce5d3e784cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4caaf23e-7807-4f1b-a33d-00a834490914" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_036aa4e0-fd73-489f-8c61-ce5d3e784cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4bcc8514-8d9c-47b3-9c5b-6cd9b413b65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d6400114-4594-409b-adb0-01358f26edb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4bcc8514-8d9c-47b3-9c5b-6cd9b413b65e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d6400114-4594-409b-adb0-01358f26edb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_755875b6-0c08-4224-aef0-4ff76b302c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4bcc8514-8d9c-47b3-9c5b-6cd9b413b65e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_755875b6-0c08-4224-aef0-4ff76b302c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4b249bc3-ba79-4361-9594-cf6126c1e7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4bcc8514-8d9c-47b3-9c5b-6cd9b413b65e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4b249bc3-ba79-4361-9594-cf6126c1e7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_38e1be04-93f9-4b95-b3bf-22041042f428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4bcc8514-8d9c-47b3-9c5b-6cd9b413b65e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_38e1be04-93f9-4b95-b3bf-22041042f428" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a1216905-6208-484b-b1a0-796965b2f3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_eb4c71f6-25d3-4cb8-9eae-5e49b70c4e58" xlink:href="moh-20220331.xsd#moh_CapitationClaimsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a1216905-6208-484b-b1a0-796965b2f3ae" xlink:to="loc_moh_CapitationClaimsPayable_eb4c71f6-25d3-4cb8-9eae-5e49b70c4e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_76505a68-6460-4e3c-b8a7-33625fcf1426" xlink:href="moh-20220331.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a1216905-6208-484b-b1a0-796965b2f3ae" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_76505a68-6460-4e3c-b8a7-33625fcf1426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_a20175ae-2ed3-4c0c-bb02-a20641d0581f" xlink:href="moh-20220331.xsd#moh_PharmacyClaimsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a1216905-6208-484b-b1a0-796965b2f3ae" xlink:to="loc_moh_PharmacyClaimsPayable_a20175ae-2ed3-4c0c-bb02-a20641d0581f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_b9f4a7f8-f0d9-4c19-b808-58bf68dad464" xlink:href="moh-20220331.xsd#moh_OtherClaimsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a1216905-6208-484b-b1a0-796965b2f3ae" xlink:to="loc_moh_OtherClaimsPayable_b9f4a7f8-f0d9-4c19-b808-58bf68dad464" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2d179384-6b0e-4b06-9a7a-486c564b479d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_d9985e1a-4c3b-4fb8-b6fe-94c1f34d05d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2d179384-6b0e-4b06-9a7a-486c564b479d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_d9985e1a-4c3b-4fb8-b6fe-94c1f34d05d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_53c857cb-2c92-4482-91ce-db8aaeaf9ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2d179384-6b0e-4b06-9a7a-486c564b479d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_53c857cb-2c92-4482-91ce-db8aaeaf9ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_a46e8130-d36f-4dd7-8597-13ac89e57bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_ee98c51b-7da5-4aab-b392-b3ae7f1ed252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_a46e8130-d36f-4dd7-8597-13ac89e57bf3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_ee98c51b-7da5-4aab-b392-b3ae7f1ed252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b64f860b-35be-4c05-9b20-035409aef4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_a46e8130-d36f-4dd7-8597-13ac89e57bf3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b64f860b-35be-4c05-9b20-035409aef4ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1f3ee94f-097f-4d1d-95b7-ecffdf7302e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_23f68699-3b27-4724-9b7c-822b4e814b59" xlink:href="moh-20220331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1f3ee94f-097f-4d1d-95b7-ecffdf7302e9" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_23f68699-3b27-4724-9b7c-822b4e814b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_55671d78-6f6e-47ba-977d-6699f5cba812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_1f3ee94f-097f-4d1d-95b7-ecffdf7302e9" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_55671d78-6f6e-47ba-977d-6699f5cba812" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>moh-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6096143c-bea0-4d64-8a46-ebe0e276f797,g:2f020790-0dbf-4089-8da8-8ebe5a4cb586-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i3e4502d7724343c583848bafcc19bfb9_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c893ed6d-ed6c-4537-8c39-222d3c6a5f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c893ed6d-ed6c-4537-8c39-222d3c6a5f74" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_74b25c20-8c9d-4c36-bbb0-512c370451c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_SharesOutstanding_74b25c20-8c9d-4c36-bbb0-512c370451c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b3d5ab17-cda4-4afa-8ab4-dbc5c88f9119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockholdersEquity_b3d5ab17-cda4-4afa-8ab4-dbc5c88f9119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38a6f2cf-9564-43e9-b337-c4c7d7ea92ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_NetIncomeLoss_38a6f2cf-9564-43e9-b337-c4c7d7ea92ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee937006-f42b-4db6-8413-58e0bc3eb1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee937006-f42b-4db6-8413-58e0bc3eb1f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_42c222dc-2247-45ad-a635-36e4f586215a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_42c222dc-2247-45ad-a635-36e4f586215a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_9d905424-120e-4f34-965c-26e1aa4f0604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_9d905424-120e-4f34-965c-26e1aa4f0604" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88659662-167c-4abf-85f4-5aa7efdbd3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88659662-167c-4abf-85f4-5aa7efdbd3e7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_efd5eacb-3c2c-43df-8f48-ffaec5c0bb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_efd5eacb-3c2c-43df-8f48-ffaec5c0bb6e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_773f3bd0-9854-4dca-9d23-905a1eb9f6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ddf29092-e18d-41f8-b693-7fb91b33f0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0cd41da1-5171-478c-a7f4-cb8bcb92d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c893ed6d-ed6c-4537-8c39-222d3c6a5f74" xlink:to="loc_us-gaap_StatementTable_0cd41da1-5171-478c-a7f4-cb8bcb92d5d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8be05066-b7a1-4099-8bf5-a0b52298217a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0cd41da1-5171-478c-a7f4-cb8bcb92d5d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8be05066-b7a1-4099-8bf5-a0b52298217a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8be05066-b7a1-4099-8bf5-a0b52298217a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8be05066-b7a1-4099-8bf5-a0b52298217a" xlink:to="loc_us-gaap_EquityComponentDomain_8be05066-b7a1-4099-8bf5-a0b52298217a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8be05066-b7a1-4099-8bf5-a0b52298217a" xlink:to="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f192906d-e24b-42d1-95a0-bbc8a3f51dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_CommonStockMember_f192906d-e24b-42d1-95a0-bbc8a3f51dfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b0c12295-0f19-4fb3-9b29-7a63916a3a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b0c12295-0f19-4fb3-9b29-7a63916a3a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fe3dedc8-3760-4857-8d06-72932fd7f39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fe3dedc8-3760-4857-8d06-72932fd7f39f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_45e1ceb2-822f-48d1-bd02-3f07e57a34be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_RetainedEarningsMember_45e1ceb2-822f-48d1-bd02-3f07e57a34be" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="i92ae3d3bb8754c40ae91b10aa1758bf3_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfReportableSegment_56b1885a-e4fb-4d08-887e-b78435509a40" xlink:href="moh-20220331.xsd#moh_NumberOfReportableSegment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_NumberOfReportableSegment_56b1885a-e4fb-4d08-887e-b78435509a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_6410f212-3d48-430b-ae40-fea28d6b8ca7" xlink:href="moh-20220331.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_6410f212-3d48-430b-ae40-fea28d6b8ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_c5fc8e25-9d41-4b5f-8e1d-f26435a221e8" xlink:href="moh-20220331.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_c5fc8e25-9d41-4b5f-8e1d-f26435a221e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_3860d471-910a-45e7-bcea-30e1033a2973" xlink:href="moh-20220331.xsd#moh_HealthPlanContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_HealthPlanContractTerm_3860d471-910a-45e7-bcea-30e1033a2973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod_eb2f8646-3e23-4e1b-bba5-c5f67899fd4a" xlink:href="moh-20220331.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_HealthPlanExtensionOptionPeriod_eb2f8646-3e23-4e1b-bba5-c5f67899fd4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e" xlink:to="loc_us-gaap_SegmentDomain_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c89f01f7-52fd-44ab-9ce8-faf97bd605ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e" xlink:to="loc_us-gaap_SegmentDomain_c89f01f7-52fd-44ab-9ce8-faf97bd605ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_a115c387-1dbb-4824-958d-4bb11e0c7d3f" xlink:href="moh-20220331.xsd#moh_HealthPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c89f01f7-52fd-44ab-9ce8-faf97bd605ce" xlink:to="loc_moh_HealthPlansMember_a115c387-1dbb-4824-958d-4bb11e0c7d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_09a0c88d-be98-4f0b-b9a6-bb71a49d894d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:to="loc_srt_RangeAxis_09a0c88d-be98-4f0b-b9a6-bb71a49d894d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09a0c88d-be98-4f0b-b9a6-bb71a49d894d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_09a0c88d-be98-4f0b-b9a6-bb71a49d894d" xlink:to="loc_srt_RangeMember_09a0c88d-be98-4f0b-b9a6-bb71a49d894d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_09a0c88d-be98-4f0b-b9a6-bb71a49d894d" xlink:to="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea9b2ad2-b656-48c5-8246-c444822ba1a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:to="loc_srt_MinimumMember_ea9b2ad2-b656-48c5-8246-c444822ba1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1a8e2d8-a0e9-405a-8f47-158d8fe44f6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:to="loc_srt_MaximumMember_d1a8e2d8-a0e9-405a-8f47-158d8fe44f6f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended" id="i1e94f111234f4067b07759c126cd2e53_SignificantAccountingPoliciesReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cd1ed4d6-71ce-4b53-899c-77a2d88e426d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8cec37d4-8035-40e0-ae15-8bf2c10924c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cd1ed4d6-71ce-4b53-899c-77a2d88e426d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8cec37d4-8035-40e0-ae15-8bf2c10924c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a334c5bf-75d1-4ad4-a8e6-1e99c08bfaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cd1ed4d6-71ce-4b53-899c-77a2d88e426d" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a334c5bf-75d1-4ad4-a8e6-1e99c08bfaec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1be773a1-a455-41bd-b2a7-e6a9db00fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a334c5bf-75d1-4ad4-a8e6-1e99c08bfaec" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1be773a1-a455-41bd-b2a7-e6a9db00fa0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1be773a1-a455-41bd-b2a7-e6a9db00fa0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1be773a1-a455-41bd-b2a7-e6a9db00fa0a" xlink:to="loc_us-gaap_ReceivableTypeDomain_1be773a1-a455-41bd-b2a7-e6a9db00fa0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1be773a1-a455-41bd-b2a7-e6a9db00fa0a" xlink:to="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_735084ef-640b-4992-b692-03690c9775cb" xlink:href="moh-20220331.xsd#moh_GovernmentReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:to="loc_moh_GovernmentReceivablesMember_735084ef-640b-4992-b692-03690c9775cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_3bd136ca-3cca-4acb-af73-d81e6513a2c1" xlink:href="moh-20220331.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:to="loc_moh_PharmacyRebateReceivablesMember_3bd136ca-3cca-4acb-af73-d81e6513a2c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_52115bb8-da00-457b-adc8-8dade18a3a4c" xlink:href="moh-20220331.xsd#moh_OtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:to="loc_moh_OtherReceivablesMember_52115bb8-da00-457b-adc8-8dade18a3a4c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="if421baae9a1245a8b3c1c049a3342569_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:href="moh-20220331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc241142-4a8e-497b-ba0f-2250033f9877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc241142-4a8e-497b-ba0f-2250033f9877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_b3a85470-34ae-4c10-9a61-f52f3ba1e872" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_b3a85470-34ae-4c10-9a61-f52f3ba1e872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_2e0c2867-f15c-4a5a-8725-226e290f3c2b" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_2e0c2867-f15c-4a5a-8725-226e290f3c2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_81319309-8247-472d-bb5e-31b236fefdc8" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_81319309-8247-472d-bb5e-31b236fefdc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_72c4ab39-47fc-4a15-98f4-341cd69c0924" xlink:href="moh-20220331.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_InvestmentsMaturityPeriod_72c4ab39-47fc-4a15-98f4-341cd69c0924" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_75da8e59-cf8f-49bf-9d3b-d906dcf62239" xlink:href="moh-20220331.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_75da8e59-cf8f-49bf-9d3b-d906dcf62239" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:href="moh-20220331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_38f834fa-d75c-459c-9995-f095c626a2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_38f834fa-d75c-459c-9995-f095c626a2e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_38f834fa-d75c-459c-9995-f095c626a2e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_38f834fa-d75c-459c-9995-f095c626a2e3" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_38f834fa-d75c-459c-9995-f095c626a2e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_ebd9cda5-e683-46ba-8740-d7bf014388aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_38f834fa-d75c-459c-9995-f095c626a2e3" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_ebd9cda5-e683-46ba-8740-d7bf014388aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_291d445a-c683-4a7e-8b04-595171ec5eb8" xlink:href="moh-20220331.xsd#moh_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_ebd9cda5-e683-46ba-8740-d7bf014388aa" xlink:to="loc_moh_COVID19Member_291d445a-c683-4a7e-8b04-595171ec5eb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c046a5b0-f9f3-4506-950e-4b7a34588183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c046a5b0-f9f3-4506-950e-4b7a34588183" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c046a5b0-f9f3-4506-950e-4b7a34588183_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c046a5b0-f9f3-4506-950e-4b7a34588183" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c046a5b0-f9f3-4506-950e-4b7a34588183_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e9b283-79f6-4952-a05b-4e99a33bc054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c046a5b0-f9f3-4506-950e-4b7a34588183" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e9b283-79f6-4952-a05b-4e99a33bc054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember_41b3bc98-a5ad-4d78-ae72-340c1c22940f" xlink:href="moh-20220331.xsd#moh_StructuredSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e9b283-79f6-4952-a05b-4e99a33bc054" xlink:to="loc_moh_StructuredSecuritiesMember_41b3bc98-a5ad-4d78-ae72-340c1c22940f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#BusinessCombinationsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="extended" id="ia9346dae95bf41a5ad0370ea1e2d1fa7_BusinessCombinationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3fd76e73-56a0-4220-a618-6f5cf7c05efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3fd76e73-56a0-4220-a618-6f5cf7c05efc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_392b9235-d918-4557-b432-55e9416b89f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_392b9235-d918-4557-b432-55e9416b89f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1cb3fdc1-eb56-4554-a684-ea42c536d298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1cb3fdc1-eb56-4554-a684-ea42c536d298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_7a1e5251-4747-49c2-900e-7afd08ef8b74" xlink:href="moh-20220331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_7a1e5251-4747-49c2-900e-7afd08ef8b74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_a8f27695-9cb9-4fd8-8023-f2624157cb7b" xlink:href="moh-20220331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_a8f27695-9cb9-4fd8-8023-f2624157cb7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_121a7595-dfb2-449d-bdd5-cbb88089e57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_121a7595-dfb2-449d-bdd5-cbb88089e57e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_121a7595-dfb2-449d-bdd5-cbb88089e57e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_121a7595-dfb2-449d-bdd5-cbb88089e57e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_121a7595-dfb2-449d-bdd5-cbb88089e57e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_121a7595-dfb2-449d-bdd5-cbb88089e57e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_33871604-8931-4bb8-ae4b-f90b58eb3650" xlink:href="moh-20220331.xsd#moh_MagellanCompleteCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:to="loc_moh_MagellanCompleteCareMember_33871604-8931-4bb8-ae4b-f90b58eb3650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember_2c6090c6-05ea-4051-8140-298ea183c38a" xlink:href="moh-20220331.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:to="loc_moh_AffinityHealthPlanIncMember_2c6090c6-05ea-4051-8140-298ea183c38a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15391204-4e85-4d7b-99cd-c21a499b845b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15391204-4e85-4d7b-99cd-c21a499b845b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15391204-4e85-4d7b-99cd-c21a499b845b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15391204-4e85-4d7b-99cd-c21a499b845b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15391204-4e85-4d7b-99cd-c21a499b845b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62ffff9d-6d7f-4de1-9cf0-025819305cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15391204-4e85-4d7b-99cd-c21a499b845b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62ffff9d-6d7f-4de1-9cf0-025819305cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember_9e235e05-f765-48d2-a24f-e4d2288dba46" xlink:href="moh-20220331.xsd#moh_MemberListsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62ffff9d-6d7f-4de1-9cf0-025819305cef" xlink:to="loc_moh_MemberListsMember_9e235e05-f765-48d2-a24f-e4d2288dba46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended" id="i014ce92e6589450eb8094dbef1fdcd0d_FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7daf6939-d994-49b7-be6d-0bed2cae54cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7daf6939-d994-49b7-be6d-0bed2cae54cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_050e6815-c0ea-4f6e-a043-a733f1dd8f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_050e6815-c0ea-4f6e-a043-a733f1dd8f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bacf2f7-4322-4ebc-93af-f07c8d8292bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bacf2f7-4322-4ebc-93af-f07c8d8292bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b21c74c7-9eb4-473e-b840-92f762cf3939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b21c74c7-9eb4-473e-b840-92f762cf3939" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64e6d298-8aa5-422f-a8bc-bf0724d46b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64e6d298-8aa5-422f-a8bc-bf0724d46b29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64e6d298-8aa5-422f-a8bc-bf0724d46b29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64e6d298-8aa5-422f-a8bc-bf0724d46b29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64e6d298-8aa5-422f-a8bc-bf0724d46b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64e6d298-8aa5-422f-a8bc-bf0724d46b29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d93d2fc-c922-4aee-a91d-88707fa11072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d93d2fc-c922-4aee-a91d-88707fa11072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_64100153-fb1c-4e2b-850b-38d4231fe222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_64100153-fb1c-4e2b-850b-38d4231fe222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_48b13798-6f2f-4ea1-8125-7b5c7871caaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_48b13798-6f2f-4ea1-8125-7b5c7871caaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9929ebc0-8c7f-484e-bbd8-22c38de08595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9929ebc0-8c7f-484e-bbd8-22c38de08595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9929ebc0-8c7f-484e-bbd8-22c38de08595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9929ebc0-8c7f-484e-bbd8-22c38de08595" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9929ebc0-8c7f-484e-bbd8-22c38de08595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9929ebc0-8c7f-484e-bbd8-22c38de08595" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5bbb5be1-28c0-44b9-92b2-05be5ead7a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5bbb5be1-28c0-44b9-92b2-05be5ead7a5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_30973455-0ec7-466e-8b5e-5bb3551816e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_30973455-0ec7-466e-8b5e-5bb3551816e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_abf8ab0b-b717-42a9-9a31-587be166d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_abf8ab0b-b717-42a9-9a31-587be166d9f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_6b089e42-7dad-4860-89fd-618e35894f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_6b089e42-7dad-4860-89fd-618e35894f84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_7a7ee6cf-dc04-4ff0-b6b9-fb8a967235ce" xlink:href="moh-20220331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_moh_MunicipalSecuritiesMember_7a7ee6cf-dc04-4ff0-b6b9-fb8a967235ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_7ab9d358-bd82-4b82-8f9e-25afe53c5f6c" xlink:href="moh-20220331.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_moh_OtherSecuritiesMember_7ab9d358-bd82-4b82-8f9e-25afe53c5f6c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i23267303ee09413d8fdede6122cf4be0_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_6fd47123-962b-4af0-a2c7-c5cbe9ae4f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_6fd47123-962b-4af0-a2c7-c5cbe9ae4f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ca4b5fe-34b3-4553-a87d-2b977cf01048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ca4b5fe-34b3-4553-a87d-2b977cf01048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d6c393ab-872b-4bb6-a807-894f5efd3bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d6c393ab-872b-4bb6-a807-894f5efd3bce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_b324fce9-7a42-4c89-9ceb-c3d2650468e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_b324fce9-7a42-4c89-9ceb-c3d2650468e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_557477fb-a942-457f-ab74-4681e140aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_557477fb-a942-457f-ab74-4681e140aa69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4502a75-2c0f-46ea-af82-54bd16129a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4502a75-2c0f-46ea-af82-54bd16129a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4502a75-2c0f-46ea-af82-54bd16129a48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4502a75-2c0f-46ea-af82-54bd16129a48" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4502a75-2c0f-46ea-af82-54bd16129a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fbad156-eafb-4a9a-8663-d6cc598c20c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4502a75-2c0f-46ea-af82-54bd16129a48" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fbad156-eafb-4a9a-8663-d6cc598c20c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_147428c7-40c9-4dfe-bd2e-8adf65819010" xlink:href="moh-20220331.xsd#moh_PassportHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fbad156-eafb-4a9a-8663-d6cc598c20c0" xlink:to="loc_moh_PassportHealthPlanIncMember_147428c7-40c9-4dfe-bd2e-8adf65819010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da994eb8-f5ca-453f-b49a-9899b764c707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da994eb8-f5ca-453f-b49a-9899b764c707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da994eb8-f5ca-453f-b49a-9899b764c707_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da994eb8-f5ca-453f-b49a-9899b764c707" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da994eb8-f5ca-453f-b49a-9899b764c707_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c596e2-064e-45a6-a92f-109095252a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da994eb8-f5ca-453f-b49a-9899b764c707" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c596e2-064e-45a6-a92f-109095252a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_08f89eb9-a32e-4c89-852d-3c591d1f949b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c596e2-064e-45a6-a92f-109095252a26" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_08f89eb9-a32e-4c89-852d-3c591d1f949b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended" id="i6a286cf3f1584d71a68c85f1a74d9a77_FairValueMeasurementsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12fbcb77-4f9e-451c-91eb-a2d4db1e4318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12fbcb77-4f9e-451c-91eb-a2d4db1e4318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1868723d-6670-474c-b9c6-40225b6b39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1868723d-6670-474c-b9c6-40225b6b39e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0f853ce-338b-4fae-b585-68f131c3f444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0f853ce-338b-4fae-b585-68f131c3f444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_40594ccc-451b-44b3-ae79-a1d4e4a3abbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c0f853ce-338b-4fae-b585-68f131c3f444" xlink:to="loc_us-gaap_SeniorNotesMember_40594ccc-451b-44b3-ae79-a1d4e4a3abbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eb873a24-9551-4d1c-b566-27ea8c1924a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:to="loc_us-gaap_DebtInstrumentAxis_eb873a24-9551-4d1c-b566-27ea8c1924a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eb873a24-9551-4d1c-b566-27ea8c1924a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb873a24-9551-4d1c-b566-27ea8c1924a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eb873a24-9551-4d1c-b566-27ea8c1924a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb873a24-9551-4d1c-b566-27ea8c1924a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_25862a30-d165-4558-8d6a-4462ffcc7f5a" xlink:href="moh-20220331.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:to="loc_moh_A4375SeniorNotesMember_25862a30-d165-4558-8d6a-4462ffcc7f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_dc4b433e-6302-4268-8ac7-c4f2a217e703" xlink:href="moh-20220331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_dc4b433e-6302-4268-8ac7-c4f2a217e703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_55375d0d-74c0-4d5e-a6fa-318b14f5f549" xlink:href="moh-20220331.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:to="loc_moh_A3875SeniorNotesMember_55375d0d-74c0-4d5e-a6fa-318b14f5f549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_790f53d4-09cd-4067-a13e-9d8894b9aeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_790f53d4-09cd-4067-a13e-9d8894b9aeb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_790f53d4-09cd-4067-a13e-9d8894b9aeb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_790f53d4-09cd-4067-a13e-9d8894b9aeb2" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_790f53d4-09cd-4067-a13e-9d8894b9aeb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_790f53d4-09cd-4067-a13e-9d8894b9aeb2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6708b80-17fd-42ee-b747-bab1e0fdcfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6708b80-17fd-42ee-b747-bab1e0fdcfe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b15a4ae1-e771-43d8-8518-5a55805be004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b15a4ae1-e771-43d8-8518-5a55805be004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f9532cb4-1ddc-45be-9ab6-7c7033adc811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f9532cb4-1ddc-45be-9ab6-7c7033adc811" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended" id="i4303189ac34f43398ff87ff33d5b46c5_InvestmentsSummaryofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b0eec8a7-2428-4947-9a58-3ddb83dd718e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b0eec8a7-2428-4947-9a58-3ddb83dd718e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_957b511e-d354-422e-890f-8e630a62fd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_957b511e-d354-422e-890f-8e630a62fd92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58a4d5c4-4ff7-46aa-8905-618cd631afb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58a4d5c4-4ff7-46aa-8905-618cd631afb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_80dc452f-1cb3-49a2-ac7f-a01a11abfb38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_80dc452f-1cb3-49a2-ac7f-a01a11abfb38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_68b1e044-95ee-4fce-9c0f-f460ef6f45d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_68b1e044-95ee-4fce-9c0f-f460ef6f45d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_450059ea-3a42-408a-a194-b0fc153336f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_68b1e044-95ee-4fce-9c0f-f460ef6f45d0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_450059ea-3a42-408a-a194-b0fc153336f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_450059ea-3a42-408a-a194-b0fc153336f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_450059ea-3a42-408a-a194-b0fc153336f3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_450059ea-3a42-408a-a194-b0fc153336f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_450059ea-3a42-408a-a194-b0fc153336f3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b20a9430-7e5f-4811-b838-7bd7b2169238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b20a9430-7e5f-4811-b838-7bd7b2169238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_d2d7b8ec-becc-4872-b641-bec0ba159faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_d2d7b8ec-becc-4872-b641-bec0ba159faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6a872809-bcf4-420d-8647-64e5433e2ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6a872809-bcf4-420d-8647-64e5433e2ca4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_04970bb8-972c-41b5-a8d1-d1778f0dbeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_04970bb8-972c-41b5-a8d1-d1778f0dbeb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_3d723a52-73ce-4f23-8df0-e1f7a169172b" xlink:href="moh-20220331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_moh_MunicipalSecuritiesMember_3d723a52-73ce-4f23-8df0-e1f7a169172b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_ef318868-5e1f-44cc-83a8-4a3dfa3428a5" xlink:href="moh-20220331.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_moh_OtherSecuritiesMember_ef318868-5e1f-44cc-83a8-4a3dfa3428a5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended" id="icd89d6ef35e347baa6b1075477475334_InvestmentsAvailableforSaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8a1e5c56-04f2-49ee-80f6-34088d891150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8a1e5c56-04f2-49ee-80f6-34088d891150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7952540e-dca7-4e47-9c5a-117868d03745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7952540e-dca7-4e47-9c5a-117868d03745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_4dc6bdc9-95ff-4199-b51b-75dd4440aea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_4dc6bdc9-95ff-4199-b51b-75dd4440aea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2bd1b160-8a49-4f77-b66a-64a8e123290f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2bd1b160-8a49-4f77-b66a-64a8e123290f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0f655f66-e568-4b85-8ca9-fb654e762be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2bd1b160-8a49-4f77-b66a-64a8e123290f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0f655f66-e568-4b85-8ca9-fb654e762be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f655f66-e568-4b85-8ca9-fb654e762be6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0f655f66-e568-4b85-8ca9-fb654e762be6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f655f66-e568-4b85-8ca9-fb654e762be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0f655f66-e568-4b85-8ca9-fb654e762be6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c3aa5045-a41c-4a2f-afc3-689dd8e3b979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c3aa5045-a41c-4a2f-afc3-689dd8e3b979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_191c7e26-4e95-47de-9139-682f80e826fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_191c7e26-4e95-47de-9139-682f80e826fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_0ab4fb5f-e972-4f76-adef-04d268599e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_0ab4fb5f-e972-4f76-adef-04d268599e22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_ee1c55ad-fbb0-4362-8a56-44d5ee4497cc" xlink:href="moh-20220331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_moh_MunicipalSecuritiesMember_ee1c55ad-fbb0-4362-8a56-44d5ee4497cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_031a73c3-4501-4e60-a0f6-b9fa10ab0c1f" xlink:href="moh-20220331.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_moh_OtherSecuritiesMember_031a73c3-4501-4e60-a0f6-b9fa10ab0c1f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended" id="ifcd1e2d9419b4ba880d51b75546a2f52_MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d2bf663b-e798-4235-b576-b07d350fbd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d2bf663b-e798-4235-b576-b07d350fbd15" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b60bd3d-86fd-48a2-b97c-a2dc66d69bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b60bd3d-86fd-48a2-b97c-a2dc66d69bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:href="moh-20220331.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_6d05b6fb-f639-4228-897c-08fcc72deac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_6d05b6fb-f639-4228-897c-08fcc72deac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0122dd66-103d-47e9-a543-6eddeb0b2ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0122dd66-103d-47e9-a543-6eddeb0b2ac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c21d46f7-b2e7-4bb4-8c32-12dbd098d25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c21d46f7-b2e7-4bb4-8c32-12dbd098d25a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:href="moh-20220331.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_130c063b-aeb8-4cdf-acdc-93a2ee816fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_130c063b-aeb8-4cdf-acdc-93a2ee816fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_79b57468-f7af-4187-8a53-7238d70980e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_79b57468-f7af-4187-8a53-7238d70980e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_3ca5e853-5229-48bf-99ed-01a6e2c876fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_3ca5e853-5229-48bf-99ed-01a6e2c876fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_f99bebca-c0a5-4e2e-ad7f-59d7aecfa4a7" xlink:href="moh-20220331.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_f99bebca-c0a5-4e2e-ad7f-59d7aecfa4a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_eed79b48-83a2-442f-95e2-5f5f6a7a12a4" xlink:href="moh-20220331.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_eed79b48-83a2-442f-95e2-5f5f6a7a12a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b7d8c7f7-512a-469f-9ca7-45755e251b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_542f6ada-69ab-4c5e-8f56-bab04254c616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d2bf663b-e798-4235-b576-b07d350fbd15" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_542f6ada-69ab-4c5e-8f56-bab04254c616" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_619a27f7-f381-4e8e-a3a3-b393c2619706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_542f6ada-69ab-4c5e-8f56-bab04254c616" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_619a27f7-f381-4e8e-a3a3-b393c2619706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_619a27f7-f381-4e8e-a3a3-b393c2619706_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_619a27f7-f381-4e8e-a3a3-b393c2619706" xlink:to="loc_us-gaap_SegmentDomain_619a27f7-f381-4e8e-a3a3-b393c2619706_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_619a27f7-f381-4e8e-a3a3-b393c2619706" xlink:to="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_902570b4-63dc-4ea6-b01a-374a3c512cd0" xlink:href="moh-20220331.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:to="loc_moh_MedicaidMember_902570b4-63dc-4ea6-b01a-374a3c512cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_a6dd1efc-af3a-42ce-bbfb-8b7f132ed1b8" xlink:href="moh-20220331.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:to="loc_moh_MedicareMember_a6dd1efc-af3a-42ce-bbfb-8b7f132ed1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_8596ff87-6eea-4224-8a99-3af09e6839ce" xlink:href="moh-20220331.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:to="loc_moh_MarketplaceMember_8596ff87-6eea-4224-8a99-3af09e6839ce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended" id="i5ac4434885f346f599ca76654b5143eb_DebtScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f003678d-c3e0-4cc7-b9bf-f698a4540abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f003678d-c3e0-4cc7-b9bf-f698a4540abc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_253a0e7c-f756-40fa-9f5a-137136187313" xlink:href="moh-20220331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_253a0e7c-f756-40fa-9f5a-137136187313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_dd230785-3c1a-46a3-beae-00bb3393dad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_dd230785-3c1a-46a3-beae-00bb3393dad7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e88c4176-dadb-4f1c-a66d-e9e541b8026b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e88c4176-dadb-4f1c-a66d-e9e541b8026b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_497e1753-da97-4d00-9e49-377bc29bff0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_497e1753-da97-4d00-9e49-377bc29bff0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_497e1753-da97-4d00-9e49-377bc29bff0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_497e1753-da97-4d00-9e49-377bc29bff0f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_497e1753-da97-4d00-9e49-377bc29bff0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_042ed156-fece-41b1-9951-bf73e4960269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_497e1753-da97-4d00-9e49-377bc29bff0f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_042ed156-fece-41b1-9951-bf73e4960269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3f098a89-9ece-4148-9180-63c3ba47928b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_042ed156-fece-41b1-9951-bf73e4960269" xlink:to="loc_us-gaap_SeniorNotesMember_3f098a89-9ece-4148-9180-63c3ba47928b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bece27b2-3647-4887-9ce1-ecb93cf4df01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:to="loc_us-gaap_DebtInstrumentAxis_bece27b2-3647-4887-9ce1-ecb93cf4df01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bece27b2-3647-4887-9ce1-ecb93cf4df01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bece27b2-3647-4887-9ce1-ecb93cf4df01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bece27b2-3647-4887-9ce1-ecb93cf4df01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bece27b2-3647-4887-9ce1-ecb93cf4df01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_0a1af721-5f77-406c-b9a0-474da9a7d572" xlink:href="moh-20220331.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:to="loc_moh_A4375SeniorNotesMember_0a1af721-5f77-406c-b9a0-474da9a7d572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b9208058-c1b4-4099-82d6-2750feee68b2" xlink:href="moh-20220331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b9208058-c1b4-4099-82d6-2750feee68b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_c322ae0d-44d0-456a-bb84-73b1baefcf5f" xlink:href="moh-20220331.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:to="loc_moh_A3875SeniorNotesMember_c322ae0d-44d0-456a-bb84-73b1baefcf5f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended" id="i7e495139911a4850bb77dbb4d561c26d_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7fe5a96-806c-4997-bd4f-99c8c4f3c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7fe5a96-806c-4997-bd4f-99c8c4f3c8e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_368b8048-c63b-4214-913c-0c82d4398dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_DebtInstrumentTerm_368b8048-c63b-4214-913c-0c82d4398dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_51b79e05-f90d-4c06-9340-4825d3ba8842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_LineOfCredit_51b79e05-f90d-4c06-9340-4825d3ba8842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a53b2b27-fb5b-49e8-850f-c2a08b57a3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a53b2b27-fb5b-49e8-850f-c2a08b57a3d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6c5f5f4c-9d04-4f78-91c4-d99c3ff134e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6c5f5f4c-9d04-4f78-91c4-d99c3ff134e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_639d4b16-1399-4b50-989a-80a40abbad46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_639d4b16-1399-4b50-989a-80a40abbad46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_639d4b16-1399-4b50-989a-80a40abbad46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_639d4b16-1399-4b50-989a-80a40abbad46" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_639d4b16-1399-4b50-989a-80a40abbad46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_639d4b16-1399-4b50-989a-80a40abbad46" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_baa6ce51-7767-4599-94d2-9241903fae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:to="loc_us-gaap_LineOfCreditMember_baa6ce51-7767-4599-94d2-9241903fae75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2cb9fbbe-c163-4845-a6e1-5ce5d63ce82b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:to="loc_us-gaap_SeniorNotesMember_2cb9fbbe-c163-4845-a6e1-5ce5d63ce82b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_78d314d6-9021-49d0-90d5-b4655f1cbcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:to="loc_us-gaap_CreditFacilityAxis_78d314d6-9021-49d0-90d5-b4655f1cbcab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_78d314d6-9021-49d0-90d5-b4655f1cbcab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_78d314d6-9021-49d0-90d5-b4655f1cbcab" xlink:to="loc_us-gaap_CreditFacilityDomain_78d314d6-9021-49d0-90d5-b4655f1cbcab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53db1bfb-ef45-49ee-ae13-4910b7dc5047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_78d314d6-9021-49d0-90d5-b4655f1cbcab" xlink:to="loc_us-gaap_CreditFacilityDomain_53db1bfb-ef45-49ee-ae13-4910b7dc5047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f1706724-285c-43a7-8b43-2328d3354a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_53db1bfb-ef45-49ee-ae13-4910b7dc5047" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f1706724-285c-43a7-8b43-2328d3354a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4fc93eba-ae5c-4fe7-bce9-836afe75c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_4fc93eba-ae5c-4fe7-bce9-836afe75c02f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4fc93eba-ae5c-4fe7-bce9-836afe75c02f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4fc93eba-ae5c-4fe7-bce9-836afe75c02f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4fc93eba-ae5c-4fe7-bce9-836afe75c02f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4fc93eba-ae5c-4fe7-bce9-836afe75c02f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_b5e9ca48-2fa9-4823-b33e-bed6993e59d6" xlink:href="moh-20220331.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:to="loc_moh_A4375SeniorNotesMember_b5e9ca48-2fa9-4823-b33e-bed6993e59d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_2c639078-a8a5-4637-862d-0efa25f49d16" xlink:href="moh-20220331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_2c639078-a8a5-4637-862d-0efa25f49d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_e8a3a06d-9ef8-4a62-a1da-7646359472c3" xlink:href="moh-20220331.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:to="loc_moh_A3875SeniorNotesMember_e8a3a06d-9ef8-4a62-a1da-7646359472c3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="extended" id="ic0cbbdff4e3840f698737dec42ecdffd_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2d747497-0537-4ca7-ab97-9722e2c6428a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2d747497-0537-4ca7-ab97-9722e2c6428a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_346d687a-fc54-4d29-894e-c3e251d2b1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_346d687a-fc54-4d29-894e-c3e251d2b1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f65a01a2-0c6d-482e-96e4-9d3d7a539001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f65a01a2-0c6d-482e-96e4-9d3d7a539001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f65a01a2-0c6d-482e-96e4-9d3d7a539001_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f65a01a2-0c6d-482e-96e4-9d3d7a539001" xlink:to="loc_us-gaap_EquityComponentDomain_f65a01a2-0c6d-482e-96e4-9d3d7a539001_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_506b4061-9404-4fdd-a852-c5e82a0a853b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f65a01a2-0c6d-482e-96e4-9d3d7a539001" xlink:to="loc_us-gaap_EquityComponentDomain_506b4061-9404-4fdd-a852-c5e82a0a853b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f165788f-d00c-4b35-8085-1816f97963a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_506b4061-9404-4fdd-a852-c5e82a0a853b" xlink:to="loc_us-gaap_CommonStockMember_f165788f-d00c-4b35-8085-1816f97963a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c9d926f0-bbfe-432e-a711-19e540117c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c9d926f0-bbfe-432e-a711-19e540117c45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c9d926f0-bbfe-432e-a711-19e540117c45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c9d926f0-bbfe-432e-a711-19e540117c45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c9d926f0-bbfe-432e-a711-19e540117c45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cedc58c5-9043-433d-9d2c-1bf306fe6a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c9d926f0-bbfe-432e-a711-19e540117c45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cedc58c5-9043-433d-9d2c-1bf306fe6a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b8109522-9b90-42f6-a9c3-776636355afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cedc58c5-9043-433d-9d2c-1bf306fe6a1d" xlink:to="loc_us-gaap_SubsequentEventMember_b8109522-9b90-42f6-a9c3-776636355afd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SegmentsScheduleofOperatingSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="extended" id="i17cbbfb0c323446d87c6a459f0cefa0e_SegmentsScheduleofOperatingSegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3a7230a1-0216-4886-ac84-8b673f27b734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_de42ab68-8686-4503-8230-7a0ba9a5e0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a7230a1-0216-4886-ac84-8b673f27b734" xlink:to="loc_us-gaap_Revenues_de42ab68-8686-4503-8230-7a0ba9a5e0d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7388c4e2-1ae1-4e17-8d4b-abd66358c6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a7230a1-0216-4886-ac84-8b673f27b734" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7388c4e2-1ae1-4e17-8d4b-abd66358c6e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_747fa34e-f823-4adf-b6ea-16ed41df3bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7388c4e2-1ae1-4e17-8d4b-abd66358c6e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_747fa34e-f823-4adf-b6ea-16ed41df3bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_747fa34e-f823-4adf-b6ea-16ed41df3bf4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_747fa34e-f823-4adf-b6ea-16ed41df3bf4" xlink:to="loc_us-gaap_SegmentDomain_747fa34e-f823-4adf-b6ea-16ed41df3bf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_747fa34e-f823-4adf-b6ea-16ed41df3bf4" xlink:to="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_0db2cf5e-b2b0-4fc9-8210-14db055ce5ef" xlink:href="moh-20220331.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_MedicaidMember_0db2cf5e-b2b0-4fc9-8210-14db055ce5ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_0c4a48c7-bb12-45e9-a0a7-134b8a431d78" xlink:href="moh-20220331.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_MedicareMember_0c4a48c7-bb12-45e9-a0a7-134b8a431d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_3739c576-edf6-47e7-b2e5-6e58eb13bd50" xlink:href="moh-20220331.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_MarketplaceMember_3739c576-edf6-47e7-b2e5-6e58eb13bd50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_151021d5-8fb7-43f6-a81f-f6544111b818" xlink:href="moh-20220331.xsd#moh_OtherProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_OtherProgramMember_151021d5-8fb7-43f6-a81f-f6544111b818" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended" id="i563c504c14674579ba2ffcba5986bd05_SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5f229d7c-1fb0-4285-bbd5-83de26516001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_GrossProfit_5f229d7c-1fb0-4285-bbd5-83de26516001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0cebed35-398b-46a9-91e5-3cb74f8b44c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_Revenues_0cebed35-398b-46a9-91e5-3cb74f8b44c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d3c68c7-1986-4670-aa91-9ea9053eb976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_CostsAndExpenses_6d3c68c7-1986-4670-aa91-9ea9053eb976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f89aea04-f09b-4ef1-9fb3-a2d2a9a00622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_OperatingIncomeLoss_f89aea04-f09b-4ef1-9fb3-a2d2a9a00622" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_df5f2c29-eae0-4ba1-b27c-9aa4576f2cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_df5f2c29-eae0-4ba1-b27c-9aa4576f2cbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50cec5c6-46f6-4a86-987a-e3d5c246af29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50cec5c6-46f6-4a86-987a-e3d5c246af29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_25329aba-c474-4cf2-b193-d2b23f7f586c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:to="loc_srt_ConsolidationItemsAxis_25329aba-c474-4cf2-b193-d2b23f7f586c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_25329aba-c474-4cf2-b193-d2b23f7f586c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_25329aba-c474-4cf2-b193-d2b23f7f586c" xlink:to="loc_srt_ConsolidationItemsDomain_25329aba-c474-4cf2-b193-d2b23f7f586c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_25329aba-c474-4cf2-b193-d2b23f7f586c" xlink:to="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9430655d-215c-47c7-9851-ca3678184428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:to="loc_us-gaap_OperatingSegmentsMember_9430655d-215c-47c7-9851-ca3678184428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_1890a471-7349-4775-a293-8ec0e68234ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_1890a471-7349-4775-a293-8ec0e68234ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3e50e671-7d1f-4598-9864-01d12d9dfe46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3e50e671-7d1f-4598-9864-01d12d9dfe46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3e50e671-7d1f-4598-9864-01d12d9dfe46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3e50e671-7d1f-4598-9864-01d12d9dfe46" xlink:to="loc_us-gaap_SegmentDomain_3e50e671-7d1f-4598-9864-01d12d9dfe46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3e50e671-7d1f-4598-9864-01d12d9dfe46" xlink:to="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_62634cbf-8b52-45a0-9062-ae174bb13ebd" xlink:href="moh-20220331.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_MedicaidMember_62634cbf-8b52-45a0-9062-ae174bb13ebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_adbd11fc-d22a-4fe5-bf5c-7f38b3622a2b" xlink:href="moh-20220331.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_MedicareMember_adbd11fc-d22a-4fe5-bf5c-7f38b3622a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_b0e03fb7-f516-416e-8208-4a2fc67c6708" xlink:href="moh-20220331.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_MarketplaceMember_b0e03fb7-f516-416e-8208-4a2fc67c6708" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_3163b373-6832-46cc-ac9d-41f7fb933a5a" xlink:href="moh-20220331.xsd#moh_OtherProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_OtherProgramMember_3163b373-6832-46cc-ac9d-41f7fb933a5a" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>moh-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6096143c-bea0-4d64-8a46-ebe0e276f797,g:2f020790-0dbf-4089-8da8-8ebe5a4cb586-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b7cc8e12-2b6e-4f55-a24c-0dabe26b5bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_7e6acf7a-ae92-4d8b-9870-c99956629e82_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bcd6415b-2b78-4234-ac27-f3c127791a52_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_43e927f5-7af9-45d0-bf51-4392f584b9a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c229e160-a517-46a6-87d3-aa5edbee0612_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46448a30-7f7f-41b3-8fcd-a8d19ff46c8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_69c7a253-e175-4ffc-adbc-cdb18781d8ec_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2d70944d-8267-448e-b874-6f8483a0ca7b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_f103160a-7ecf-40c3-9386-995c965b20f6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Dividend Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:to="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_579f0605-cd40-4fe4-83d1-402638b4bf8c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_6bccfdf9-1aa7-4262-b1dc-a769776f04da_terseLabel_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Due to Government Agencies</link:label>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves Reported to Other Agencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:to="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherClaimsPayable_560008fe-b661-45d7-a6f0-66dd7bd32fcf_terseLabel_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_label_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_documentation_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable" xlink:href="moh-20220331.xsd#moh_OtherClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherClaimsPayable" xlink:to="lab_moh_OtherClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_9234ae89-c320-43d2-87d7-443ff28a71d0_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_836dac4f-8e96-44a1-9086-43deb0173c46_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MagellanCompleteCareMember_ced6a55b-dbc7-4da0-a3be-cca7526c1946_terseLabel_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care</link:label>
    <link:label id="lab_moh_MagellanCompleteCareMember_label_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care [Member]</link:label>
    <link:label id="lab_moh_MagellanCompleteCareMember_documentation_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember" xlink:href="moh-20220331.xsd#moh_MagellanCompleteCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MagellanCompleteCareMember" xlink:to="lab_moh_MagellanCompleteCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7cef0605-4962-45b2-b915-27cde0dec646_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_86de704a-3a75-4788-9932-9860abe80583_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0e6295ce-c7d9-4e21-b97e-31e74bea8156_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_603fcd22-5959-41e9-94e5-99fbe3ae4516_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f9a442e9-c9f7-4eab-a53d-1e6b7bec903e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6916671c-b8a4-4a93-872b-ea7d48497242_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f97f6da4-2ef2-4b0c-9e06-7d596c95353e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ddf07c12-0e32-493a-aa9d-428a67fe3f7a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f553a7c7-3759-47f8-b3af-46d860b75c97_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_7e74ab41-da72-45fb-ab3c-4bd62d2c5bac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bc8f8dff-45d8-4144-9001-c776326ebeb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7316bcce-d595-4a95-9ffc-2e704105595a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities settled</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a4e19e70-c2c3-4e48-a797-5830b8b83210_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities settled</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1fc65ffa-dc24-40ac-b3bf-214974472e36_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3ae47c8f-cacf-412a-95f9-50b760fdc63f_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_de4a9c29-8647-4ec1-a9ae-237c7cc92464_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PassportHealthPlanIncMember_fda9030b-6343-492d-b996-2df237911ba2_terseLabel_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan, Inc.</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_label_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc [Member]</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember" xlink:href="moh-20220331.xsd#moh_PassportHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PassportHealthPlanIncMember" xlink:to="lab_moh_PassportHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_8a093979-3561-449b-8974-3fab975440d2_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_cba03560-7695-4e29-b7da-74f54efb8151_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_fe92d421-4c73-43f8-8895-8ad43b74ac41_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_8faca018-a147-4a79-b8b0-e096f957fc4a_totalLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:href="moh-20220331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_1bd9a49d-b667-4714-ab17-78f792e60f32_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81c7c042-b27e-4b2c-bf81-982e0b837d8a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_93ad70f1-a8db-4cdc-a3e9-0c7bd9b15df7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a02ddfdf-a1ad-407a-9055-a1ea963086ef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_06f6c6c2-cad0-4a8c-8e07-1f0c2e8b121d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6db9af48-7377-4996-ba3b-3c398d67a91c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b43eef6c-898c-4272-b089-278c01ae0e79_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d68e29c3-1a4a-46c6-8e45-0bd1916af58b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_36b5c963-70fa-40a1-93db-5f5e01e777ed_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ae0250e6-ce23-495b-bdf6-bc47336ad43f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1611a047-f036-4475-b2f1-c4da3cc32eeb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1d3e8707-4c6b-4b91-a72d-e5e2f9e48490_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1374c982-c777-4be0-9047-4e4af164b857_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c0e0a7ae-3148-4136-ae0d-1baf4b0cfbd4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a24f0de6-f573-4cbf-896d-ec65ee3b09a6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8a4fbe96-57f0-4b16-9d4a-bbb2b5d26c91_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_222595ae-30e7-4671-908b-7b1b9207fcbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Segment Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ac442f2c-7a53-4e29-a6bf-e5d1e498eeca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c017bd69-7900-4669-8fd1-1875c079ebed_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_77c6760b-2c34-4225-b161-ba865cc61074_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_56b7a7f9-ebd1-4407-ae17-e2310dd5a3c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_dae482ae-f80b-432f-82d4-541f68d5a0ae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7fd5f2bd-c4bc-4d37-99d6-0b98f5f2958b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bd8ba5ed-67f3-41ba-9cd8-0a11f1a13137_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_292c446b-c4d8-4a0e-8e3e-c012d7ac2701_terseLabel_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod" xlink:href="moh-20220331.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsMaturityPeriod" xlink:to="lab_moh_InvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_70a1088b-19a8-4f5f-bcd5-4f5b8212499f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8e40a15f-5552-466c-aac7-6c07db853788_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_08bfab10-bb2a-41e5-a59b-1dd1486e6ed6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_625b7fcd-5649-44db-b894-1a72a5eceaf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_4c54ade2-c043-4a25-b93f-3eba4441285b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e03034c7-50d4-42d3-905d-c0f0d8334cdf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_292cffc2-b350-46c7-8ea7-f113d8154ef1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_649fe86c-307b-44ad-8534-d980ab93145c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_ad1363e4-c776-4278-8e65-b0ef56c01d8d_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_ec0df97d-f84c-4a62-9c46-3286fcf15f2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_36046f94-1e6f-456c-9c6c-89eb8f28dbd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3b0f8c3f-0e02-41eb-b630-8e82a89eb1c5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6a3f866b-34a4-459d-a35c-151ed66e73d8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A3875SeniorNotesMember_bef59865-adf1-489b-ab2c-2d4dde025c42_terseLabel_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes due 2032</link:label>
    <link:label id="lab_moh_A3875SeniorNotesMember_label_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A3875SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember" xlink:href="moh-20220331.xsd#moh_A3875SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A3875SeniorNotesMember" xlink:to="lab_moh_A3875SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_83c76359-cb60-483d-83d5-1c29b2817b98_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_544d19ec-187c-4887-ad0a-507c9340e4b4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_959c906c-13ab-4322-8811-8b0bc2cb6952_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_cd8e52ca-73c0-4f8a-9720-341854bf0339_terseLabel_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to:</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:href="moh-20220331.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_StructuredSecuritiesMember_01e1644f-8a1a-4035-a1cc-58ce64eb8d39_terseLabel_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities</link:label>
    <link:label id="lab_moh_StructuredSecuritiesMember_label_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities [Member]</link:label>
    <link:label id="lab_moh_StructuredSecuritiesMember_documentation_en-US" xlink:label="lab_moh_StructuredSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structured Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember" xlink:href="moh-20220331.xsd#moh_StructuredSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_StructuredSecuritiesMember" xlink:to="lab_moh_StructuredSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9b2625d0-42bd-47a0-a09e-87ef1ad4f90a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3ae12646-40a4-4189-bf52-11859cc9aa40_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_816ba376-cd0a-4a6e-9131-4859a3d07298_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_aa3f2ad9-f535-4a91-bdb7-d55878796e83_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4b42318b-a6d2-4f97-bb20-254314232b52_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Maturities of Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_38c360c8-d4b2-4d9a-ba09-9d942be4150d_terseLabel_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension option</link:label>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_label_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Extension Option, Period</link:label>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_documentation_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Extension Option, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod" xlink:href="moh-20220331.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanExtensionOptionPeriod" xlink:to="lab_moh_HealthPlanExtensionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_339cceb4-3d6b-4a3b-b167-24be4a2c2f75_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_120ce57b-6561-4c59-a0a1-becbac45b7c5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_f20e2ed5-dfdc-4734-8dcd-249018185335_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired membership with a preliminary fair value</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_16d9bd01-f3ef-49a3-82f2-f947bc25f0da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8b3d915f-b429-439a-ad02-07e4df6fc19a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_18653209-3348-4915-a150-c5f708607b6b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4240b390-71a3-428c-9a6d-4aac9af92bdd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid to seller</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5700fe45-954f-4bd8-ab4f-bb1ffb947469_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CapitationClaimsPayable_bcbe3dc7-696d-42e5-b838-2689eda0fcff_terseLabel_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_label_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_documentation_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable" xlink:href="moh-20220331.xsd#moh_CapitationClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CapitationClaimsPayable" xlink:to="lab_moh_CapitationClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9ac8b29c-fdcb-44af-97d3-0ef662abe903_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7db318fc-d026-4cb2-820c-8a2d906963af_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_6a447d43-391a-40e2-bf6e-1ee37a7f8900_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_32ebb98c-bbee-4262-8e5c-6ae67d99c5fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_88d88472-927c-4108-a41e-70cda02aa75c_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_2f03c0fd-c295-4604-8b64-f88b55b50ea6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7a931bbb-2621-4aa0-9d6f-08283cbcd252_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9b99ecd9-adcc-4756-8a6d-033945bb2ad3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_01aa32c4-525b-48c1-aa6a-da592b04bea9_terseLabel_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding at the beginning of the period ( in shares)</link:label>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_label_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Excluding Restricted Stock Awards</link:label>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_documentation_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Excluding Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:href="moh-20220331.xsd#moh_SharesOutstandingExcludingRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:to="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a8b03892-7a0a-42f6-bf20-5b2ba3c17aa1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8bd8f8e9-95c2-4802-b694-14f34b30231e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_4688d6ab-6b23-46f3-9c23-746796c45a3f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_6cef7da3-4e85-43e7-8378-ddcbc707837b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_NumberOfReportableSegment_5938d6e5-04f4-40ce-9f83-719283bdd2d7_terseLabel_en-US" xlink:label="lab_moh_NumberOfReportableSegment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable segment</link:label>
    <link:label id="lab_moh_NumberOfReportableSegment_label_en-US" xlink:label="lab_moh_NumberOfReportableSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reportable Segment</link:label>
    <link:label id="lab_moh_NumberOfReportableSegment_documentation_en-US" xlink:label="lab_moh_NumberOfReportableSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfReportableSegment" xlink:href="moh-20220331.xsd#moh_NumberOfReportableSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_NumberOfReportableSegment" xlink:to="lab_moh_NumberOfReportableSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a60d0bf5-5f46-4cd2-9e7d-5b42cec0dd16_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0d5bf783-e59c-4316-89c6-3b144b93fddf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Denominators for The Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_6175ef55-c907-462e-af05-0133e67bb10f_terseLabel_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_label_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_documentation_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:href="moh-20220331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:to="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2bc23e25-f109-48da-89dc-460acc95f3eb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aa1907ea-d423-4054-9713-d4721bbe9918_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4b887115-477b-4c86-81bd-4523b932b46d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_fe833762-b284-44df-b3c0-f38772612592_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_189f9032-70b2-4aff-9e95-012da3ab7b76_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f4457512-1d75-4117-a974-053330ccb112_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c4278649-8b60-4d24-95cb-291b907d95fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2faf1a0e-2546-40c7-9bd0-8884b397cda8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_69abe4cb-28ba-44d5-b6fc-1974789c7946_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration due for minimum member</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_2d53770c-1768-4bf0-bc55-c1f5456045d6_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f1b1fa72-9fae-46e1-a449-3ac65ee371a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_4d590ad8-3d68-4b99-ae22-e43c16dbf9d2_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period claims, favorable development</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_1b33f710-06be-492c-85e8-096cc9108343_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_935f3774-7855-408c-a523-ca74ff9fccf5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_a186b77e-0138-4354-a739-b6833ce2a2bd_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_6da37962-cf0f-456f-9d6b-df41377d6693_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_845b90cf-e3bb-48f7-88b5-bdc837e86b6f_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Premium Revenue By Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:href="moh-20220331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0ac90fba-f6cc-438a-8353-ae28584cc926_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_b8f26d5d-dc46-4857-a394-4ca10e0fbb79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_8ad8255b-4560-4fb0-9f9b-dbb7fc29b57d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_d830c300-22e8-4c24-91b6-1729ca41355d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8501a46d-a063-405a-896d-49eb8f5dba3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contractual interest rate on notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e0a983f5-551e-4b73-b92c-f5102c1845a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_3e7f4c4a-7898-4827-af7c-569ac00ebf06_terseLabel_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation and Interim Financial Information</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="moh-20220331.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c39ddf08-26cc-4e60-9fcc-3c31a50f0032_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_caabc80c-ffc9-4c06-8f8b-77319bcbeed7_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium revenue</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a04b5e24-0d4f-4e6c-a07d-cb26ffd1b33e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_15af3067-be29-4500-8a1a-a32ab42ad76b_terseLabel_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with programs</link:label>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_label_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States With Government-Sponsored Healthcare Programs</link:label>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_documentation_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States With Government-Sponsored Healthcare Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:href="moh-20220331.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:to="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_b7bfca35-2ebb-401e-9f4d-f14cb4149253_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4697f16a-300b-4853-8acc-d86680e441bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e63593e4-62c0-48b3-82f4-4a74fe9d5308_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_e32fb894-3fd4-457f-a4c4-9af9bad6b4e6_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_48ef89c8-b0b0-4a29-984e-8633a8cdc315_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_61f5b5f1-ccf1-45c2-8b36-a8431bf72646_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_8685704e-97c6-4ca8-8f79-df83eec98c70_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-risk and other provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable, Adjustments, Change In Provider</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable, Adjustments, Change in Provider</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:href="moh-20220331.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_b8a91897-097d-4975-9510-f72b8c6a2ac1_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:href="moh-20220331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_861cad48-296e-406b-b149-913686c018e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d0d3b48c-9d45-4cb2-a266-df84352d96a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_754d9710-5d61-4815-8c14-c5d54df1495a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_cb3c12de-a09e-4481-abeb-e58061b2fa75_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_21e4f064-7467-415a-9495-fdafef01fad7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_50824c33-c4db-47da-906e-20497336a90d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_9bd43c38-8592-4f12-b7cf-66fbaedc54c4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_4234e416-3e18-4941-a2e1-d32f95a294fc_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_81b6d8da-de5b-4a29-8108-cf3cb80d73ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_377aa8a3-3eae-4f1e-a5b0-11e74e789bcc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_17d66481-d2ef-4ffa-910d-5102550cbb97_terseLabel_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:href="moh-20220331.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_2eb380c2-1515-4a74-8901-bce63100b6df_terseLabel_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc</link:label>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_label_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc [Member]</link:label>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember" xlink:href="moh-20220331.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffinityHealthPlanIncMember" xlink:to="lab_moh_AffinityHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_949d0f96-35e0-41a5-917b-dc133d76a215_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_90a228aa-2651-413a-b8c7-78cc99ef33a1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3e7aea42-52e1-4ce1-b436-c7f7f029695f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1b988c4-95bb-4373-b4d9-1daa12b844cb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3c5be505-7af3-41ea-907c-bf66b054d266_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_c50a59b5-d32c-43a3-a069-6456ffcd294b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_c3fd53bd-16e0-4861-8095-0bffeac0cad0_terseLabel_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod" xlink:href="moh-20220331.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsAverageMaturityPeriod" xlink:to="lab_moh_InvestmentsAverageMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_98c41b27-11b4-4d1b-8583-88b317885e82_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyClaimsPayable_a2eebe6e-cc50-4a7f-b831-139889dcf4e6_terseLabel_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_label_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_documentation_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable" xlink:href="moh-20220331.xsd#moh_PharmacyClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyClaimsPayable" xlink:to="lab_moh_PharmacyClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_6bbb56f6-7365-46b3-885a-90fbb116844b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c46702ef-06b4-42aa-bf5c-3b3e41fef00c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_044e77db-b8b4-4476-8e7d-21ae658c2da1_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of The Change in Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_label_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_documentation_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:href="moh-20220331.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:to="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27d99358-4ea3-44a6-88e1-1f8ca85ff026_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_ac8504f5-7738-4fc2-aed6-d09bea37e673_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b08e75b6-1f75-4587-811f-8a281292a6ff_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_57c103cc-88f7-43c6-ae45-f48c940d0a7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9ff41bde-3dba-4218-a45f-8b818be47164_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_836fb0d6-09d5-41fe-9a59-c36217868dcf_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, due in one year or less</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_18c26933-7f8f-43c2-bc88-778d6c1578de_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanContractTerm_2b334388-78c6-4047-8626-458aa6a9ac5b_terseLabel_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_label_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_documentation_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm" xlink:href="moh-20220331.xsd#moh_HealthPlanContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanContractTerm" xlink:to="lab_moh_HealthPlanContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_38491a23-9bb2-437c-bda0-9a3930a71996_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurements of Senior Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6a14cdc7-dd81-417a-9851-60d7cfb81662_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b70fa577-b133-461c-b34e-1f6aa3b19a32_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_13c5d5bc-126b-45c2-a719-239fd08b0597_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:href="moh-20220331.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:to="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_fa78e420-f714-4eec-827e-8ac252fd04c2_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7afbb3a6-de18-4f70-99c3-832f41276e3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_40e76341-bf97-40a5-bd72-c5fac276de7f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicareMember_1e10c1ab-88d5-4215-bd26-3b4caf018f26_terseLabel_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_moh_MedicareMember_label_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_moh_MedicareMember_documentation_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember" xlink:href="moh-20220331.xsd#moh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicareMember" xlink:to="lab_moh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_33e8ff00-5998-462e-a570-9283be8964f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d1bbff4f-394b-4f09-a7e5-bed333b907bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a45600d3-fc0f-468c-872d-a821adb0f7dd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_GovernmentReceivablesMember_41e1931b-2901-4260-8b3f-fb9e933fed37_terseLabel_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government receivables</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_label_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_documentation_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember" xlink:href="moh-20220331.xsd#moh_GovernmentReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_GovernmentReceivablesMember" xlink:to="lab_moh_GovernmentReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_26bf0db4-cafe-4ee7-a7e5-072483145854_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_398115b7-07ab-4fcc-8146-38d033dfaa35_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MemberListsMember_c68c6c8a-ce39-484b-91d7-611bee6583ba_terseLabel_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member list</link:label>
    <link:label id="lab_moh_MemberListsMember_label_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Lists [Member]</link:label>
    <link:label id="lab_moh_MemberListsMember_documentation_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Lists</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember" xlink:href="moh-20220331.xsd#moh_MemberListsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MemberListsMember" xlink:to="lab_moh_MemberListsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_07e2f396-5d79-4593-a864-78fc3f1eeb65_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PremiumTaxExpenses_9f5e5fcc-04e5-4942-9b12-17e66606e996_terseLabel_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_label_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Tax Expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_documentation_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An assessment levied by a state government on the net premium income collected.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses" xlink:href="moh-20220331.xsd#moh_PremiumTaxExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PremiumTaxExpenses" xlink:to="lab_moh_PremiumTaxExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d16407e9-c1b0-4c72-8778-82a4d1f05868_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical care costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9ce84a76-c61b-41d2-aa41-a38e3de66046_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_69666abb-22f0-4ff0-8c9d-4d9b4fc02de2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_790d61ee-d938-46bd-8d29-9b06482837c8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_08ae8e1e-1057-4f96-ad11-84dabeb99282_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number&#160;of Positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_3ff1377c-5f7c-4e4b-9948-41971cfd838c_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bc737e59-5a93-4a46-8edc-6ca1180e10c0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_1dd44e64-3bc3-495a-9f50-5596c0887dbc_terseLabel_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_label_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_documentation_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:href="moh-20220331.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:to="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_3c442b93-0e47-44c8-b8d7-fa9bd4311f40_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_679ec322-8dca-4a18-b165-9557ddd4aef9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherSecuritiesMember_ba68bc13-f6dc-4b7b-9c24-926a7f59b9a0_terseLabel_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_label_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities [Member]</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_documentation_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember" xlink:href="moh-20220331.xsd#moh_OtherSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherSecuritiesMember" xlink:to="lab_moh_OtherSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_5100d440-fccb-45be-8bb7-7e6d5ddcae09_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_24c9dc7b-dcdc-4fce-9e9c-7603ef618e3a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under letter of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_891889ed-d58d-49e5-a97e-c075ea56f671_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5e9b4be4-be61-41c0-8263-0368099fca09_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_c1953a64-45ad-4ded-941d-f7e933b52bfc_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlansMember_b599a0e8-9b5d-4381-bce0-4a0f28ecd86a_terseLabel_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans</link:label>
    <link:label id="lab_moh_HealthPlansMember_label_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans [Member]</link:label>
    <link:label id="lab_moh_HealthPlansMember_documentation_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember" xlink:href="moh-20220331.xsd#moh_HealthPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlansMember" xlink:to="lab_moh_HealthPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_51f2d7d4-e460-40ac-a009-0520b23ad43b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_29e2ddc9-7c77-4422-aaf6-2a3f931443ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6b6dd83c-e417-47f4-9a54-731699bcf627_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5c8995ab-995e-4f0d-9a0b-3bdb07198355_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_3657473a-f309-433d-a566-abaded840d46_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3785ab9c-e9dd-421a-aa0b-13ac817c6e45_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_da87bb2a-0a27-4617-800e-f47d398a56c9_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_600b5ecc-0407-422d-89f4-81ba8b64d17e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_4a91341b-2ff6-4c2c-bbd9-db01eccf72cd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_f987d57c-bd1c-45d5-9659-da08519b2607_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:href="moh-20220331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_97021595-c8bd-486e-aae8-534032c32cd2_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4c27214e-5e44-440a-b0a6-5b4c5c2ddf27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_6869dce0-ac48-4cb5-937f-e1ac200c12ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_07b43048-ead0-443d-b762-b2d7d14b7876_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_2e14a5c4-f0d2-40de-b38a-40ba52704322_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_064bfbf1-595b-4ae8-a097-ac2288d7618b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Health Care Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e75926e5-e9fa-47c5-9f30-2669e598f7b5_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_44d3a4c6-08f3-4476-ba2d-11e0cd7aaeea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b52c4f30-42f8-4944-b739-76657f11a361_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_03e1536b-1f51-48ab-9cbe-e2373a705cb3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_65a9cd21-dcfe-4a0f-be90-c71a9d507d0c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_a9d4d78a-2eb9-413b-bc9a-b6ea02d26a2c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_19faea58-a3a2-4709-94a8-e0e4b40baf11_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_d009b4a5-a10a-4643-a380-7e4d7e187047_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_32332448-212d-49ed-a993-89a6f94caa11_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_b2264574-a24f-45f3-a185-2f2023e38f40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in premiums</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Premiums Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_68cd5b07-73ed-4c8e-950a-b7e02aace689_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1c2fe92f-d477-4481-83e7-83e021924013_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4858ca16-25a0-48a3-a2eb-7e9740a18cc9_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_763da94f-584f-442f-b1b7-2b605e25864c_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_f25014e9-69ef-4c1a-9781-1e4f5d36f931_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: other operating revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dab2f489-92fe-42bc-94c5-6807f03f9a44_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_004b1238-b7b0-4e7d-81c4-3550a606f790_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_6064ffbb-7ede-4c7d-be77-3b8fb9f124a8_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2bd3c1a6-1c44-4219-8076-b5b1e8a3bee6_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6e3e82e7-fe66-4312-aa9c-840267e646b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_608d795a-693d-4002-bb13-3e0dd812dab0_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_d8778e36-e92e-480c-81ba-d9c6e2078979_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c22f8208-7e0c-4ae7-bef8-e552cbdcc5b7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3bfc1647-7c70-4c6e-b2ac-2ab580ce9f2a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_a9c594b8-9d7e-476c-8ce2-359ce584b455_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_1265e34e-ca4b-4c2a-9897-949600fb87d3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, and intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b05d16e9-846f-4ceb-9a31-3129407fe384_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96a45329-fc82-4e5c-bf6f-6c0070246a71_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_339545ef-2e5a-4472-9352-5d1478f5bed1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a1670f20-86e5-4170-8c41-1a1a9f8aa2da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_dd93ef69-6bd0-4cfc-ab5c-a08dbd6bf033_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherMedicareProgram_ede6fde5-6739-4294-962d-9cf5410f82c7_terseLabel_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_label_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_documentation_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram" xlink:href="moh-20220331.xsd#moh_OtherMedicareProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherMedicareProgram" xlink:to="lab_moh_OtherMedicareProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_0ce1f4f9-39d8-4804-9ce7-b1ee8969d46b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_d57e3752-d9f4-473e-8812-8e2aeb2d22fe_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e0a28605-4058-4002-9d44-828da4f4c2e2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f95f2a6f-39ca-4f39-8780-a66aa5875fda_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b4fdf50-c944-41c0-92b6-06b2aa7dc123_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f6af2bf-c22c-4fa9-8c7a-8157f9bac31f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86e66338-0c5b-4ea2-853a-e30e86a9502b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_1a4de851-f4ba-47ed-aecc-8154aa44d4af_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_035532e9-824e-428e-8c3e-e3d0a4b97acb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: other operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_eac48459-09e7-4fa3-aee6-542c5c4389b9_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, due one year through five years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2a8aefac-f622-42c7-bc84-06dc7b937ed1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cfc28d0f-b416-48fb-a24c-f702179f120a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7f3f715f-91c8-4beb-bd5c-f7ab20f20e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ff3e34a-857f-45d6-b9bf-7523addf0886_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bce0508f-c79d-45bf-a671-7d7f4fd6fb5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A4375SeniorNotesMember_9e72e322-e02f-4fc5-9fab-1ff99124c959_terseLabel_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2028</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_label_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember" xlink:href="moh-20220331.xsd#moh_A4375SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A4375SeniorNotesMember" xlink:to="lab_moh_A4375SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherProgramMember_545493a7-3e98-4e1b-bb8f-69874c663c4b_terseLabel_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherProgramMember_label_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Program [Member]</link:label>
    <link:label id="lab_moh_OtherProgramMember_documentation_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember" xlink:href="moh-20220331.xsd#moh_OtherProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherProgramMember" xlink:to="lab_moh_OtherProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7de1c299-3cbd-4c0a-a516-08346962d7b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_6e68c94a-763a-4774-8690-fa2240e934b2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized investment loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_608da545-f56c-4afd-9775-16d02f11f7cc_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_98d48fc5-ad36-4f4d-bccc-af931fded8cb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bfe9c609-b24e-4dbc-a8cd-7d836d487e7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b2320873-ca92-46e3-8c47-6f49eff1a7e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4475dd82-1321-40ee-8b98-5d4ae2a61626_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b2cb6af9-4966-40b7-bfa8-0c38f7e3295b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Revenue Recognition and Amounts Due Government Agencies and Contractual Provisions That May Adjust or Limit Revenue or Profit</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fba8e69e-b6a9-41c3-a43a-227c055e8f71_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_3746085e-b5a4-4845-9311-1729a6eb8ca1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01e9872d-54c4-43aa-a237-60624d8e03e1_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_21910477-ae1c-4e81-a4ef-30a348433bb9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_COVID19Member_a69a833e-edd5-4ba5-8bd1-4c3c9a427604_terseLabel_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_moh_COVID19Member_label_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_moh_COVID19Member_documentation_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member" xlink:href="moh-20220331.xsd#moh_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_COVID19Member" xlink:to="lab_moh_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_90951426-766d-46ac-b618-134f93a3373d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f1454037-fa00-46fb-9c08-dcf5d708ae06_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_b7135ab7-5c70-4eb0-ad7c-200cad3496ec_terseLabel_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims incurred but not paid (&#8220;IBNP&#8221;)</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_label_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_documentation_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:href="moh-20220331.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:to="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_7812cb8a-8520-46f8-8c97-16a8dbe052a1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares issued:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2c871dea-4258-4965-8860-a10f4b082f5b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5645612f-48f2-415b-83e3-a625a0b25e0f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_3358d099-758b-4342-abf8-e5b026325ac2_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:href="moh-20220331.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5e7c044c-5162-4975-b26a-9578c491d25c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_19af306b-7f2e-4613-9ff3-a263cd49c58a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized gain (loss)</link:label>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Fair Value Hedges Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_09886774-55d1-4036-976e-03e19f232a37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_68f53a1f-c532-4a2c-9da1-9297ccd1e4cb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_dc0e5f97-9fb0-4396-9a99-39a7dc970ba5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_70432975-1277-4609-8969-7229f5308deb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_88e025bb-0b98-4dfc-b823-5bfb72287350_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1338d4a-9bc7-4d6b-9d69-37f13b44da80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_3c2eba21-2856-4da5-96e0-429200eab8ae_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8d41017d-34ae-4093-bbcc-c7807c37c6b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f1f995cb-ae51-46cf-93c9-a32217da3592_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_003b2567-4dfa-4f11-9679-eade8538584c_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs, approximately</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_label_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Members Eligible For The Health Care Programs</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_documentation_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:href="moh-20220331.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:to="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9e43df62-3d5e-4902-8a7a-426f6bbedc3e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_bf8429a9-eb7b-4ef7-b114-4d7c78304de4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0aebcbc5-c84b-448a-b21a-32d175bc13a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b947a82-f8c0-46e3-ad8d-363383d3269f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9e7d0d87-0c11-4550-a579-0053571c0770_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_da87d809-4860-439d-8354-7d3b2e06ffd5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_2f522268-4c8b-4d05-8112-1201411aa610_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable [Text Block]</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:href="moh-20220331.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fac2df30-25fb-4483-9c1c-2b1376f16374_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_284661f4-e419-48ba-be16-8c4f3b29ca4a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_912004a1-c171-4480-b796-6e99fdd010fb_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_49835142-d765-4e33-a3ff-3d8bc8ba09b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MarketplaceMember_fe1b15e8-d1b5-4ac3-9a8c-27a45625ac06_terseLabel_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace</link:label>
    <link:label id="lab_moh_MarketplaceMember_label_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace [Member]</link:label>
    <link:label id="lab_moh_MarketplaceMember_documentation_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember" xlink:href="moh-20220331.xsd#moh_MarketplaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MarketplaceMember" xlink:to="lab_moh_MarketplaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_5bf1b361-6279-47d0-b943-60c9bd64f7d6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_11e68e71-5a88-41d5-b64a-2535a4064948_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fd79dfba-223d-4ab5-88b2-33fb049f2c51_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_09f960b1-3f2b-40f4-8d57-ccdaca3cf451_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_285d4a9c-4b36-4388-8f17-5981d0cf8212_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_55e02cde-a837-4fb0-b33a-4f00abc6bc79_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-risk provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:href="moh-20220331.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a6339da5-7e61-425c-873e-9b447f6f089b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c0989325-63f6-487a-b032-358a113fe072_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5f0ce474-c224-4d54-8fbb-d51530ea78c9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96a438ac-105e-4540-bd97-5686846cdfe7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0549ccbf-6a60-426f-bcbe-2e39af347fec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_8b9152ef-0f8b-4a4b-949e-297023338bbc_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to:</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:href="moh-20220331.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:to="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_94a7e5cb-cf3b-4ec7-8fee-233c30b5b359_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_3eb97b29-353c-4c4f-93dd-d4084b7d62bb_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_label_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_documentation_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:href="moh-20220331.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:to="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_aad40b12-815c-41aa-9af8-fdf4ee93c19b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9445d4f3-38c4-47a2-a586-e2078987ec93_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7baaec79-3ddf-43fb-977e-3dcd746e5ab7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d79084c0-a0e7-41b4-acb1-e731fc7dfc0e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MunicipalSecuritiesMember_a4f824b2-0581-4d98-b380-254db9ae4b7f_terseLabel_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_label_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Securities [Member]</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_documentation_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember" xlink:href="moh-20220331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MunicipalSecuritiesMember" xlink:to="lab_moh_MunicipalSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_48535ac2-0288-4ca4-a349-2aebef749a69_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherReceivablesMember_a3bf3538-6572-4670-94de-4ae8888235d6_terseLabel_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_label_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_documentation_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember" xlink:href="moh-20220331.xsd#moh_OtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherReceivablesMember" xlink:to="lab_moh_OtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_57784478-1988-4000-8344-92d6a20527f5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fc1cc45d-3787-40a8-8b3c-60248f39c0fa_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicaidMember_9f659964-9cc5-4cb3-8908-cd6edde84f15_terseLabel_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_moh_MedicaidMember_label_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_moh_MedicaidMember_documentation_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember" xlink:href="moh-20220331.xsd#moh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicaidMember" xlink:to="lab_moh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c2b2ecd5-63f9-46e1-9ffc-c314a0f97c9d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_69361d99-310e-46f3-a95f-0af58e822927_terseLabel_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy rebate receivables</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_label_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_documentation_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember" xlink:href="moh-20220331.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyRebateReceivablesMember" xlink:to="lab_moh_PharmacyRebateReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_97d75df0-85a1-4040-829e-c4ac739017e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_c6ea228d-9c9c-43a7-b4bf-115082a3b56f_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_fbd3bb33-1a18-4056-b6c4-df8ae7ed2363_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f202181b-9a7c-41ec-ac98-50a9da76a753_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_655cd633-56be-4219-93c3-21742c05c737_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eab3d0c1-503b-432e-8cb9-9a008ff35cc4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_716a784f-9164-4596-8cc3-a515fd3568f7_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_69127837-82a5-4dfa-9173-5c13b92d0798_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4bb2cc51-e06e-458d-8e5a-58a8bf596d86_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_44087e2d-9d33-4c57-8b8f-259ed32bdf7a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b356fcca-b8d0-4bbb-8f2a-00c61eab33b4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_44e51839-b50e-4c8d-8f80-0fdd350f5451_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_b6db4e66-c4e1-4ad9-bba5-70f976a3dd6a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72fd36c5-a6ac-4cb1-aa54-537ae5c0ec11_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_0c3cfaba-f514-4172-81ec-8c0cc26cbcd0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_87dd288e-02df-44d0-ae7a-aa51fd0a9f92_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8086aa22-d3cd-4ac8-ac8d-b79d73e557b8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9983b1e6-a07c-423c-adf6-77f98e1e390c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3531401e-dbd8-4aeb-b756-e18ba0c1b310_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_942ffd11-ff05-47fa-861e-a1e323eee88b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c46cd68d-9673-4c9b-9188-838738869ec2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_bddaeba9-8936-4e2c-8515-52a5e3bffbe2_terseLabel_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes due 2030</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_label_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes [Member]</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_documentation_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:href="moh-20220331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:to="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8f922518-3fc6-4d09-8819-a7b9ae6d25f2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8b3a0ca3-c69f-4ca9-a2f3-84202d318472_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e3f44599-740b-4dfa-a422-e70a6082af6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4251eafa-dbdf-4edc-8370-7db8e2bfc239_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_89cb3e3b-b402-4ca6-adb0-a4f70d646a5f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_2deece9c-a6b9-4e58-9c70-20fa4b0e2396_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities held to maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_e8ab2000-1181-4562-a973-eb16e2bb651e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at March&#160;31, 2022, and 58 million shares at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f245779f-1a6c-479c-8061-e9ad380752fe_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_a9f8f880-2f8b-4d9f-97fe-5922ba41bce3_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:href="moh-20220331.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_463f9cab-4bb8-4562-84dd-edeeb5935d17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_c8c02317-a1ae-473a-b399-2394e99035aa_terseLabel_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired balances, net of post-acquisition adjustments</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_label_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_documentation_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:href="moh-20220331.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:to="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_9766ba2b-7771-4b80-8ef2-9a9631558d0b_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:href="moh-20220331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_74c4a58b-24c9-4ca6-9d09-f83909856918_negatedLabel_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock withheld to settle employee tax obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_label_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_documentation_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:href="moh-20220331.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:to="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_326e4319-94c5-484c-83dd-45a07e5f29e7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b28d4966-ad4b-49ff-8304-f158cd88d1af_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_58e264d0-9d91-4a18-b57a-0c5d96bfa15b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1da30017-17c2-4b0d-b9ba-353d1e9fc388_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>moh-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6096143c-bea0-4d64-8a46-ebe0e276f797,g:2f020790-0dbf-4089-8da8-8ebe5a4cb586-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_12d3c17c-80ea-40a4-937b-4418b8f433f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_DocumentType_12d3c17c-80ea-40a4-937b-4418b8f433f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_61590acc-6d2a-4edb-9d62-bfc0c98aa267" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_DocumentQuarterlyReport_61590acc-6d2a-4edb-9d62-bfc0c98aa267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1cb1e038-fc74-406d-b03f-fea23b96ffde" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_DocumentPeriodEndDate_1cb1e038-fc74-406d-b03f-fea23b96ffde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_564b7b2f-8840-4f2a-987e-695862a53764" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_DocumentTransitionReport_564b7b2f-8840-4f2a-987e-695862a53764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6e0c1c22-c283-4910-868a-81e8c937bc6b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityFileNumber_6e0c1c22-c283-4910-868a-81e8c937bc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_266dcaca-e1f1-4a5b-b120-3bef94735e70" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityRegistrantName_266dcaca-e1f1-4a5b-b120-3bef94735e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ba798e88-33c2-4b85-b756-e1a0a743a363" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ba798e88-33c2-4b85-b756-e1a0a743a363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5c944a95-1120-4a92-965c-d79e4982d4aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityTaxIdentificationNumber_5c944a95-1120-4a92-965c-d79e4982d4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_26930a29-1c9d-4c59-97eb-b94ce848ed54" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityAddressAddressLine1_26930a29-1c9d-4c59-97eb-b94ce848ed54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_beb82365-8471-4740-a435-c8ddad57292e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityAddressAddressLine2_beb82365-8471-4740-a435-c8ddad57292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2816fafd-4d5b-453e-b880-2574e43c70cc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityAddressCityOrTown_2816fafd-4d5b-453e-b880-2574e43c70cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_460d7c9b-8e54-4551-ad6e-1c8b66da8b49" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityAddressStateOrProvince_460d7c9b-8e54-4551-ad6e-1c8b66da8b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_225d6cfd-f959-4380-a30a-0c39067d4b22" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityAddressPostalZipCode_225d6cfd-f959-4380-a30a-0c39067d4b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_272c487b-8f1b-472a-b2b3-891ec9d6a40d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_CityAreaCode_272c487b-8f1b-472a-b2b3-891ec9d6a40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9d4c0797-f15f-49ed-9899-a42459a76845" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_LocalPhoneNumber_9d4c0797-f15f-49ed-9899-a42459a76845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d8023901-0df7-44ed-9a52-4a99027fab85" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_Security12bTitle_d8023901-0df7-44ed-9a52-4a99027fab85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1b5c4902-67e0-45fd-a555-bc6e5b90204d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_TradingSymbol_1b5c4902-67e0-45fd-a555-bc6e5b90204d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_41267cc4-5fe6-401f-ae42-a36fdaeb4561" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_SecurityExchangeName_41267cc4-5fe6-401f-ae42-a36fdaeb4561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c1cfc858-7934-423c-9af4-b17a2acf1a48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityCurrentReportingStatus_c1cfc858-7934-423c-9af4-b17a2acf1a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_dcc3b3c6-65b4-4a9c-a426-6bb1086c0509" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityInteractiveDataCurrent_dcc3b3c6-65b4-4a9c-a426-6bb1086c0509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3f614efb-44a4-4ee9-8804-842420936029" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityFilerCategory_3f614efb-44a4-4ee9-8804-842420936029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bb07554b-9787-4b9f-af8e-377173a7d2a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntitySmallBusiness_bb07554b-9787-4b9f-af8e-377173a7d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6f82f163-56d8-437f-9125-f4b517973b3e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityEmergingGrowthCompany_6f82f163-56d8-437f-9125-f4b517973b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1e1ef1dd-ce10-420b-a510-1c81cd79c133" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityShellCompany_1e1ef1dd-ce10-420b-a510-1c81cd79c133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d37568b2-0c28-4464-b56d-eeaa1dd18c8b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d37568b2-0c28-4464-b56d-eeaa1dd18c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_592c36e1-7781-45c9-8220-454a27d693e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_EntityCentralIndexKey_592c36e1-7781-45c9-8220-454a27d693e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_28c7f56b-a7b7-4565-9183-aac0d14e1f63" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_CurrentFiscalYearEndDate_28c7f56b-a7b7-4565-9183-aac0d14e1f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_47a81deb-3419-4e0d-8ccb-6436a8bcb0d7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_DocumentFiscalYearFocus_47a81deb-3419-4e0d-8ccb-6436a8bcb0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1e10e750-9b91-4889-9445-33b788a40d43" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1e10e750-9b91-4889-9445-33b788a40d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f254557d-2cd2-4e04-b568-65dc0b79daa1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c4f8d1ce-4552-47c2-aaa0-ae9e67427a75" xlink:to="loc_dei_AmendmentFlag_f254557d-2cd2-4e04-b568-65dc0b79daa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_71d32ec9-0097-4471-9aba-f362229f8313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:to="loc_us-gaap_RevenuesAbstract_71d32ec9-0097-4471-9aba-f362229f8313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_bebb5945-8277-41e4-a3d2-b79dd59fec74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_71d32ec9-0097-4471-9aba-f362229f8313" xlink:to="loc_us-gaap_PremiumsEarnedNet_bebb5945-8277-41e4-a3d2-b79dd59fec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_22deb9c6-1d09-4513-b00f-02bd6589c2b0" xlink:href="moh-20220331.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_71d32ec9-0097-4471-9aba-f362229f8313" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_22deb9c6-1d09-4513-b00f-02bd6589c2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_ad8e14be-9119-4f99-a1e8-8860431d2ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_71d32ec9-0097-4471-9aba-f362229f8313" xlink:to="loc_us-gaap_NetInvestmentIncome_ad8e14be-9119-4f99-a1e8-8860431d2ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_8e2ac8f9-ae6d-4b03-a675-d6900d36aa61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_71d32ec9-0097-4471-9aba-f362229f8313" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_8e2ac8f9-ae6d-4b03-a675-d6900d36aa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d14f9b75-0902-453e-9092-36c4f82abfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_71d32ec9-0097-4471-9aba-f362229f8313" xlink:to="loc_us-gaap_Revenues_d14f9b75-0902-453e-9092-36c4f82abfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_04511640-b9ce-4d69-873f-95bdfdb639a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_04511640-b9ce-4d69-873f-95bdfdb639a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5507b137-68a9-41bb-892a-8d96cc5ad54a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5507b137-68a9-41bb-892a-8d96cc5ad54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_a9b8e700-c71c-4bcb-95db-8bc41fd155a5" xlink:href="moh-20220331.xsd#moh_PremiumTaxExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:to="loc_moh_PremiumTaxExpenses_a9b8e700-c71c-4bcb-95db-8bc41fd155a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fb9a85b6-95e3-4c81-b779-24a2aaf3b9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:to="loc_us-gaap_DepreciationAndAmortization_fb9a85b6-95e3-4c81-b779-24a2aaf3b9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_6d2cd332-814c-4ce9-b3a9-a5a05eccfa16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_6d2cd332-814c-4ce9-b3a9-a5a05eccfa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e07c4407-a452-4582-aac2-ca795558a83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:to="loc_us-gaap_CostsAndExpenses_e07c4407-a452-4582-aac2-ca795558a83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1e1329bd-b41f-4cf8-9547-57b96a20ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_47ce676d-7743-4d24-851d-8bf78360717b" xlink:to="loc_us-gaap_OperatingIncomeLoss_1e1329bd-b41f-4cf8-9547-57b96a20ec25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_452d6a2c-0086-434a-9ee6-3305749718b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_452d6a2c-0086-434a-9ee6-3305749718b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_570584a0-1faf-49d8-84af-2846fb60fd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_452d6a2c-0086-434a-9ee6-3305749718b4" xlink:to="loc_us-gaap_InterestExpense_570584a0-1faf-49d8-84af-2846fb60fd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5cf579e8-41b7-4ba0-b8b5-bab19dff3062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_452d6a2c-0086-434a-9ee6-3305749718b4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5cf579e8-41b7-4ba0-b8b5-bab19dff3062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bc92b3e-b850-441e-8c10-aca4acd8df89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bc92b3e-b850-441e-8c10-aca4acd8df89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f7a5e616-b06b-4cf9-b389-31e14218b5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f7a5e616-b06b-4cf9-b389-31e14218b5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2e97b984-7030-4cf3-9f08-84122f634421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:to="loc_us-gaap_NetIncomeLoss_2e97b984-7030-4cf3-9f08-84122f634421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_55277668-8ba7-4e21-a94b-499cb3f2bfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_02bb2f37-c436-402d-b692-fcb7f63a0f26" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_55277668-8ba7-4e21-a94b-499cb3f2bfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d4cf9d2f-85de-45e8-bb0b-d8e86c382710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_55277668-8ba7-4e21-a94b-499cb3f2bfa8" xlink:to="loc_us-gaap_EarningsPerShareBasic_d4cf9d2f-85de-45e8-bb0b-d8e86c382710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aa33cc57-1a91-4e47-be47-e8463f761b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_55277668-8ba7-4e21-a94b-499cb3f2bfa8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aa33cc57-1a91-4e47-be47-e8463f761b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f6d6569b-f6d0-4d0c-b8dd-9d5eda6adbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a10af6ab-4867-4fd0-800f-94e73d5293b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f6d6569b-f6d0-4d0c-b8dd-9d5eda6adbf6" xlink:to="loc_us-gaap_NetIncomeLoss_a10af6ab-4867-4fd0-800f-94e73d5293b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7836ac77-302f-4bbc-ac02-70aca6b402a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f6d6569b-f6d0-4d0c-b8dd-9d5eda6adbf6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7836ac77-302f-4bbc-ac02-70aca6b402a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_09482a62-f795-45ae-a81c-180ad7519f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7836ac77-302f-4bbc-ac02-70aca6b402a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_09482a62-f795-45ae-a81c-180ad7519f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_da977b4f-a1cf-42fb-8541-06a8030786b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7836ac77-302f-4bbc-ac02-70aca6b402a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_da977b4f-a1cf-42fb-8541-06a8030786b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1af02ed6-50b6-4d68-8dd2-4af1467389d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7836ac77-302f-4bbc-ac02-70aca6b402a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1af02ed6-50b6-4d68-8dd2-4af1467389d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_18574bfd-f8d9-49d1-a42f-b82b18f4f13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f6d6569b-f6d0-4d0c-b8dd-9d5eda6adbf6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_18574bfd-f8d9-49d1-a42f-b82b18f4f13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ee7ed1d3-2460-40cf-ba53-64adb5d00ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee7ed1d3-2460-40cf-ba53-64adb5d00ad5" xlink:to="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d81184e9-3b05-4069-9601-5c7ef679260e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d81184e9-3b05-4069-9601-5c7ef679260e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e22e38d6-da72-46e7-ae2a-cbca09412281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d81184e9-3b05-4069-9601-5c7ef679260e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e22e38d6-da72-46e7-ae2a-cbca09412281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_eb2c2508-629a-4d54-8810-006a88604756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d81184e9-3b05-4069-9601-5c7ef679260e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_eb2c2508-629a-4d54-8810-006a88604756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_40651b62-59d2-452d-bf26-bdda6a81f803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d81184e9-3b05-4069-9601-5c7ef679260e" xlink:to="loc_us-gaap_ReceivablesNetCurrent_40651b62-59d2-452d-bf26-bdda6a81f803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ebfca9db-bea9-4ba3-b10c-9ef58d449c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d81184e9-3b05-4069-9601-5c7ef679260e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ebfca9db-bea9-4ba3-b10c-9ef58d449c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3aab2e11-edda-43c3-b1ef-ee9d928f62af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d81184e9-3b05-4069-9601-5c7ef679260e" xlink:to="loc_us-gaap_AssetsCurrent_3aab2e11-edda-43c3-b1ef-ee9d928f62af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a4a1ba26-2a91-4c62-a5da-520028630d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a4a1ba26-2a91-4c62-a5da-520028630d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_fa79dcdd-59fe-4a32-9f63-7f0010ab556c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_fa79dcdd-59fe-4a32-9f63-7f0010ab556c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_3a12b947-cbbd-414c-bfd8-30af7434c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_3a12b947-cbbd-414c-bfd8-30af7434c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_bd44c367-188f-41ae-82c2-13d4e1523b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_bd44c367-188f-41ae-82c2-13d4e1523b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f4071242-ae00-4995-b188-6374769c67a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f4071242-ae00-4995-b188-6374769c67a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7234ed4b-5349-46a9-ac2a-fb9e04349101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_abb24ffb-f9d2-45b9-9be2-c3b7d9eb8cd1" xlink:to="loc_us-gaap_Assets_7234ed4b-5349-46a9-ac2a-fb9e04349101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ee7ed1d3-2460-40cf-ba53-64adb5d00ad5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4ed3e110-0a38-4aaf-a6e1-402188333bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4ed3e110-0a38-4aaf-a6e1-402188333bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5b7a7ffc-6fbc-4307-9349-067a870a5410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ed3e110-0a38-4aaf-a6e1-402188333bf6" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5b7a7ffc-6fbc-4307-9349-067a870a5410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_269268f7-114c-4c23-a03b-fe7ca8d7cd99" xlink:href="moh-20220331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ed3e110-0a38-4aaf-a6e1-402188333bf6" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_269268f7-114c-4c23-a03b-fe7ca8d7cd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_43c57520-1ebe-419b-8358-3cec45b4e8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ed3e110-0a38-4aaf-a6e1-402188333bf6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_43c57520-1ebe-419b-8358-3cec45b4e8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca8be345-3d8f-46d0-9eba-b5596aeaf8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ed3e110-0a38-4aaf-a6e1-402188333bf6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ca8be345-3d8f-46d0-9eba-b5596aeaf8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3eb83e48-85b0-43ae-af6c-b0b8321c84c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4ed3e110-0a38-4aaf-a6e1-402188333bf6" xlink:to="loc_us-gaap_LiabilitiesCurrent_3eb83e48-85b0-43ae-af6c-b0b8321c84c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3c4cecc8-6e27-422a-94d9-80efeb432b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3c4cecc8-6e27-422a-94d9-80efeb432b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_778c8d5c-3322-4f1e-b982-05c2385549f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_778c8d5c-3322-4f1e-b982-05c2385549f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_eaf4fa26-45ee-478f-83cd-05f6ed9580ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_eaf4fa26-45ee-478f-83cd-05f6ed9580ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_19a5cdfc-e8b3-42cb-a108-8368e4c4b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:to="loc_us-gaap_Liabilities_19a5cdfc-e8b3-42cb-a108-8368e4c4b5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_92b3cd2d-7238-4179-b911-b5a394458337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:to="loc_us-gaap_CommonStockValueOutstanding_92b3cd2d-7238-4179-b911-b5a394458337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4e825e3a-ca42-40ac-bfa1-bafc24737f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:to="loc_us-gaap_PreferredStockValue_4e825e3a-ca42-40ac-bfa1-bafc24737f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_029e1211-a4ff-49a0-9e43-9cc62a2a93ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_029e1211-a4ff-49a0-9e43-9cc62a2a93ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_df29ced2-12b7-4611-b50a-583ff8723107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_df29ced2-12b7-4611-b50a-583ff8723107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9e4dace5-6c5a-4920-a729-134edb96275c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9e4dace5-6c5a-4920-a729-134edb96275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_caaf36ef-a981-43e8-a9c3-0b324f11a0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2c9af738-a4af-4bcd-85b9-1b7218682441" xlink:to="loc_us-gaap_StockholdersEquity_caaf36ef-a981-43e8-a9c3-0b324f11a0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_83254292-81dc-44b5-aced-6dbe969a9b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_470a1223-b8a1-41f4-9788-cb6f1eb9fd4a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_83254292-81dc-44b5-aced-6dbe969a9b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1bdbe51c-f0cc-4aa0-ae78-9abfc7325ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1bdbe51c-f0cc-4aa0-ae78-9abfc7325ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d1f31f58-4da2-40bc-8ef4-25ced2526394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d1f31f58-4da2-40bc-8ef4-25ced2526394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0763d92d-19cb-4369-826b-22a27d0202d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0763d92d-19cb-4369-826b-22a27d0202d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0390f420-3353-4a44-8142-49ea32779260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0390f420-3353-4a44-8142-49ea32779260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dc7895ae-6cec-463b-82dd-6516e49c9ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dc7895ae-6cec-463b-82dd-6516e49c9ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4e029548-4eb7-4303-a716-b881e58e049e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4e029548-4eb7-4303-a716-b881e58e049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f09d2ce2-38bc-4cca-9dc9-e83336930ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0e64b25-40bd-4605-8495-43e22fe2ab31" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f09d2ce2-38bc-4cca-9dc9-e83336930ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_55ca16e4-b01f-4c70-8669-380af990504f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0cd41da1-5171-478c-a7f4-cb8bcb92d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_55ca16e4-b01f-4c70-8669-380af990504f" xlink:to="loc_us-gaap_StatementTable_0cd41da1-5171-478c-a7f4-cb8bcb92d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8be05066-b7a1-4099-8bf5-a0b52298217a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0cd41da1-5171-478c-a7f4-cb8bcb92d5d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8be05066-b7a1-4099-8bf5-a0b52298217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8be05066-b7a1-4099-8bf5-a0b52298217a" xlink:to="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f192906d-e24b-42d1-95a0-bbc8a3f51dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_CommonStockMember_f192906d-e24b-42d1-95a0-bbc8a3f51dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b0c12295-0f19-4fb3-9b29-7a63916a3a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b0c12295-0f19-4fb3-9b29-7a63916a3a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fe3dedc8-3760-4857-8d06-72932fd7f39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fe3dedc8-3760-4857-8d06-72932fd7f39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_45e1ceb2-822f-48d1-bd02-3f07e57a34be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4898311e-4e8b-43ba-8f6d-daa412e7669a" xlink:to="loc_us-gaap_RetainedEarningsMember_45e1ceb2-822f-48d1-bd02-3f07e57a34be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c893ed6d-ed6c-4537-8c39-222d3c6a5f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0cd41da1-5171-478c-a7f4-cb8bcb92d5d1" xlink:to="loc_us-gaap_StatementLineItems_c893ed6d-ed6c-4537-8c39-222d3c6a5f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c893ed6d-ed6c-4537-8c39-222d3c6a5f74" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_74b25c20-8c9d-4c36-bbb0-512c370451c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_SharesOutstanding_74b25c20-8c9d-4c36-bbb0-512c370451c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b3d5ab17-cda4-4afa-8ab4-dbc5c88f9119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockholdersEquity_b3d5ab17-cda4-4afa-8ab4-dbc5c88f9119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38a6f2cf-9564-43e9-b337-c4c7d7ea92ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_NetIncomeLoss_38a6f2cf-9564-43e9-b337-c4c7d7ea92ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee937006-f42b-4db6-8413-58e0bc3eb1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ee937006-f42b-4db6-8413-58e0bc3eb1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_42c222dc-2247-45ad-a635-36e4f586215a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_42c222dc-2247-45ad-a635-36e4f586215a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_9d905424-120e-4f34-965c-26e1aa4f0604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_9d905424-120e-4f34-965c-26e1aa4f0604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88659662-167c-4abf-85f4-5aa7efdbd3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88659662-167c-4abf-85f4-5aa7efdbd3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_efd5eacb-3c2c-43df-8f48-ffaec5c0bb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_efd5eacb-3c2c-43df-8f48-ffaec5c0bb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_773f3bd0-9854-4dca-9d23-905a1eb9f6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_SharesOutstanding_773f3bd0-9854-4dca-9d23-905a1eb9f6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ddf29092-e18d-41f8-b693-7fb91b33f0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8bfea5ab-2921-479b-8529-61ab392c292e" xlink:to="loc_us-gaap_StockholdersEquity_ddf29092-e18d-41f8-b693-7fb91b33f0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20220331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b90248cb-1154-4816-b3eb-286c80fb7446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da2f0077-52f0-4c22-b0a1-8587c000fa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b90248cb-1154-4816-b3eb-286c80fb7446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da2f0077-52f0-4c22-b0a1-8587c000fa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68d21aef-b7d8-46bd-8558-0cd2f128b03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da2f0077-52f0-4c22-b0a1-8587c000fa9e" xlink:to="loc_us-gaap_NetIncomeLoss_68d21aef-b7d8-46bd-8558-0cd2f128b03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_127c614b-02c6-4e65-b7b4-d976f75c4714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da2f0077-52f0-4c22-b0a1-8587c000fa9e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_127c614b-02c6-4e65-b7b4-d976f75c4714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_aca1646f-a833-4c55-b13b-12ab29a87e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_127c614b-02c6-4e65-b7b4-d976f75c4714" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_aca1646f-a833-4c55-b13b-12ab29a87e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e9c101fd-c7a4-476d-a0aa-1b3a18b9e6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_127c614b-02c6-4e65-b7b4-d976f75c4714" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e9c101fd-c7a4-476d-a0aa-1b3a18b9e6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d6f9ef8c-2d24-4749-a42f-159bfb3f77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_127c614b-02c6-4e65-b7b4-d976f75c4714" xlink:to="loc_us-gaap_ShareBasedCompensation_d6f9ef8c-2d24-4749-a42f-159bfb3f77e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d73215d1-a872-4645-b9f7-cec71a331fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_127c614b-02c6-4e65-b7b4-d976f75c4714" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d73215d1-a872-4645-b9f7-cec71a331fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_127c614b-02c6-4e65-b7b4-d976f75c4714" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_970ab793-13a2-4bf7-a073-251b1d4e6402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_970ab793-13a2-4bf7-a073-251b1d4e6402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99d2731e-5eb8-4202-8a2f-6ff90e1266d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99d2731e-5eb8-4202-8a2f-6ff90e1266d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_5bec2049-2df2-46bf-8f25-dce4e0adb7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_5bec2049-2df2-46bf-8f25-dce4e0adb7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_e00ac37b-3acf-4c22-b1c5-61929196980e" xlink:href="moh-20220331.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_e00ac37b-3acf-4c22-b1c5-61929196980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6edcc61a-a81e-416a-b8b5-772a833ce700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6edcc61a-a81e-416a-b8b5-772a833ce700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dbae1a0b-6516-48d8-bec1-aed71b567193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dbae1a0b-6516-48d8-bec1-aed71b567193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b38b3d6d-436a-483b-8532-03b2b5a2d83a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_78a4a340-1837-4563-b8bb-9fa9f20b48f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b38b3d6d-436a-483b-8532-03b2b5a2d83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3cd8d9e-c5fb-4c51-b6ec-65a124602318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_da2f0077-52f0-4c22-b0a1-8587c000fa9e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3cd8d9e-c5fb-4c51-b6ec-65a124602318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39cc60d3-d363-411d-abb1-f84dc8daa580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b90248cb-1154-4816-b3eb-286c80fb7446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39cc60d3-d363-411d-abb1-f84dc8daa580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5067faf1-8e55-48dc-8acd-9c2354ae2173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39cc60d3-d363-411d-abb1-f84dc8daa580" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5067faf1-8e55-48dc-8acd-9c2354ae2173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_46a68a7d-0671-426c-8cf9-33e82137ae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39cc60d3-d363-411d-abb1-f84dc8daa580" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_46a68a7d-0671-426c-8cf9-33e82137ae3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3d4241ab-1f17-40b9-a8e4-f4f764378977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39cc60d3-d363-411d-abb1-f84dc8daa580" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3d4241ab-1f17-40b9-a8e4-f4f764378977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8f081632-8d71-4287-8443-cd50165139b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39cc60d3-d363-411d-abb1-f84dc8daa580" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8f081632-8d71-4287-8443-cd50165139b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55220996-d60f-44ad-8f5a-782a672f78e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39cc60d3-d363-411d-abb1-f84dc8daa580" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55220996-d60f-44ad-8f5a-782a672f78e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_686ac698-e182-443a-9756-4cdb61f1e7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b90248cb-1154-4816-b3eb-286c80fb7446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_686ac698-e182-443a-9756-4cdb61f1e7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_7dae8496-8c0a-491f-98b6-fd5b7e6c065f" xlink:href="moh-20220331.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_686ac698-e182-443a-9756-4cdb61f1e7ae" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_7dae8496-8c0a-491f-98b6-fd5b7e6c065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_03dcf6e3-5eb4-4d87-bc09-7e3eee6a438a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_686ac698-e182-443a-9756-4cdb61f1e7ae" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_03dcf6e3-5eb4-4d87-bc09-7e3eee6a438a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bf51f7fe-f90d-45a7-adf7-54dd3c099857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_686ac698-e182-443a-9756-4cdb61f1e7ae" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_bf51f7fe-f90d-45a7-adf7-54dd3c099857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ac8565ec-f1a6-4018-98da-543d4f076d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_686ac698-e182-443a-9756-4cdb61f1e7ae" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ac8565ec-f1a6-4018-98da-543d4f076d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_58ff63ac-e8ff-4ad1-b001-598453abde2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_686ac698-e182-443a-9756-4cdb61f1e7ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_58ff63ac-e8ff-4ad1-b001-598453abde2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64fbb075-5cf8-4af4-b88e-608cad24f92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b90248cb-1154-4816-b3eb-286c80fb7446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64fbb075-5cf8-4af4-b88e-608cad24f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b1cf189-6aa4-45e8-bacb-e8582eaecda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b90248cb-1154-4816-b3eb-286c80fb7446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b1cf189-6aa4-45e8-bacb-e8582eaecda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63fce4a2-8b18-4301-8ac1-89526d3c2c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b90248cb-1154-4816-b3eb-286c80fb7446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63fce4a2-8b18-4301-8ac1-89526d3c2c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20220331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53889708-1b81-4b3c-918d-e08ef9f5382d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dea512cf-d959-45a8-9b4f-004d060bac3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53889708-1b81-4b3c-918d-e08ef9f5382d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dea512cf-d959-45a8-9b4f-004d060bac3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b92dd3e-b097-4e3a-a93d-7d338e1e8ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6b92dd3e-b097-4e3a-a93d-7d338e1e8ac4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c89f01f7-52fd-44ab-9ce8-faf97bd605ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d71b6be-73e2-4f9a-8c0b-6d1c3b03606e" xlink:to="loc_us-gaap_SegmentDomain_c89f01f7-52fd-44ab-9ce8-faf97bd605ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_a115c387-1dbb-4824-958d-4bb11e0c7d3f" xlink:href="moh-20220331.xsd#moh_HealthPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c89f01f7-52fd-44ab-9ce8-faf97bd605ce" xlink:to="loc_moh_HealthPlansMember_a115c387-1dbb-4824-958d-4bb11e0c7d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_09a0c88d-be98-4f0b-b9a6-bb71a49d894d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:to="loc_srt_RangeAxis_09a0c88d-be98-4f0b-b9a6-bb71a49d894d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_09a0c88d-be98-4f0b-b9a6-bb71a49d894d" xlink:to="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea9b2ad2-b656-48c5-8246-c444822ba1a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:to="loc_srt_MinimumMember_ea9b2ad2-b656-48c5-8246-c444822ba1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1a8e2d8-a0e9-405a-8f47-158d8fe44f6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a8295d22-1701-4972-9ddd-83eecb84cae8" xlink:to="loc_srt_MaximumMember_d1a8e2d8-a0e9-405a-8f47-158d8fe44f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_08da7540-4d12-4357-be04-c1b3b250ca48" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfReportableSegment_56b1885a-e4fb-4d08-887e-b78435509a40" xlink:href="moh-20220331.xsd#moh_NumberOfReportableSegment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_NumberOfReportableSegment_56b1885a-e4fb-4d08-887e-b78435509a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_6410f212-3d48-430b-ae40-fea28d6b8ca7" xlink:href="moh-20220331.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_6410f212-3d48-430b-ae40-fea28d6b8ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_c5fc8e25-9d41-4b5f-8e1d-f26435a221e8" xlink:href="moh-20220331.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_c5fc8e25-9d41-4b5f-8e1d-f26435a221e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_3860d471-910a-45e7-bcea-30e1033a2973" xlink:href="moh-20220331.xsd#moh_HealthPlanContractTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_HealthPlanContractTerm_3860d471-910a-45e7-bcea-30e1033a2973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod_eb2f8646-3e23-4e1b-bba5-c5f67899fd4a" xlink:href="moh-20220331.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a800abf5-93cc-4df4-baf9-173991b621bd" xlink:to="loc_moh_HealthPlanExtensionOptionPeriod_eb2f8646-3e23-4e1b-bba5-c5f67899fd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bbe6f599-54e8-4e69-a07a-a434d0eb3262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0747e896-c95e-4d2e-90c1-dbbfc783f056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bbe6f599-54e8-4e69-a07a-a434d0eb3262" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0747e896-c95e-4d2e-90c1-dbbfc783f056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_3fff197f-79ea-4789-bf4f-a3c8f422839b" xlink:href="moh-20220331.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_3fff197f-79ea-4789-bf4f-a3c8f422839b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b0ce3e29-0747-452d-b72d-83096a1dd707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_us-gaap_UseOfEstimates_b0ce3e29-0747-452d-b72d-83096a1dd707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7aadc9e4-bafb-4cb0-bf3d-249a52a54199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7aadc9e4-bafb-4cb0-bf3d-249a52a54199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_58369240-e336-4895-9606-affaaebcf706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_58369240-e336-4895-9606-affaaebcf706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_66836da1-9d6e-4365-9f82-eb48ee401537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_66836da1-9d6e-4365-9f82-eb48ee401537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_3c3d3214-407e-4981-b97a-8ad65c99faed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_3c3d3214-407e-4981-b97a-8ad65c99faed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6a27ed21-268a-40ac-a2df-dc18ea657d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6a27ed21-268a-40ac-a2df-dc18ea657d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f0bd7bd-542a-42c7-adef-94b96ae99445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28a8e50f-30c3-4594-b96a-c9a3be716a01" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f0bd7bd-542a-42c7-adef-94b96ae99445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4bc50d54-5497-468f-acdd-d4594c05b586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_452275a4-91a0-4df3-b9f7-082f82657cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4bc50d54-5497-468f-acdd-d4594c05b586" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_452275a4-91a0-4df3-b9f7-082f82657cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_05947762-b338-4919-8638-9b2113036e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4bc50d54-5497-468f-acdd-d4594c05b586" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_05947762-b338-4919-8638-9b2113036e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1482927b-64c7-4794-a356-9fa5fc1e4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4bc50d54-5497-468f-acdd-d4594c05b586" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1482927b-64c7-4794-a356-9fa5fc1e4b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_7dfeb674-c7f4-4a6f-9113-f6e239c20ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4bc50d54-5497-468f-acdd-d4594c05b586" xlink:to="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_7dfeb674-c7f4-4a6f-9113-f6e239c20ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_efc5d5eb-d303-44b4-b8e5-7281bb59cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b64a2331-f578-416b-8883-694db2d2f65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_efc5d5eb-d303-44b4-b8e5-7281bb59cc62" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b64a2331-f578-416b-8883-694db2d2f65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3d90c00d-27e4-4215-b7dd-3dbab5ff8d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_efc5d5eb-d303-44b4-b8e5-7281bb59cc62" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3d90c00d-27e4-4215-b7dd-3dbab5ff8d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e561746f-028d-48d4-8e2c-19a122ffe697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_efc5d5eb-d303-44b4-b8e5-7281bb59cc62" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e561746f-028d-48d4-8e2c-19a122ffe697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1c0a8296-acd3-4a1a-8159-e221877d0ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a334c5bf-75d1-4ad4-a8e6-1e99c08bfaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c0a8296-acd3-4a1a-8159-e221877d0ea2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a334c5bf-75d1-4ad4-a8e6-1e99c08bfaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1be773a1-a455-41bd-b2a7-e6a9db00fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a334c5bf-75d1-4ad4-a8e6-1e99c08bfaec" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1be773a1-a455-41bd-b2a7-e6a9db00fa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1be773a1-a455-41bd-b2a7-e6a9db00fa0a" xlink:to="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_735084ef-640b-4992-b692-03690c9775cb" xlink:href="moh-20220331.xsd#moh_GovernmentReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:to="loc_moh_GovernmentReceivablesMember_735084ef-640b-4992-b692-03690c9775cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_3bd136ca-3cca-4acb-af73-d81e6513a2c1" xlink:href="moh-20220331.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:to="loc_moh_PharmacyRebateReceivablesMember_3bd136ca-3cca-4acb-af73-d81e6513a2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_52115bb8-da00-457b-adc8-8dade18a3a4c" xlink:href="moh-20220331.xsd#moh_OtherReceivablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_1ed27f19-67e6-4fb3-a5d7-bff400b8c5a5" xlink:to="loc_moh_OtherReceivablesMember_52115bb8-da00-457b-adc8-8dade18a3a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cd1ed4d6-71ce-4b53-899c-77a2d88e426d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a334c5bf-75d1-4ad4-a8e6-1e99c08bfaec" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cd1ed4d6-71ce-4b53-899c-77a2d88e426d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8cec37d4-8035-40e0-ae15-8bf2c10924c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_cd1ed4d6-71ce-4b53-899c-77a2d88e426d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8cec37d4-8035-40e0-ae15-8bf2c10924c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a1ffd4f1-c0e9-406c-bf27-2f916b6593f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_c10a0f12-c0c0-486c-a059-940c02c89a97" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1ffd4f1-c0e9-406c-bf27-2f916b6593f3" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_c10a0f12-c0c0-486c-a059-940c02c89a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_888bda2c-cb49-46f1-9b66-77513ba66ac5" xlink:href="moh-20220331.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_c10a0f12-c0c0-486c-a059-940c02c89a97" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_888bda2c-cb49-46f1-9b66-77513ba66ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_59b00499-fa60-4650-a74c-7a7a78e650f9" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_c10a0f12-c0c0-486c-a059-940c02c89a97" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_59b00499-fa60-4650-a74c-7a7a78e650f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_2410bdd2-3943-4ec4-8e84-fae8a9461d67" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1ffd4f1-c0e9-406c-bf27-2f916b6593f3" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_2410bdd2-3943-4ec4-8e84-fae8a9461d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_d02e06c6-2a81-4171-9d69-e8d424a1a8f2" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_2410bdd2-3943-4ec4-8e84-fae8a9461d67" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_d02e06c6-2a81-4171-9d69-e8d424a1a8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_24b3a66f-077e-4224-95e4-ef961432ca0d" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_2410bdd2-3943-4ec4-8e84-fae8a9461d67" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_24b3a66f-077e-4224-95e4-ef961432ca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_07183678-f976-450a-ab19-ee393391b99c" xlink:href="moh-20220331.xsd#moh_OtherMedicareProgram"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_2410bdd2-3943-4ec4-8e84-fae8a9461d67" xlink:to="loc_moh_OtherMedicareProgram_07183678-f976-450a-ab19-ee393391b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_02b4f0a1-88fa-409b-8170-c08f4f0a725a" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1ffd4f1-c0e9-406c-bf27-2f916b6593f3" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_02b4f0a1-88fa-409b-8170-c08f4f0a725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_e65e607b-545f-471d-b714-9c63a376ebbe" xlink:href="moh-20220331.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_02b4f0a1-88fa-409b-8170-c08f4f0a725a" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_e65e607b-545f-471d-b714-9c63a376ebbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_25810f11-73b2-4e9b-9ab3-f3cba59c3f55" xlink:href="moh-20220331.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_02b4f0a1-88fa-409b-8170-c08f4f0a725a" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_25810f11-73b2-4e9b-9ab3-f3cba59c3f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_92330913-3030-4377-a43d-130dbc9dd054" xlink:href="moh-20220331.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_02b4f0a1-88fa-409b-8170-c08f4f0a725a" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_92330913-3030-4377-a43d-130dbc9dd054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_ac4f605f-2954-4c0a-a7a3-fa6432b88f4b" xlink:href="moh-20220331.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1ffd4f1-c0e9-406c-bf27-2f916b6593f3" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_ac4f605f-2954-4c0a-a7a3-fa6432b88f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_69bfb9d5-f065-453b-bee6-ecb71a6a5b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:href="moh-20220331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69bfb9d5-f065-453b-bee6-ecb71a6a5b26" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_38f834fa-d75c-459c-9995-f095c626a2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_38f834fa-d75c-459c-9995-f095c626a2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_ebd9cda5-e683-46ba-8740-d7bf014388aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_38f834fa-d75c-459c-9995-f095c626a2e3" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_ebd9cda5-e683-46ba-8740-d7bf014388aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_291d445a-c683-4a7e-8b04-595171ec5eb8" xlink:href="moh-20220331.xsd#moh_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_ebd9cda5-e683-46ba-8740-d7bf014388aa" xlink:to="loc_moh_COVID19Member_291d445a-c683-4a7e-8b04-595171ec5eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c046a5b0-f9f3-4506-950e-4b7a34588183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c046a5b0-f9f3-4506-950e-4b7a34588183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e9b283-79f6-4952-a05b-4e99a33bc054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c046a5b0-f9f3-4506-950e-4b7a34588183" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e9b283-79f6-4952-a05b-4e99a33bc054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_StructuredSecuritiesMember_41b3bc98-a5ad-4d78-ae72-340c1c22940f" xlink:href="moh-20220331.xsd#moh_StructuredSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94e9b283-79f6-4952-a05b-4e99a33bc054" xlink:to="loc_moh_StructuredSecuritiesMember_41b3bc98-a5ad-4d78-ae72-340c1c22940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:href="moh-20220331.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_66b79aee-4901-41f1-bc53-cabd5130ac38" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc241142-4a8e-497b-ba0f-2250033f9877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_bc241142-4a8e-497b-ba0f-2250033f9877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_b3a85470-34ae-4c10-9a61-f52f3ba1e872" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_b3a85470-34ae-4c10-9a61-f52f3ba1e872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_2e0c2867-f15c-4a5a-8725-226e290f3c2b" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_2e0c2867-f15c-4a5a-8725-226e290f3c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_81319309-8247-472d-bb5e-31b236fefdc8" xlink:href="moh-20220331.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_81319309-8247-472d-bb5e-31b236fefdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_72c4ab39-47fc-4a15-98f4-341cd69c0924" xlink:href="moh-20220331.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_InvestmentsMaturityPeriod_72c4ab39-47fc-4a15-98f4-341cd69c0924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_75da8e59-cf8f-49bf-9d3b-d906dcf62239" xlink:href="moh-20220331.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_410bab5e-ee22-434b-9f33-d0c1a7972fad" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_75da8e59-cf8f-49bf-9d3b-d906dcf62239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="moh-20220331.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d960b992-00a0-46d3-a527-70235e593a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3731780d-dde6-4d74-9cb5-4155e4f31a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d960b992-00a0-46d3-a527-70235e593a91" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3731780d-dde6-4d74-9cb5-4155e4f31a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="moh-20220331.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7cec2fc3-0fb3-4655-b934-303b6535f774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3ee37bea-c719-4cb5-9bd0-18ac63369a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7cec2fc3-0fb3-4655-b934-303b6535f774" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3ee37bea-c719-4cb5-9bd0-18ac63369a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#NetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ff1c0858-8147-45f3-bd8d-d848247d43b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_053c4272-4e1f-4204-96f1-f2d89f8a06a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff1c0858-8147-45f3-bd8d-d848247d43b3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_053c4272-4e1f-4204-96f1-f2d89f8a06a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f8b0d21-3f0a-4f2e-a439-2e40bf5c0974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_053c4272-4e1f-4204-96f1-f2d89f8a06a4" xlink:to="loc_us-gaap_NetIncomeLoss_5f8b0d21-3f0a-4f2e-a439-2e40bf5c0974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_787c5e5c-4cfa-4e79-a3b1-ea35ffeca106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff1c0858-8147-45f3-bd8d-d848247d43b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_787c5e5c-4cfa-4e79-a3b1-ea35ffeca106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SharesOutstandingExcludingRestrictedStockAwards_22907735-702a-4034-a08d-39c923a23162" xlink:href="moh-20220331.xsd#moh_SharesOutstandingExcludingRestrictedStockAwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_787c5e5c-4cfa-4e79-a3b1-ea35ffeca106" xlink:to="loc_moh_SharesOutstandingExcludingRestrictedStockAwards_22907735-702a-4034-a08d-39c923a23162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_721aabf2-ef2b-489a-9660-2f9d6ad0220f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_787c5e5c-4cfa-4e79-a3b1-ea35ffeca106" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_721aabf2-ef2b-489a-9660-2f9d6ad0220f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_c64ed31f-26cc-457b-8da3-77b7eeeb255b" xlink:href="moh-20220331.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_721aabf2-ef2b-489a-9660-2f9d6ad0220f" xlink:to="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_c64ed31f-26cc-457b-8da3-77b7eeeb255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_57527204-75d9-4aad-838a-e2fed889e23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_721aabf2-ef2b-489a-9660-2f9d6ad0220f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_57527204-75d9-4aad-838a-e2fed889e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_89cfa8e3-d355-45b7-82e9-bf3918b339a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_721aabf2-ef2b-489a-9660-2f9d6ad0220f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_89cfa8e3-d355-45b7-82e9-bf3918b339a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_2212bbd1-4c8e-44a8-bf46-49870d66e56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_787c5e5c-4cfa-4e79-a3b1-ea35ffeca106" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_2212bbd1-4c8e-44a8-bf46-49870d66e56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_765c74b0-735f-4180-b9f3-52ae3b23dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_2212bbd1-4c8e-44a8-bf46-49870d66e56a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_765c74b0-735f-4180-b9f3-52ae3b23dee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c6cb9456-3616-428f-ad2e-f69a453944e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff1c0858-8147-45f3-bd8d-d848247d43b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c6cb9456-3616-428f-ad2e-f69a453944e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fd1e9d36-87fb-4285-979b-da41d5506f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff1c0858-8147-45f3-bd8d-d848247d43b3" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fd1e9d36-87fb-4285-979b-da41d5506f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dde8b81e-a56f-4190-9404-5dd66a265eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fd1e9d36-87fb-4285-979b-da41d5506f0d" xlink:to="loc_us-gaap_EarningsPerShareBasic_dde8b81e-a56f-4190-9404-5dd66a265eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7c3f0c9f-b4ff-4f9a-94ef-8909f366041f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fd1e9d36-87fb-4285-979b-da41d5506f0d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7c3f0c9f-b4ff-4f9a-94ef-8909f366041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20220331.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4142be3e-982a-4fa6-8271-bde929c4043f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8d9b6663-6e50-4783-a314-d4b1a29795ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4142be3e-982a-4fa6-8271-bde929c4043f" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8d9b6663-6e50-4783-a314-d4b1a29795ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#BusinessCombinationsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c63c2969-58ff-4b7e-a198-7880457b8d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c63c2969-58ff-4b7e-a198-7880457b8d84" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_121a7595-dfb2-449d-bdd5-cbb88089e57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_121a7595-dfb2-449d-bdd5-cbb88089e57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_121a7595-dfb2-449d-bdd5-cbb88089e57e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_33871604-8931-4bb8-ae4b-f90b58eb3650" xlink:href="moh-20220331.xsd#moh_MagellanCompleteCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:to="loc_moh_MagellanCompleteCareMember_33871604-8931-4bb8-ae4b-f90b58eb3650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember_2c6090c6-05ea-4051-8140-298ea183c38a" xlink:href="moh-20220331.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ef854ed-bee1-4cb1-a589-cf904418579b" xlink:to="loc_moh_AffinityHealthPlanIncMember_2c6090c6-05ea-4051-8140-298ea183c38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15391204-4e85-4d7b-99cd-c21a499b845b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15391204-4e85-4d7b-99cd-c21a499b845b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62ffff9d-6d7f-4de1-9cf0-025819305cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15391204-4e85-4d7b-99cd-c21a499b845b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62ffff9d-6d7f-4de1-9cf0-025819305cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember_9e235e05-f765-48d2-a24f-e4d2288dba46" xlink:href="moh-20220331.xsd#moh_MemberListsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62ffff9d-6d7f-4de1-9cf0-025819305cef" xlink:to="loc_moh_MemberListsMember_9e235e05-f765-48d2-a24f-e4d2288dba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5f156ea6-acd0-4f2b-b6d3-470ff2481e23" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3fd76e73-56a0-4220-a618-6f5cf7c05efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3fd76e73-56a0-4220-a618-6f5cf7c05efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_392b9235-d918-4557-b432-55e9416b89f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_392b9235-d918-4557-b432-55e9416b89f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1cb3fdc1-eb56-4554-a684-ea42c536d298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1cb3fdc1-eb56-4554-a684-ea42c536d298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_7a1e5251-4747-49c2-900e-7afd08ef8b74" xlink:href="moh-20220331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_7a1e5251-4747-49c2-900e-7afd08ef8b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_a8f27695-9cb9-4fd8-8023-f2624157cb7b" xlink:href="moh-20220331.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_437ee98b-6991-4e1e-86a1-28b25aa9d93c" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies_a8f27695-9cb9-4fd8-8023-f2624157cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ee5f4e7c-ac57-402d-a3be-3807ae21ec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1548cf58-d8a5-4192-be24-67a8619572cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ee5f4e7c-ac57-402d-a3be-3807ae21ec4d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1548cf58-d8a5-4192-be24-67a8619572cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_15d436c0-cf92-4aa5-a171-a50dcf4e1a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e64d258c-9282-4ee6-a371-b34d1b0a6e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15d436c0-cf92-4aa5-a171-a50dcf4e1a03" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e64d258c-9282-4ee6-a371-b34d1b0a6e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6404bec-a285-431d-9d91-e53d054c9dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15d436c0-cf92-4aa5-a171-a50dcf4e1a03" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6404bec-a285-431d-9d91-e53d054c9dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_42d2c516-9c5d-41cc-b1c1-41f47352efd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42d2c516-9c5d-41cc-b1c1-41f47352efd1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64e6d298-8aa5-422f-a8bc-bf0724d46b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64e6d298-8aa5-422f-a8bc-bf0724d46b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64e6d298-8aa5-422f-a8bc-bf0724d46b29" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2d93d2fc-c922-4aee-a91d-88707fa11072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2d93d2fc-c922-4aee-a91d-88707fa11072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_64100153-fb1c-4e2b-850b-38d4231fe222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_64100153-fb1c-4e2b-850b-38d4231fe222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_48b13798-6f2f-4ea1-8125-7b5c7871caaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b54fbe1a-74b4-4cdc-93b8-3e191fb4ec9d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_48b13798-6f2f-4ea1-8125-7b5c7871caaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9929ebc0-8c7f-484e-bbd8-22c38de08595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9929ebc0-8c7f-484e-bbd8-22c38de08595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9929ebc0-8c7f-484e-bbd8-22c38de08595" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5bbb5be1-28c0-44b9-92b2-05be5ead7a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5bbb5be1-28c0-44b9-92b2-05be5ead7a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_30973455-0ec7-466e-8b5e-5bb3551816e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_30973455-0ec7-466e-8b5e-5bb3551816e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_abf8ab0b-b717-42a9-9a31-587be166d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_abf8ab0b-b717-42a9-9a31-587be166d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_6b089e42-7dad-4860-89fd-618e35894f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_6b089e42-7dad-4860-89fd-618e35894f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_7a7ee6cf-dc04-4ff0-b6b9-fb8a967235ce" xlink:href="moh-20220331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_moh_MunicipalSecuritiesMember_7a7ee6cf-dc04-4ff0-b6b9-fb8a967235ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_7ab9d358-bd82-4b82-8f9e-25afe53c5f6c" xlink:href="moh-20220331.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d25995-0197-4209-a33a-e98b97594880" xlink:to="loc_moh_OtherSecuritiesMember_7ab9d358-bd82-4b82-8f9e-25afe53c5f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6da11e2c-881a-4a57-993a-22c5e8f09294" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7daf6939-d994-49b7-be6d-0bed2cae54cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_7daf6939-d994-49b7-be6d-0bed2cae54cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_050e6815-c0ea-4f6e-a043-a733f1dd8f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_050e6815-c0ea-4f6e-a043-a733f1dd8f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bacf2f7-4322-4ebc-93af-f07c8d8292bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bacf2f7-4322-4ebc-93af-f07c8d8292bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b21c74c7-9eb4-473e-b840-92f762cf3939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3efa6f77-ecc6-4348-b421-6be6b78c4954" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b21c74c7-9eb4-473e-b840-92f762cf3939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_16de3386-f03d-449a-a4d9-72e2e266c33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_16de3386-f03d-449a-a4d9-72e2e266c33a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d4502a75-2c0f-46ea-af82-54bd16129a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d4502a75-2c0f-46ea-af82-54bd16129a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fbad156-eafb-4a9a-8663-d6cc598c20c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d4502a75-2c0f-46ea-af82-54bd16129a48" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fbad156-eafb-4a9a-8663-d6cc598c20c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_147428c7-40c9-4dfe-bd2e-8adf65819010" xlink:href="moh-20220331.xsd#moh_PassportHealthPlanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7fbad156-eafb-4a9a-8663-d6cc598c20c0" xlink:to="loc_moh_PassportHealthPlanIncMember_147428c7-40c9-4dfe-bd2e-8adf65819010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da994eb8-f5ca-453f-b49a-9899b764c707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da994eb8-f5ca-453f-b49a-9899b764c707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c596e2-064e-45a6-a92f-109095252a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_da994eb8-f5ca-453f-b49a-9899b764c707" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c596e2-064e-45a6-a92f-109095252a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_08f89eb9-a32e-4c89-852d-3c591d1f949b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c596e2-064e-45a6-a92f-109095252a26" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_08f89eb9-a32e-4c89-852d-3c591d1f949b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3913d406-c81c-468e-8ed3-e204cad127da" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_6fd47123-962b-4af0-a2c7-c5cbe9ae4f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_6fd47123-962b-4af0-a2c7-c5cbe9ae4f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ca4b5fe-34b3-4553-a87d-2b977cf01048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6ca4b5fe-34b3-4553-a87d-2b977cf01048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d6c393ab-872b-4bb6-a807-894f5efd3bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_d6c393ab-872b-4bb6-a807-894f5efd3bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_b324fce9-7a42-4c89-9ceb-c3d2650468e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_b324fce9-7a42-4c89-9ceb-c3d2650468e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_557477fb-a942-457f-ab74-4681e140aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a8a57d10-c151-4648-b4a6-af64a139f3b0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_557477fb-a942-457f-ab74-4681e140aa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1850ad7c-4a82-4072-99f1-6c53fad89c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1850ad7c-4a82-4072-99f1-6c53fad89c78" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0f853ce-338b-4fae-b585-68f131c3f444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_71ae43a9-c4b0-44ff-975d-c8c57e53e2f7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0f853ce-338b-4fae-b585-68f131c3f444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_40594ccc-451b-44b3-ae79-a1d4e4a3abbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c0f853ce-338b-4fae-b585-68f131c3f444" xlink:to="loc_us-gaap_SeniorNotesMember_40594ccc-451b-44b3-ae79-a1d4e4a3abbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eb873a24-9551-4d1c-b566-27ea8c1924a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:to="loc_us-gaap_DebtInstrumentAxis_eb873a24-9551-4d1c-b566-27ea8c1924a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb873a24-9551-4d1c-b566-27ea8c1924a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_25862a30-d165-4558-8d6a-4462ffcc7f5a" xlink:href="moh-20220331.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:to="loc_moh_A4375SeniorNotesMember_25862a30-d165-4558-8d6a-4462ffcc7f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_dc4b433e-6302-4268-8ac7-c4f2a217e703" xlink:href="moh-20220331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_dc4b433e-6302-4268-8ac7-c4f2a217e703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_55375d0d-74c0-4d5e-a6fa-318b14f5f549" xlink:href="moh-20220331.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5367174-4619-4f70-922d-e1308dd954bf" xlink:to="loc_moh_A3875SeniorNotesMember_55375d0d-74c0-4d5e-a6fa-318b14f5f549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_790f53d4-09cd-4067-a13e-9d8894b9aeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_790f53d4-09cd-4067-a13e-9d8894b9aeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_790f53d4-09cd-4067-a13e-9d8894b9aeb2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6708b80-17fd-42ee-b747-bab1e0fdcfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6708b80-17fd-42ee-b747-bab1e0fdcfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b15a4ae1-e771-43d8-8518-5a55805be004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b15a4ae1-e771-43d8-8518-5a55805be004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f9532cb4-1ddc-45be-9ab6-7c7033adc811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e6989ee5-41d5-4750-a5d0-c1a0d019862c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_f9532cb4-1ddc-45be-9ab6-7c7033adc811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8cb9c214-bf39-4b74-8970-bde881108f1b" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12fbcb77-4f9e-451c-91eb-a2d4db1e4318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12fbcb77-4f9e-451c-91eb-a2d4db1e4318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1868723d-6670-474c-b9c6-40225b6b39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5a957910-c6ef-4882-b089-e1365ccf0a16" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1868723d-6670-474c-b9c6-40225b6b39e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20220331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b61e7b15-598e-4b80-8778-2ced2a76ef5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_45c0972e-ebb4-4870-9f18-1d994a0c910a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b61e7b15-598e-4b80-8778-2ced2a76ef5d" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_45c0972e-ebb4-4870-9f18-1d994a0c910a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d0fb798-de3b-48ea-b5aa-60816883c966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6b6c757e-e42e-4787-899c-eee271da9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d0fb798-de3b-48ea-b5aa-60816883c966" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6b6c757e-e42e-4787-899c-eee271da9b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2cd44990-9414-4335-a1d3-a23906934779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d0fb798-de3b-48ea-b5aa-60816883c966" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2cd44990-9414-4335-a1d3-a23906934779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b14e5fbe-c8b2-4ac7-a872-e8793d3be0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d0fb798-de3b-48ea-b5aa-60816883c966" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b14e5fbe-c8b2-4ac7-a872-e8793d3be0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d0d45744-519c-46e5-b48b-c0d2e45bc8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_68b1e044-95ee-4fce-9c0f-f460ef6f45d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d0d45744-519c-46e5-b48b-c0d2e45bc8b1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_68b1e044-95ee-4fce-9c0f-f460ef6f45d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_450059ea-3a42-408a-a194-b0fc153336f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_68b1e044-95ee-4fce-9c0f-f460ef6f45d0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_450059ea-3a42-408a-a194-b0fc153336f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_450059ea-3a42-408a-a194-b0fc153336f3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b20a9430-7e5f-4811-b838-7bd7b2169238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b20a9430-7e5f-4811-b838-7bd7b2169238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_d2d7b8ec-becc-4872-b641-bec0ba159faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_d2d7b8ec-becc-4872-b641-bec0ba159faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6a872809-bcf4-420d-8647-64e5433e2ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6a872809-bcf4-420d-8647-64e5433e2ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_04970bb8-972c-41b5-a8d1-d1778f0dbeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_04970bb8-972c-41b5-a8d1-d1778f0dbeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_3d723a52-73ce-4f23-8df0-e1f7a169172b" xlink:href="moh-20220331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_moh_MunicipalSecuritiesMember_3d723a52-73ce-4f23-8df0-e1f7a169172b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_ef318868-5e1f-44cc-83a8-4a3dfa3428a5" xlink:href="moh-20220331.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f15dd9e2-4bcd-40d4-88c3-71b7d723579f" xlink:to="loc_moh_OtherSecuritiesMember_ef318868-5e1f-44cc-83a8-4a3dfa3428a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_68b1e044-95ee-4fce-9c0f-f460ef6f45d0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b0eec8a7-2428-4947-9a58-3ddb83dd718e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b0eec8a7-2428-4947-9a58-3ddb83dd718e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_957b511e-d354-422e-890f-8e630a62fd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_957b511e-d354-422e-890f-8e630a62fd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58a4d5c4-4ff7-46aa-8905-618cd631afb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58a4d5c4-4ff7-46aa-8905-618cd631afb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_80dc452f-1cb3-49a2-ac7f-a01a11abfb38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ef9943f-cc39-4d40-8ed9-f704353e4897" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_80dc452f-1cb3-49a2-ac7f-a01a11abfb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0fa5a58e-94f0-44a2-a354-c15f00da76c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8322cebe-72ae-4423-8821-87550fcec0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0fa5a58e-94f0-44a2-a354-c15f00da76c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8322cebe-72ae-4423-8821-87550fcec0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5ba20e72-473b-414b-9648-71b83746b680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8322cebe-72ae-4423-8821-87550fcec0ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5ba20e72-473b-414b-9648-71b83746b680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e57692f1-8d76-4d12-9f12-61a611d302e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8322cebe-72ae-4423-8821-87550fcec0ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e57692f1-8d76-4d12-9f12-61a611d302e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_212253b0-38b1-4bea-9fec-ca926fe45159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8322cebe-72ae-4423-8821-87550fcec0ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_212253b0-38b1-4bea-9fec-ca926fe45159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_9979dcfc-ba31-41d6-a8f6-6ce08885a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8322cebe-72ae-4423-8821-87550fcec0ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_9979dcfc-ba31-41d6-a8f6-6ce08885a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ecf9e79a-9595-4243-8300-358c0f13e552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8322cebe-72ae-4423-8821-87550fcec0ae" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ecf9e79a-9595-4243-8300-358c0f13e552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13399c0e-586a-4a0d-a688-64ccfd54fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0fa5a58e-94f0-44a2-a354-c15f00da76c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13399c0e-586a-4a0d-a688-64ccfd54fd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ed32ac75-afec-4e32-9679-40a61a03b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13399c0e-586a-4a0d-a688-64ccfd54fd5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ed32ac75-afec-4e32-9679-40a61a03b0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b17861bd-19ba-4f57-9d87-9ac10c88fa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13399c0e-586a-4a0d-a688-64ccfd54fd5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b17861bd-19ba-4f57-9d87-9ac10c88fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_49f2da44-ee93-400f-8d8f-cb48da99bde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13399c0e-586a-4a0d-a688-64ccfd54fd5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_49f2da44-ee93-400f-8d8f-cb48da99bde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_03bb6500-920c-4d70-8460-e00e2d034d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13399c0e-586a-4a0d-a688-64ccfd54fd5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_03bb6500-920c-4d70-8460-e00e2d034d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c0e471f1-7191-49f8-a730-bfb08a92d9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13399c0e-586a-4a0d-a688-64ccfd54fd5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_c0e471f1-7191-49f8-a730-bfb08a92d9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5d4ce5a7-7bce-4aa6-a132-152b6b672098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_3393811a-e4aa-4dbc-97a7-425b0b4cd2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5d4ce5a7-7bce-4aa6-a132-152b6b672098" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss_3393811a-e4aa-4dbc-97a7-425b0b4cd2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_8216d4ab-16cf-40b2-b874-12728bea14a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5d4ce5a7-7bce-4aa6-a132-152b6b672098" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_8216d4ab-16cf-40b2-b874-12728bea14a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_dc3fc505-e587-4c6c-85f3-1e344b897d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5d4ce5a7-7bce-4aa6-a132-152b6b672098" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_dc3fc505-e587-4c6c-85f3-1e344b897d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_50ac94da-dc81-45ff-bdc8-1de122373607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2bd1b160-8a49-4f77-b66a-64a8e123290f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_50ac94da-dc81-45ff-bdc8-1de122373607" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2bd1b160-8a49-4f77-b66a-64a8e123290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0f655f66-e568-4b85-8ca9-fb654e762be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2bd1b160-8a49-4f77-b66a-64a8e123290f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0f655f66-e568-4b85-8ca9-fb654e762be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0f655f66-e568-4b85-8ca9-fb654e762be6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c3aa5045-a41c-4a2f-afc3-689dd8e3b979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c3aa5045-a41c-4a2f-afc3-689dd8e3b979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_191c7e26-4e95-47de-9139-682f80e826fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_191c7e26-4e95-47de-9139-682f80e826fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_0ab4fb5f-e972-4f76-adef-04d268599e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_0ab4fb5f-e972-4f76-adef-04d268599e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_ee1c55ad-fbb0-4362-8a56-44d5ee4497cc" xlink:href="moh-20220331.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_moh_MunicipalSecuritiesMember_ee1c55ad-fbb0-4362-8a56-44d5ee4497cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_031a73c3-4501-4e60-a0f6-b9fa10ab0c1f" xlink:href="moh-20220331.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afc7c5b2-b4d5-451a-b215-dfde640a4374" xlink:to="loc_moh_OtherSecuritiesMember_031a73c3-4501-4e60-a0f6-b9fa10ab0c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2bd1b160-8a49-4f77-b66a-64a8e123290f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8a1e5c56-04f2-49ee-80f6-34088d891150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8a1e5c56-04f2-49ee-80f6-34088d891150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7952540e-dca7-4e47-9c5a-117868d03745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7952540e-dca7-4e47-9c5a-117868d03745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_4dc6bdc9-95ff-4199-b51b-75dd4440aea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1663a9f-6746-41ce-bfad-0c0909b33791" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_4dc6bdc9-95ff-4199-b51b-75dd4440aea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_30ac1fbc-b691-4fd2-9c69-0596369ec298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_9923425e-6ed0-4bfc-ad4e-dd96af16aa93" xlink:href="moh-20220331.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_30ac1fbc-b691-4fd2-9c69-0596369ec298" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_9923425e-6ed0-4bfc-ad4e-dd96af16aa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_11e633cd-e915-4a0a-b1cb-2601a8d8ce52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_fb416acd-cd25-4d95-9ea3-dc208d757af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_11e633cd-e915-4a0a-b1cb-2601a8d8ce52" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_fb416acd-cd25-4d95-9ea3-dc208d757af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_91ba5911-0208-4fdf-b903-1057365d99f6" xlink:href="moh-20220331.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_11e633cd-e915-4a0a-b1cb-2601a8d8ce52" xlink:to="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_91ba5911-0208-4fdf-b903-1057365d99f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28399d46-c26e-4719-ba56-124954fb0f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_819d3344-a6d3-4728-8802-853b19bf38d9" xlink:href="moh-20220331.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28399d46-c26e-4719-ba56-124954fb0f51" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_819d3344-a6d3-4728-8802-853b19bf38d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_fbc1b983-1524-4cd6-b59c-31c803e78046" xlink:href="moh-20220331.xsd#moh_PharmacyClaimsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28399d46-c26e-4719-ba56-124954fb0f51" xlink:to="loc_moh_PharmacyClaimsPayable_fbc1b983-1524-4cd6-b59c-31c803e78046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_52853fb4-a59c-4a1e-8075-13e2a3c28eea" xlink:href="moh-20220331.xsd#moh_CapitationClaimsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28399d46-c26e-4719-ba56-124954fb0f51" xlink:to="loc_moh_CapitationClaimsPayable_52853fb4-a59c-4a1e-8075-13e2a3c28eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_5d5915b9-e66d-4a61-be7a-ed2982172191" xlink:href="moh-20220331.xsd#moh_OtherClaimsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28399d46-c26e-4719-ba56-124954fb0f51" xlink:to="loc_moh_OtherClaimsPayable_5d5915b9-e66d-4a61-be7a-ed2982172191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_25ddd82b-41e3-4e8f-9191-72cd77087c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_28399d46-c26e-4719-ba56-124954fb0f51" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_25ddd82b-41e3-4e8f-9191-72cd77087c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_790809c7-fa33-4675-9b96-6e5003754ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable_df255dad-8e66-4e57-ae5e-225c6f34bb15" xlink:href="moh-20220331.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_790809c7-fa33-4675-9b96-6e5003754ffd" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayable_df255dad-8e66-4e57-ae5e-225c6f34bb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_dbce95ba-4b06-4b9d-bf17-e4c11a356d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_790809c7-fa33-4675-9b96-6e5003754ffd" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_dbce95ba-4b06-4b9d-bf17-e4c11a356d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_d1f282fe-faf4-49a1-9d44-9fe8a30fff21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_542f6ada-69ab-4c5e-8f56-bab04254c616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_d1f282fe-faf4-49a1-9d44-9fe8a30fff21" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_542f6ada-69ab-4c5e-8f56-bab04254c616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_619a27f7-f381-4e8e-a3a3-b393c2619706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_542f6ada-69ab-4c5e-8f56-bab04254c616" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_619a27f7-f381-4e8e-a3a3-b393c2619706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_619a27f7-f381-4e8e-a3a3-b393c2619706" xlink:to="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_902570b4-63dc-4ea6-b01a-374a3c512cd0" xlink:href="moh-20220331.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:to="loc_moh_MedicaidMember_902570b4-63dc-4ea6-b01a-374a3c512cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_a6dd1efc-af3a-42ce-bbfb-8b7f132ed1b8" xlink:href="moh-20220331.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:to="loc_moh_MedicareMember_a6dd1efc-af3a-42ce-bbfb-8b7f132ed1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_8596ff87-6eea-4224-8a99-3af09e6839ce" xlink:href="moh-20220331.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f68c506e-399f-4bb1-9846-2be8386788f6" xlink:to="loc_moh_MarketplaceMember_8596ff87-6eea-4224-8a99-3af09e6839ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d2bf663b-e798-4235-b576-b07d350fbd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_542f6ada-69ab-4c5e-8f56-bab04254c616" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d2bf663b-e798-4235-b576-b07d350fbd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_d2bf663b-e798-4235-b576-b07d350fbd15" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b60bd3d-86fd-48a2-b97c-a2dc66d69bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b60bd3d-86fd-48a2-b97c-a2dc66d69bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:href="moh-20220331.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_6d05b6fb-f639-4228-897c-08fcc72deac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_6d05b6fb-f639-4228-897c-08fcc72deac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0122dd66-103d-47e9-a543-6eddeb0b2ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0122dd66-103d-47e9-a543-6eddeb0b2ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c21d46f7-b2e7-4bb4-8c32-12dbd098d25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_7c592d79-97c2-4c07-b96b-dd68c8a71001" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c21d46f7-b2e7-4bb4-8c32-12dbd098d25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:href="moh-20220331.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_130c063b-aeb8-4cdf-acdc-93a2ee816fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_130c063b-aeb8-4cdf-acdc-93a2ee816fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_79b57468-f7af-4187-8a53-7238d70980e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_79b57468-f7af-4187-8a53-7238d70980e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_3ca5e853-5229-48bf-99ed-01a6e2c876fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_6d028071-5390-45be-b131-e317cd74d0de" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_3ca5e853-5229-48bf-99ed-01a6e2c876fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_f99bebca-c0a5-4e2e-ad7f-59d7aecfa4a7" xlink:href="moh-20220331.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_f99bebca-c0a5-4e2e-ad7f-59d7aecfa4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_eed79b48-83a2-442f-95e2-5f5f6a7a12a4" xlink:href="moh-20220331.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_eed79b48-83a2-442f-95e2-5f5f6a7a12a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b7d8c7f7-512a-469f-9ca7-45755e251b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_233f8911-0198-4cf1-8637-6249699da0c7" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b7d8c7f7-512a-469f-9ca7-45755e251b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20220331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e44be043-a918-47d1-9fc5-3cc2ab26d479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_4664787f-d817-4855-83d9-52972db72e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e44be043-a918-47d1-9fc5-3cc2ab26d479" xlink:to="loc_us-gaap_LongTermDebtTextBlock_4664787f-d817-4855-83d9-52972db72e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20220331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_522d51ae-fd82-4be9-a77d-c67474537324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_401b88ed-e4bc-4f0a-8b56-083371c7fba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_522d51ae-fd82-4be9-a77d-c67474537324" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_401b88ed-e4bc-4f0a-8b56-083371c7fba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_13ef4c5b-29f0-4acf-a816-3fa4e382c82a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_13ef4c5b-29f0-4acf-a816-3fa4e382c82a" xlink:to="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_497e1753-da97-4d00-9e49-377bc29bff0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_497e1753-da97-4d00-9e49-377bc29bff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_042ed156-fece-41b1-9951-bf73e4960269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_497e1753-da97-4d00-9e49-377bc29bff0f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_042ed156-fece-41b1-9951-bf73e4960269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3f098a89-9ece-4148-9180-63c3ba47928b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_042ed156-fece-41b1-9951-bf73e4960269" xlink:to="loc_us-gaap_SeniorNotesMember_3f098a89-9ece-4148-9180-63c3ba47928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bece27b2-3647-4887-9ce1-ecb93cf4df01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:to="loc_us-gaap_DebtInstrumentAxis_bece27b2-3647-4887-9ce1-ecb93cf4df01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bece27b2-3647-4887-9ce1-ecb93cf4df01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_0a1af721-5f77-406c-b9a0-474da9a7d572" xlink:href="moh-20220331.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:to="loc_moh_A4375SeniorNotesMember_0a1af721-5f77-406c-b9a0-474da9a7d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b9208058-c1b4-4099-82d6-2750feee68b2" xlink:href="moh-20220331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_b9208058-c1b4-4099-82d6-2750feee68b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_c322ae0d-44d0-456a-bb84-73b1baefcf5f" xlink:href="moh-20220331.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caf0666a-cc51-4158-8430-73834024073a" xlink:to="loc_moh_A3875SeniorNotesMember_c322ae0d-44d0-456a-bb84-73b1baefcf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_768b82a2-d7a4-4293-a847-bb234a2b3ec7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f003678d-c3e0-4cc7-b9bf-f698a4540abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f003678d-c3e0-4cc7-b9bf-f698a4540abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_253a0e7c-f756-40fa-9f5a-137136187313" xlink:href="moh-20220331.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_253a0e7c-f756-40fa-9f5a-137136187313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_dd230785-3c1a-46a3-beae-00bb3393dad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_dd230785-3c1a-46a3-beae-00bb3393dad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e88c4176-dadb-4f1c-a66d-e9e541b8026b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_44c6ffad-eb32-421f-82a4-e6d0159a63b6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e88c4176-dadb-4f1c-a66d-e9e541b8026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7c850e95-7adc-4dfe-bd62-73e104649f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7c850e95-7adc-4dfe-bd62-73e104649f66" xlink:to="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_639d4b16-1399-4b50-989a-80a40abbad46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_639d4b16-1399-4b50-989a-80a40abbad46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_639d4b16-1399-4b50-989a-80a40abbad46" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_baa6ce51-7767-4599-94d2-9241903fae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:to="loc_us-gaap_LineOfCreditMember_baa6ce51-7767-4599-94d2-9241903fae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_2cb9fbbe-c163-4845-a6e1-5ce5d63ce82b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b65d3b-f35e-4d37-8f4e-fce6fbf9c85f" xlink:to="loc_us-gaap_SeniorNotesMember_2cb9fbbe-c163-4845-a6e1-5ce5d63ce82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_78d314d6-9021-49d0-90d5-b4655f1cbcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:to="loc_us-gaap_CreditFacilityAxis_78d314d6-9021-49d0-90d5-b4655f1cbcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53db1bfb-ef45-49ee-ae13-4910b7dc5047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_78d314d6-9021-49d0-90d5-b4655f1cbcab" xlink:to="loc_us-gaap_CreditFacilityDomain_53db1bfb-ef45-49ee-ae13-4910b7dc5047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f1706724-285c-43a7-8b43-2328d3354a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_53db1bfb-ef45-49ee-ae13-4910b7dc5047" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f1706724-285c-43a7-8b43-2328d3354a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4fc93eba-ae5c-4fe7-bce9-836afe75c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_4fc93eba-ae5c-4fe7-bce9-836afe75c02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4fc93eba-ae5c-4fe7-bce9-836afe75c02f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_b5e9ca48-2fa9-4823-b33e-bed6993e59d6" xlink:href="moh-20220331.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:to="loc_moh_A4375SeniorNotesMember_b5e9ca48-2fa9-4823-b33e-bed6993e59d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_2c639078-a8a5-4637-862d-0efa25f49d16" xlink:href="moh-20220331.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_2c639078-a8a5-4637-862d-0efa25f49d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_e8a3a06d-9ef8-4a62-a1da-7646359472c3" xlink:href="moh-20220331.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ebe77f2f-7f7c-4959-bb1f-a363c347b81e" xlink:to="loc_moh_A3875SeniorNotesMember_e8a3a06d-9ef8-4a62-a1da-7646359472c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ddce762c-e52a-4890-a966-827804a6bc4c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7fe5a96-806c-4997-bd4f-99c8c4f3c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7fe5a96-806c-4997-bd4f-99c8c4f3c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_368b8048-c63b-4214-913c-0c82d4398dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_DebtInstrumentTerm_368b8048-c63b-4214-913c-0c82d4398dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_51b79e05-f90d-4c06-9340-4825d3ba8842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_LineOfCredit_51b79e05-f90d-4c06-9340-4825d3ba8842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a53b2b27-fb5b-49e8-850f-c2a08b57a3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a53b2b27-fb5b-49e8-850f-c2a08b57a3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6c5f5f4c-9d04-4f78-91c4-d99c3ff134e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ab9ef48-ee5a-43c4-8bf5-36c683fcb802" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6c5f5f4c-9d04-4f78-91c4-d99c3ff134e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20220331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4e00ae53-6714-4ef2-8e6c-8059e85840a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8e0322d0-9373-488c-9d85-dcc2af14bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4e00ae53-6714-4ef2-8e6c-8059e85840a6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8e0322d0-9373-488c-9d85-dcc2af14bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d2d56b86-419c-4f59-836a-2e1ed23f858a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d2d56b86-419c-4f59-836a-2e1ed23f858a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f65a01a2-0c6d-482e-96e4-9d3d7a539001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f65a01a2-0c6d-482e-96e4-9d3d7a539001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_506b4061-9404-4fdd-a852-c5e82a0a853b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f65a01a2-0c6d-482e-96e4-9d3d7a539001" xlink:to="loc_us-gaap_EquityComponentDomain_506b4061-9404-4fdd-a852-c5e82a0a853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f165788f-d00c-4b35-8085-1816f97963a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_506b4061-9404-4fdd-a852-c5e82a0a853b" xlink:to="loc_us-gaap_CommonStockMember_f165788f-d00c-4b35-8085-1816f97963a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c9d926f0-bbfe-432e-a711-19e540117c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c9d926f0-bbfe-432e-a711-19e540117c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cedc58c5-9043-433d-9d2c-1bf306fe6a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c9d926f0-bbfe-432e-a711-19e540117c45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cedc58c5-9043-433d-9d2c-1bf306fe6a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b8109522-9b90-42f6-a9c3-776636355afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cedc58c5-9043-433d-9d2c-1bf306fe6a1d" xlink:to="loc_us-gaap_SubsequentEventMember_b8109522-9b90-42f6-a9c3-776636355afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fbd2912-68d5-4367-a990-5854a83b5b85" xlink:to="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2d747497-0537-4ca7-ab97-9722e2c6428a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2d747497-0537-4ca7-ab97-9722e2c6428a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_346d687a-fc54-4d29-894e-c3e251d2b1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1aa2c172-b949-45d0-ba4a-e03fbc039fe5" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_346d687a-fc54-4d29-894e-c3e251d2b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20220331.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c2984a5f-51e8-40b8-b245-1face6573bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_c09049ff-a00a-4d1a-be9a-d768291ecd64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c2984a5f-51e8-40b8-b245-1face6573bf3" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_c09049ff-a00a-4d1a-be9a-d768291ecd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20220331.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_81bbf9a3-8c22-4cc6-938d-b025c4bc7530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6246fb85-29e4-47be-82a6-a2dbde6d040b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_81bbf9a3-8c22-4cc6-938d-b025c4bc7530" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6246fb85-29e4-47be-82a6-a2dbde6d040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_24960424-b90e-4ec0-b280-4c9c84ade479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfReportableSegment_06ab101a-9c26-48df-9064-c2d153db7039" xlink:href="moh-20220331.xsd#moh_NumberOfReportableSegment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_24960424-b90e-4ec0-b280-4c9c84ade479" xlink:to="loc_moh_NumberOfReportableSegment_06ab101a-9c26-48df-9064-c2d153db7039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SegmentsScheduleofOperatingSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_246dffe9-6c5a-4c45-b958-bd3aaeae3802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7388c4e2-1ae1-4e17-8d4b-abd66358c6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_246dffe9-6c5a-4c45-b958-bd3aaeae3802" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7388c4e2-1ae1-4e17-8d4b-abd66358c6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_747fa34e-f823-4adf-b6ea-16ed41df3bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7388c4e2-1ae1-4e17-8d4b-abd66358c6e8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_747fa34e-f823-4adf-b6ea-16ed41df3bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_747fa34e-f823-4adf-b6ea-16ed41df3bf4" xlink:to="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_0db2cf5e-b2b0-4fc9-8210-14db055ce5ef" xlink:href="moh-20220331.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_MedicaidMember_0db2cf5e-b2b0-4fc9-8210-14db055ce5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_0c4a48c7-bb12-45e9-a0a7-134b8a431d78" xlink:href="moh-20220331.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_MedicareMember_0c4a48c7-bb12-45e9-a0a7-134b8a431d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_3739c576-edf6-47e7-b2e5-6e58eb13bd50" xlink:href="moh-20220331.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_MarketplaceMember_3739c576-edf6-47e7-b2e5-6e58eb13bd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_151021d5-8fb7-43f6-a81f-f6544111b818" xlink:href="moh-20220331.xsd#moh_OtherProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6d5e0372-6881-45ac-8f28-9370fce88935" xlink:to="loc_moh_OtherProgramMember_151021d5-8fb7-43f6-a81f-f6544111b818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3a7230a1-0216-4886-ac84-8b673f27b734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7388c4e2-1ae1-4e17-8d4b-abd66358c6e8" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_3a7230a1-0216-4886-ac84-8b673f27b734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_de42ab68-8686-4503-8230-7a0ba9a5e0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3a7230a1-0216-4886-ac84-8b673f27b734" xlink:to="loc_us-gaap_Revenues_de42ab68-8686-4503-8230-7a0ba9a5e0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20220331.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1f94d76d-e79c-412b-9671-82d633a11f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1f94d76d-e79c-412b-9671-82d633a11f1f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_25329aba-c474-4cf2-b193-d2b23f7f586c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:to="loc_srt_ConsolidationItemsAxis_25329aba-c474-4cf2-b193-d2b23f7f586c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_25329aba-c474-4cf2-b193-d2b23f7f586c" xlink:to="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9430655d-215c-47c7-9851-ca3678184428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:to="loc_us-gaap_OperatingSegmentsMember_9430655d-215c-47c7-9851-ca3678184428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_1890a471-7349-4775-a293-8ec0e68234ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_07d23822-ef27-4fbe-b78a-29fefb70ced5" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_1890a471-7349-4775-a293-8ec0e68234ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3e50e671-7d1f-4598-9864-01d12d9dfe46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3e50e671-7d1f-4598-9864-01d12d9dfe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3e50e671-7d1f-4598-9864-01d12d9dfe46" xlink:to="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_62634cbf-8b52-45a0-9062-ae174bb13ebd" xlink:href="moh-20220331.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_MedicaidMember_62634cbf-8b52-45a0-9062-ae174bb13ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_adbd11fc-d22a-4fe5-bf5c-7f38b3622a2b" xlink:href="moh-20220331.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_MedicareMember_adbd11fc-d22a-4fe5-bf5c-7f38b3622a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_b0e03fb7-f516-416e-8208-4a2fc67c6708" xlink:href="moh-20220331.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_MarketplaceMember_b0e03fb7-f516-416e-8208-4a2fc67c6708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_3163b373-6832-46cc-ac9d-41f7fb933a5a" xlink:href="moh-20220331.xsd#moh_OtherProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_39223bcf-d043-4e6f-8d39-fdee9e4d2df0" xlink:to="loc_moh_OtherProgramMember_3163b373-6832-46cc-ac9d-41f7fb933a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b984b3a-7e1f-4207-8903-19e1fa51be12" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5f229d7c-1fb0-4285-bbd5-83de26516001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_GrossProfit_5f229d7c-1fb0-4285-bbd5-83de26516001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0cebed35-398b-46a9-91e5-3cb74f8b44c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_Revenues_0cebed35-398b-46a9-91e5-3cb74f8b44c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d3c68c7-1986-4670-aa91-9ea9053eb976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_CostsAndExpenses_6d3c68c7-1986-4670-aa91-9ea9053eb976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f89aea04-f09b-4ef1-9fb3-a2d2a9a00622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_OperatingIncomeLoss_f89aea04-f09b-4ef1-9fb3-a2d2a9a00622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_df5f2c29-eae0-4ba1-b27c-9aa4576f2cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_df5f2c29-eae0-4ba1-b27c-9aa4576f2cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50cec5c6-46f6-4a86-987a-e3d5c246af29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c934cb34-5a84-4d4e-8f70-6ebc6bc65bb5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50cec5c6-46f6-4a86-987a-e3d5c246af29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80a9076e-f62d-442a-a6eb-1861ac71001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5bb63f52-0e10-43e8-abf8-32a020f58cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80a9076e-f62d-442a-a6eb-1861ac71001b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5bb63f52-0e10-43e8-abf8-32a020f58cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>moh-20220331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 moh-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$&17AI9@  34T *@    @ ! $[  (
M   4   (2H=I  0    !   (7IR=  $    H   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-H96EL82!(
M861E<G-B97)G97(   60 P "    %   $*R0!  "    %   $,"2D0 "
M S<R  "2D@ "     S<R  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@
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M7HK!0MJV?,2S[$<UXQ5OG_F?2MM=07D"S6DT<\3?=>-@P/XBI:^?/#WB2_\
M#E\)[&0F,G][ Q^20>X]??M7NVD:K;ZUI4%_9G,4RYP>JGH0?<&N*O0=)WZ'
MNX#,88Q-6M)=/\B[1117.>H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M??".%F\17LX^ZEKL/'=G4C_T$USXE)TG<]+*Y2CC(6_K0]<HHHKQ#[\****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$\5U;QSVTJ30RJ'CD1@RNI&001U%? M>P_!;XM'PU<Q>'?$4W_$GF?%O._\
MRZ.3W/\ <)//H>>F:!V/IVBD4AE!4@@C(([TM BIJU\=,T6]OUB,YM;>281
MXW[5)VYP<9QCI7E/A3X_P^*O%6G:);^')87O9=AE:[#!!@DG&SGI[5ZCK_\
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MQ.!6O9?"G6II@+R:VMHL_,VXNWX ?XBO2_#WARQ\-Z?]FL$)9N99G^](??\
MH*TK8F"BU%W9S8#*JTZJG55HKOU-:BBBO(/M KY^\7V:6'B_4K>( ()RR@=
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M4444 >D?!_\ X^]5_P!R/^;5ZE7EOP?_ ./O5?\ <C_FU>I5XN*_C,^[R?\
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M^UM7CN'MA*L3?9T#,I;.#@D<<8_&L+P?\7?#GC?7#I6BQWPN!"TQ,\*JNU2
M>0QYY%9WQ_B\SX1WC9QY=Q WU^<#^M>5_LU?\E)U#_L$R?\ HZ&@9]/UYWXD
M^-?ACPIXCN]$U:#41=VA4.8X496W(K@@[_1AUQ7HE8-WX'\+ZAJ<VHZAX?TZ
M\NYB#)-<VZREB %&=P/8"@1PW_#1O@K_ )Y:K_X#+_\ %T?\-&^"O^>6J_\
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MOUZI7-/\.?!CR!_^$7TI&!!!BM$3!'<;0,5TM @HHHH **** "BBB@ HHHH
M*^??%O\ R..J_P#7T_\ .OH*OGWQ;_R..J_]?3_SKOP7QL^=S[^##U_0QZ**
M*]0^0"BBB@#TCX/_ /'WJO\ N1_S:N9\>_\ (]:G_OK_ .@+73?!_P#X^]5_
MW(_YM7,^/?\ D>M3_P!]?_0%KCA_O,O3_(]RM_R*J7^)_J<[11178>&%%%%
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M^1WT/_L(V_\ Z,6@$>W/XU^. C8_\(I".#RMF21]!OKUOP3>:QJ'@S3[KQ-
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M:>)O^?./_O\ I_C7M]%..+J122L9U,EPU2;FV[MWW7^1XA_PK3Q-_P ^<?\
MW_3_ !H_X5IXF_Y\X_\ O^G^->WT57UVIY$?V%A>[^]?Y'B'_"M/$W_/G'_W
M_3_&C_A6OB;_ )\X_P#O^G^->WT4?7:GD']A87N_O7^1PGPZ\,:IX>N+]]4@
M6(3*@3;(&S@G/3ZUW=%%<M2;J2YF>KA\/##4E2ALCY3U#X%>/KR^N[S^S[7,
MT[N$^UIDY.<]<=_6OJM22H)&TD<@]J6BH.@XGXM^'=5\5?#VYTG0H$GNIIHC
MM>0)\JL&)R3CM7GWP?\ A;XI\%^/3J.MVD*VCV<D7F17"MAB5(&.O\->[T4
M0WB-+8SI&-SM&P49ZDBOEC3O@7\1+2^AN[>TM;:>VD66)WNHVPRG(..1P0.M
M?5M% 'A-SIGQ_:,?\36WDYZ1&V0_^@"O5/ L&O6?@>QB\6,\VL()/M!:179C
MYC%?F''W=M=%10!XUX ^'?B:+XM7_C'QG;0Q-*DDD 2=9"DCG:%X[*F1^5>R
MT44 >8_&WX?7_CG0]/?0H4EU&RG.%>0(#$X^;D^ZK^M8GP9\#>,_ ?B"[AUF
MTA_LJ^A!D:.Y5O+E7E3C.>A8' [CTKVFB@#A?C!X9U7Q;X!?2]"MUGNGN8WV
MM(J *N23DD5Y!X6^%'Q5\)7[ZCX>:SL+N6$PNS312'86!(PP8=54Y'-?3-%
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M]P))"/T-=K\-/"FL^&M)OIO%5^NH:UJ5SY]Q.KE\*% 5,D#I@].!G XKM**
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591973480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLINA HEALTHCARE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4204626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Oceangate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Long Beach,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">435-3666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MOH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001179929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591275928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premium revenue</a></td>
<td class="nump">$ 7,531<span></span>
</td>
<td class="nump">$ 6,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareOrganizationPremiumTaxRevenue', window );">Premium tax revenue</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Investment income</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Other revenue</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">7,770<span></span>
</td>
<td class="nump">6,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Medical care costs</a></td>
<td class="nump">6,563<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PremiumTaxExpenses', window );">Premium tax expenses</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,398<span></span>
</td>
<td class="nump">6,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationPremiumTaxRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Premium Tax Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationPremiumTaxRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PremiumTaxExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An assessment levied by a state government on the net premium income collected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PremiumTaxExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596854232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized investment loss</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Less: effect of income taxes</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591371416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,804<span></span>
</td>
<td class="nump">$ 4,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">2,988<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,156<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,146<span></span>
</td>
<td class="nump">10,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill, and intangible assets, net</a></td>
<td class="nump">1,305<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,360<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable</a></td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">2,613<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,041<span></span>
</td>
<td class="nump">7,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">2,174<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,566<span></span>
</td>
<td class="nump">9,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at March&#160;31, 2022, and 58 million shares at December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,794<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 12,360<span></span>
</td>
<td class="nump">$ 12,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590511368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">59,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596776792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 2,096<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 1,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">2,164<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 2,794<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="num">$ (81)<span></span>
</td>
<td class="nump">$ 2,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591329736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities', window );">Medical claims and benefits payable</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td>
<td class="num">(403)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and capitalized software</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations', window );">Common stock withheld to settle employee tax obligations</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash and cash equivalents</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">$ 4,866<span></span>
</td>
<td class="nump">$ 4,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Withheld to Settle Employee Tax Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CommonStockWithheldToSettleEmployeeTaxObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in health care insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989593926024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we served approximately 5.1&#160;million members eligible for government-sponsored healthcare programs, located across 19 states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMy_742266a5-3364-47ae-b977-fd809341826f">three</span>&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we submitted our RFP response. We expect the award to be announced in early August 2022, with an effective date of January 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP, with awards estimated to be announced in the fourth quarter of 2022, and start of operations in September 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible two-year extension was ratified in September 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989593955688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth amounts due government agencies, categorized by program:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three months ended March 31, 2022, we recognized approximately $28 million related to such risk corridors, primarily in the Medicaid segment, compared to $110&#160;million recognized in the three months ended March 31, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of March&#160;31, 2022, Marketplace risk adjustment payables amounted to $949 million and related receivables amounted to $33 million, for a net payable of $916 million. As of December&#160;31, 2021, Marketplace risk adjustment payables amounted to $902 million and related receivables amounted to $7 million, for a net payable of $895 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596671976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.39&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. </span></div>(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596705688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cigna. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $60&#160;million. We acquired membership and a provider network with a preliminary fair value of approximately $36 million. We allocated the remaining $24 million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. </span>Affinity. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for initial purchase consideration of approximately $176&#160;million. In the three months ended March&#160;31, 2022, we recorded various measurement period adjustments, including a decrease of $25&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $4&#160;million to &#8220;Amounts due government agencies.&#8221; In the aggregate, we recorded a net increase of $11&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596675192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2021 Annual Report on Form 10-K, Note 5, &#8220;Fair Value Measurements.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the three months ended March 31, 2022 and 2021, we recognized a loss of $4 million and $8&#160;million, respectively, for the increase in the fair value of the contingent consideration liabilities described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 financial instruments at March&#160;31, 2022 are comprised solely of contingent consideration liabilities of $8 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Such liabilities are recorded at fair value on a recurring basis. In the three months ended March 31, 2022, the estimated fair value of contingent purchase consideration increased by approximately $4 million, relating to an operating income guarantee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2022 we paid the seller $43&#160;million, of which $23&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $20&#160;million was for the first payment of the consideration due for the operating income guarantee. For the amounts paid in the three months ended March 31, 2022, $20 million has been presented in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221; The remaining balance of the liabilities is reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596671416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of March&#160;31, 2022 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains and losses were insignificant for the three months ended March 31, 2022, and 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at March&#160;31, 2022, and December&#160;31, 2021, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2022, and December&#160;31, 2021.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Investments Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $221 million at March&#160;31, 2022, of which $190 million will mature in one year or less, and $31&#160;million will mature in one through five years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596683368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableTextBlock', window );">Medical Claims and Benefits Payable</a></td>
<td class="text">Medical Claims and Benefits Payable <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $322 million and $226 million as of March&#160;31, 2022, and December&#160;31, 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2021, and 2020 developed favorably by approximately $206 million and $194 million as of March&#160;31, 2022, and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in the three months ended March 31, 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our  estimates in 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical claims and benefits payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989681284600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (the &#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of March&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of March&#160;31, 2022, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.375% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $800 million aggregate principal amount of senior notes (the &#8220;4.375% Notes&#8221;) outstanding as of March&#160;31, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.875% Notes due 2030. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $650 million aggregate principal amount of senior notes (the &#8220;3.875% Notes due 2030&#8221;) outstanding as of March&#160;31, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.</span></div>3.875% Notes due 2032. We had $750 million aggregate principal amount of senior notes (the &#8220;3.875% Notes due 2032&#8221;) outstanding as of March&#160;31, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989594691256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity In September 2021, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  As of April&#160;27, 2022, we have purchased 85,000 shares under the stock purchase program approved in 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596714744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#8220;MCR&#8221;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989593932296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, the repayment of previously billed and collected revenues and reputational damage.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. The appellate briefing has concluded and no assurances can be given regarding the ultimate outcome. Under the Court&#8217;s June 16, 2021 final Order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#8220;MHPR&#8221;) filed a complaint asserting, among other claims, breach of contract against the Puerto Rico Health Insurance Administration (&#8220;ASES&#8221;). On September 13, 2021, in addition to filing its answer to MHPR&#8217;s complaint, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. The counterclaim alleges that MHPR and the Company breached contractual obligations by failing to pay providers, and seeks damages and various equitable remedies. On October 8, 2021, MHPR filed its reply to the counterclaim, denying all the allegations, and on November 1, 2021, the Company filed its answer to the third-party complaint. On December 3, 2021, MHPR filed a request for disbursement of illegally withheld funds, and ASES filed its opposition. At a status hearing on January 19, 2022, the Court heard MHPR&#8217;s request for disbursement. The Court has not ruled on the request. On March 23, 2022, the Court informed the parties that it will appoint a Special Commissioner to review the merits of the entire case, with the assigned judge retaining final authority over any resolution. The parties are negotiating the engagement of the Special Commissioner. This matter is in its early stages and remains subject to significant additional proceedings, and no prediction can be made as to the outcome. No gain or loss is probable and reasonably estimable with regard to either MHPR&#8217;s complaint or the counterclaim of ASES.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596891736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock', window );">Consolidation and Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.</span></div>The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Premium Revenue Recognition and Amounts Due Government Agencies and Contractual Provisions That May Adjust or Limit Revenue or Profit</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#8220;Significant Accounting Policies,&#8221; under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div>Contractual Provisions That May Adjust or Limit Revenue or ProfitMany of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.<div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three months ended March 31, 2022, we recognized approximately $28 million related to such risk corridors, primarily in the Medicaid segment, compared to $110&#160;million recognized in the three months ended March 31, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div>Risk Adjustment. Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidation And Interim Financial Information, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596929320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and cash equivalents</a></td>
<td class="text">The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text">The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Receivables</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock', window );">Schedule of Amounts Due to Government Agencies</a></td>
<td class="text">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies,&#8221; in the accompanying consolidated balance sheets. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth amounts due government agencies, categorized by program:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reserves reported to other federal agencies or authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReservesReportedToOtherAgenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596668360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Denominators for The Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.39&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. </span></div>(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596273928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurements of Senior Notes</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596234312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text">The following tables summarize our current investments as of the dates indicated:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Investments</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of March&#160;31, 2022 are summarized below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2022, and December&#160;31, 2021.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596272536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock', window );">Schedule of Components of The Change in Medical Claims and Benefits Payable</a></td>
<td class="text">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. <div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989593920792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long Term Debt</a></td>
<td class="text">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989593942904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Segment Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income taxes. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, investment income, and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590581080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> member in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>position </div>
<div>member </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_NumberOfReportableSegment', window );">Reportable segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension option</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms', window );">Number of members eligible for the health care programs, approximately | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms', window );">Number of states with programs | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members eligible for the health care programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Contract Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanExtensionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Extension Option, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanExtensionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_NumberOfReportableSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Reportable Segment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_NumberOfReportableSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of States With Government-Sponsored Healthcare Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591345256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,804<span></span>
</td>
<td class="nump">$ 4,438<span></span>
</td>
<td class="nump">$ 4,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</a></td>
<td class="nump">$ 4,866<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 4,497<span></span>
</td>
<td class="nump">$ 4,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590479416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 2,156<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember', window );">Government receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember', window );">Pharmacy rebate receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590409160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Amounts Due To Government Agencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract', window );"><strong>Medicaid program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther', window );">Other</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract', window );"><strong>Medicare program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing', window );">Risk adjustment and Part D risk sharing</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_OtherMedicareProgram', window );">Other</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract', window );"><strong>Marketplace program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment', window );">Risk adjustment</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold', window );">Minimum MLR</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesOther', window );">Other</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Total amounts due government agencies</a></td>
<td class="nump">$ 2,613<span></span>
</td>
<td class="nump">$ 2,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies Medicare Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesRiskAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premiums Liability, Medical Care Costs Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherMedicareProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Medicare Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherMedicareProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591403592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable', window );">Risk adjustment payable</a></td>
<td class="num">$ (949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable', window );">Risk adjustment receivable</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable', window );">Risk adjustment, net payable</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_InvestmentsMaturityPeriod', window );">Maturity period (less than)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember', window );">Structured Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_InvestmentsAverageMaturityPeriod', window );">Average maturity period (less than)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPremiumsReceivable', window );">Reduction in premiums</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Average Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of premium revenue by health plan type.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPremiumsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the premium receivable balance on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPremiumsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_StructuredSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591508312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_SharesOutstandingExcludingRestrictedStockAwards', window );">Shares outstanding at the beginning of the period ( in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average number of shares issued:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_WeightedAverageNumberofSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Stock purchases (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic net income per share (in shares)</a></td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">57.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted net income per share (in shares)</a></td>
<td class="nump">58.7<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_SharesOutstandingExcludingRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Outstanding, Excluding Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_SharesOutstandingExcludingRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_WeightedAverageNumberofSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares, Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_WeightedAverageNumberofSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590590024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Oct. 25, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember', window );">Magellan Complete Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember', window );">Magellan Complete Care | Member list</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquired membership with a preliminary fair value</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember', window );">Affinity Health Plan, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable', window );">Medical claims and benefits payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies', window );">Amounts due government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_MemberListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_MemberListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989587714648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 2,988<span></span>
</td>
<td class="nump">$ 3,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,988<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">598<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,988<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">598<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590365352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized gain (loss)</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Paid to seller</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Consideration due for minimum member</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan, Inc. | (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591641720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 2,174<span></span>
</td>
<td class="nump">$ 2,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 2,126<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 789<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 713<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989587863896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 3,094<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">2,988<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">598<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590357592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Contractual Maturities of Available-for-Sale Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">3,094<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 2,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596786248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Debt securities held to maturity</a></td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Amortized cost, due in one year or less</a></td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">Amortized cost, due one year through five years</a></td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267963-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590376296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>position </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>security </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2,428<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | position</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 1,516<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | position</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | position</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | security</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | security</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | security</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590565016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount', window );">Claims incurred but not paid (&#8220;IBNP&#8221;)</a></td>
<td class="nump">$ 2,521<span></span>
</td>
<td class="nump">$ 2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PharmacyClaimsPayable', window );">Pharmacy payable</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_CapitationClaimsPayable', window );">Capitation payable</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_OtherClaimsPayable', window );">Other</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total</a></td>
<td class="nump">$ 3,601<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 2,839<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CapitationClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitation Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CapitationClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PharmacyClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PharmacyClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596231160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayable', window );">Non-risk provider payables</a></td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior period claims, favorable development</a></td>
<td class="num">$ (206)<span></span>
</td>
<td class="num">$ (194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590711992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">6,769<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">6,563<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">4,197<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">6,396<span></span>
</td>
<td class="nump">5,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">96<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">2,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">5,424<span></span>
</td>
<td class="nump">4,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">5,270<span></span>
</td>
<td class="nump">4,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">3,402<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">5,035<span></span>
</td>
<td class="nump">4,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">93<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">771<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components of medical care costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable, Adjustments, Change in Provider</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for medical care costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591860664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred debt issuance costs</a></td>
<td class="num">$ (26)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">$ 2,174<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989596751832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under letter of credit</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 650,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989590582152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 27, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased of common stock (in shares)</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989593911368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_NumberOfReportableSegment', window );">Reportable segment</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_NumberOfReportableSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Reportable Segment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_NumberOfReportableSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989587817512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Operating Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,770<span></span>
</td>
<td class="nump">$ 6,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">5,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139989591671688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">$ 7,770<span></span>
</td>
<td class="nump">$ 6,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">(7,398)<span></span>
</td>
<td class="num">(6,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">5,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Marketplace</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other operating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">$ (820)<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>moh-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:moh="http://www.molinahealthcare.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="moh-20220331.xsd" xlink:type="simple"/>
    <context id="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5088f3c4c0b64cf3a6113fcf094799c3_I20220422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-04-22</instant>
        </period>
    </context>
    <context id="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i78a364e3f02f45059e7d588902f74a7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d495bb1496443bf84bdb17358ef9e27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfbbdfebf5e0417db5c15c1f2203e943_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i210479d51b0949d4b306fa898f8ab68e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0a791bedc8c497a9b951c0a54286c99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9197f15ee9d540a0993914efdd5e51cd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd4a419317fc4c44910821bd8c61e989_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e97722ed58740a3af7cda41b611b9c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1fa7fde4814471db3810635d40bdbdc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67e78bf8f50943f1aa07fa55e4049d43_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib45bf3fe8b354f538d45f5c9cbfd0225_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97b8c89c2c664032b3e7c570dd406ef5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id82c487ce2bc462599459c0507d1ca62_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i995ada66e7f14440b7cfd0a914ac8acf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff011ca48c834fabbfb52d9e98555c1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0199bf3103774fb5b433a7b2f787c39d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdcb8a23a1fc4ae8a13e0ed56f15658f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63e99d1b775642728d269200485a7951_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e7d8195295e452a9c89b318b1b39b4b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c1fa8ff9f704dc4a9aafd83714c7904_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaeb68bdab10a46ea8ce7f8f06b183910_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie3691bc168b04f23adb9b834865b296d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i84780b904fcb43cf980043acfdf85931_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i56c66fd9d79140e89e5a2167138c066a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if6201f33888046d1a89c449d69d0e023_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia6768c723a834132a8dff21a78dbcbc9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if2550091eda44588baae1b353781d6f9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2a15fbb627e648a9b3cfcb7d23c86eb5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8851606cc612421ab07daae70b687796_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i71bef60ed3804c7b985e0a7f9eb18119_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3fb5e9c9ed8a4e7a8212fec43122957e_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6b6fd4fee764ab083cdc892e2c0c076_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib83542a544914da9a096018bb51d522d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if33590d339e94d2d901dd2dd40d1f5ad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i756495c112ec486ca365574f64977791_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iced25630f7f04a17b0750b5a726c2fdf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie6984c064c12462fac6706daa823e721_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42b0a19236ea419588cf999ba5003db3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib16fa21da2b342b1b9b512fecc011c4a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i60d5b3e94914400d9df6eef34274142b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:StructuredSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i0df831b90dca48389c4a46065aa0e36b_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i4224640832fc459a976f07601ca3b865_D20211025-20211025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i90c70e6d3865429ab8c21490e9d52463_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icc9841f89feb4b6f833b989726c603b7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2d24f62cc41249a59883cfafb9f90a0b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9d6f584300eb4da4b4a6f02de502ee05_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9fd269fb2ad24963b173ecee97871066_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iba8f3df78577405d89b78540630ab85b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib601f7ea9e1544bba2449d05dd7b52fb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6b6c43599fc843d0829a435fbdc90272_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i12e5991e34f746b4a7de6f87d9b23770_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib57bf75d7d2d40ce88df34d243fb7161_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i80581b9110ec4a21aad1d72ab421ff09_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i914e26952f0846cbab0b1ae7d986cd2f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibb15836aa8ef41a0ab9a6005c565e6af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i611e6b094ace4fdb8726ca8580b06107_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib8a014ebcaec4257afdea4362d4f7dcd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib53a531742ed4dd185794ef0fece2924_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icc43d4329cfd4c3da7fcc8ab7fc08335_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic9ec83ce9f514a99ba56f61ebd1703d2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2530162568594c229e21427834758000_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i385070469b464b4c8f16f134196230a2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8232d132f78246a9b19395e9881b3b9e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8a461815e0cd4109af3d6157d9306450_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2599f46d545f4a9694a18ef8b64edd24_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2566bfad24064edcb4c6f1cc871fe634_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i66eb009ac1814de594979994b70ed488_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0f6d9575386442c88a03e9392c8d4680_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i45dcb81690184808b8b2e4355d718016_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc3230becc0c4828baf9d10e3a700d76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3aa407138475458aaaef37293a812835_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7278ef49c004479caacda424a824f532_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffb6f235c56e4125932f967ec4150a5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8a92024a5dd4f20a93bb06874c6c09f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief0d79f965424c5688f2b4927964c092_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i568adc428eb44729bae4b7054ca3ecf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54ceccf75bcd408a9bf4399875c3a587_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6246e151bd44c8ea675865e0681f3e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2814ecb054554ae0ac8032339ced6fc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3dcacd3393d4b038db393a7e50dcb86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f5bf030bb894331af4cc030aaf8955d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1727e43bcce4e9f99238725b4368289_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3215d158f874704ae5a909e76a9ffef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8096af143794d6ba663925f6c296688_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcd80b1629894491abd8c97b39181c6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1308b34078d94ba9a442e2340bb7d947_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75af6a9d0fe3485ea6fb3e7b00fc7df8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id47adc9834a74a3abd37340b07640e50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic15681f11c644b1fb6bc25282ff28394_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib12dbc47902b42e7bd4cd39167f525fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30977d23049a41d78ef8f2e721e78cae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d6aa324dfe249378a208c3b0ce83c03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f5e3d221ec54558b758b1d1fa20008d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76c52f1b8250479b8972444c6c5e8a60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3145ece7ff6a499db53f8fe074c21db2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i740cf33bc2fe44aa91439e45ae7070d5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25ba2b9f8f70480582002fca729cdf80_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9e413d250b1c4d62b2a2ce56ec990ee3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6e17e3d8ee2e4532b2cedd534f9c43c7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5d82ade78bd740c5a619b23a903384cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e68e13a919f45a69729166fad740cce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59df97eaf2b1410da01b135ea8df9e67_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i16fb8f79f27a4ba1975a3c0080fac1f1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i416b558733524b4eb313dc3fd149027e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9cc71c1998d340b785d6c9e22719d163_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i531b1272dc854f2d96ea4aaa8c7ac85b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2db08fccd6a24dd4923b782282695b76_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8b3cfafe3e344d1c81dc96f60ad4e0b6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifc601537972b46fe9d996ede277d82de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idd44300529054baab8274cb4fdd4c646_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i571d57dd721148bcba35827581b9aab2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35e7bbcc8d91489a9ac9423421979dce_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3510f01da59140459a2feaa5c20cc72f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibfb73d2285af40bb99c52adb7201908c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1eca5b1af11a4d5592dd3ab9138e6d87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i137c985bf2b84d7284fe720707605375_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i64fd06cf9ff3480e80700431d359cc79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i860bf70640a44ea9b73b26a8d15aba5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if190d4db77c042b58e04f6bd35da403b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdf71eb3d9cc444083f1b2554c284e40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0826354779264443891d6a415136b373_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7174960f5b134c548aa4d81b816b31fb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idea26c2873f4475288eeedd9a1ca9042_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i27309968abdf4262bb2205ee58ad5acc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib37da93f7f23442d8e258fd0d8326698_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaebf3329ac42485e9cb9a16f9bd00f59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib653e5e8294241fb8b57acb7b6fc82ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idaa7e42e08294660a93554586f9e98e6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i358fe90d0eb44486b61c0746c2230690_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib11ad222d0b546dd9ac72ba5f96d48c9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id580a7d8949142a485d23eb67d12db45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fb8113f4fdf46a6a6d5465c3af10b83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id84833fac2b9441da5a93a848c1d7ae7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc7656849cc94666be3e0a7a222c0a01_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e05d493b2494afe9d2924b87d069e98_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i90a498059fcf4606b716a944ac2ec8b6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iba47bf9899884717ab70af9ee14f9c2c_D20220427-20220427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-27</startDate>
            <endDate>2022-04-27</endDate>
        </period>
    </context>
    <context id="i8119dbb6aa8f4209831488917ed525c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib72ca4bc7ef0408bbf17ce916c1f6509_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e316ab4ba32437c958ac31c5508c0b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id9d80104f1b540928f8ac1ddc8014d3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i65b5ad20d89f472cad8dfcd21eda5886_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i07ce4db9efe048acac76f18d5fa8a4e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4eb923c3c38347a98af734e4bc95e64b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e922a7c4de84239b28fe388eb3877de_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6da7d7575ad342f2b9348f4fc572b689_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88f4e15da99f48ff99edb0138e60332a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3bebfc17f52c4711b46e9ec3c87538ce_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i503f2f6a1ef14912910191aaf1ea287a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9508779f4b0c40619e8754cfbb98b602_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72f137a107044827823d5b3929276fde_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>moh:segment</measure>
    </unit>
    <unit id="member">
        <measure>moh:member</measure>
    </unit>
    <unit id="position">
        <measure>moh:position</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>moh:security</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl8zLTEtMS0xLTQxOTI1_b2296ba7-4ecf-4092-9438-d7b8f8729b39">0001179929</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl80LTEtMS0xLTQxOTI1_4ce06493-a6c5-40d8-98d1-e728de56a479">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl81LTEtMS0xLTQxOTI1_5e67a796-f06c-4982-a4fd-bd4fb4df9438">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl82LTEtMS0xLTQxOTI1_d2e37668-da95-4e05-8014-71caeea3acf8">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80L2ZyYWc6NWQ4ZDJhOGY0NjJjNDllZGFhYzM4NmQwZjVhODQxY2YvdGFibGU6MzA5NjU3Zjk0Mzg0NDRlNjgwYjMwOWZjNGVkYzIwN2YvdGFibGVyYW5nZTozMDk2NTdmOTQzODQ0NGU2ODBiMzA5ZmM0ZWRjMjA3Zl83LTEtMS0xLTQxOTI1_16d1bd90-490b-4a4f-9faf-8ea00a8adf06">false</dei:AmendmentFlag>
    <moh:HealthPlanContractTerm
      contextRef="i8851606cc612421ab07daae70b687796_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMy_742266a5-3364-47ae-b977-fd809341826f">P3Y</moh:HealthPlanContractTerm>
    <dei:DocumentType
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk3_cf270ac3-28e1-491f-8337-243220a37cbf">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6YzdlNzgyZGY2MDkwNDc1ODlkOThmYmQ5ZWIwOGU5NWEvdGFibGVyYW5nZTpjN2U3ODJkZjYwOTA0NzU4OWQ5OGZiZDllYjA4ZTk1YV8wLTAtMS0xLTQxOTI1_091ce782-e722-4d8c-b7b9-ed9403f5980c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8xMzc_b7292708-6758-40de-a7d2-f2b7138e7fb1">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMyMjY4ODQ1MzBkNDE3ZWJmNDk1M2M2YWI5ODM2MDUvdGFibGVyYW5nZTo1MzIyNjg4NDUzMGQ0MTdlYmY0OTUzYzZhYjk4MzYwNV8wLTAtMS0xLTQxOTI1_d5145005-27fa-4313-afdf-04617d1953fa">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAz_c37666fb-af6c-4599-9d93-b0e1073dcad2">001-31719</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTA0_d18369e4-442c-4208-93cd-b32f74bedbfc">MOLINA HEALTHCARE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8wLTAtMS0xLTQxOTI1_8ee437e6-3076-4034-8c1a-37c0b4307a15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8wLTMtMS0xLTQxOTI1_1d76ad20-27f1-46bd-9e71-d3c53872e2f8">13-4204626</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8zLTAtMS0xLTQxOTI1L3RleHRyZWdpb246ODMzNDY1ZWI4MWM2NDc1YWJiZTYzMGY1OGFhYWQ0NWJfNA_e205b282-87e0-4aed-bcbf-d1c9275ca202">200 Oceangate</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV8zLTAtMS0xLTQxOTI1L3RleHRyZWdpb246ODMzNDY1ZWI4MWM2NDc1YWJiZTYzMGY1OGFhYWQ0NWJfOA_45b050c6-32ed-47bc-a964-f12966e4566a">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV80LTAtMS0xLTQxOTI1_f97637de-867d-481c-9870-3bd82a70221a">Long Beach,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV80LTEtMS0xLTQxOTI1_464b63f9-f9f1-4b25-984a-fe22c5fa38fd">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6ZDAzMDFiZWI3YTYzNGFlNjhjYzA3NGU5MGRlMmI5ZjUvdGFibGVyYW5nZTpkMDMwMWJlYjdhNjM0YWU2OGNjMDc0ZTkwZGUyYjlmNV80LTMtMS0xLTQxOTI1_d9fe1a02-2850-486a-b068-6b3ee334c9f5">90802</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk4_ab44b1fe-3517-4b20-863c-d85868bf4a88">562</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk5_5173c3f7-394e-46e9-87d5-5fab8f6145f9">435-3666</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMwMzNjYWUyZjIxNGU3OWE3MWUwZWNkODczMGYwNWIvdGFibGVyYW5nZTo1MzAzM2NhZTJmMjE0ZTc5YTcxZTBlY2Q4NzMwZjA1Yl8xLTAtMS0xLTQxOTI1_26065fac-638f-4f80-bf26-f5512fc702f8">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMwMzNjYWUyZjIxNGU3OWE3MWUwZWNkODczMGYwNWIvdGFibGVyYW5nZTo1MzAzM2NhZTJmMjE0ZTc5YTcxZTBlY2Q4NzMwZjA1Yl8xLTEtMS0xLTQxOTI1_a31db9f3-64c4-4d40-aabc-940abb19b724">MOH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGFibGU6NTMwMzNjYWUyZjIxNGU3OWE3MWUwZWNkODczMGYwNWIvdGFibGVyYW5nZTo1MzAzM2NhZTJmMjE0ZTc5YTcxZTBlY2Q4NzMwZjA1Yl8xLTItMS0xLTQxOTI1_fbd62aac-645a-4af9-b179-600d16b622bb">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk0_cb82bf12-5e84-48bc-859d-26a2b3b40bb6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDk1_2a5dcda5-4081-4892-9e89-a7c227d454d0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF81NDk3NTU4MTQxMDIy_1e3cbc3f-45fd-4471-a87f-8adf74d42362">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAw_e3135d05-952b-43b0-875d-ab3008677a55">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAx_def02d58-fa7b-47af-be9f-e22994e5f555">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMTAy_f7314a0c-da1e-4dd3-93c7-f9ec411bca52">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5088f3c4c0b64cf3a6113fcf094799c3_I20220422"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xL2ZyYWc6Y2U1ZjNlZTIzZjc5NGE2YTgyZDk4ZTQzMzZmYTljNTAvdGV4dHJlZ2lvbjpjZTVmM2VlMjNmNzk0YTZhODJkOThlNDMzNmZhOWM1MF8yMDky_9d79818e-0e45-40b6-9707-b049418266f4"
      unitRef="shares">58700000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PremiumsEarnedNet
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNS0xLTEtMS00MTkyNQ_5dbf4135-2010-45d3-912f-321693aeb9a0"
      unitRef="usd">7531000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNS0zLTEtMS00MTkyNQ_df390563-a786-49fa-8fd1-4a70017c4a98"
      unitRef="usd">6306000000</us-gaap:PremiumsEarnedNet>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNi0xLTEtMS00MTkyNQ_3bc3fcaa-4354-498c-8709-0292dbbb7b51"
      unitRef="usd">208000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfNi0zLTEtMS00MTkyNQ_23d90c04-2956-46aa-b936-85eb54e17a23"
      unitRef="usd">187000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <us-gaap:NetInvestmentIncome
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOC0xLTEtMS00MTkyNQ_ed14f852-a4ab-475c-bc27-e0a21d45d914"
      unitRef="usd">11000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOC0zLTEtMS00MTkyNQ_8a61adbf-58a1-4a50-af95-6e988ccc9102"
      unitRef="usd">9000000</us-gaap:NetInvestmentIncome>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOS0xLTEtMS00MTkyNQ_ebfa9c1e-3431-480a-8a0b-2c9f9b8e5fc2"
      unitRef="usd">20000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfOS0zLTEtMS00MTkyNQ_93c7adfb-c3dd-4a01-ae55-73eef239153f"
      unitRef="usd">20000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:Revenues
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTAtMS0xLTEtNDE5MjU_d035d567-6d01-4aee-8e25-03bc06f95873"
      unitRef="usd">7770000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTAtMy0xLTEtNDE5MjU_931a39da-6987-4b90-99b4-954c2c3eb9b9"
      unitRef="usd">6522000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTItMS0xLTEtNDE5MjU_a05e355b-36b6-4b70-8689-c38ac359e393"
      unitRef="usd">6563000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTItMy0xLTEtNDE5MjU_e4deeda0-b966-45f0-9e24-2c66243797c1"
      unitRef="usd">5474000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTMtMS0xLTEtNDE5MjU_ab801fa6-acf5-4759-b2dd-a44518bd8fea"
      unitRef="usd">571000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTMtMy0xLTEtNDE5MjU_c3f5e546-77cd-4e84-900a-07f0d7d308bf"
      unitRef="usd">473000000</us-gaap:GeneralAndAdministrativeExpense>
    <moh:PremiumTaxExpenses
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTQtMS0xLTEtNDE5MjU_f60d4c4e-4bd0-432d-b109-bd1de9dda84a"
      unitRef="usd">208000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTQtMy0xLTEtNDE5MjU_4f8b1fac-016b-49cf-a171-9bd74ebed72c"
      unitRef="usd">187000000</moh:PremiumTaxExpenses>
    <us-gaap:DepreciationAndAmortization
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTYtMS0xLTEtNDE5MjU_be499acc-f302-476c-be55-dd5608dba7b2"
      unitRef="usd">40000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTYtMy0xLTEtNDE5MjU_4b92331a-d098-45d1-aa96-7298cb1d308f"
      unitRef="usd">33000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTctMS0xLTEtNDE5MjU_7903c74e-0eb1-410a-8d23-8810e58ebbfd"
      unitRef="usd">16000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTctMy0xLTEtNDE5MjU_58579eec-6ec8-4931-8f93-4aa4bb2d2c48"
      unitRef="usd">20000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:CostsAndExpenses
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTgtMS0xLTEtNDE5MjU_f9d2f5a8-34a3-4827-90b6-7edf6b3a4d5a"
      unitRef="usd">7398000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTgtMy0xLTEtNDE5MjU_452f75b1-5437-4ede-90ea-855282adf987"
      unitRef="usd">6187000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTktMS0xLTEtNDE5MjU_24aec44f-5b09-40b7-bd36-2241ae982a91"
      unitRef="usd">372000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMTktMy0xLTEtNDE5MjU_b53dc0ff-06ad-42f5-bd93-3eaea0baa2c5"
      unitRef="usd">335000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjEtMS0xLTEtNDE5MjU_a42c0828-270e-4cc1-97af-c3ec2d1da89c"
      unitRef="usd">28000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjEtMy0xLTEtNDE5MjU_c2f57e75-d262-46aa-a1ef-1a28c4ed269e"
      unitRef="usd">30000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjMtMS0xLTEtNDE5MjU_fedf7469-6e4f-43ad-9c87-1b73405c3b06"
      unitRef="usd">-28000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjMtMy0xLTEtNDE5MjU_d6914f04-0a45-4922-8601-a4c22f0d5bce"
      unitRef="usd">-30000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjQtMS0xLTEtNDE5MjU_4c1f44af-5e7d-4baa-baac-bca8a94983f6"
      unitRef="usd">344000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjQtMy0xLTEtNDE5MjU_aa00929e-3ef3-4a56-a2da-6904dcb85e00"
      unitRef="usd">305000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjUtMS0xLTEtNDE5MjU_7587f837-bbfa-44fb-9f70-f335063ead98"
      unitRef="usd">86000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjUtMy0xLTEtNDE5MjU_947037a9-88f9-4c1c-8c1e-e3194e0ab9b0"
      unitRef="usd">77000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjYtMS0xLTEtNDE5MjU_3c915a28-52d0-4977-a429-8687a78a584d"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjYtMy0xLTEtNDE5MjU_385e0c0c-503a-4bfb-af7f-dc9b773960b2"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjgtMS0xLTEtNDE5MjU_5320cb19-0abe-4d20-a29f-a9fa30e05bdb"
      unitRef="usdPerShare">4.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjgtMy0xLTEtNDE5MjU_ee6c2bfe-9273-4eef-b774-dc3238885f05"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjktMS0xLTEtNDE5MjU_c0844af2-23f0-4902-963e-0806794614ea"
      unitRef="usdPerShare">4.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOjkxYTUzZDhkNDc0MzQ4Mjg5MWJkYmYyMGU3ZDY0OTAwL3RhYmxlcmFuZ2U6OTFhNTNkOGQ0NzQzNDgyODkxYmRiZjIwZTdkNjQ5MDBfMjktMy0xLTEtNDE5MjU_f416eec0-7f2a-4268-bb43-005798070794"
      unitRef="usdPerShare">3.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNC0xLTEtMS00MTkyNQ_01b9fbe6-f6a9-45e8-948f-3ac51e30bf3a"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNC0zLTEtMS00MTkyNQ_04352930-8481-4e0a-8dde-465bb90f1fb6"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNi0xLTEtMS00MTkyNQ_25319112-6581-4495-b95f-b262836e74bb"
      unitRef="usd">-100000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNi0zLTEtMS00MTkyNQ_3c792a0d-42aa-48dd-b386-48907e052419"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNy0xLTEtMS00MTkyNQ_c0e1e760-bf85-431f-a9d4-598653456503"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfNy0zLTEtMS00MTkyNQ_8099c27f-c7e1-4ba9-b473-5d092f7ac54d"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOC0xLTEtMS00MTkyNQ_1df7a77d-4d06-46ce-b18b-cb1ba37bf5c6"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOC0zLTEtMS00MTkyNQ_badbb3c0-bf73-4202-8b9d-e4bfd402aca8"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOS0xLTEtMS00MTkyNQ_d9a8c235-ae26-4c14-a075-aaf02bbb910c"
      unitRef="usd">182000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xMy9mcmFnOjgxMzM5YTQ4NDJmODRlODk5MDliNjY2MDI1MjA2ODQyL3RhYmxlOmQ5NDhmZTgwNDgzZjRhNmQ5ZWQ4OTRkMjZmMTc2NWM0L3RhYmxlcmFuZ2U6ZDk0OGZlODA0ODNmNGE2ZDllZDg5NGQyNmYxNzY1YzRfOS0zLTEtMS00MTkyNQ_dee91e33-3072-401b-94ef-1747c9dbdc40"
      unitRef="usd">217000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNi0xLTEtMS00MTkyNQ_116231ad-cdd5-41bc-8d1a-87f169f3493e"
      unitRef="usd">4804000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNi0zLTEtMS00MTkyNQ_d2420aeb-093c-44cd-ba38-f1d982ad2259"
      unitRef="usd">4438000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNy0xLTEtMS00MTkyNQ_d839a372-9ee8-4762-9295-96ccd7ee0d24"
      unitRef="usd">2988000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfNy0zLTEtMS00MTkyNQ_76f5578b-d01b-4cdb-9e1f-b39afac90d33"
      unitRef="usd">3202000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOC0xLTEtMS00MTkyNQ_14ccb453-55de-43e8-afe2-b3184be663b7"
      unitRef="usd">2156000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOC0zLTEtMS00MTkyNQ_a4fe39e9-3e5f-43b3-b11c-5206d65a4b49"
      unitRef="usd">2177000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOS0xLTEtMS00MTkyNQ_14360b4a-a47f-405f-ad22-08a2879d769c"
      unitRef="usd">198000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfOS0zLTEtMS00MTkyNQ_80aa63d2-7f3d-4a72-977e-7b17195e72d9"
      unitRef="usd">247000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTAtMS0xLTEtNDE5MjU_db873b86-29d7-40a5-9de0-915894825026"
      unitRef="usd">10146000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTAtMy0xLTEtNDE5MjU_3364ee0c-78e1-4162-ad0d-87360360c015"
      unitRef="usd">10064000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTEtMS0xLTEtNDE5MjU_8bbdc46c-f467-4921-a5f1-4a6789fc7020"
      unitRef="usd">393000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTEtMy0xLTEtNDE5MjU_631edce7-f540-4a27-a1c7-87144ada160e"
      unitRef="usd">396000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTItMS0xLTEtNDE5MjU_a142a60a-5c92-44fe-ad27-b3feeeff04a0"
      unitRef="usd">1305000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTItMy0xLTEtNDE5MjU_49a661a7-8b9d-4e4c-ab64-afe28cebd53b"
      unitRef="usd">1252000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTMtMS0xLTEtNDE5MjU_702b62be-ed38-4f08-bda1-39e7ca7cb1e6"
      unitRef="usd">221000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTMtMy0xLTEtNDE5MjU_83e8445a-3475-488c-afb3-0d92edad107a"
      unitRef="usd">212000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTQtMS0xLTEtNDE5MjU_64768bb1-2d36-44b7-b768-932e388274b0"
      unitRef="usd">114000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTQtMy0xLTEtNDE5MjU_19c6208b-17a7-4e1f-bdaa-2928f011996c"
      unitRef="usd">106000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTUtMS0xLTEtNDE5MjU_a2a1d884-e17d-4c71-bc95-5b92309936d6"
      unitRef="usd">181000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTUtMy0xLTEtNDE5MjU_88b3a193-12ca-4d64-bb5c-95172f8365b2"
      unitRef="usd">179000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTYtMS0xLTEtNDE5MjU_8871a6f3-bb20-48b2-820b-41b846341850"
      unitRef="usd">12360000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMTYtMy0xLTEtNDE5MjU_3759067a-af2b-426e-a5d2-6c58ac37d4e3"
      unitRef="usd">12209000000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjAtMS0xLTEtNDE5MjU_652063d9-57da-458b-82dc-453f2891ca0b"
      unitRef="usd">3601000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjAtMy0xLTEtNDE5MjU_db2d7efd-b903-47df-9e84-3e30e717f98a"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjEtMS0xLTEtNDE5MjU_cf4d8f52-a8ac-4015-83fb-6cae704d159c"
      unitRef="usd">2613000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjEtMy0xLTEtNDE5MjU_d2a1cf5c-6b3b-4bcd-81a4-c768b7f96022"
      unitRef="usd">2472000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjItMS0xLTEtNDE5MjU_4e972244-42ae-4db9-a0f1-0ba201020145"
      unitRef="usd">809000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjItMy0xLTEtNDE5MjU_9e51257c-30b8-4588-a08d-b85371d11e70"
      unitRef="usd">842000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjMtMS0xLTEtNDE5MjU_c309f5c3-59d1-4a4b-88dc-a633e7402e55"
      unitRef="usd">18000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjMtMy0xLTEtNDE5MjU_e328fe0f-e562-479e-baf5-1b81959cf8d4"
      unitRef="usd">370000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjQtMS0xLTEtNDE5MjU_f0a88e92-a37c-4c0b-86bd-035a59d9233b"
      unitRef="usd">7041000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjQtMy0xLTEtNDE5MjU_108d0574-e647-4cff-b870-b3c0bff8494d"
      unitRef="usd">7047000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjUtMS0xLTEtNDE5MjU_2de1b7ff-3d96-4a77-a0cc-aa62c63d1fb5"
      unitRef="usd">2174000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjUtMy0xLTEtNDE5MjU_5f6c9b4d-625c-48a1-896a-83a53beeb57b"
      unitRef="usd">2173000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjYtMS0xLTEtNDE5MjU_5977cf69-6301-46b5-a26b-d50bd47dcdac"
      unitRef="usd">217000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjYtMy0xLTEtNDE5MjU_2411ac95-5d40-44fd-81fb-5520ffea808f"
      unitRef="usd">219000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjctMS0xLTEtNDE5MjU_2a6284a9-1857-43bd-bb6d-3d246bececad"
      unitRef="usd">134000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjctMy0xLTEtNDE5MjU_f9cd4b47-a7cd-4fa7-9da6-30a8f49761c0"
      unitRef="usd">140000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjgtMS0xLTEtNDE5MjU_064a113f-9f61-463e-8652-b23b25534da9"
      unitRef="usd">9566000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMjgtMy0xLTEtNDE5MjU_0fca9a13-4316-448a-89e0-3062648c6f8b"
      unitRef="usd">9579000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18xOQ_50a58f93-17a6-43f3-b9f7-9afd42e0b83b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18xOQ_bed5e657-a523-4470-b62a-49cd82a70958"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18zMw_c2bf3665-8de3-44bd-8c31-0ad416ada7d7"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N18zMw_fbfd6646-d742-4bb4-826b-1b8b78a62c30"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N182OA_46c5f5e7-eae5-4821-aa94-705cf34ed4ea"
      unitRef="shares">59000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjplNjczNmQ3MjE2Y2E0ZjAyOTU0MmViNWNjYTBmYmM4N184OQ_328c0fc2-99c6-4be9-b04f-bd525178e2e0"
      unitRef="shares">58000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMS0xLTEtNDE5MjU_510e506b-fe6e-42ca-8af8-f7158ea13439"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzAtMy0xLTEtNDE5MjU_c80e0ac4-ab14-47a9-9298-1ec14e5d9f13"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8yMg_2631d387-fcb6-4a2e-a667-63e3f4c6510d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8yMg_4fc9b716-b5df-46c5-84e1-6c4e787690f8"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8zNg_8e37d505-0e8c-47eb-92a0-833058014f1d"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF8zNg_bec920d4-9d65-4776-9b79-4c6ec4778554"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_41514d74-16e0-42ca-ae18-d2e09c150b05"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_5a6620c7-41d9-49db-8a00-e6ca69b3d07d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_dddee989-a408-441e-8449-e1be50176b62"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiOGU2ZjUxZTUzMTE0M2EzOTczZGFkNjFhMzVjNDJjNF81OA_f220d742-9765-402a-b09f-a7c80278a200"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMS0xLTEtNDE5MjU_ef1bac42-59d4-4f0e-9126-51014784d7d6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzEtMy0xLTEtNDE5MjU_3f3aafb6-d877-4ada-973b-8631a0fb9ef3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzItMS0xLTEtNDE5MjU_ab301366-3e88-4bea-b717-baa639c88f67"
      unitRef="usd">218000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzItMy0xLTEtNDE5MjU_ec3fd03c-f413-4668-a312-6cdc92fa1737"
      unitRef="usd">236000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzMtMS0xLTEtNDE5MjU_4c76f2fb-4c80-4cd8-9a77-6cb15c5c653b"
      unitRef="usd">-81000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzMtMy0xLTEtNDE5MjU_de86c31d-54a2-4792-92af-ad67732861f6"
      unitRef="usd">-5000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzQtMS0xLTEtNDE5MjU_1534c1cf-7ad9-4426-a080-267eb7b40229"
      unitRef="usd">2657000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzQtMy0xLTEtNDE5MjU_7c6d473c-dedc-47d9-aa14-083ac2f2c9ff"
      unitRef="usd">2399000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzUtMS0xLTEtNDE5MjU_b464d6eb-bbda-4484-ac4f-9ac93db03fef"
      unitRef="usd">2794000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzUtMy0xLTEtNDE5MjU_478734f5-1960-4601-bb85-41154e65b466"
      unitRef="usd">2630000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzYtMS0xLTEtNDE5MjU_a4b62da2-2620-48b2-811a-379d1070b2aa"
      unitRef="usd">12360000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xNi9mcmFnOjIwY2Q0NjdjOGE0ZTQ4OTM4MjAyMGVjMjI1OTM0MjFiL3RhYmxlOmQyZGEyNzQ3MzNhZjQ0NzNhYTE3OWNjMDViMGFiNzlhL3RhYmxlcmFuZ2U6ZDJkYTI3NDczM2FmNDQ3M2FhMTc5Y2MwNWIwYWI3OWFfMzYtMy0xLTEtNDE5MjU_903a39ce-de67-472d-97ec-4bef021f41a1"
      unitRef="usd">12209000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4d495bb1496443bf84bdb17358ef9e27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS0xLTEtMS00MTkyNQ_41148aa6-557f-48e7-8103-cd429e6efc97"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4d495bb1496443bf84bdb17358ef9e27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS0zLTEtMS00MTkyNQ_4a0420c2-528b-41c4-bdf1-f633015fc462"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibfbbdfebf5e0417db5c15c1f2203e943_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS01LTEtMS00MTkyNQ_5179271c-3c03-4b79-8108-f9ecd48737b3"
      unitRef="usd">236000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i210479d51b0949d4b306fa898f8ab68e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS03LTEtMS00MTkyNQ_f36a42f8-5445-4627-acb8-150de7358b72"
      unitRef="usd">-5000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0a791bedc8c497a9b951c0a54286c99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS05LTEtMS00MTkyNQ_93bca112-4bb4-47ae-9a49-d03432204653"
      unitRef="usd">2399000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNS0xMS0xLTEtNDE5MjU_6e68d91c-2de6-4988-b758-85f78a850ce6"
      unitRef="usd">2630000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9197f15ee9d540a0993914efdd5e51cd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNi05LTEtMS00MTkyNQ_b0ee8fc7-5a6d-4620-9110-d1a0578b7d3c"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfNi0xMS0xLTEtNDE5MjU_bfba73ec-90e1-45a4-9ea1-2c5fc58d4167"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icd4a419317fc4c44910821bd8c61e989_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTYtNy0xLTEtNDE5MjU_3c1ddd4f-5c28-49ca-b98e-1ce2bbeae66e"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTYtMTEtMS0xLTQxOTI1_3fc6b632-e482-46cc-8ce0-8b2f8879ac6e"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3e97722ed58740a3af7cda41b611b9c1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTctMS0xLTEtNDE5MjU_75742506-6225-4b8f-9242-1062bd2f10b4"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib1fa7fde4814471db3810635d40bdbdc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTctNS0xLTEtNDE5MjU_731cc2c7-af11-49e7-93ee-fc8efd572e78"
      unitRef="usd">-18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTctMTEtMS0xLTQxOTI1_68a51aa1-2c87-47bc-b526-649ecaff57d2"
      unitRef="usd">-18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i67e78bf8f50943f1aa07fa55e4049d43_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtMS0xLTEtNDE5MjU_a9eb5c38-55d2-4a4d-973c-d104bbaecd44"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i67e78bf8f50943f1aa07fa55e4049d43_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtMy0xLTEtNDE5MjU_b045c54f-4fef-4b58-9f91-145ed9e5c19e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib45bf3fe8b354f538d45f5c9cbfd0225_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtNS0xLTEtNDE5MjU_0240f41c-ddd7-4711-98c7-3ba7a19841f6"
      unitRef="usd">218000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97b8c89c2c664032b3e7c570dd406ef5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtNy0xLTEtNDE5MjU_91addf92-64f2-4423-9228-300521841349"
      unitRef="usd">-81000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id82c487ce2bc462599459c0507d1ca62_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtOS0xLTEtNDE5MjU_bfc3cf18-58af-41ae-9163-910f5351cc6a"
      unitRef="usd">2657000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOmNjMGRhZmQ3MGU5MTRlM2I4YjgwODE4ZTAyN2EwYjczL3RhYmxlcmFuZ2U6Y2MwZGFmZDcwZTkxNGUzYjhiODA4MThlMDI3YTBiNzNfMTgtMTEtMS0xLTQxOTI1_c4591611-c7c7-4d89-a22c-8d2252806ef3"
      unitRef="usd">2794000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i995ada66e7f14440b7cfd0a914ac8acf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS0xLTEtMS00MTkyNQ_01fc285c-a879-4924-b02e-444937caacda"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i995ada66e7f14440b7cfd0a914ac8acf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS0zLTEtMS00MTkyNQ_5bc7acea-d51c-47e5-8aba-3a2d39e6aaf9"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff011ca48c834fabbfb52d9e98555c1c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS01LTEtMS00MTkyNQ_6ffeed3d-7f61-4b0b-abd3-c1fec0a392db"
      unitRef="usd">199000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0199bf3103774fb5b433a7b2f787c39d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS03LTEtMS00MTkyNQ_55accc4a-a597-4642-8f11-2f47cd156d5b"
      unitRef="usd">37000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdcb8a23a1fc4ae8a13e0ed56f15658f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS05LTEtMS00MTkyNQ_9b05f5ed-c9fd-4ae1-be35-4892a01f4257"
      unitRef="usd">1860000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63e99d1b775642728d269200485a7951_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNS0xMS0xLTEtNDE5MjU_2b5b43dc-c30d-4540-bd9b-19066bed5cf4"
      unitRef="usd">2096000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3e7d8195295e452a9c89b318b1b39b4b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNi05LTEtMS00MTkyNQ_447693aa-ad40-4660-822c-3f8f3fad1af4"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNi0xMS0xLTEtNDE5MjU_43edcd18-e897-4ebd-be4d-c9d2bd13b774"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i4c1fa8ff9f704dc4a9aafd83714c7904_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy0xLTEtMS00MTkyNQ_cfcbc9ce-d584-40fc-80f5-6d30692747e4"
      unitRef="shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iaeb68bdab10a46ea8ce7f8f06b183910_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy01LTEtMS00MTkyNQ_3dbbe64f-e7c1-4d7a-804e-bba6c55b9a8c"
      unitRef="usd">2000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3e7d8195295e452a9c89b318b1b39b4b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy05LTEtMS00MTkyNQ_e27893fe-b7d1-40f8-a680-b7229d5ed671"
      unitRef="usd">120000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfNy0xMS0xLTEtNDE5MjU_b66f4d69-ea47-40c6-bb48-d70703ff20a0"
      unitRef="usd">122000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie3691bc168b04f23adb9b834865b296d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTYtNy0xLTEtNDE5MjU_89695fec-4ddd-4f47-910f-90b00e5b71cd"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTYtMTEtMS0xLTQxOTI1_0f6bbc93-6c13-4309-a541-804724968cdd"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaeb68bdab10a46ea8ce7f8f06b183910_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTctNS0xLTEtNDE5MjU_e6dccdeb-9fce-4c6d-b28c-7ebba31dcfcd"
      unitRef="usd">-27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTctMTEtMS0xLTQxOTI1_a11327d8-6e41-49bd-a80d-26298c8f0b75"
      unitRef="usd">-27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i84780b904fcb43cf980043acfdf85931_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtMS0xLTEtNDE5MjU_589e473f-2fa1-4ee5-bd63-ab10616e7b55"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i84780b904fcb43cf980043acfdf85931_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtMy0xLTEtNDE5MjU_5f888e79-75f2-4371-b315-9150db2de8dd"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56c66fd9d79140e89e5a2167138c066a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtNS0xLTEtNDE5MjU_0e793471-b039-4b39-a819-1ca6c6b5c69a"
      unitRef="usd">170000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6201f33888046d1a89c449d69d0e023_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtNy0xLTEtNDE5MjU_0cd07c51-7edd-478c-9b14-d12d9dbc0701"
      unitRef="usd">26000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6768c723a834132a8dff21a78dbcbc9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtOS0xLTEtNDE5MjU_bcfec61a-de1b-4a65-a07a-8ee501b0e5c4"
      unitRef="usd">1968000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2550091eda44588baae1b353781d6f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8xOS9mcmFnOmY5ZGE1MTRlOTY2NTRjOTliMWU1ZWJmZGU4ZjFjYzViL3RhYmxlOjBhZTk1MzY3YjU0MTQ5OTdiN2VjZWM5OTE5YmRjMWY4L3RhYmxlcmFuZ2U6MGFlOTUzNjdiNTQxNDk5N2I3ZWNlYzk5MTliZGMxZjhfMTgtMTEtMS0xLTQxOTI1_fd01e6cf-364f-4175-bc36-e9a9f2da7857"
      unitRef="usd">2164000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNS0xLTEtMS00MTkyNQ_d49f59de-3282-447a-ba11-6229319084c1"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNS0zLTEtMS00MTkyNQ_5b5d48f7-b5f2-4a72-bde4-951939532f88"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNy0xLTEtMS00MTkyNQ_cc6fb692-2e55-47dc-8b82-9f4afdadafc5"
      unitRef="usd">40000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNy0zLTEtMS00MTkyNQ_42cbcc45-b26a-4700-b2d6-51ad17296401"
      unitRef="usd">33000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOC0xLTEtMS00MTkyNQ_b9a0b8e5-4ff4-4141-bf76-b67c2b05d8c4"
      unitRef="usd">-16000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOC0zLTEtMS00MTkyNQ_27aac6a0-9a7a-4910-bc17-784d4e79abb3"
      unitRef="usd">-6000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOS0xLTEtMS00MTkyNQ_210123ca-3ddc-4bb2-8c1d-356570db823a"
      unitRef="usd">34000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfOS0zLTEtMS00MTkyNQ_8e5d585f-0d4f-451c-83bd-610e91f45405"
      unitRef="usd">24000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTEtMS0xLTEtNDE5MjU_da3c9114-596f-44c4-8629-4e5125410332"
      unitRef="usd">-8000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTEtMy0xLTEtNDE5MjU_78a69990-5059-4775-8622-f73f610f5d21"
      unitRef="usd">12000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTMtMS0xLTEtNDE5MjU_a27ada32-5790-4a49-8844-f79bcc1482e3"
      unitRef="usd">-21000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTMtMy0xLTEtNDE5MjU_b290097f-812e-418c-b007-98fbfe58afc1"
      unitRef="usd">98000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTQtMS0xLTEtNDE5MjU_cb5489de-755c-415a-9874-fa4c92cbde8f"
      unitRef="usd">32000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTQtMy0xLTEtNDE5MjU_b9bb788c-80ab-49b6-9979-8d38c44b8d52"
      unitRef="usd">15000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTUtMS0xLTEtNDE5MjU_d40a46ce-2173-4c61-8f96-ba5b7b0c135b"
      unitRef="usd">263000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTUtMy0xLTEtNDE5MjU_308249cf-0e4f-4c1f-bccd-b886c92a14da"
      unitRef="usd">168000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTYtMS0xLTEtNDE5MjU_5ae7de7b-8c58-41ed-b2fe-e4233c7aeb52"
      unitRef="usd">137000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTYtMy0xLTEtNDE5MjU_b39672b4-7cc6-4390-bebe-638b57a85381"
      unitRef="usd">432000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTctMS0xLTEtNDE5MjU_9a902882-fadd-450d-86f8-f2dda6fcf802"
      unitRef="usd">-81000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTctMy0xLTEtNDE5MjU_39fafd7f-0734-4d59-ae19-eefedb60c666"
      unitRef="usd">16000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTgtMS0xLTEtNDE5MjU_d3375e83-20ae-40bb-990f-803f4d72301a"
      unitRef="usd">-352000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTgtMy0xLTEtNDE5MjU_04e9fed3-d37b-4b04-994d-25610ef7af41"
      unitRef="usd">-304000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTktMS0xLTEtNDE5MjU_1fa80a27-d611-41d4-b876-587b8db06e5c"
      unitRef="usd">67000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMTktMy0xLTEtNDE5MjU_0e91ec68-7e3e-4c4d-b8b6-55655e7f2bd3"
      unitRef="usd">66000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjAtMS0xLTEtNDE5MjU_469527f1-8a3a-43c3-9f1a-7d860c08db0e"
      unitRef="usd">363000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjAtMy0xLTEtNDE5MjU_bd3acc4b-510e-4ab4-8e34-10b8fcac90c6"
      unitRef="usd">568000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjItMS0xLTEtNDE5MjU_a97ca345-fc33-4f47-a767-1a3d0406c2ef"
      unitRef="usd">403000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjItMy0xLTEtNDE5MjU_f9910f91-e1ac-4a8c-a336-eed4821134df"
      unitRef="usd">388000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjMtMS0xLTEtNDE5MjU_27054653-5b1a-4ced-958d-eeb00318895a"
      unitRef="usd">513000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjMtMy0xLTEtNDE5MjU_8daebfee-3c69-45e0-b96e-3d24f546938d"
      unitRef="usd">308000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjQtMS0xLTEtNDE5MjU_3812e177-b68c-4486-a1e8-69c7e4f65e60"
      unitRef="usd">23000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjQtMy0xLTEtNDE5MjU_7022e7bf-0959-4cfc-bd2c-ce02d83a2559"
      unitRef="usd">16000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjYtMS0xLTEtNDE5MjU_f07d6d8b-0bc0-45cd-9415-05c9bf269858"
      unitRef="usd">13000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjYtMy0xLTEtNDE5MjU_c6c37564-33d9-4dbc-a369-feaacd9c0ef7"
      unitRef="usd">-9000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjctMS0xLTEtNDE5MjU_b42fd6a0-959f-42e1-b5fa-b033e4f86b4c"
      unitRef="usd">74000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMjctMy0xLTEtNDE5MjU_dd791810-e3bd-4ba5-8602-4b72ca327281"
      unitRef="usd">-87000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzAtMS0xLTEtNDE5MjU_cf17dc42-f2da-4084-8047-923113da9d74"
      unitRef="usd">52000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzAtMy0xLTEtNDE5MjU_b407060d-8707-4c94-a534-dc68aeada45d"
      unitRef="usd">51000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzEtMS0xLTEtNDE5MjU_9ab97f11-02d5-41ff-86f1-6c66aa8d1aba"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzEtMy0xLTEtNDE5MjU_5c6fb2a7-6a5c-4545-a50c-eb77a55e7cf3"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzItMS0xLTEtNDc3OTM_dd5d694c-aad3-4061-8e47-a955620fcc30"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfMzItMy0xLTEtNDc3OTM_b81e2565-7c39-4c85-87bc-859267ee0759"
      unitRef="usd">128000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDAtMS0xLTEtNDE5MjU_d9a2137e-7478-4a53-8dc1-9592be2cd1b0"
      unitRef="usd">-5000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDAtMy0xLTEtNDE5MjU_55fb4851-5f50-4306-b420-b73ee093a8e9"
      unitRef="usd">-8000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDEtMS0xLTEtNDE5MjU_b31ea7cf-580b-4802-8cec-054875387e88"
      unitRef="usd">-77000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDEtMy0xLTEtNDE5MjU_59228f10-41d8-4b23-9942-a2389f73470e"
      unitRef="usd">-207000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDItMS0xLTEtNDE5MjU_f53642eb-d7b1-4a59-a5c9-28842c8593db"
      unitRef="usd">360000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDItMy0xLTEtNDE5MjU_47f4cec1-b46e-4a3b-a144-5295a1540beb"
      unitRef="usd">274000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDMtMS0xLTEtNDE5MjU_d39d20e8-4dbe-49b8-b608-d182f17528b6"
      unitRef="usd">4506000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63e99d1b775642728d269200485a7951_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDMtMy0xLTEtNDE5MjU_275184c1-a808-4fb0-acad-e5fe905f31b1"
      unitRef="usd">4223000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDQtMS0xLTEtNDE5MjU_b7ea3421-168c-4cf9-a21d-b2789d9e9e6f"
      unitRef="usd">4866000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2550091eda44588baae1b353781d6f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8yMi9mcmFnOmQxOGEyNzZlMDg5NzQ4ZDQ4NWI1NjMyZmIxNzA2NzFmL3RhYmxlOjczYmRlMmRhZGMyZjQyMjE5Zjk3OTRjYjM3NjViZmMxL3RhYmxlcmFuZ2U6NzNiZGUyZGFkYzJmNDIyMTlmOTc5NGNiMzc2NWJmYzFfNDQtMy0xLTEtNDE5MjU_0c60c7e6-5640-4385-b251-cd20643f9cc4"
      unitRef="usd">4497000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMwOQ_2e9e9368-dfcd-4534-90fb-2c9a27516d19">Organization and Basis of Presentation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#x201c;Marketplace&#x201d;). We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, we served approximately 5.1&#160;million members eligible for government-sponsored healthcare programs, located across 19 states.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our state Medicaid contracts typically have terms of&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMy_742266a5-3364-47ae-b977-fd809341826f"&gt;three&lt;/span&gt;&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#x201c;RFPs&#x201d;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#x201c;ABD&#x201d;); and regions or service areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we submitted our RFP response. We expect the award to be announced in early August 2022, with an effective date of January 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP, with awards estimated to be announced in the fourth quarter of 2022, and start of operations in September 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Acquisition&#x2014;Medicaid and Medicare. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we closed on our acquisition of Cigna Corporation&#x2019;s Texas Medicaid and Medicare-Medicaid Plan (&#x201c;MMP&#x201d;) contracts, along with certain operating assets. See Note 4, &#x201c;Business Combinations,&#x201d; for further information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nevada Procurement&#x2014;Medicaid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible two-year extension was ratified in September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <moh:NumberOfReportableSegment
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfMTA5OTUxMTY0MDc0NA_49c96d44-a6a4-4f5f-ba20-c1c1d4d199cc"
      unitRef="segment">4</moh:NumberOfReportableSegment>
    <moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms
      contextRef="i2a15fbb627e648a9b3cfcb7d23c86eb5_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNTg3_670180d5-6521-4db1-88b2-e765aea34de8"
      unitRef="member">5100000</moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms>
    <moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms
      contextRef="i2a15fbb627e648a9b3cfcb7d23c86eb5_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNjY4_7ff86fc5-b86a-4aea-8ce7-ba05a1118c9b"
      unitRef="position">19</moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms>
    <moh:HealthPlanContractTerm
      contextRef="i71bef60ed3804c7b985e0a7f9eb18119_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzM4_29ae773a-bb91-440e-aa40-32876d58a2ad">P5Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanContractTerm
      contextRef="i3fb5e9c9ed8a4e7a8212fec43122957e_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfODI0NjMzNzIyMTEwMw_cc58b790-7307-4deb-9757-8a7c87d113c4">P4Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="i3fb5e9c9ed8a4e7a8212fec43122957e_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfODI0NjMzNzIyMTEwNA_138a3056-90d2-4715-8720-adf4a1afce09">P2Y</moh:HealthPlanExtensionOptionPeriod>
    <moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzMwMg_a8193228-c50e-468c-a1ab-da8ec1259f2c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the entire year ending December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2021.</moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zMS9mcmFnOmMwNmY5NGUzZDA1YjQyZDZiMTM5NzliYjNjYWM5MzFjL3RleHRyZWdpb246YzA2Zjk0ZTNkMDViNDJkNmIxMzk3OWJiM2NhYzkzMWNfNzI5OQ_ed66eeb4-8dd8-4c58-b9ec-e76c01fb4da5">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc3Ng_d481e446-af66-43a5-9698-523f9704af91">Significant Accounting Policies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#x201c;Significant Accounting Policies,&#x201d; under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#x201c;Amounts due government agencies,&#x201d; in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth amounts due government agencies, categorized by program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three months ended March 31, 2022, we recognized approximately $28 million related to such risk corridors, primarily in the Medicaid segment, compared to $110&#160;million recognized in the three months ended March 31, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of March&#160;31, 2022, Marketplace risk adjustment payables amounted to $949 million and related receivables amounted to $33 million, for a net payable of $916 million. As of December&#160;31, 2021, Marketplace risk adjustment payables amounted to $902 million and related receivables amounted to $7 million, for a net payable of $895 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzczNQ_f52f7bc5-d88e-4000-b998-044559103164">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc2NQ_f515bf59-d915-45c4-8fb7-b1f7dead58d2">The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc2OA_ed67e3dc-70ab-48a6-8f68-9bab7ca09a65">The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNC0xLTEtMS00MTkyNQ_61d71ac9-2dab-4c30-a5db-fef8aed2969b"
      unitRef="usd">4804000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if2550091eda44588baae1b353781d6f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNC0zLTEtMS00MTkyNQ_b232e9d8-44bc-4f33-a587-76a88388f867"
      unitRef="usd">4431000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNS0xLTEtMS00MTkyNQ_9e8b9017-edc8-4d09-adc0-e3b42b1ed7e6"
      unitRef="usd">62000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if2550091eda44588baae1b353781d6f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNS0zLTEtMS00MTkyNQ_fe73b1af-ac3a-44b2-b0d0-b354681edab0"
      unitRef="usd">66000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNi0xLTEtMS00MTkyNQ_701dc28f-6e03-4774-b92f-b26ad27a2542"
      unitRef="usd">4866000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2550091eda44588baae1b353781d6f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjNmMDhlNWI3Njg0MTQ1ZTQ5YjViMDY1MGM3MjJiN2FhL3RhYmxlcmFuZ2U6M2YwOGU1Yjc2ODQxNDVlNDliNWIwNjUwYzcyMmI3YWFfNi0zLTEtMS00MTkyNQ_2173c886-e59c-4765-bbfe-7258f59b2e6e"
      unitRef="usd">4497000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc4OA_1cf82b24-9be4-4851-ae99-8e9b77001f90">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc0Ng_4718a2b0-4f50-4671-b4eb-f48bc3586f83">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id6b6fd4fee764ab083cdc892e2c0c076_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfMy0xLTEtMS00MTkyNQ_f7a5393b-f55d-4647-b4ea-faf0bb72a085"
      unitRef="usd">1589000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib83542a544914da9a096018bb51d522d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfMy0zLTEtMS00MTkyNQ_271fa9fc-09b2-4451-97a3-f8d56000b1bf"
      unitRef="usd">1566000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if33590d339e94d2d901dd2dd40d1f5ad_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNC0xLTEtMS00MTkyNQ_f852148c-14bb-42f0-aaf1-2cb5dbb04e11"
      unitRef="usd">306000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i756495c112ec486ca365574f64977791_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNC0zLTEtMS00MTkyNQ_97c2430a-0476-4a43-8177-f6278ae1b41a"
      unitRef="usd">276000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="iced25630f7f04a17b0750b5a726c2fdf_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNi0xLTEtMS00MTkyNQ_131afd22-3589-45ab-b7a3-bf5dc3bce792"
      unitRef="usd">261000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie6984c064c12462fac6706daa823e721_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfNi0zLTEtMS00MTkyNQ_2a862445-417c-4d2f-b751-b7c98098326c"
      unitRef="usd">335000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfOC0xLTEtMS00MTkyNQ_0f2fcc99-3fd6-4e8b-8250-ee46aaa14a4b"
      unitRef="usd">2156000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjU4ZThiOGFjMWVlMDQ5ZWE5YjFiZmE1ZTc4NjVjYmQ1L3RhYmxlcmFuZ2U6NThlOGI4YWMxZWUwNDllYTliMWJmYTVlNzg2NWNiZDVfOC0zLTEtMS00MTkyNQ_ecbe0a74-7312-4d73-86dd-36e64d4540d6"
      unitRef="usd">2177000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc4OQ_60d7c0ea-abbe-4d00-87b1-046c86d35f22">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our 2021 Annual Report on Form 10-K, Note 2, &#x201c;Significant Accounting Policies,&#x201d; under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;Contractual Provisions That May Adjust or Limit Revenue or ProfitMany of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-1&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three months ended March 31, 2022, we recognized approximately $28 million related to such risk corridors, primarily in the Medicaid segment, compared to $110&#160;million recognized in the three months ended March 31, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace Program&lt;/span&gt;&lt;/div&gt;Risk Adjustment. Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReservesReportedToOtherAgenciesTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc0MQ_99c39e3c-002c-43a4-8ece-e551f00a5558">Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#x201c;Amounts due government agencies,&#x201d; in the accompanying consolidated balance sheets. &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth amounts due government agencies, categorized by program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReservesReportedToOtherAgenciesTextBlock>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNC0xLTEtMS00MTkyNQ_c69c1fdb-facb-4043-b138-953f8baaf4c6"
      unitRef="usd">1033000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNC0zLTEtMS00MTkyNQ_342ae047-8ac7-45e7-8b06-ac7d19fdc4e1"
      unitRef="usd">1016000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNS0xLTEtMS00MTkyNQ_506110d0-5a5d-4711-834b-8f22c828d904"
      unitRef="usd">270000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNS0zLTEtMS00MTkyNQ_941f5fdc-9a18-498e-b687-3ede4430d100"
      unitRef="usd">263000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNy0xLTEtMS00MTkyNQ_75e54ba6-6a0b-4b6d-aff5-61461628a644"
      unitRef="usd">105000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfNy0zLTEtMS00MTkyNQ_e0a1d4e9-f22d-401c-b2ef-8a0ebef6082d"
      unitRef="usd">89000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOC0xLTEtMS00MTkyNQ_af6a4a26-f9d4-472e-937e-7f10be052a22"
      unitRef="usd">103000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOC0zLTEtMS00MTkyNQ_903bc611-2e0a-40df-ae51-8ce3d70029ec"
      unitRef="usd">101000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:OtherMedicareProgram
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOS0xLTEtMS00MTkyNQ_6e90b706-2fda-49fa-a055-4edbbeba2515"
      unitRef="usd">31000000</moh:OtherMedicareProgram>
    <moh:OtherMedicareProgram
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfOS0zLTEtMS00MTkyNQ_3944ca43-4532-4c02-8fb3-e6cf29680cdc"
      unitRef="usd">35000000</moh:OtherMedicareProgram>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTEtMS0xLTEtNDE5MjU_e5b28047-4ad0-4475-b8d3-e9d1c9791949"
      unitRef="usd">949000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTEtMy0xLTEtNDE5MjU_6ac42bb5-4597-412d-8529-ce89a84cbab1"
      unitRef="usd">902000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTItMS0xLTEtNDE5MjU_48a2866b-19f6-47c8-b777-5d977b5c8f5e"
      unitRef="usd">20000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTItMy0xLTEtNDE5MjU_08bb5bac-52c3-4352-b55d-958ed30f4292"
      unitRef="usd">18000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTMtMS0xLTEtNDE5MjU_eb8a3525-7b82-41c3-9334-d2717abee7da"
      unitRef="usd">102000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTMtMy0xLTEtNDE5MjU_f73d6274-c730-4b62-b5c2-4a52b9757521"
      unitRef="usd">48000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTUtMS0xLTEtNDE5MjU_033b8f9b-2780-44e2-a8c4-1bcceb9d5d67"
      unitRef="usd">2613000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RhYmxlOjFlNmRhY2EwZTJjNTQwOTE5ODIzZjA5YmRmMGNlYzFkL3RhYmxlcmFuZ2U6MWU2ZGFjYTBlMmM1NDA5MTk4MjNmMDliZGYwY2VjMWRfMTUtMy0xLTEtNDE5MjU_478edaa4-445d-455b-8f9f-d10e31abf8be"
      unitRef="usd">2472000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i42b0a19236ea419588cf999ba5003db3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfMzY1NA_279b301b-565f-45d3-894a-d43848da7b9f"
      unitRef="usd">-28000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="ib16fa21da2b342b1b9b512fecc011c4a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfMTA5OTUxMTYzNjMyMA_98150e94-007e-4d62-8483-a23db576b653"
      unitRef="usd">-110000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNDk3NA_805ac04f-8150-4abd-b11d-c578720ed9d2"
      unitRef="usd">-949000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTAxMw_0b4c5c16-5760-4e4d-97c2-9a2013e4fa21"
      unitRef="usd">33000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTAzOA_1ce5fbae-9771-447d-855e-41569fd9209d"
      unitRef="usd">916000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTE2MA_1eaee581-959b-4e82-a0ed-fa566cf2971e"
      unitRef="usd">902000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTE5OQ_4d0f471d-afb1-4b29-99f5-636dece1a160"
      unitRef="usd">7000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTIyNA_475ce609-2964-499e-87bf-b493584962d9"
      unitRef="usd">895000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc4NQ_25c2c8c8-42bc-43d7-a6b0-7f74cf34c679">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <moh:InvestmentsMaturityPeriod
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTg1MA_2229aa53-3b74-40eb-9b34-24c28fb123a2">P15Y</moh:InvestmentsMaturityPeriod>
    <moh:InvestmentsAverageMaturityPeriod
      contextRef="i60d5b3e94914400d9df6eef34274142b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNTg2Nw_6dc76ec8-2e81-4f48-8ee5-a840cc209caf">P15Y</moh:InvestmentsAverageMaturityPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc3Mw_6abcb3a4-cc66-488a-acf4-33a73e2cbdce">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNC9mcmFnOjA0ZDUwNTQ4ZGNiNTQyYmZiNjY0YjQyNDQzZDFlMzUxL3RleHRyZWdpb246MDRkNTA1NDhkY2I1NDJiZmI2NjRiNDI0NDNkMWUzNTFfNzc3NA_be0f0195-c7da-43b3-b972-28e471301171">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RleHRyZWdpb246OGQzNmUwODc3MjhhNDkyYzlhNmNkY2U1MmZjNzk3MTNfMjg4_a206de2a-06fa-4021-a6d9-cfe9c9b131a1">Net Income Per Share &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of basic and diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. &lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RleHRyZWdpb246OGQzNmUwODc3MjhhNDkyYzlhNmNkY2U1MmZjNzk3MTNfMjk2_005cdf22-6265-469e-a53c-7f46c462e349">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of basic and diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. &lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNS0xLTEtMS00MTkyNQ_3a7c9f46-5cad-48f5-a408-d82c4fe5d46b"
      unitRef="usd">258000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNS0zLTEtMS00MTkyNQ_f8b1bae0-c504-4de7-bf35-48a72505cdf9"
      unitRef="usd">228000000</us-gaap:NetIncomeLoss>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNy0xLTEtMS00MTkyNQ_fa401802-ff41-4f82-8bc7-513c8f54fc47"
      unitRef="shares">57900000</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i63e99d1b775642728d269200485a7951_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfNy0zLTEtMS00MTkyNQ_234c3f7b-c30d-47ab-ad0a-241228211ae2"
      unitRef="shares">58000000.0</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0xLTEtMS00NzU4MQ_c72b8fdc-acb0-443d-b49e-4c55e3a6c8b9"
      unitRef="shares">100000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0zLTEtMS00NzU4MQ_99898b62-d207-4b03-aaac-93cdc8e09b27"
      unitRef="shares">100000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0xLTEtMS00MTkyNQ_b604d912-37d9-4338-a984-69a6cfcab9f6"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfOS0zLTEtMS00MTkyNQ_e14caf3d-9c42-4306-978d-6620fd4b08c2"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTEtMS0xLTEtNDE5MjU_e2757c4e-bd72-4f8c-b733-55bc9b1c8a9c"
      unitRef="shares">58000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTEtMy0xLTEtNDE5MjU_67d9c995-f1a4-4ba7-90e9-1c93c48ba0d3"
      unitRef="shares">57700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTMtMS0xLTEtNDE5MjU_7051ad27-6d5d-4d81-a8d4-68671f5a552f"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTMtMy0xLTEtNDE5MjU_d063fb57-297b-4539-ba08-19991b677818"
      unitRef="shares">900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTUtMS0xLTEtNDE5MjU_a99b5fda-e419-4ee5-849d-cc06ed58267b"
      unitRef="shares">58700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTUtMy0xLTEtNDE5MjU_85a87cf4-b444-4f44-895e-9ff2a3444985"
      unitRef="shares">58600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTctMS0xLTEtNDE5MjU_42363ac3-f538-4922-b367-bb6b4e24df33"
      unitRef="usdPerShare">4.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTctMy0xLTEtNDE5MjU_968e0a06-9a9d-484b-996d-1746bdb43b05"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTgtMS0xLTEtNDE5MjU_0955baee-d7ee-4b0c-b024-5d403870d448"
      unitRef="usdPerShare">4.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl8zNy9mcmFnOjhkMzZlMDg3NzI4YTQ5MmM5YTZjZGNlNTJmYzc5NzEzL3RhYmxlOmEzN2YzZTRiMjhmNzQ1YzRhNGRkODI0YmY4YzU5YWIzL3RhYmxlcmFuZ2U6YTM3ZjNlNGIyOGY3NDVjNGE0ZGQ4MjRiZjhjNTlhYjNfMTgtMy0xLTEtNDE5MjU_38531f97-7de8-4b33-b395-67b6ef09d623"
      unitRef="usdPerShare">3.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfNzM3_87f31299-19de-4d7d-9b74-36d93c1969a6">Business Combinations&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cigna. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we closed on our acquisition of Cigna Corporation&#x2019;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $60&#160;million. We acquired membership and a provider network with a preliminary fair value of approximately $36 million. We allocated the remaining $24 million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. &lt;/span&gt;Affinity. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for initial purchase consideration of approximately $176&#160;million. In the three months ended March&#160;31, 2022, we recorded various measurement period adjustments, including a decrease of $25&#160;million to &#x201c;Medical claims and benefits payable,&#x201d; and an increase of $4&#160;million to &#x201c;Amounts due government agencies.&#x201d; In the aggregate, we recorded a net increase of $11&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMTA5OTUxMTYzNDE0NQ_5e5a8b4b-dffc-47ff-b206-9d7e33a1699e"
      unitRef="usd">60000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i0df831b90dca48389c4a46065aa0e36b_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMjE5OTAyMzI2MjU1OA_466f2007-2ffe-429e-aaf2-98d860c7ab00"
      unitRef="usd">36000000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfODI0NjMzNzIxNDcwMQ_c564e3d1-e1f1-4943-ae1e-2d29eef551aa"
      unitRef="usd">24000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i4224640832fc459a976f07601ca3b865_D20211025-20211025"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfOTM0NTg0ODg0MjUyOQ_1871eb0d-1581-4a67-8ec8-0bb8b27ffd45"
      unitRef="usd">176000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable
      contextRef="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMTA5OTUxMTYzNDYyOQ_16d4be13-61de-4635-b50c-1a7ed5b82203"
      unitRef="usd">25000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies
      contextRef="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfMTA5OTUxMTYzNDYxNw_b7689033-20fb-4be8-ae36-d4e4ca0cdba2"
      unitRef="usd">4000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i3bb2daff7a104d45996e4c4d086f4b5a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80MC9mcmFnOjRhY2VmZWFiN2MwYzRmMzU5ODQ1NjQ3Y2IxZGNmZjRiL3RleHRyZWdpb246NGFjZWZlYWI3YzBjNGYzNTk4NDU2NDdjYjFkY2ZmNGJfNzY5NjU4MTQwMTEwMQ_ccde1337-66ce-4180-8039-73f3ee6d8976"
      unitRef="usd">11000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjQ5Ng_d5292e12-0da1-4f52-baec-306b850a9d1a">Fair Value Measurements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2021 Annual Report on Form 10-K, Note 5, &#x201c;Fair Value Measurements.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net changes in fair value of Level 3 financial instruments are reported in &#x201c;Other&#x201d; operating expenses in our consolidated statements of income. In the three months ended March 31, 2022 and 2021, we recognized a loss of $4 million and $8&#160;million, respectively, for the increase in the fair value of the contingent consideration liabilities described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Level 3 financial instruments at March&#160;31, 2022 are comprised solely of contingent consideration liabilities of $8 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Such liabilities are recorded at fair value on a recurring basis. In the three months ended March 31, 2022, the estimated fair value of contingent purchase consideration increased by approximately $4 million, relating to an operating income guarantee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended March 31, 2022 we paid the seller $43&#160;million, of which $23&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $20&#160;million was for the first payment of the consideration due for the operating income guarantee. For the amounts paid in the three months ended March 31, 2022, $20 million has been presented in &#x201c;Financing activities&#x201d; in the accompanying consolidated statements of cash flows, with the balance reflected in &#x201c;Operating activities.&#x201d; The remaining balance of the liabilities is reported in &#x201c;Accounts payable, accrued liabilities and other&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &#x2013; Disclosure Only&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjE5OTAyMzI1OTg0Nw_da4b6839-8309-4db1-b600-ec12ea6d3428"
      unitRef="usd">-4000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTA5OTUxMTYzMjA1NA_d5a77f4a-bc9b-4dc6-a67c-5c280765ae48"
      unitRef="usd">-8000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjQ5OA_df84bd3d-aaeb-4a83-82ee-182145191d52">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at March&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC0xLTEtMS00MTkyNQ_8885a75e-af5f-4917-aa26-efed7f3d8a26"
      unitRef="usd">1808000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icc9841f89feb4b6f833b989726c603b7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC0zLTEtMS00MTkyNQ_99cb6fff-44ec-4c16-b02f-f0b57dd75540"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2d24f62cc41249a59883cfafb9f90a0b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC01LTEtMS00MTkyNQ_9140066f-19df-426e-9542-5310bac22a8a"
      unitRef="usd">1808000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9d6f584300eb4da4b4a6f02de502ee05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNC03LTEtMS00MTkyNQ_cf4d0259-3a44-4c21-a610-4379d952b68a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9fd269fb2ad24963b173ecee97871066_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS0xLTEtMS00MTkyNQ_4d64a429-c097-4fe5-b9ab-7eeb692c748f"
      unitRef="usd">598000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iba8f3df78577405d89b78540630ab85b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS0zLTEtMS00MTkyNQ_87c69da1-f7e9-490f-bbaa-cace5f8ab7cb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib601f7ea9e1544bba2449d05dd7b52fb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS01LTEtMS00MTkyNQ_b0cfc19b-67f1-4f53-850d-06d16779ae3b"
      unitRef="usd">598000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6b6c43599fc843d0829a435fbdc90272_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNS03LTEtMS00MTkyNQ_f176af6c-4acc-4038-9cb0-44f519bbf6a9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0xLTEtMS00OTMwOA_e2d14328-ee65-49dc-9456-64c95a3f0e25"
      unitRef="usd">252000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i12e5991e34f746b4a7de6f87d9b23770_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0zLTEtMS00OTMwOA_617c6f67-17a0-4682-872c-aaa5b6fe2c37"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib57bf75d7d2d40ce88df34d243fb7161_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi01LTEtMS00OTMwOA_9134ac15-12cc-4e0f-9451-6acea7ca631a"
      unitRef="usd">252000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i80581b9110ec4a21aad1d72ab421ff09_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi03LTEtMS00OTMwOA_cdbf5d7f-5032-4584-a0c2-0a6b4f9a40e7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0xLTEtMS00MTkyNQ_7175afca-056f-41dc-9944-ca7d6d127f6a"
      unitRef="usd">174000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibb15836aa8ef41a0ab9a6005c565e6af_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi0zLTEtMS00MTkyNQ_999ef367-130f-4d08-af6e-9345ebd332fe"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i611e6b094ace4fdb8726ca8580b06107_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi01LTEtMS00MTkyNQ_ee79ecd9-4aa1-4db4-9c78-cb953d374404"
      unitRef="usd">174000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib8a014ebcaec4257afdea4362d4f7dcd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfNi03LTEtMS00MTkyNQ_0fdf7665-a210-4dd5-98d9-785624e1ceaa"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC0xLTEtMS00MTkyNQ_e45577ab-a050-4e03-bed8-1dd91a986147"
      unitRef="usd">117000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icc43d4329cfd4c3da7fcc8ab7fc08335_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC0zLTEtMS00MTkyNQ_43f7861d-f3bd-4b68-b357-2bfd914796a2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic9ec83ce9f514a99ba56f61ebd1703d2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC01LTEtMS00MTkyNQ_953a9edd-54ef-4321-ae52-54902524142c"
      unitRef="usd">117000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2530162568594c229e21427834758000_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfOC03LTEtMS00MTkyNQ_308c3c09-5b57-4919-bfe4-94c148bd83be"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItMS0xLTEtNDE5MjU_66651d8e-8d1f-4053-874c-d57e82d170b4"
      unitRef="usd">39000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8232d132f78246a9b19395e9881b3b9e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItMy0xLTEtNDE5MjU_b3a22412-f3a0-4624-8af8-d878be3e5d17"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8a461815e0cd4109af3d6157d9306450_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItNS0xLTEtNDE5MjU_8d719568-d278-4874-b28e-bde394b3c29c"
      unitRef="usd">39000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2599f46d545f4a9694a18ef8b64edd24_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTItNy0xLTEtNDE5MjU_82deb29b-fc88-42dd-9c5e-a290a58948c8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtMS0xLTEtNDE5MjU_16b9307b-2f1c-47a1-af2c-a47ed4592db5"
      unitRef="usd">2988000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtMy0xLTEtNDE5MjU_6aafb9f8-216e-40ff-b27c-f857a9817644"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2566bfad24064edcb4c6f1cc871fe634_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtNS0xLTEtNDE5MjU_62c69b5d-9aab-464a-b8a8-0463d6892fdd"
      unitRef="usd">2988000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i66eb009ac1814de594979994b70ed488_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTMtNy0xLTEtNDE5MjU_f130354e-62d8-471a-b10d-94aaf50da97b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtMS0xLTEtNDE5MjU_207af0e5-6f92-49e0-b398-333c956e4990"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtMy0xLTEtNDE5MjU_12cb9273-24d1-4b0e-bc56-acab50953f4d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2566bfad24064edcb4c6f1cc871fe634_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtNS0xLTEtNDE5MjU_9aee4289-7567-43c4-bb31-562e4608e379"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0f6d9575386442c88a03e9392c8d4680_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTUtNy0xLTEtNDE5MjU_5542b10d-2b0b-40a5-93a0-d31bae9210a0"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtMS0xLTEtNDE5MjU_34202721-b65a-40db-9229-c244181bede5"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia6f2c39fc7f64fac82da1216ad4a207b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtMy0xLTEtNDE5MjU_2ff698f6-5b1c-4453-92a5-f8235df67ec1"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2566bfad24064edcb4c6f1cc871fe634_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtNS0xLTEtNDE5MjU_fff749be-efce-4565-9186-5dbc20a1e910"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i66eb009ac1814de594979994b70ed488_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOmIzNjg4OGJlZWI1NjQwNGJiOGE4MzgyZmNlMzQ3MzZlL3RhYmxlcmFuZ2U6YjM2ODg4YmVlYjU2NDA0YmI4YTgzODJmY2UzNDczNmVfMTYtNy0xLTEtNDE5MjU_f9c85d8b-ed49-4ff9-9903-b715d1e9db3e"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC0xLTEtMS00MTkyNQ_a1b27d33-3e59-486d-85ee-36971634507c"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idc3230becc0c4828baf9d10e3a700d76_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC0zLTEtMS00MTkyNQ_ed71ad61-d393-4fc2-a9e6-f51e98518b71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3aa407138475458aaaef37293a812835_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC01LTEtMS00MTkyNQ_3905b644-87ef-4f63-b8a3-1918331b5c11"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7278ef49c004479caacda424a824f532_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNC03LTEtMS00MTkyNQ_64741ae8-7019-4ecb-be55-308fdffc3bb2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iffb6f235c56e4125932f967ec4150a5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS0xLTEtMS00MTkyNQ_fdd2cfca-4069-454d-886b-15141a0e9c0b"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id8a92024a5dd4f20a93bb06874c6c09f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS0zLTEtMS00MTkyNQ_06305f42-654e-4ec4-aae4-c6d6fc08b356"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ief0d79f965424c5688f2b4927964c092_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS01LTEtMS00MTkyNQ_3ddec9db-53ed-4311-8b37-3760a5f8420a"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i568adc428eb44729bae4b7054ca3ecf0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNS03LTEtMS00MTkyNQ_992efaaf-4d46-496d-88ce-f85309884a76"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0xLTEtMS00OTMxMw_61efff9b-1023-40b5-9f7a-90f71df12c35"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id6246e151bd44c8ea675865e0681f3e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0zLTEtMS00OTMxMw_17ff6462-9f09-4aec-9329-504590c0b952"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2814ecb054554ae0ac8032339ced6fc3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi01LTEtMS00OTMxMw_832e156b-2f8a-41eb-be80-bc076eed7460"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia3dcacd3393d4b038db393a7e50dcb86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi03LTEtMS00OTMxMw_b164ccf9-bdaf-4330-a3a2-64488d043f55"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0xLTEtMS00MTkyNQ_367fab4f-63d9-4d8c-869a-d0f81d857de3"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if1727e43bcce4e9f99238725b4368289_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi0zLTEtMS00MTkyNQ_57635d8a-868f-4c35-af93-10313bd7e11f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia3215d158f874704ae5a909e76a9ffef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi01LTEtMS00MTkyNQ_21a08f94-b120-4828-99b1-1951e234693f"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie8096af143794d6ba663925f6c296688_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfNi03LTEtMS00MTkyNQ_2e230ab3-d0a9-45a7-9e04-f7c5fe061ae7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC0xLTEtMS00MTkyNQ_3b652136-3796-4167-b02f-d86954ec1160"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1308b34078d94ba9a442e2340bb7d947_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC0zLTEtMS00MTkyNQ_1db632d4-a682-4fe8-9932-8a3f0969c625"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i75af6a9d0fe3485ea6fb3e7b00fc7df8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC01LTEtMS00MTkyNQ_91f46796-f4e6-41bb-b5dd-94667120186e"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id47adc9834a74a3abd37340b07640e50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfOC03LTEtMS00MTkyNQ_27717d4c-ba9d-4c7b-a9cc-e3df9d9d4860"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtMS0xLTEtNDE5MjU_803a73f8-bda6-4275-bc8c-f27d16e7e08d"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib12dbc47902b42e7bd4cd39167f525fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtMy0xLTEtNDE5MjU_cfcc79b2-8a54-4031-80d4-98e88fcdd5a9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i30977d23049a41d78ef8f2e721e78cae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtNS0xLTEtNDE5MjU_e46620ca-bd21-46ac-9b32-9bee8b357743"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4d6aa324dfe249378a208c3b0ce83c03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTEtNy0xLTEtNDE5MjU_70bea3be-0186-4794-b8c6-9ba65c90a166"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItMS0xLTEtNDE5MjU_1ab8e8c1-2c8a-42de-bf8a-eb0fe039ffdc"
      unitRef="usd">3202000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f5e3d221ec54558b758b1d1fa20008d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItMy0xLTEtNDE5MjU_10f937f9-6528-4c36-92bb-af0919a2ce70"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i76c52f1b8250479b8972444c6c5e8a60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItNS0xLTEtNDE5MjU_1172951b-1f96-4e15-8f59-14649d34d9e3"
      unitRef="usd">3202000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTItNy0xLTEtNDE5MjU_46ba4825-6dda-4e19-a966-73c1e66b509c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtMS0xLTEtNDE5MjU_3b3edfac-397b-4096-87ea-7b91d5a180cf"
      unitRef="usd">47000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2f5e3d221ec54558b758b1d1fa20008d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtMy0xLTEtNDE5MjU_7fdeb1ee-310e-4dac-97c8-bf6fc090519a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i76c52f1b8250479b8972444c6c5e8a60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtNS0xLTEtNDE5MjU_3620ee3e-a055-4cac-8815-668f24c4f979"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTQtNy0xLTEtNDE5MjU_190c5d83-1c28-47f3-8507-95569f57eb0f"
      unitRef="usd">47000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtMS0xLTEtNDE5MjU_3dfb7928-aad4-49cd-8c5e-b5a43668a3ad"
      unitRef="usd">47000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2f5e3d221ec54558b758b1d1fa20008d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtMy0xLTEtNDE5MjU_b501f99e-af10-4c4f-9405-f674088a724a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i76c52f1b8250479b8972444c6c5e8a60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtNS0xLTEtNDE5MjU_9fc2b83f-dd83-41fd-9ba2-0323f13b8ab2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9f8ac643d5ec4ed3a96f2086f769d3e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjMzNzE5ODg2YWRlZDRhMWZhOTViYzhmM2MwMzBmZjkyL3RhYmxlcmFuZ2U6MzM3MTk4ODZhZGVkNGExZmE5NWJjOGYzYzAzMGZmOTJfMTUtNy0xLTEtNDE5MjU_2b4a3dec-3ec4-46e5-a7d0-d813c63c4d21"
      unitRef="usd">47000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0f6d9575386442c88a03e9392c8d4680_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTM0Mw_5542b10d-2b0b-40a5-93a0-d31bae9210a0"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTA5OTUxMTYzMTAzMA_da4b6839-8309-4db1-b600-ec12ea6d3428"
      unitRef="usd">-4000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3145ece7ff6a499db53f8fe074c21db2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTA5OTUxMTYzNDI1MA_cd13ac56-85b4-44c2-8994-59255a1b77f1"
      unitRef="usd">43000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i3145ece7ff6a499db53f8fe074c21db2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMTYyNA_61a2f5f3-54fb-4a91-8539-ccdc7f2d0665"
      unitRef="usd">23000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="i740cf33bc2fe44aa91439e45ae7070d5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjE5OTAyMzI2MDQyNA_c5202855-e527-485d-968d-02ea1c24bb98"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjE5OTAyMzI2MTE2NA_9ab97f11-02d5-41ff-86f1-6c66aa8d1aba"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RleHRyZWdpb246NGExNjY1NmUwZDliNGQwNGFjMjczM2MzOTJhN2M1NmZfMjUyMA_6e077cca-6321-45f0-9366-8f607050181b">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC0wLTEtMS00MTkyNS90ZXh0cmVnaW9uOmRiZDk4MTVmNDkzNTQ1OTRhYmQyYTYwMmY1ZTQ4ZTJlXzQ_d3659b07-b12a-4436-b6b1-c884b1b68ae5"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9e413d250b1c4d62b2a2ce56ec990ee3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC0xLTEtMS00MTkyNQ_468d3e19-5a59-4921-b869-b29d5e48ea8f"
      unitRef="usd">791000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6e17e3d8ee2e4532b2cedd534f9c43c7_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC0zLTEtMS00MTkyNQ_d6ff3605-3d25-41b2-9800-a03d7a31fd27"
      unitRef="usd">789000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5d82ade78bd740c5a619b23a903384cd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC01LTEtMS00MTkyNQ_68587951-e9be-4a07-b44f-081e7d12e964"
      unitRef="usd">791000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i8e68e13a919f45a69729166fad740cce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNC03LTEtMS00MTkyNQ_0cd7d97a-7990-412b-aeb3-e00f730e5e7a"
      unitRef="usd">829000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0wLTEtMS00MTkyNS90ZXh0cmVnaW9uOjEzZThmMDk5YzllYjRhOTNhMTU1OTBmMzRjZWFlYzkyXzQ_022c73e4-7acb-4b50-8b07-28c62d184a37"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i16fb8f79f27a4ba1975a3c0080fac1f1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0xLTEtMS00MTkyNQ_a0dc7817-df09-47a0-a3f7-b629cf0ae823"
      unitRef="usd">642000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i416b558733524b4eb313dc3fd149027e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0zLTEtMS00MTkyNQ_537faca5-8565-4a52-80e2-e79c3eb54a2b"
      unitRef="usd">624000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9cc71c1998d340b785d6c9e22719d163_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi01LTEtMS00MTkyNQ_d47626e9-3a97-42bf-ac1e-db9d3809f2cd"
      unitRef="usd">642000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i531b1272dc854f2d96ea4aaa8c7ac85b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi03LTEtMS00MTkyNQ_5465e969-3c68-4ff6-ba08-2d4c55e0ce98"
      unitRef="usd">675000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0wLTEtMS00NjYzOS90ZXh0cmVnaW9uOjJjYWM1ZmM2YmE3OTRhOWY4ZjExNDc2MmE4YmY3MWFmXzEwOTk1MTE2Mjc4MDc_4e837c9c-61ad-4104-b466-30e5d32c4fc2"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i8b3cfafe3e344d1c81dc96f60ad4e0b6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0xLTEtMS00NDU5Mw_f52da29b-9019-4187-9641-999a6921e270"
      unitRef="usd">741000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ifc601537972b46fe9d996ede277d82de_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi0zLTEtMS00NDU5Mw_c3f29cc6-1bb0-4494-bf9e-23fe7af8165b"
      unitRef="usd">713000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="idd44300529054baab8274cb4fdd4c646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi01LTEtMS00NDU5MA_c930cf1f-3d83-44a7-91f3-1fd5a0859f5b"
      unitRef="usd">740000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i571d57dd721148bcba35827581b9aab2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNi03LTEtMS00NDU5MA_81ba82c3-f230-451a-ba76-22fa8b1e36f4"
      unitRef="usd">760000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i35e7bbcc8d91489a9ac9423421979dce_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy0xLTEtMS00MTkyNQ_f01be3c4-b421-4975-a155-d67b592f9332"
      unitRef="usd">2174000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3510f01da59140459a2feaa5c20cc72f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy0zLTEtMS00MTkyNQ_3e4c3c39-1c05-4b27-a58b-94199599b0e0"
      unitRef="usd">2126000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ibfb73d2285af40bb99c52adb7201908c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy01LTEtMS00MTkyNQ_4de91d05-98aa-4519-95a2-66f70b67e6ac"
      unitRef="usd">2173000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1eca5b1af11a4d5592dd3ab9138e6d87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80My9mcmFnOjRhMTY2NTZlMGQ5YjRkMDRhYzI3MzNjMzkyYTdjNTZmL3RhYmxlOjFmZmY4YWVkOTYzNTRmYzU4YzdlMWExNzY2NTRiYjA2L3RhYmxlcmFuZ2U6MWZmZjhhZWQ5NjM1NGZjNThjN2UxYTE3NjY1NGJiMDZfNy03LTEtMS00MTkyNQ_99c9b145-92fe-4ab3-afd0-ac2107c47d0e"
      unitRef="usd">2264000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RleHRyZWdpb246NjI4ODAxYmQ1ZmMxNDI4MzgxMzI5MDkzY2EwMTZiMzJfNzY5NjU4MTM5NTc3Mw_e18ec03e-6c97-41a2-9b08-fe21ba9388e7">Investments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our current investments as of March&#160;31, 2022 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains and losses were insignificant for the three months ended March 31, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that unrealized losses at March&#160;31, 2022, and December&#160;31, 2021, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2022, and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Investments Held-to-Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $221 million at March&#160;31, 2022, of which $190 million will mature in one year or less, and $31&#160;million will mature in one through five years.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RleHRyZWdpb246NjI4ODAxYmQ1ZmMxNDI4MzgxMzI5MDkzY2EwMTZiMzJfMTI2Mg_f17f7321-0b13-4601-9496-6be71e5cbac1">The following tables summarize our current investments as of the dates indicated:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS0xLTEtMS00MTkyNQ_35f4a8ba-1e2e-4602-a1ca-4be68672fde3"
      unitRef="usd">1874000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS0zLTEtMS00MTkyNQ_88e2bc0b-48ff-424d-883b-8e265ec35435"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS01LTEtMS00MTkyNQ_274ce038-d479-4027-9a4f-9462973ae7ea"
      unitRef="usd">67000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNS03LTEtMS00MTkyNQ_1eb5f4f4-5d37-4644-a48a-0d86430d9e0d"
      unitRef="usd">1808000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi0xLTEtMS00MTkyNQ_b2c45655-9235-4f92-b747-93c051dc6d45"
      unitRef="usd">622000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi0zLTEtMS00MTkyNQ_db84477b-091c-40c5-beab-5f9cc898dda7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi01LTEtMS00MTkyNQ_7bd21fe3-1ebb-40fe-8674-a4638d14ad65"
      unitRef="usd">24000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNi03LTEtMS00MTkyNQ_0c0b0b6d-180c-4457-9f19-685e1c6d0029"
      unitRef="usd">598000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0xLTEtMS00OTMxOA_c2fd0fb0-c11d-4528-a263-ab4fcba42385"
      unitRef="usd">261000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0zLTEtMS00OTMxOA_aecc3e8d-0d28-4646-b967-37aaad04a29c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy01LTEtMS00OTMxOA_c973af68-36ec-41b2-881b-0ab4f363a253"
      unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy03LTEtMS00OTMxOA_9e3b6f59-3fa7-42b0-b448-22af4c018715"
      unitRef="usd">252000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0xLTEtMS00MTkyNQ_bd2059a4-a171-494b-a809-39249bd62a96"
      unitRef="usd">174000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy0zLTEtMS00MTkyNQ_afcd310e-7c05-4160-a5eb-019df20ac68f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy01LTEtMS00MTkyNQ_b7697e09-810c-4e33-a938-bfd08191f945"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i914e26952f0846cbab0b1ae7d986cd2f_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfNy03LTEtMS00MTkyNQ_20d39557-a2f4-4ad1-95aa-8703b8dda93c"
      unitRef="usd">174000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS0xLTEtMS00MTkyNQ_2e21f198-e8e5-4669-b35f-951d3992051f"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS0zLTEtMS00MTkyNQ_d05856ef-0a77-4b50-9f04-beee08afda2c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS01LTEtMS00MTkyNQ_dcd7d12e-a8a3-4c5d-a48b-fd2e8aa93c6f"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfOS03LTEtMS00MTkyNQ_8b3c29f5-473e-4d92-8e3a-0e3d673ebd29"
      unitRef="usd">117000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtMS0xLTEtNDE5MjU_6150c5a7-9ff3-48c9-91f4-6128e55f1d73"
      unitRef="usd">40000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtMy0xLTEtNDE5MjU_8b30b258-ef36-4442-85b2-b97ec567a1de"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtNS0xLTEtNDE5MjU_8c6ae669-8134-4636-ac72-f5861aab50c2"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTMtNy0xLTEtNDE5MjU_e56c37d3-58a0-4a65-8c65-bcc4e4878ff7"
      unitRef="usd">39000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtMS0xLTEtNDE5MjU_e3b7ec91-e9e9-42e4-9650-5768f28ec8ee"
      unitRef="usd">3094000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtMy0xLTEtNDE5MjU_1d0ceeff-7091-40f0-9814-55a777aef35b"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtNS0xLTEtNDE5MjU_4659f9e0-ef69-4c08-8b51-40dae7a6447d"
      unitRef="usd">107000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjY2NzEwNzg2NWY0ODRkNzg4YmYxZjc3ZDdlOTc0ZGQwL3RhYmxlcmFuZ2U6NjY3MTA3ODY1ZjQ4NGQ3ODhiZjFmNzdkN2U5NzRkZDBfMTQtNy0xLTEtNDE5MjU_e3e8f6a9-f944-4600-8440-84d3cdf6f8e1"
      unitRef="usd">2988000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS0xLTEtMS00MTkyNQ_d8a2715e-be91-40c2-aea7-f5e36cdd6272"
      unitRef="usd">1836000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS0zLTEtMS00MTkyNQ_5d58e870-796e-4a61-b817-4f800c38d3fd"
      unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS01LTEtMS00MTkyNQ_d98f131e-6f1b-46ef-94dc-f0398b84ceca"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNS03LTEtMS00MTkyNQ_efd317e9-1986-478c-8b12-7cf2e5a3fa84"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi0xLTEtMS00MTkyNQ_2bc86d55-c4ce-4e04-9982-7f99706421af"
      unitRef="usd">616000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi0zLTEtMS00MTkyNQ_df8a85e7-1f89-434a-abda-26aa493f8bed"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi01LTEtMS00MTkyNQ_e73ca7ba-fae9-495c-8913-6c978e24871b"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNi03LTEtMS00MTkyNQ_36cf4f8e-0952-4fd2-8c56-2c38035b1c61"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0xLTEtMS00OTMyMw_584371ac-2399-480b-9004-03ec0f86e81d"
      unitRef="usd">248000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0zLTEtMS00OTMyMw_7da5ab54-e708-4f0c-8051-7b32cbc707f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy01LTEtMS00OTMyMw_b3df01a7-8d49-48d0-a889-4f578b1f2cdd"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy03LTEtMS00OTMyMw_3ae5ec95-8a7e-4e05-9391-e10956db0d5a"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0xLTEtMS00MTkyNQ_45cc06b3-7228-47cc-8e6b-7d825dbac03a"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy0zLTEtMS00MTkyNQ_0167ebef-1380-4ded-8b24-11483652d10d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy01LTEtMS00MTkyNQ_50b4dec2-ada0-4661-9242-a7ca586b0c2e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2f5bf030bb894331af4cc030aaf8955d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfNy03LTEtMS00MTkyNQ_918c6637-ae9f-4105-8309-2160476a92f6"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS0xLTEtMS00MTkyNQ_1afff04d-1f5d-4380-96ca-70a5cb3947c4"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS0zLTEtMS00MTkyNQ_752a9887-d8a7-4e67-bb54-9d34139b1240"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS01LTEtMS00MTkyNQ_615c636d-4f4a-44ca-8144-e566d17d8f17"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfOS03LTEtMS00MTkyNQ_2b8eddf7-df27-4ac5-a69e-0a4e6e68f991"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItMS0xLTEtNDE5MjU_df9a2212-4e59-4765-b4df-53cd4ed57a2c"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItMy0xLTEtNDE5MjU_930855fd-0593-4594-83d8-c1cd772d2bd8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItNS0xLTEtNDE5MjU_86c4928b-fb56-441e-b075-4794306ba09c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTItNy0xLTEtNDE5MjU_e9bffb94-218f-4c1e-93ac-4436a3a9e782"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtMS0xLTEtNDE5MjU_4d86ff88-8b29-4163-82e4-a3ba33d7c8e1"
      unitRef="usd">3208000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtMy0xLTEtNDE5MjU_d454e8e6-3730-4cbf-86d5-d46769b795d4"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtNS0xLTEtNDE5MjU_7d152edb-7c0e-453b-862f-2ad7dd167b17"
      unitRef="usd">18000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOmIxODNhYmQ2MWQwMzQxMmZhMGI5N2Q4MTJhYzg3YjFhL3RhYmxlcmFuZ2U6YjE4M2FiZDYxZDAzNDEyZmEwYjk3ZDgxMmFjODdiMWFfMTMtNy0xLTEtNDE5MjU_27bd4040-9130-4e26-9360-1ec721b6080b"
      unitRef="usd">3202000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RleHRyZWdpb246NjI4ODAxYmQ1ZmMxNDI4MzgxMzI5MDkzY2EwMTZiMzJfMTI0NQ_5be0c3d7-e056-4d51-8d6e-c23be1114e23">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our current investments as of March&#160;31, 2022 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfMy0xLTEtMS00MTkyNQ_a53d4b6c-4672-40ea-a88d-eb08d4265187"
      unitRef="usd">466000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfMy0zLTEtMS00MTkyNQ_7268d036-7cf2-4211-b520-de2574eb73b3"
      unitRef="usd">466000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNC0xLTEtMS00MTkyNQ_0524fc5e-5ff6-47bd-971e-dbaa884165be"
      unitRef="usd">1733000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNC0zLTEtMS00MTkyNQ_e735fe68-cfb6-4c87-b1a9-70dffbc828b7"
      unitRef="usd">1668000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNS0xLTEtMS00MTkyNQ_10f5a1bc-eef0-4931-a000-38382ad0b283"
      unitRef="usd">318000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNS0zLTEtMS00MTkyNQ_e6aa24da-9b4e-4845-9354-0c8597b1df8f"
      unitRef="usd">306000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNi0xLTEtMS00MTkyNQ_66dbc9c6-6328-4067-bce2-c1ad078a817e"
      unitRef="usd">577000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNi0zLTEtMS00MTkyNQ_b7e38e10-53be-4671-ba19-9c57a8d7aa27"
      unitRef="usd">548000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNy0xLTEtMS00MTkyNQ_6c97e5c0-612a-4952-a0ba-57af03851a53"
      unitRef="usd">3094000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl80Ni9mcmFnOjYyODgwMWJkNWZjMTQyODM4MTMyOTA5M2NhMDE2YjMyL3RhYmxlOjhlZjFiMTRjOTdiNDQ5ZmJiYzk2YzhlNzI3NzI1YWFiL3RhYmxlcmFuZ2U6OGVmMWIxNGM5N2I0NDlmYmJjOTZjOGU3Mjc3MjVhYWJfNy0zLTEtMS00MTkyNQ_5f1e009a-330c-4049-974e-80347e2d35c8"
      unitRef="usd">2988000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RleHRyZWdpb246NGY3NDQyNjAyZDlmNDljMmJhNzI5YzkyYmNkZjRjZjdfMjQw_b8053ebb-0c3f-4af9-a6ba-b24b5ac83256">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of March&#160;31, 2022, and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0xLTEtMS00MTkyNQ_f9cfc33b-3cd5-42bd-83ad-379d944ea8b8"
      unitRef="usd">1516000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0zLTEtMS00MTkyNQ_394533bf-0a35-4fea-a293-f59f446a87ed"
      unitRef="usd">67000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0zLTEtMS00MTkyNQ_c51bffca-17ac-4807-809d-6e01e8ab659f"
      unitRef="usd">67000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i90c70e6d3865429ab8c21490e9d52463_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC01LTEtMS00MTkyNQ_d66e33eb-2c2b-47be-a0b2-e331ff5ed4b6"
      unitRef="position">624</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC03LTEtMS00MTkyNQ_26b24672-be04-4a5a-b1ed-da7e05bbf413"
      unitRef="usd">1063000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC05LTEtMS00MTkyNQ_36e51b84-01ba-4343-9fd6-6b5b1e9bd1d1"
      unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i45dcb81690184808b8b2e4355d718016_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNC0xMS0xLTEtNDE5MjU_8b8684ee-c69f-4891-a5d7-afbfbc5091cd"
      unitRef="position">395</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0xLTEtMS00MTkyNQ_bb778413-70ca-4039-90c5-29145b2e40f9"
      unitRef="usd">582000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0zLTEtMS00MTkyNQ_00e371ce-c5de-4f1e-9169-fe6a03bf43f7"
      unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0zLTEtMS00MTkyNQ_8b12d7ae-4882-4b35-bfa8-96373365bf70"
      unitRef="usd">24000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i137c985bf2b84d7284fe720707605375_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS01LTEtMS00MTkyNQ_85e66bf3-e9b2-4bd8-93f2-bfe6fa003ff8"
      unitRef="position">238</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS03LTEtMS00MTkyNQ_687d503f-03fc-4dbf-8037-5e6b85dccc2c"
      unitRef="usd">408000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS05LTEtMS00MTkyNQ_a5fb7757-e7e9-4aca-a5b6-015a62932cd1"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i64fd06cf9ff3480e80700431d359cc79_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNS0xMS0xLTEtNDE5MjU_da8a5085-0b34-4612-a336-1a3aaef6b7da"
      unitRef="position">146</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi0xLTEtMS00MTkyNQ_032483e1-b6e3-49af-aec4-715f86de98b5"
      unitRef="usd">208000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi0zLTEtMS00MTkyNQ_db3b56a9-f4a9-4f28-9aea-2e08d8166937"
      unitRef="usd">9000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ibc478537e5e44dc99aedd4cb99c6aa05_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi01LTEtMS00MTkyNQ_0922e180-12e4-43c1-96c8-902700e58ad6"
      unitRef="security">99</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi03LTEtMS00MTkyNQ_9aae9c6b-bcb4-4159-8af5-7565a9ae1176"
      unitRef="usd">166000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi05LTEtMS00MTkyNQ_74fb3d51-456e-4b1f-b208-7b203f50c394"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i54ceccf75bcd408a9bf4399875c3a587_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfNi0xMS0xLTEtNDE5MjU_27ef0858-7f75-4028-99e9-89800d27dcd1"
      unitRef="security">75</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC0xLTEtMS00MTkyNQ_04b4aa45-2527-4230-9804-54ff0571f35c"
      unitRef="usd">97000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC0zLTEtMS00MTkyNQ_503af639-4b1b-41a2-b971-0d81d488cd6e"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ib53a531742ed4dd185794ef0fece2924_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC01LTEtMS00MTkyNQ_8e8dabb0-55f2-49a5-ad4d-30d728e92c7e"
      unitRef="security">120</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC03LTEtMS00MTkyNQ_f363c18b-62dc-4497-9891-80e40e495b0c"
      unitRef="usd">69000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC05LTEtMS00MTkyNQ_aff29cfd-e03e-4eba-a26a-8ad1bc61e63b"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ibcd80b1629894491abd8c97b39181c6f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOC0xMS0xLTEtNDE5MjU_88b97f94-10bc-44c0-b215-e1c4d373c6f9"
      unitRef="security">61</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS0xLTEtMS00OTI1NQ_af1f2724-00a2-437c-b4ef-c79ce18d4620"
      unitRef="usd">25000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS0zLTEtMS00OTI1NQ_0ded89b9-051a-43b3-b46f-dd85bab61a87"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i385070469b464b4c8f16f134196230a2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS01LTEtMS00OTI1NQ_77bdf9a3-d8d0-45d2-a3e5-72da335f0513"
      unitRef="security">10</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS03LTEtMS00OTc3OQ_a2145b14-effb-4b7d-a5ca-effd2a2143b1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS05LTEtMS00OTc3OQ_a7327378-dc47-445f-9288-59db46317557"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ic15681f11c644b1fb6bc25282ff28394_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfOS0xMS0xLTEtNDk3Nzk_40efd2bc-7f41-4d67-a6d9-194dce443658"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMS0xLTEtNDE5MjU_e9b9950d-53e9-4f46-acdf-01c87b9bbf31"
      unitRef="usd">2428000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMy0xLTEtNDE5MjU_6524a3c9-4435-4078-a609-27d352409a1c"
      unitRef="usd">107000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMy0xLTEtNDE5MjU_bedcb40f-f805-465e-a371-cd18aa97b146"
      unitRef="usd">107000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItNS0xLTEtNDE5MjU_5cfbd4c8-2f83-43c7-832c-d6262a81ce2c"
      unitRef="position">1091</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItNy0xLTEtNDE5MjU_4914c0af-5241-46ea-a186-5dc4a6287440"
      unitRef="usd">1706000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItOS0xLTEtNDE5MjU_20c39548-b18e-44b7-9110-4465a7e0dd9a"
      unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81Mi9mcmFnOjRmNzQ0MjYwMmQ5ZjQ5YzJiYTcyOWM5MmJjZGY0Y2Y3L3RhYmxlOmVlNDZkM2JjZmUyODRkYmE5OTU0NTdhNThmYzJjMmE3L3RhYmxlcmFuZ2U6ZWU0NmQzYmNmZTI4NGRiYTk5NTQ1N2E1OGZjMmMyYTdfMTItMTEtMS0xLTQxOTI1_c8f20511-916a-4d39-b89d-1e7aaf830bf1"
      unitRef="position">677</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81OC9mcmFnOmNiMmVjNGRjYTAwMzQwODJiZjViNzQ3YmFlOWQ2MDYwL3RleHRyZWdpb246Y2IyZWM0ZGNhMDAzNDA4MmJmNWI3NDdiYWU5ZDYwNjBfOTg3_d4eb6b16-e945-4b65-a397-a53bc0acd9cf"
      unitRef="usd">221000000</us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81OC9mcmFnOmNiMmVjNGRjYTAwMzQwODJiZjViNzQ3YmFlOWQ2MDYwL3RleHRyZWdpb246Y2IyZWM0ZGNhMDAzNDA4MmJmNWI3NDdiYWU5ZDYwNjBfMTAwNg_39d0ec61-181c-4a19-87b1-c99fd5dfabbf"
      unitRef="usd">190000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl81OC9mcmFnOmNiMmVjNGRjYTAwMzQwODJiZjViNzQ3YmFlOWQ2MDYwL3RleHRyZWdpb246Y2IyZWM0ZGNhMDAzNDA4MmJmNWI3NDdiYWU5ZDYwNjBfMTA0Ng_52d09fe4-46df-43c0-804d-606f934b2862"
      unitRef="usd">31000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <moh:MedicalClaimsAndBenefitsPayableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTQxMg_4dbf6c7d-eb3f-4a8f-b300-cc66376ea518">Medical Claims and Benefits Payable &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other&#x201d; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $322 million and $226 million as of March&#160;31, 2022, and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of medical claims and benefits payable recorded at December 31, 2021, and 2020 developed favorably by approximately $206 million and $194 million as of March&#160;31, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable prior year development recognized in the three months ended March 31, 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our  estimates in 2021.&lt;/span&gt;&lt;/div&gt;</moh:MedicalClaimsAndBenefitsPayableTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTQxMw_7f40ce0e-eb20-454a-a86e-5999ebd75587">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfMy0xLTEtMS00MTkyNQ_74825bb3-828e-4f81-a285-9558e1835e33"
      unitRef="usd">2521000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfMy0zLTEtMS00MTkyNQ_3332c654-267f-491d-9d73-822d40a0d8d1"
      unitRef="usd">2486000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:PharmacyClaimsPayable
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNC0xLTEtMS00MTkyNQ_3b6ed2d6-056b-422b-bd4b-68b47725965e"
      unitRef="usd">240000000</moh:PharmacyClaimsPayable>
    <moh:PharmacyClaimsPayable
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNC0zLTEtMS00MTkyNQ_7f6c6789-f04c-461e-a38e-be797f94b9f5"
      unitRef="usd">219000000</moh:PharmacyClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNS0xLTEtMS00MTkyNQ_2f2b5bdc-13fa-4054-b7f6-618d16660af8"
      unitRef="usd">95000000</moh:CapitationClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNS0zLTEtMS00MTkyNQ_0ca64ba7-dbd9-4b58-8932-00001bbdcbc5"
      unitRef="usd">82000000</moh:CapitationClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNi0xLTEtMS00MTkyNQ_ddaa5e0c-c554-48e7-8c93-5cc8048499f1"
      unitRef="usd">745000000</moh:OtherClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfNi0zLTEtMS00MTkyNQ_469b191e-ed5f-4214-a5d6-be36032f2bda"
      unitRef="usd">576000000</moh:OtherClaimsPayable>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfOC0xLTEtMS00MTkyNQ_e409c3cc-d4e7-41e0-a240-713a0c2e6a51"
      unitRef="usd">3601000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOjQ1ODU1NjRjOTFkYTQyMjk4YjA0YzZjOWNjYjJhOGQ2L3RhYmxlcmFuZ2U6NDU4NTU2NGM5MWRhNDIyOThiMDRjNmM5Y2NiMmE4ZDZfOC0zLTEtMS00MTkyNQ_a0aaea61-2e14-495b-8f8e-479f3c6add30"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfNDQ1_afd896ed-e5f7-4202-8f5d-58b3e548d5c1"
      unitRef="usd">322000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfNDUy_18a9f83f-3157-46d7-b974-aa36af52fbaa"
      unitRef="usd">226000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTQyOQ_00ff22f3-11a3-4b6f-b5e3-31226a7d4d20">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported. &lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i860bf70640a44ea9b73b26a8d15aba5b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC0xLTEtMS00MTkyNQ_7c512453-1a89-45d9-9c92-ac979147a09e"
      unitRef="usd">2580000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if190d4db77c042b58e04f6bd35da403b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC0zLTEtMS00MTkyNQ_7c308fd6-010d-4d2f-bad2-d5eaf2fd1cc8"
      unitRef="usd">404000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="icdf71eb3d9cc444083f1b2554c284e40_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC01LTEtMS00MTkyNQ_0d2eca9b-efaf-4fac-80be-b29b0dbb8626"
      unitRef="usd">379000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNC03LTEtMS00MTkyNQ_29f13ae3-26a7-40d3-bfa5-4d60317ef433"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi0xLTEtMS00MTkyNQ_604be576-4294-4cb9-8516-b887170c1894"
      unitRef="usd">5424000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi0zLTEtMS00MTkyNQ_960fb8c8-3fc7-442e-8c68-7a38e7fd75f4"
      unitRef="usd">840000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi01LTEtMS00MTkyNQ_bc69a424-d288-4286-a6c0-9502ebfbe54a"
      unitRef="usd">505000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNi03LTEtMS00MTkyNQ_bbefb26e-b1e7-4416-86f8-1f67cbb704ca"
      unitRef="usd">6769000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy0xLTEtMS00MTkyNQ_537b7e82-59a1-42b1-b5d6-e2d150e1a60f"
      unitRef="usd">-154000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy0zLTEtMS00MTkyNQ_13fc9383-18d4-4221-bc04-e6a5e6783ab1"
      unitRef="usd">-25000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy01LTEtMS00MTkyNQ_715613a9-b541-4ca9-a61b-f9c8b95c0af4"
      unitRef="usd">-27000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfNy03LTEtMS00MTkyNQ_af91632b-0447-4f6a-b578-5e1e3447e0f7"
      unitRef="usd">-206000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC0xLTEtMS00MTkyNQ_c13a23d8-40ff-4102-8110-662b6762f4e1"
      unitRef="usd">5270000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC0zLTEtMS00MTkyNQ_1a3b06f3-633c-498c-b4aa-4cd3e8dbaae9"
      unitRef="usd">815000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC01LTEtMS00MTkyNQ_768f3e8b-75a0-4d65-81cc-61c108fbf0d2"
      unitRef="usd">478000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfOC03LTEtMS00MTkyNQ_a5dff92e-1e9c-4045-badf-f5f72606e77a"
      unitRef="usd">6563000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtMS0xLTEtNDE5MjU_f8ea0cbd-a71b-42b5-acc5-9c6109e7f46c"
      unitRef="usd">3402000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtMy0xLTEtNDE5MjU_acad6cf0-afaf-4727-b4fa-8fc1d450bec4"
      unitRef="usd">465000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtNS0xLTEtNDE5MjU_44339427-2230-4613-9ea1-6b019d455027"
      unitRef="usd">330000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTAtNy0xLTEtNDE5MjU_eb2d6c21-8fec-4113-89d9-10543528813f"
      unitRef="usd">4197000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtMS0xLTEtNDE5MjU_00525a12-be4d-49f2-9b4c-356ddcecfd9b"
      unitRef="usd">1633000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtMy0xLTEtNDE5MjU_fd0af921-7150-4ca4-b328-f29aea1fa67b"
      unitRef="usd">306000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtNS0xLTEtNDE5MjU_75ea090b-6766-4a05-9191-9fb34c1c8e50"
      unitRef="usd">260000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTEtNy0xLTEtNDE5MjU_39dd1b4c-7adb-481f-99b5-c9f52d8c69cb"
      unitRef="usd">2199000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItMS0xLTEtNDE5MjU_4c1afb6f-5b41-4137-8a0c-bb3af23678c2"
      unitRef="usd">5035000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItMy0xLTEtNDE5MjU_03d80694-3e70-4310-9c37-4bff38ef7378"
      unitRef="usd">771000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItNS0xLTEtNDE5MjU_972e8a69-3398-48c1-88ad-c09dfc50ac8a"
      unitRef="usd">590000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTItNy0xLTEtNDE5MjU_42e043f6-fa52-427d-96ee-8b2ea17d8be3"
      unitRef="usd">6396000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtMS0xLTEtNDE5MjU_f8db2116-4e2c-4dea-a638-dce374a8aeb1"
      unitRef="usd">-25000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtMy0xLTEtNDE5MjU_fcb9cac5-a15c-49b7-8a8d-8ce23ab65433"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtNS0xLTEtNDE5MjU_fcf6833a-b819-4a5e-8ea1-36b09da3d2ed"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTMtNy0xLTEtNDE5MjU_278ee324-c06f-4a4d-aad8-f5381acad1c6"
      unitRef="usd">-25000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtMS0xLTEtNDE5MjU_baeb23ee-75d3-42b1-8ed8-2730b6f63ea8"
      unitRef="usd">93000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtMy0xLTEtNDE5MjU_2396c2ae-97da-4ec1-981a-886fe701593f"
      unitRef="usd">3000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtNS0xLTEtNDE5MjU_3bdbe976-f37f-4225-8b54-15aaac878e57"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTQtNy0xLTEtNDE5MjU_14f61eaf-2fcf-47f8-bb56-56ffde9e8ba0"
      unitRef="usd">96000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i7174960f5b134c548aa4d81b816b31fb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtMS0xLTEtNDE5MjU_3bdd3969-a7c2-4663-9fc5-76efc1944b27"
      unitRef="usd">2883000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idea26c2873f4475288eeedd9a1ca9042_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtMy0xLTEtNDE5MjU_5fe7a6c8-6d18-46cc-bd26-1c7eba9841dd"
      unitRef="usd">451000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i27309968abdf4262bb2205ee58ad5acc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtNS0xLTEtNDE5MjU_94468130-1467-4c85-9529-a545ef565b1b"
      unitRef="usd">267000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmZlM2MzMGE4Mzc3MjQ2MGZhMWNmZjAzYWRhMmQ2MjQ3L3RhYmxlcmFuZ2U6ZmUzYzMwYTgzNzcyNDYwZmExY2ZmMDNhZGEyZDYyNDdfMTUtNy0xLTEtNDE5MjU_3ccd13c3-53ba-4377-80fc-e10a018fcfff"
      unitRef="usd">3601000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ib37da93f7f23442d8e258fd0d8326698_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC0xLTEtMS00MTkyNQ_150adf5b-f152-41eb-800e-1bdfc1d0809e"
      unitRef="usd">2129000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iaebf3329ac42485e9cb9a16f9bd00f59_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC0zLTEtMS00MTkyNQ_5368a299-9b73-42dd-9eb9-afbc82f05e3e"
      unitRef="usd">392000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ib653e5e8294241fb8b57acb7b6fc82ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC01LTEtMS00MTkyNQ_84eb22ea-3b7d-45d0-9cdf-40e16bc92e56"
      unitRef="usd">175000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i63e99d1b775642728d269200485a7951_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNC03LTEtMS00MTkyNQ_3db145cb-9352-45e2-b432-e83aa123b054"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi0xLTEtMS00MTkyNQ_89d80af0-71e0-483c-ac7a-721c6435d427"
      unitRef="usd">4394000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi0zLTEtMS00MTkyNQ_fca4aae6-d935-4923-a871-32890be77480"
      unitRef="usd">738000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi01LTEtMS00MTkyNQ_7861e0d2-bcd4-4b3a-909c-ed0af9a78816"
      unitRef="usd">536000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNi03LTEtMS00MTkyNQ_a7961df9-e2b2-4849-b295-c679bb6811a6"
      unitRef="usd">5668000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy0xLTEtMS00MTkyNQ_ee18c57f-3ec0-4398-8f58-c117c6c1acdb"
      unitRef="usd">-158000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy0zLTEtMS00MTkyNQ_de6fbc91-0180-4a4b-abf5-9661ad20f703"
      unitRef="usd">-16000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy01LTEtMS00MTkyNQ_c6a70c6d-2de1-4ae5-b63e-395149caf072"
      unitRef="usd">-20000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfNy03LTEtMS00MTkyNQ_5c413a34-8762-400d-b299-9a3650e46c24"
      unitRef="usd">-194000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC0xLTEtMS00MTkyNQ_dafa2575-6040-45c5-aaed-6b6a1eef50a4"
      unitRef="usd">4236000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC0zLTEtMS00MTkyNQ_e41f73f7-7ed2-4063-acfe-dda3af801a78"
      unitRef="usd">722000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC01LTEtMS00MTkyNQ_0c68a7f8-748d-4911-92d2-dfa47b30b3ef"
      unitRef="usd">516000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfOC03LTEtMS00MTkyNQ_e59d91bf-53fd-4ad7-98f7-0dbe9e8143d5"
      unitRef="usd">5474000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtMS0xLTEtNDE5MjU_aab4da9a-d95e-4e97-9043-78ee49b8a1ce"
      unitRef="usd">2790000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtMy0xLTEtNDE5MjU_117ac91c-c5cc-48a5-8a82-fa3a64044cc3"
      unitRef="usd">410000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtNS0xLTEtNDE5MjU_8170aac8-cd34-4dbc-9455-8dc5dfeb4688"
      unitRef="usd">313000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTAtNy0xLTEtNDE5MjU_1c7ed189-2352-4946-bfc4-4f5309ceae0e"
      unitRef="usd">3513000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtMS0xLTEtNDE5MjU_aa816df8-c088-4896-9428-57260e5f1b9d"
      unitRef="usd">1364000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtMy0xLTEtNDE5MjU_735f6fe2-7cbe-465d-aeaf-9e35e09529ff"
      unitRef="usd">304000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtNS0xLTEtNDE5MjU_747c5855-f16c-4efb-8e7c-4a45d402896c"
      unitRef="usd">113000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTEtNy0xLTEtNDE5MjU_a74865b2-d70c-4a54-a703-c21fd2f4f9f3"
      unitRef="usd">1781000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItMS0xLTEtNDE5MjU_462960c4-f690-4ec4-aabb-74ad591a58b6"
      unitRef="usd">4154000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItMy0xLTEtNDE5MjU_17f29c0f-64a0-4b35-947d-ef0a9a268320"
      unitRef="usd">714000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItNS0xLTEtNDE5MjU_db15991f-5f9b-427f-9329-84c025377067"
      unitRef="usd">426000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTItNy0xLTEtNDE5MjU_8f62ada5-248a-452c-a10a-b119440499e4"
      unitRef="usd">5294000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMS0xLTEtNDQ4MTg_d383a0ea-0fa5-482f-9f4d-0c90131a0b1d"
      unitRef="usd">8000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMy0xLTEtNDQ4MzI_7d4180fe-ad59-4fc1-9ab0-cf2d7da4c1dc"
      unitRef="usd">-33000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNS0xLTEtNDQ4Mzg_995e1ced-4333-4703-ab84-bc8eba1699ba"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNy0xLTEtNDQ4NDQ_7216a82b-02f9-4cd6-9bda-0ac35f0f48d8"
      unitRef="usd">-25000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMS0xLTEtNDE5MjU_9e99ef60-b3fc-453c-8771-729e2ba52deb"
      unitRef="usd">-11000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtMy0xLTEtNDE5MjU_bf3a8aec-f5c1-4253-b544-21f44d5d8698"
      unitRef="usd">-1000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNS0xLTEtNDE5MjU_853fbf2b-0f66-472c-b3a2-79cb50138504"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTMtNy0xLTEtNDE5MjU_166c9186-66ea-4649-8907-494503563ae8"
      unitRef="usd">-12000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idaa7e42e08294660a93554586f9e98e6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtMS0xLTEtNDE5MjU_b4574d41-e3fb-4e9f-88fb-a058d1381350"
      unitRef="usd">2208000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i358fe90d0eb44486b61c0746c2230690_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtMy0xLTEtNDE5MjU_ff971fc8-fbf0-4f30-aa30-9f2bb1468737"
      unitRef="usd">366000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ib11ad222d0b546dd9ac72ba5f96d48c9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtNS0xLTEtNDE5MjU_de3560c3-beb6-41be-bae6-9f82137057a4"
      unitRef="usd">265000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if2550091eda44588baae1b353781d6f9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RhYmxlOmRiNmY0YmM3ZmM0OTQ1Njg4MmE5ZGZmMmRiYjU4ZmEyL3RhYmxlcmFuZ2U6ZGI2ZjRiYzdmYzQ5NDU2ODgyYTlkZmYyZGJiNThmYTJfMTQtNy0xLTEtNDE5MjU_7f4ef71c-1ec4-498c-9d96-999a04a05002"
      unitRef="usd">2839000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTA0Nw_af91632b-0447-4f6a-b578-5e1e3447e0f7"
      unitRef="usd">-206000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82MS9mcmFnOmIzYjgyNTlmNzA5ZDRmZGZiMDM2NTlmZWZjMTdhNTdlL3RleHRyZWdpb246YjNiODI1OWY3MDlkNGZkZmIwMzY1OWZlZmMxN2E1N2VfMTA1NA_5c413a34-8762-400d-b299-9a3650e46c24"
      unitRef="usd">-194000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjU4MQ_c011b713-3afd-468f-836c-b17f603cef93">Debt &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to a credit agreement (the &#x201c;Credit Agreement&#x201d;) which includes a revolving credit facility (&#x201c;Credit Facility&#x201d;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains customary non-financial and financial covenants. As of March&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of March&#160;31, 2022, no amounts were outstanding under the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;4.375% Notes due 2028.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $800 million aggregate principal amount of senior notes (the &#x201c;4.375% Notes&#x201d;) outstanding as of March&#160;31, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;3.875% Notes due 2030. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $650 million aggregate principal amount of senior notes (the &#x201c;3.875% Notes due 2030&#x201d;) outstanding as of March&#160;31, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.&lt;/span&gt;&lt;/div&gt;3.875% Notes due 2032. We had $750 million aggregate principal amount of senior notes (the &#x201c;3.875% Notes due 2032&#x201d;) outstanding as of March&#160;31, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjU3NQ_89b4b017-7218-4454-b091-88d1b3d6ae19">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfOC0wLTEtMS00MTkyNS90ZXh0cmVnaW9uOjk2ZGM5OTg5MjYxMzQ4NjRiYTAyY2NiOTI2ZDM0NjJmXzQ_d3659b07-b12a-4436-b6b1-c884b1b68ae5"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfOC0xLTEtMS00MTkyNQ_854b16ae-9578-4e62-8e13-a1abf7a35073"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="id580a7d8949142a485d23eb67d12db45_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfOC0zLTEtMS00MTkyNQ_b03b6e73-06e9-4d88-999c-8b2a97951c15"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMC0xLTEtNDE5MjUvdGV4dHJlZ2lvbjpiY2EyYmJkYjRjMDQ0MzU5OTliMGYwY2MzNzk4ZGZmZl80_022c73e4-7acb-4b50-8b07-28c62d184a37"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMS0xLTEtNDE5MjU_0051640e-ea08-4c48-91c7-855526d9d40b"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i1fb8113f4fdf46a6a6d5465c3af10b83_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMy0xLTEtNDE5MjU_39a2ad8c-8848-4cab-a6f0-4d6b6c783f68"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMC0xLTEtNDM2NDgvdGV4dHJlZ2lvbjowYmJiMWVhMDk3Y2U0MmRkODg4YWQ3MTQ1NzI2NDQyNl80_522708cd-e63b-440e-97d6-e746ad7b9dd6"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMS0xLTEtNDM2NzI_e34ec4ae-5e89-4457-be71-73ef3aafabed"
      unitRef="usd">750000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="id84833fac2b9441da5a93a848c1d7ae7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTAtMy0xLTEtNDM2NzI_1c0a0323-feb8-4dc6-ac03-e2669e7202cb"
      unitRef="usd">750000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTEtMS0xLTEtNDE5MjU_978f41a2-4756-4394-b469-1668b5faa100"
      unitRef="usd">26000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTEtMy0xLTEtNDE5MjU_99921f3e-9d06-428b-84f9-9d2673774701"
      unitRef="usd">27000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTItMS0xLTEtNDE5MjU_52ad453e-a90e-4a91-9820-69bb47732b9b"
      unitRef="usd">2174000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i78a364e3f02f45059e7d588902f74a7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RhYmxlOjQwMGZiZDA4Yzc2ODRhOTc5MDRkMTliNzA0YmQzYjZlL3RhYmxlcmFuZ2U6NDAwZmJkMDhjNzY4NGE5NzkwNGQxOWI3MDRiZDNiNmVfMTItMy0xLTEtNDE5MjU_7d925767-4d30-47e5-9c64-1217a5a30018"
      unitRef="usd">2173000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifc7656849cc94666be3e0a7a222c0a01_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMzYy_e493a59e-fa0b-47e9-aeec-95432ddb07c3"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i1e05d493b2494afe9d2924b87d069e98_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfNDI1_998066d5-0b89-4b90-bc75-b50cc50cdd2b">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="ifc7656849cc94666be3e0a7a222c0a01_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA1Ng_29d72fb0-80f6-4223-af33-6e90314334b7"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTc2MA_d3659b07-b12a-4436-b6b1-c884b1b68ae5"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTc4Ng_c601efd4-0e65-47da-b19d-aab54973ff4e"
      unitRef="usd">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTgzOA_d3659b07-b12a-4436-b6b1-c884b1b68ae5"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25ba2b9f8f70480582002fca729cdf80_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTk0OA_d3659b07-b12a-4436-b6b1-c884b1b68ae5"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjI5NA_022c73e4-7acb-4b50-8b07-28c62d184a37"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjMyMA_6bc0c671-01ee-4c34-90f2-d34eaeefa475"
      unitRef="usd">650000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjM3Mg_022c73e4-7acb-4b50-8b07-28c62d184a37"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i59df97eaf2b1410da01b135ea8df9e67_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMjQ4Ng_022c73e4-7acb-4b50-8b07-28c62d184a37"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTAxMg_4e837c9c-61ad-4104-b466-30e5d32c4fc2"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTA0OA_7a995503-777c-4662-8d69-afbd9b68dbee"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTAyMQ_4e837c9c-61ad-4104-b466-30e5d32c4fc2"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2db08fccd6a24dd4923b782282695b76_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82NC9mcmFnOmU0Zjg3YTYwMTE5NDQyYjRhMDJmOGUxNDhiNDk3MDMzL3RleHRyZWdpb246ZTRmODdhNjAxMTk0NDJiNGEwMmY4ZTE0OGI0OTcwMzNfMTA5OTUxMTYzMTAzMA_4e837c9c-61ad-4104-b466-30e5d32c4fc2"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82Ny9mcmFnOjg2OTQ4ODY1NzAwYTRjMmNiYjEwOTY0MGE3MTQwYTdlL3RleHRyZWdpb246ODY5NDg4NjU3MDBhNGMyY2JiMTA5NjQwYTcxNDBhN2VfMTIxNw_3a4d3c2d-511a-45e3-a13e-7d265b2ce9f4">Stockholders' Equity In September 2021, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program, which superseded the stock purchase program approved by our board of directors in September 2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law.  As of April&#160;27, 2022, we have purchased 85,000 shares under the stock purchase program approved in 2021.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i90a498059fcf4606b716a944ac2ec8b6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82Ny9mcmFnOjg2OTQ4ODY1NzAwYTRjMmNiYjEwOTY0MGE3MTQwYTdlL3RleHRyZWdpb246ODY5NDg4NjU3MDBhNGMyY2JiMTA5NjQwYTcxNDBhN2VfOTM0NTg0ODgzNzg1NQ_3f54cafb-6024-4184-bf78-1915d59539c6"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iba47bf9899884717ab70af9ee14f9c2c_D20220427-20220427"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl82Ny9mcmFnOjg2OTQ4ODY1NzAwYTRjMmNiYjEwOTY0MGE3MTQwYTdlL3RleHRyZWdpb246ODY5NDg4NjU3MDBhNGMyY2JiMTA5NjQwYTcxNDBhN2VfOTM0NTg0ODgzNzg2OA_6d453b9c-8850-4c17-b824-bde3354f17a3"
      unitRef="shares">85000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RleHRyZWdpb246ZDJlNDMwNjUwODBlNDNlZDk2OWViNDhmYjg4MDllYjhfMzAyMA_df165ae6-6b4b-4d1e-a788-22caeeef82d8">Segments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we provide in Wisconsin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (&#x201c;MCR&#x201d;). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, investment income, and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <moh:NumberOfReportableSegment
      contextRef="ia6ed8f4ffb7f4280987302cfd7c51209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RleHRyZWdpb246ZDJlNDMwNjUwODBlNDNlZDk2OWViNDhmYjg4MDllYjhfMTA5OTUxMTYzMjQwNA_49c96d44-a6a4-4f5f-ba20-c1c1d4d199cc"
      unitRef="segment">4</moh:NumberOfReportableSegment>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RleHRyZWdpb246ZDJlNDMwNjUwODBlNDNlZDk2OWViNDhmYjg4MDllYjhfMzAyOQ_7614a9d2-8936-44e9-8c79-eb4d8a6a88c7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, investment income, and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, depreciation and amortization, and other operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="ia52a8ec2d38a4b2bb8c8c0c5ac370e63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNS0xLTEtMS00MTkyNQ_c859dea8-9e82-4e6e-9f1d-d6317e956336"
      unitRef="usd">6187000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb6d37d67bda43ddb19fa07362897f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNS0zLTEtMS00MTkyNQ_64386e63-7ba1-40fe-b213-8ee2c4ff6e1e"
      unitRef="usd">5020000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i071287ba7a264caabe9630e5f73d4394_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNi0xLTEtMS00MTkyNQ_5978bbb2-e3b9-4fde-8362-d982b4370471"
      unitRef="usd">949000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib008cca2d03348d2a7d1f2278b9ecfe3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNi0zLTEtMS00MTkyNQ_ecfd4fdb-9b69-45e7-9a6e-9a56e3053078"
      unitRef="usd">805000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0826354779264443891d6a415136b373_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNy0xLTEtMS00MTkyNQ_ecaae174-2854-4a25-9aba-65b59f16d88a"
      unitRef="usd">616000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6d4fb7a36f24270aa58b5037fb775bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfNy0zLTEtMS00MTkyNQ_c75fbc3b-30cd-4715-ace8-5d03db608acf"
      unitRef="usd">680000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8119dbb6aa8f4209831488917ed525c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOC0xLTEtMS00MTkyNQ_13729aa4-7e1f-440b-b102-c5b765cec365"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib72ca4bc7ef0408bbf17ce916c1f6509_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOC0zLTEtMS00MTkyNQ_1bc726ea-dd72-496d-bc52-86a678cdc4c0"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOS0xLTEtMS00MTkyNQ_be266fc4-7cc8-46a1-bb0c-3de1200e2a25"
      unitRef="usd">7770000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjEwY2FiZmYxMGRmZjQxZDZhMDBjOWE4Njg2MTIyMTQ4L3RhYmxlcmFuZ2U6MTBjYWJmZjEwZGZmNDFkNmEwMGM5YTg2ODYxMjIxNDhfOS0zLTEtMS00MTkyNQ_15d413ce-3e36-48ff-a919-05a4f50d0791"
      unitRef="usd">6522000000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="i6e316ab4ba32437c958ac31c5508c0b5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNS0xLTEtMS00MTkyNQ_2f81d446-165f-4aa6-bcdb-0059a13edc68"
      unitRef="usd">710000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id9d80104f1b540928f8ac1ddc8014d3e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNS0zLTEtMS00MTkyNQ_106cf550-75a8-4e85-afaf-254d549ab069"
      unitRef="usd">604000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i65b5ad20d89f472cad8dfcd21eda5886_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNi0xLTEtMS00MTkyNQ_b2760ae8-667e-4a2c-959f-d51f8f281f14"
      unitRef="usd">128000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i07ce4db9efe048acac76f18d5fa8a4e5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNi0zLTEtMS00MTkyNQ_bf00bbf1-0eb7-4fa8-85a4-aaceaa9f0ba1"
      unitRef="usd">77000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4eb923c3c38347a98af734e4bc95e64b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNy0xLTEtMS00MTkyNQ_9d67aa65-61e7-4604-8406-9deac39819a4"
      unitRef="usd">130000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i2e922a7c4de84239b28fe388eb3877de_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfNy0zLTEtMS00MTkyNQ_a5d50f4f-6db6-404d-a7e9-3f997bee2d24"
      unitRef="usd">151000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6da7d7575ad342f2b9348f4fc572b689_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOC0xLTEtMS00MTkyNQ_ba1712c5-2bbd-489d-89a5-4bef5cde6642"
      unitRef="usd">3000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i88f4e15da99f48ff99edb0138e60332a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOC0zLTEtMS00MTkyNQ_bb653fee-9c77-432c-9790-e90af2d538b4"
      unitRef="usd">4000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3bebfc17f52c4711b46e9ec3c87538ce_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOS0xLTEtMS00MTkyNQ_62e4fbda-04ac-4c9d-8aeb-cb6443304a5e"
      unitRef="usd">971000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i503f2f6a1ef14912910191aaf1ea287a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfOS0zLTEtMS00MTkyNQ_f58fc068-c3f1-47d4-a87d-6538b515aa73"
      unitRef="usd">836000000</us-gaap:GrossProfit>
    <us-gaap:Revenues
      contextRef="i9508779f4b0c40619e8754cfbb98b602_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTAtMS0xLTEtNDE5MjU_ef68bf27-d3b3-4e99-a748-0f4a9bc71af0"
      unitRef="usd">221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72f137a107044827823d5b3929276fde_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTAtMy0xLTEtNDE5MjU_40be0a6d-88bb-45bc-bdfd-b4daa4c40502"
      unitRef="usd">199000000</us-gaap:Revenues>
    <us-gaap:CostsAndExpenses
      contextRef="i9508779f4b0c40619e8754cfbb98b602_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTEtMS0xLTEtNDE5MjU_ac1a6e65-4759-4271-b89d-8f20458904d4"
      unitRef="usd">820000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i72f137a107044827823d5b3929276fde_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTEtMy0xLTEtNDE5MjU_79e75447-822e-4d7d-9cc1-dbfb68e7afdc"
      unitRef="usd">700000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTItMS0xLTEtNDE5MjU_afb8fedf-cf96-4596-9a75-5817e3bb5945"
      unitRef="usd">372000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTItMy0xLTEtNDE5MjU_be35cc69-10d9-49ed-9514-02467c30c8e7"
      unitRef="usd">335000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTMtMS0xLTEtNDE5MjU_1c2d705c-2b59-43aa-b6f1-2fbd137c0e93"
      unitRef="usd">-28000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTMtMy0xLTEtNDE5MjU_c3cd4acc-b840-41b0-8dfc-a00338fa8288"
      unitRef="usd">-30000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTQtMS0xLTEtNDE5MjU_1b70badf-e00c-4558-babd-40ceca51521d"
      unitRef="usd">344000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie0e245640f9b460abdead4f0f421e71c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83MC9mcmFnOmQyZTQzMDY1MDgwZTQzZWQ5NjllYjQ4ZmI4ODA5ZWI4L3RhYmxlOjczMTU4OTQyYTgzNjQyOWY4NTgyMWMyOWI1MzM2NjRlL3RhYmxlcmFuZ2U6NzMxNTg5NDJhODM2NDI5Zjg1ODIxYzI5YjUzMzY2NGVfMTQtMy0xLTEtNDE5MjU_05d528f0-8121-4eb9-93df-bb8357b98192"
      unitRef="usd">305000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3M2YyMjQ4M2QyYzQ5MDM5NmI1OTc3MjUwMzgwMDdmL3NlYzpkNzNmMjI0ODNkMmM0OTAzOTZiNTk3NzI1MDM4MDA3Zl83My9mcmFnOjYzM2YxNjg3ZjY1MTRhM2JhYWVmYmZhYzk4MjY0OGMzL3RleHRyZWdpb246NjMzZjE2ODdmNjUxNGEzYmFhZWZiZmFjOTgyNjQ4YzNfNDA5OA_3e78b58d-1c6f-4316-82c5-6f4d0b6265de">Commitments and Contingencies &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, the repayment of previously billed and collected revenues and reputational damage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky RFP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. The appellate briefing has concluded and no assurances can be given regarding the ultimate outcome. Under the Court&#x2019;s June 16, 2021 final Order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Puerto Rico.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#x201c;MHPR&#x201d;) filed a complaint asserting, among other claims, breach of contract against the Puerto Rico Health Insurance Administration (&#x201c;ASES&#x201d;). On September 13, 2021, in addition to filing its answer to MHPR&#x2019;s complaint, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. The counterclaim alleges that MHPR and the Company breached contractual obligations by failing to pay providers, and seeks damages and various equitable remedies. On October 8, 2021, MHPR filed its reply to the counterclaim, denying all the allegations, and on November 1, 2021, the Company filed its answer to the third-party complaint. On December 3, 2021, MHPR filed a request for disbursement of illegally withheld funds, and ASES filed its opposition. At a status hearing on January 19, 2022, the Court heard MHPR&#x2019;s request for disbursement. The Court has not ruled on the request. On March 23, 2022, the Court informed the parties that it will appoint a Special Commissioner to review the merits of the entire case, with the assigned judge retaining final authority over any resolution. The parties are negotiating the engagement of the Special Commissioner. This matter is in its early stages and remains subject to significant additional proceedings, and no prediction can be made as to the outcome. No gain or loss is probable and reasonably estimable with regard to either MHPR&#x2019;s complaint or the counterclaim of ASES.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MH4BQ^M @TG<'/7<X1&VC*A .[NS/D89:)5;$H3\M?R8+[F<2LE6+A2MY(DG
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MGLC5Y0Y( JPTD,_?*!67F[*#^C/,[']02P,$%     @ 9F"<5 *>4"OL @
M$@@  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R-5MMNXC 0_14KZL.N
MU#8D7 (5('&KBE0N:MKNPVH? IF0J([-V@:Z^_4[=B#E$J)](;$SY\PYX\O0
MWG'Q(6, 13Y3RF3'BI5:/]BV7,:0!O*>KX'AEXB+-% X%"M;K@4$H0&EU'8K
ME8:=!@FSNFTS-Q?=-M\HFC"8"R(W:1J(/WV@?->Q'.LP\9*L8J4G[&Y[':S
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MZ #\'G&N#@.=(/\;T/T'4$L#!!0    ( &9@G%01@N6BR@4  !07   8
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M L($Z/MSSM7;Q.R U8$G_ =02P,$%     @ 9F"<5"-<;]5N!   71(  !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6S%6%UOHS@4_2M6--),I:9@""2,
MDDC-EZ::MNDFZ:Q6JWUPP0FH!F>,T\S\^[6!DN 8FNZ,M"\)3NXY'-_+O0?H
M[RE[3D.,.?@1DR0=M$+.MY\-(_5#'*/TBFYQ(OY94Q8C+I9L8Z1;AE&0@6)B
M6*;I&C&*DM:PG_WVP(9]NN,D2O # ^DNCA'[.<*$[@<MV'K]81%M0BY_,(;]
M+=K@)>:/VP<F5D;)$D0Q3M*()H#A]:!U#3_/+%,"LHAO$=ZG1\= ;N6)TF>Y
MN D&+5,JP@3[7%(@\?6"QY@0R21T?"](6^4Y)?#X^)5]EFU>;.8)I7A,R9]1
MP,-!J]<" 5ZC'>$+NO^"BPTYDL^G),T^P;Z(-5O WZ6<Q@58*(BC)/]&/XI$
M' &@70.P"H!U+L N +8"L+HU@$X!Z"@ NP[@% !'E=2K ;@%P,URGR<KR_0$
M<33L,[H'3$8+-GF0E2M#BP1'B;RREIR)?R.!X\/Q_'XYO[V97*^F$[!<B:^[
MZ?UJ">8SL9J/OWZ9WTZFB^5',/WC\6;U%VB#Q^4$?/IP =(0,9R"* %W$2'B
M*DDOP8?C9=_@0J \C>$78D:Y&*M&S(IR1#2P<3-L3.-87*1+3OUG#7K2C+X.
M@DA>Y(B !Q0%;;&#,=I&>B73-[A\?Q?O".(X ',>8@:$-M'QH6S%%PQN::I+
MRZR9=8&Y&!&"<HI8$B4;A<(0)2_K;I5UMS+.3@WG"&^B1)*)OB0H\3'X)#:>
MU_0"( XFV+\"-KP$EFF9NIKD_-V,7\ZOEZ'C]8T7C2:[U&2_4],9.D8YIWND
MPS(]MU22BST-,JL1D],(Z'G5F.EIC-VMALPT-#W7U.>E4^:EDZ'LFKS<)+XP
MC5242"0C.[J0?99=[R$E 6:IZ,_ONXC_!'\O*"% #-T]8L$_#1>*4Y[<:2S*
MO7"W*/%IC'7)=TXN LOJ*2EICJF(<DM1;J.HO+?\2F\1T5N7(,%<I],]T="&
M4*EN<TQ%9[?4V6W464RF5%8*;'?,#T7QTN-6TW565R-$KZ-7ZNC]!QVZ1/4T
MY[8LI5<T04K(3,M3TP=>N0NO<1=+F;*VO(\(LMJ+PB,YN77[\#02E5Z=-,=4
M)$+SX*=FH\AI$C1,U3O$RFD&M4YGGH[5FF:!1QX/WZ/I#!VC@K'2M=#M*&.U
MB&J:JQHBV%6"IKJS*2-\IB/RW+K<''P0_D8CU)=,XX1UL@Y6"'_1"_55LS5Y
MM$VU:F^[H8[(=M6JG0:U';5J.B*OYD8!'AP1_@^6" ^>"'_%%*'&\1S5%=\(
MJ@H[^"+\S<8(-:[7/2ET<U!5Z\$;8;,YUHWSM^P1GOICC3W"@S_"9H-\C[5
MG;?UU 9J#JK*/!@@;'; \\W%TF;NU/'J[MFM@^%9[S*\,W2,"L;*/7O74\U%
M$Z6.*1V16HJI)JC=4V[^9CHFUU'O!HRC!VWYXD7L5(SI%!"\%C#SJBN:FN7O
M,O(%I]OLV?N)<O$DGQV&&(GQ) /$_VM*^>M"/LZ7;Y2&_P)02P,$%     @
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ME%D!EI=BLM.Y>B"F.YVK!V(/#_U=!]'C_1UQ 5] SXNOF.<HFROPC H/A2A
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MV!!G& U/O&9'?PZI->D!E8/Z<Y4B*I1OT&NK#@=)R%,*PD-Q-Z3B'EKH_KQ
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M$H%M^W_[0:8./7=CB#MX&)9\9:+U!KQ>&);<??@ _26\^@]02P,$%     @
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M[L.SPD*R-SP6%AN&SJ;O+PN(@U0/BQ2Z+(^[D%AL\V?+KQM&<>#])H1T7DB
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M<_VQR7+Z5%E7,?2ABKA>K%PS,K-':6VVTI:<O=PAG6?7YHB$SVFCD6*N6F+
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MX07XOM;:C2]L8/I'X^:_4$L#!!0    ( &9@G%2 $<9VN@4  %,.   9
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M?P"I U6U#Q'$F)0/^D^4D!3",(9.49$R:!P@>?CVHFF^^^;L5?.#U<90(RQ
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M!>H3O^51"E.!L-G+P4(Y3$ONN#%:O $J0*.SZI13GAM=?DO<7N0E]$B5?HH
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M[7"'\8_X$,,1QP)XGVOMV@4[Z*ZAU_\"4$L#!!0    ( &9@G%0X6L"1Z @
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M;T"NK81*$59)'1N#$S>#Y'$>,@G"&==E6>O[90^132-0L>SS^07/B$<P@9T
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MHA30GF@!GM?.Q>$''3!^N[S^%U!+ P04    " !F8)Q4@#R/^ZT,  "A(P
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MOR3,7@R]'CSZS/_G:OAJAR[:E(HXLO#$AWTXH[INH[KNQ:H[R$.3/-_Y<%Z
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MHZ;@)O=/-PO^SEZ];YJOS>MP6CV*]LNKIR4&F NL5,F7:!I>]?'_NZF>:]7
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MDE]9M%Z SPO#+G<+;Z!_MS?_ 5!+ P04    " !F8)Q4LU;Y^_@#  "1"P
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M;$OJJ6C9@/2%H:0[@1WT77KU!U!+ P04    " !F8)Q4Q_YC+HL#   S"
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MLNP$7CYHS ->?EHCW.-.&R?4%OZX7%MG:$?\>0*^&."+ %]\!$\'A>\E@M[
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M0RP0%6AW /?72MG]Q!GH.]_9OU!+ P04    " !F8)Q4[J]MA*P"  "I!P
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M"ZZNT8JJ&T.],'+C7KZ5-/B.NFF)O124!>#_0DKSMK"/:=N=TS]02P,$%
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MXV<)*!N YS.)OM4+>_&Y#YWT/U!+ P04    " !F8)Q4!54!"!0#   U"@
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MK7,F8&:8<6&#,2OL;=+P[2,QPBTMZ^\M>N)&3^STQ$?TW&,BESG_A2DLJ9;
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MJA9#C *IN!09@T55]_.A+G+4?2"\"S#\"%"(D"5\Z@^_HXLZ'!Z'!VH&ZFE
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M\,/WBL.)9-NRY3]G4K*L/-Q0LJ2\ *CK*Z9V?-5)\16A_FHT^1]02P,$%
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MU1]&(,T&_3P1 M\GYNJM/[4F?P%02P,$%     @ 9F"<5(HL !E  @  $@4
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M@BU ?;\6HGF]:"<X'&BZ^P=02P,$%     @ 9F"<5,Z4A @E P  @ L  !D
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M[.]SK_M:8PT]EK.VFSE-=G_3^.8 CTG+8Q+D<52J"JM#BS26R]P1J?"%T:0
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M./.#=@?P_E)A9YN-2]#^BIC_!%!+ P04    " !F8)Q4(S)C2&@"  #)!@
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ME_/_"CCJ]<@_ZQNVR>.=V[-2$PXY*H.;&994-8VS,8RL7"O928.-R0T+_-:
MLAMP/9?2G S;G;JO5_(/4$L#!!0    ( &9@G%2R7FJZSP$  +@#   9
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;'V346^;,!#'OXK%TR9M,8%VG2I
M:EI-V\.F*%'7AVH/!BY@U=C,OH3NV^]L"&+2TA?PV7>_^]^=G0W&OK@6 -EK
MI[3+HQ:QO^7<52UTPJU,#YI.#L9V LFT#7>]!5&'H$[Q)(X_\4Y('159V-O:
M(C-'5%+#UC)W[#IA_VQ F2&/UM%Y8R>;%OT&+[)>-+ '?.RWEBP^4VK9@7;2
M:&;AD$=WZ]M-ZOV#PT\)@UNLF:^D-.;%&]_J/(J](%!0H2<(^IW@'I3R()+Q
M>V)&<TH?N%R?Z5]"[51+*1S<&_4D:VSSZ'/$:CB(H\*=&;["5,^UYU5&N?!E
MP^B;4L;JZ-!T4S#9G=3C7[Q.?5@$))<"DBD@";K'1$'E@T!19-8,S'IOHOE%
M*#5$DSBI_5#V:.E44AP6>VBHQ>C81_9#6"M\C]B[!T AE7N?<:0<WI-7$V\S
M\I(+O._"KEBZ_L"2.$G<"/^7PDGA+#.9928!F[XMD^V@-Q:E;MCS7>G0TE!_
MO8%/9WP:\%<7\"-6E K8?S6/E8^,F\#PE_U47&7\M$S+%X/P=YJZT4CMF((#
MQ<2KF^N(V?&>C ::/LRF-$B3#LN6GA98[T#G!V/P;/AQSX^U^ M02P,$%
M  @ 9F"<5'7[9TWL @  :@H  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&ULO991;]HP$,>_BA7UH96V)DX@H14@%;IIE89:@;H]3'MPDX-83>S,-M!]
M^]E."!D-4874OA#;N?_Y[F=SN>&6BV>9 BCTDF=,CIQ4J>+:=66<0D[D)2^
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M_B;-,A5'S#RI<):S>7&-Z;+"A 8P87##"KD6X)<BH<E+?T_EUR2)]DE>(F=
ME<$IP/ K0#Y"%CR+U[M#!QS<<(YU/.SF7!&^85RFQ4IQ66W(DO>?WY0YN)8T
M%W\[)ALWDXWU9..!R2Z2Y PPN:8<J+W/B9Z/TR=:;*GUW53A AVN%(&G>1B&
M_LQ[:A/6-PHF);5/%J23!NG$B?0;%:(/E3XKQ1)VJ%6\L(7B),33J(/58A7
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M]:?%*!S0#6P4#KL5SD[UJXY&;,0)PX]G&QO1PNX*ZA#;M?L+MG%W9=N,)G"
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M4$L! A0#%     @ 9F"<5 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !F8)Q43DVG^N\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !F8)Q4F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( &9@G%3G,P#[304   <6   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !F8)Q44)N2 VL$  "2$0  &               @(&1#0  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 9F"<5 *>4"OL @  $@@  !@
M             ("!,A(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( &9@G%01@N6BR@4  !07   8              " @505  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !F8)Q4[Y<DUL,"  #\
M"   &               @(%4&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ 9F"<5"-<;]5N!   71(  !@              ("!31X
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &9@G%36U?>L
M#08  # 8   8              " @?$B  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !F8)Q4#PREOSL'  "N$0  &
M@($T*0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 9F"<
M5-WG3Y\$#@  6"8  !@              ("!I3   'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( &9@G%17I2ZC4@,  ) '   9
M      " @=\^  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ 9F"<5.G0==I< P  .P<  !D              ("!:$(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !F8)Q4W;VL2&X'  !)%0
M&0              @('[10  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( &9@G%1KQ_)?G0<  &X3   9              " @:!-  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 9F"<5%?H7E"
M!@  W1   !D              ("!=%4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !F8)Q4@!'&=KH%  !3#@  &0
M@($K7   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &9@
MG%2PI-%J+ ,  .D&   9              " @1QB  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ 9F"<5$%JDW?)!0  D@X  !D
M         ("!?V4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !F8)Q4.%K D>@(  #'%   &0              @(%_:P  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &9@G%2 /(_[K0P  *$C
M   9              " @9YT  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ 9F"<5$;CH7Z#!   /P\  !D              ("!@H$
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !F8)Q4_/LV
MR' #  ##!P  &0              @($\A@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( &9@G%2S5OG[^ ,  )$+   9
M  " @>.)  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M9F"<5$W71\RR!   TPP  !D              ("!$HX  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !F8)Q4#MRTX%<%   *#@  &0
M            @('[D@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( &9@G%3K/L2OMP(  +$%   9              " @8F8  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 9F"<5,?^8RZ+ P
M,P@  !D              ("!=YL  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !F8)Q4\D10M#P#   %"P  &0              @($Y
MGP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &9@G%3N
MKVV$K (  *D'   9              " @:RB  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ 9F"<5*P;B8*S @  ] @  !D
M     ("!CZ4  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M" !F8)Q4!54!"!0#   U"@  &0              @(%YJ   >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &9@G%2[+Y$L0@,  'T*   9
M              " @<2K  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!
M A0#%     @ 9F"<5!5SK_/+ P  4PT  !D              ("!/:\  'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !F8)Q4HI6R(RX#
M  #Q"0  &0              @($_LP  >&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;%!+ 0(4 Q0    ( &9@G%3/;"HWU08  -$W   9              "
M@:2V  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 9F"<
M5"S*<35S P  A@P  !D              ("!L+T  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " !F8)Q4&//2TPL$  !T%0  &0
M        @(%:P0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( &9@G%0QEV:ZTP0  $$:   9              " @9S%  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 9F"<5,PKD\GA @  =@D
M !D              ("!ILH  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " !F8)Q4BBP &4 "   2!0  &0              @(&^S0
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &9@G%2:^H^>
M% 0  ,H3   9              " @370  !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ 9F"<5#R-))3* @  0@@  !D
M ("!@-0  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !F
M8)Q45.!98Y@"  !8!@  &0              @(&!UP  >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &9@G%39 31AB@8  -PD   9
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M970T-RYX;6Q02P$"% ,4    " !F8)Q4=?MG3>P"  !J"@  &0
M    @(&3[   >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M &9@G%1"/],YF@0  *(6   9              " @;;O  !X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ 9F"<5.RU3",= P  :A$   T
M             ( !A_0  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !F8)Q4
MEXJ[',     3 @  "P              @ '/]P  7W)E;',O+G)E;'-02P$"
M% ,4    " !F8)Q41,D?"S8$  "^(   #P              @ &X^   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ 9F"<5(YA./J] 0  >AT  !H
M         ( !&_T  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ 9F"<5)PKTP^] 0  =QT  !,              ( !$/\  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #D .0"&#P  _@ !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>228</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Medical Claims and Benefits Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</Role>
      <ShortName>Medical Claims and Benefits Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomePerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Investments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables</Role>
      <ShortName>Medical Claims and Benefits Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Debt</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Segments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails</Role>
      <ShortName>Significant Accounting Policies - Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails</Role>
      <ShortName>Significant Accounting Policies - Amounts Due To Government Agencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomePerShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsDetails</Role>
      <ShortName>Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/BusinessCombinations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails</Role>
      <ShortName>Fair Value Measurements - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Contractual Maturities of Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/StockholdersEquity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Segments - Schedule of Operating Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails</Role>
      <ShortName>Segments - Schedule of Operating Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="moh-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails</Role>
      <ShortName>Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="moh-20220331.htm">moh-20220331.htm</File>
    <File>moh-20220331.xsd</File>
    <File>moh-20220331_cal.xml</File>
    <File>moh-20220331_def.xml</File>
    <File>moh-20220331_lab.xml</File>
    <File>moh-20220331_pre.xml</File>
    <File>moh1q22_ex311.htm</File>
    <File>moh1q22_ex312.htm</File>
    <File>moh1q22_ex321.htm</File>
    <File>moh1q22_ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moh-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="593">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "moh-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 165,
   "dts": {
    "calculationLink": {
     "local": [
      "moh-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "moh-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "moh-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "moh-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "moh-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "moh-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 367,
   "entityCount": 1,
   "hidden": {
    "http://www.molinahealthcare.com/20220331": 1,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 6
   },
   "keyCustom": 38,
   "keyStandard": 190,
   "memberCustom": 19,
   "memberStandard": 22,
   "nsprefix": "moh",
   "nsuri": "http://www.molinahealthcare.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.molinahealthcare.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Net Income Per Share",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Business Combinations",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Fair Value Measurements",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Investments",
     "role": "http://www.molinahealthcare.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Medical Claims and Benefits Payable",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable",
     "shortName": "Medical Claims and Benefits Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Debt",
     "role": "http://www.molinahealthcare.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Stockholders' Equity",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Segments",
     "role": "http://www.molinahealthcare.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.molinahealthcare.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Investments (Tables)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Medical Claims and Benefits Payable (Tables)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables",
     "shortName": "Medical Claims and Benefits Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Debt (Tables)",
     "role": "http://www.molinahealthcare.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Segments (Tables)",
     "role": "http://www.molinahealthcare.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moh:NumberOfReportableSegment",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i3fb5e9c9ed8a4e7a8212fec43122957e_D20210901-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "moh:HealthPlanContractTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "if2550091eda44588baae1b353781d6f9_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Significant Accounting Policies - Receivables (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails",
     "shortName": "Significant Accounting Policies - Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "id6b6fd4fee764ab083cdc892e2c0c076_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails",
     "shortName": "Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Net Income Per Share (Details)",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShareDetails",
     "shortName": "Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i78a364e3f02f45059e7d588902f74a7b_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "moh:SharesOutstandingExcludingRestrictedStockAwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Business Combinations (Details)",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsDetails",
     "shortName": "Business Combinations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i6a0eefe8a36340c3a6f222bdc1c7ee10_D20220101-20220101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i35e7bbcc8d91489a9ac9423421979dce_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
     "shortName": "Fair Value Measurements - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i35e7bbcc8d91489a9ac9423421979dce_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Investments - Summary of Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
     "shortName": "Investments - Summary of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Investments - Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails",
     "shortName": "Medical Claims and Benefits Payable - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i78a364e3f02f45059e7d588902f74a7b_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Debt - Schedule of Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
     "shortName": "Debt - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i1e05d493b2494afe9d2924b87d069e98_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i1e05d493b2494afe9d2924b87d069e98_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "iba47bf9899884717ab70af9ee14f9c2c_D20220427-20220427",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "iba47bf9899884717ab70af9ee14f9c2c_D20220427-20220427",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moh:NumberOfReportableSegment",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Segments - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails",
     "shortName": "Segments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Segments - Schedule of Operating Segment Information (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails",
     "shortName": "Segments - Schedule of Operating Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
     "shortName": "Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i3bebfc17f52c4711b46e9ec3c87538ce_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "ia6ed8f4ffb7f4280987302cfd7c51209_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i995ada66e7f14440b7cfd0a914ac8acf_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i995ada66e7f14440b7cfd0a914ac8acf_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20220331.htm",
      "contextRef": "i632c4e46fe4e49099acc346d4e4e5968_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "moh_A3875SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.875% Senior Notes",
        "label": "3.875% Senior Notes [Member]",
        "terseLabel": "3.875% Notes due 2032"
       }
      }
     },
     "localname": "A3875SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_A4375SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Senior Notes",
        "label": "4.375% Senior Notes [Member]",
        "terseLabel": "4.375% Notes due 2028"
       }
      }
     },
     "localname": "A4375SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffinityHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affinity Health Plan, Inc",
        "label": "Affinity Health Plan, Inc [Member]",
        "terseLabel": "Affinity Health Plan, Inc"
       }
      }
     },
     "localname": "AffinityHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "terseLabel": "Risk adjustment, net payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "terseLabel": "Risk adjustment payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "terseLabel": "Risk adjustment receivable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 3.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "label": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "terseLabel": "Minimum MLR"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "terseLabel": "Marketplace program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 5.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid, Other",
        "label": "Amounts Due To Government Agencies, Medicaid, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidOther",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "terseLabel": "Medicaid program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 4.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "label": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies Medicare Program",
        "label": "Amounts Due To Government Agencies Medicare Program [Abstract]",
        "terseLabel": "Medicare program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 1.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "label": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "terseLabel": "Risk adjustment and Part D risk sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 6.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Other",
        "label": "Amounts Due to Government Agencies, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesOther",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesRiskAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 7.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment",
        "label": "Amounts Due to Government Agencies, Risk Adjustment",
        "terseLabel": "Risk adjustment"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesRiskAdjustment",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members eligible for the health care programs.",
        "label": "Business Combination, Number Of Members Eligible For The Health Care Programs",
        "terseLabel": "Number of members eligible for the health care programs, approximately"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Amounts due Government Agencies",
        "terseLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAmountsDueGovernmentAgencies",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "terseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CapitationClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitation Claims Payable",
        "label": "Capitation Claims Payable",
        "terseLabel": "Capitation payable"
       }
      }
     },
     "localname": "CapitationClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CommonStockWithheldToSettleEmployeeTaxObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Withheld to Settle Employee Tax Obligations",
        "label": "Common Stock Withheld to Settle Employee Tax Obligations",
        "negatedLabel": "Common stock withheld to settle employee tax obligations"
       }
      }
     },
     "localname": "CommonStockWithheldToSettleEmployeeTaxObligations",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "label": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "terseLabel": "Schedule of Components of The Change in Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ComponentsOfMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of medical care costs.",
        "label": "Components Of Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to:"
       }
      }
     },
     "localname": "ComponentsOfMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "label": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "terseLabel": "Consolidation and Interim Financial Information"
       }
      }
     },
     "localname": "ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_GovernmentReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Receivables [Member]",
        "label": "Government Receivables [Member]",
        "terseLabel": "Government receivables"
       }
      }
     },
     "localname": "GovernmentReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthCareOrganizationPremiumTaxRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Premium Tax Revenue",
        "label": "Health Care Organization, Premium Tax Revenue",
        "terseLabel": "Premium tax revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationPremiumTaxRevenue",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthPlanContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Contract Term",
        "label": "Health Plan, Contract Term",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "HealthPlanContractTerm",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlanExtensionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Extension Option, Period",
        "label": "Health Plan, Extension Option, Period",
        "terseLabel": "Extension option"
       }
      }
     },
     "localname": "HealthPlanExtensionOptionPeriod",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health plans.",
        "label": "Health Plans [Member]",
        "terseLabel": "Health Plans"
       }
      }
     },
     "localname": "HealthPlansMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Medical Premium Liability Due to Agency",
        "label": "Increase (Decrease) In Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_InvestmentsAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Average Maturity Period",
        "label": "Investments, Average Maturity Period",
        "terseLabel": "Average maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsAverageMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_InvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Maturity Period",
        "label": "Investments, Maturity Period",
        "terseLabel": "Maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments",
        "terseLabel": "Acquired balances, net of post-acquisition adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "terseLabel": "Claims incurred but not paid (\u201cIBNP\u201d)"
       }
      }
     },
     "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "label": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "terseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MagellanCompleteCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Magellan Complete Care [Member]",
        "label": "Magellan Complete Care [Member]",
        "terseLabel": "Magellan Complete Care"
       }
      }
     },
     "localname": "MagellanCompleteCareMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MarketplaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketplace",
        "label": "Marketplace [Member]",
        "terseLabel": "Marketplace"
       }
      }
     },
     "localname": "MarketplaceMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable",
        "label": "Medical Claims And Benefits Payable",
        "terseLabel": "Non-risk provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable, Adjustments, Change in Provider",
        "label": "Medical Claims And Benefits Payable, Adjustments, Change In Provider",
        "terseLabel": "Change in non-risk and other provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical claims and benefits payable.",
        "label": "Medical Claims And Benefits Payable [Text Block]",
        "terseLabel": "Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_MedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premium Liability Due to Agency",
        "label": "Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies",
        "totalLabel": "Total amounts due government agencies"
       }
      }
     },
     "localname": "MedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 8.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premiums Liability, Medical Care Costs Threshold",
        "label": "Medical Premiums Liability, Medical Care Costs Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "MedicalPremiumsLiabilityMedicalCareCostsThreshold",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MemberListsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Lists",
        "label": "Member Lists [Member]",
        "terseLabel": "Member list"
       }
      }
     },
     "localname": "MemberListsMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MunicipalSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Municipal securities.",
        "label": "Municipal Securities [Member]",
        "terseLabel": "Municipal securities"
       }
      }
     },
     "localname": "MunicipalSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_NumberOfReportableSegment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Reportable Segment",
        "label": "Number Of Reportable Segment",
        "terseLabel": "Reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegment",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of States With Government-Sponsored Healthcare Programs",
        "label": "Number Of States With Government-Sponsored Healthcare Programs",
        "terseLabel": "Number of states with programs"
       }
      }
     },
     "localname": "NumberOfStatesWithGovernmentSponsoredHealthcarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_OtherClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Claims Payable",
        "label": "Other Claims Payable",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherMedicareProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 2.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Medicare Program",
        "label": "Other Medicare Program",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMedicareProgram",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Program",
        "label": "Other Program [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProgramMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivables [Member]",
        "label": "Other Receivables [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Securities",
        "label": "Other Securities [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PassportHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Passport Health Plan Inc",
        "label": "Passport Health Plan Inc [Member]",
        "terseLabel": "Passport Health Plan, Inc."
       }
      }
     },
     "localname": "PassportHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for medical care costs.",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_PharmacyClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Claims Payable",
        "label": "Pharmacy Claims Payable",
        "terseLabel": "Pharmacy payable"
       }
      }
     },
     "localname": "PharmacyClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PharmacyRebateReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Rebate Receivables [Member]",
        "label": "Pharmacy Rebate Receivables [Member]",
        "terseLabel": "Pharmacy rebate receivables"
       }
      }
     },
     "localname": "PharmacyRebateReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PremiumTaxExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An assessment levied by a state government on the net premium income collected.",
        "label": "Premium Tax Expenses",
        "terseLabel": "Premium tax expenses"
       }
      }
     },
     "localname": "PremiumTaxExpenses",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Line Items]",
        "terseLabel": "Schedule of Premium Revenue by Health Plan Type [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeLineItems",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Table]",
        "terseLabel": "Schedule Of Premium Revenue By Health Plan Type [Table]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeTable",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_SharesOutstandingExcludingRestrictedStockAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Outstanding, Excluding Restricted Stock Awards",
        "label": "Shares, Outstanding, Excluding Restricted Stock Awards",
        "terseLabel": "Shares outstanding at the beginning of the period ( in shares)"
       }
      }
     },
     "localname": "SharesOutstandingExcludingRestrictedStockAwards",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moh_StructuredSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structured Securities [Member]",
        "label": "Structured Securities [Member]",
        "terseLabel": "Structured Securities"
       }
      }
     },
     "localname": "StructuredSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ThreePointEightSevenFivePercentSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Senior Notes",
        "label": "Three Point Eight Seven Five Percent Senior Notes [Member]",
        "terseLabel": "3.875% Notes due 2030"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentSeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_WeightedAverageNumberofSharesShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Number of Shares, Share Based Compensation",
        "label": "Weighted Average Number of Shares, Share Based Compensation",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberofSharesShareBasedCompensation",
     "nsuri": "http://www.molinahealthcare.com/20220331",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r93",
      "r140",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r160",
      "r164",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r242",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r93",
      "r140",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r160",
      "r164",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r242",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r250",
      "r275",
      "r320",
      "r322",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r429",
      "r481",
      "r482",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r250",
      "r275",
      "r320",
      "r322",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r429",
      "r481",
      "r482",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r250",
      "r275",
      "r310",
      "r320",
      "r322",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r429",
      "r481",
      "r482",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r250",
      "r275",
      "r310",
      "r320",
      "r322",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r429",
      "r481",
      "r482",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r42",
      "r44",
      "r45",
      "r463",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r45",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r359",
      "r483",
      "r484",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r325",
      "r326",
      "r327",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r188",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r148",
      "r155",
      "r162",
      "r197",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r245",
      "r246",
      "r356",
      "r360",
      "r378",
      "r395",
      "r397",
      "r437",
      "r461"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r37",
      "r91",
      "r197",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r245",
      "r246",
      "r356",
      "r360",
      "r378",
      "r395",
      "r397"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r180",
      "r183",
      "r454"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r180",
      "r182",
      "r453"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r180",
      "r184",
      "r455"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r180",
      "r185",
      "r456"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r180",
      "r181",
      "r452"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r319",
      "r321",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r346",
      "r347",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Paid to seller"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r345",
      "r348",
      "r350"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r24",
      "r83"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r83",
      "r85"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r379"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r185",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by commercial real estate mortgage loans.",
        "label": "Commercial Mortgage Backed Securities [Member]",
        "verboseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at March\u00a031, 2022, and 58 million shares at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r60",
      "r444",
      "r470"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r130",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r298",
      "r299",
      "r308"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r311",
      "r318",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r64",
      "r431"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Medical care costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedTerseLabel": "Less: other operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r90",
      "r93",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r391",
      "r438",
      "r439",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r247",
      "r265",
      "r266",
      "r389",
      "r391",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r256",
      "r265",
      "r266",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Percentage of contractual interest rate on notes",
        "verboseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r90",
      "r93",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r32",
      "r90",
      "r93",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r290",
      "r293",
      "r294",
      "r295",
      "r388",
      "r389",
      "r391",
      "r392",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r191",
      "r210",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r191",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Total Number\u00a0of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Debt securities, available-for-sale",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r190",
      "r209",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "auth_ref": [
      "r199",
      "r204",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Excluding Accrued Interest, before Allowance for Credit Loss",
        "terseLabel": "Debt securities held to maturity"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r25",
      "r390"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r81",
      "r222"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r143"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r111",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r366",
      "r367",
      "r445",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r111",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r366",
      "r367",
      "r445",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income per share - Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r125",
      "r198",
      "r289",
      "r296",
      "r325",
      "r326",
      "r327",
      "r338",
      "r339",
      "r365",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r483",
      "r484",
      "r485",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r256",
      "r265",
      "r266",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r368",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r256",
      "r265",
      "r266",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r369",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r256",
      "r265",
      "r266",
      "r368",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r256",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r256",
      "r311",
      "r312",
      "r317",
      "r318",
      "r369",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r256",
      "r265",
      "r266",
      "r311",
      "r312",
      "r317",
      "r318",
      "r369",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r256",
      "r265",
      "r266",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r369",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r256",
      "r265",
      "r266",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r209",
      "r211",
      "r212",
      "r213",
      "r264",
      "r287",
      "r364",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r216",
      "r218",
      "r220",
      "r221",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Acquired membership with a preliminary fair value"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.",
        "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
        "negatedLabel": "Recognized gain (loss)"
       }
      }
     },
     "localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r214",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r63",
      "r91",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164",
      "r197",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r245",
      "r246",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "verboseLabel": "Total margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "auth_ref": [
      "r187",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five",
        "terseLabel": "Amortized cost, due one year through five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "auth_ref": [
      "r186",
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Amortized cost, due in one year or less"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164",
      "r434",
      "r442",
      "r448",
      "r472"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r106",
      "r107",
      "r146",
      "r333",
      "r340",
      "r341",
      "r473"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r329",
      "r330",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r80",
      "r430"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in health care insurance liability balances during the period.",
        "label": "Increase (Decrease) in Health Care Insurance Liabilities",
        "terseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPremiumsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the premium receivable balance on the balance sheet.",
        "label": "Increase (Decrease) in Premiums Receivable",
        "negatedTerseLabel": "Reduction in premiums"
       }
      }
     },
     "localname": "IncreaseDecreaseInPremiumsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r118"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill, and intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.",
        "label": "Interest and Dividend Income, Operating",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "InterestAndDividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r56",
      "r142",
      "r387",
      "r390",
      "r447"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Contractual Maturities of Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r435",
      "r457",
      "r492",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r91",
      "r156",
      "r197",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r245",
      "r246",
      "r357",
      "r360",
      "r361",
      "r378",
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r91",
      "r197",
      "r378",
      "r397",
      "r440",
      "r465"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r91",
      "r197",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r245",
      "r246",
      "r357",
      "r360",
      "r361",
      "r378",
      "r395",
      "r396",
      "r397"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r475",
      "r478"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical claims and benefits payable, ending balance",
        "periodStartLabel": "Medical claims and benefits payable, beginning balance",
        "totalLabel": "Total",
        "verboseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Prior years"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Insurance Claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r11",
      "r439",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount outstanding under letter of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r32",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r29"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other operating"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r177",
      "r311",
      "r312",
      "r318",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r46",
      "r49",
      "r55",
      "r59",
      "r82",
      "r91",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r115",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164",
      "r197",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r245",
      "r246",
      "r367",
      "r378",
      "r443",
      "r468"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other expenses, net",
        "negatedTotalLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expenses, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r148",
      "r154",
      "r158",
      "r161",
      "r164"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r47",
      "r50",
      "r354",
      "r355",
      "r358"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss, net",
        "totalLabel": "Other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r39",
      "r42",
      "r192"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized investment loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Less: effect of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Contingent consideration liabilities settled",
        "terseLabel": "Contingent consideration liabilities settled"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.",
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "terseLabel": "Consideration due for minimum member"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r78",
      "r477"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "totalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Common stock purchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and capitalized software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r397"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r441",
      "r467",
      "r474",
      "r489"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premium revenue"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r38",
      "r223",
      "r394"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, equipment, and capitalized software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r14",
      "r21",
      "r397",
      "r466",
      "r491"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "verboseLabel": "Total receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r171",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReservesReportedToOtherAgenciesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of reserves reported to other federal agencies or authorities.",
        "label": "Reserves Reported to Other Agencies [Table Text Block]",
        "terseLabel": "Schedule of Amounts Due to Government Agencies"
       }
      }
     },
     "localname": "ReservesReportedToOtherAgenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r8",
      "r83",
      "r85",
      "r436",
      "r462"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "verboseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r296",
      "r328",
      "r397",
      "r464",
      "r486",
      "r488"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r198",
      "r325",
      "r326",
      "r327",
      "r338",
      "r339",
      "r365",
      "r483",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Premium Revenue Recognition and Amounts Due Government Agencies and Contractual Provisions That May Adjust or Limit Revenue or Profit"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r57",
      "r91",
      "r139",
      "r140",
      "r153",
      "r159",
      "r160",
      "r166",
      "r167",
      "r169",
      "r197",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r239",
      "r241",
      "r243",
      "r245",
      "r246",
      "r378",
      "r448"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "totalLabel": "Total revenue",
        "verboseLabel": "Add: other operating revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Receivables"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r32",
      "r93",
      "r265",
      "r267",
      "r290",
      "r293",
      "r294",
      "r295",
      "r388",
      "r389",
      "r392",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Denominators for The Computation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements of Senior Notes"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r8",
      "r85",
      "r436",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r148",
      "r151",
      "r157",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r148",
      "r151",
      "r157",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Segment Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r34",
      "r88",
      "r126",
      "r127",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r282",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r136",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r225",
      "r226",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r148",
      "r152",
      "r158",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r136",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r215",
      "r224",
      "r225",
      "r226",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r125",
      "r198",
      "r289",
      "r296",
      "r325",
      "r326",
      "r327",
      "r338",
      "r339",
      "r365",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r483",
      "r484",
      "r485",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r125",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r289",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r296",
      "r323",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r12",
      "r13",
      "r289",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Common stock purchases (in shares)",
        "terseLabel": "Repurchased of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r12",
      "r13",
      "r289",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Common stock purchases"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r18",
      "r19",
      "r91",
      "r172",
      "r197",
      "r378",
      "r397"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r274",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r386",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r386",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r386",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior years",
        "verboseLabel": "Prior period claims, favorable development"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r194",
      "r195",
      "r196",
      "r264",
      "r287",
      "r364",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r110",
      "r118"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Denominator for diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "negatedTerseLabel": "Stock purchases (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r118"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Denominator for basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted-average number of shares issued:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6283291-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267963-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r498": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r499": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r501": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r502": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r503": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r504": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r505": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r506": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r507": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r508": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r509": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r510": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r511": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001179929-22-000080-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001179929-22-000080-xbrl.zip
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MEC)^?308@(#?M(?>=K:C':SU0AW<S5)M;/[PA)/1<H!?4!<>NX>"K53@ARJ
MKZD ]Q%+;ABRT@M0@:"1T8&@J*@.44C+%:@ H:\R+#R:]"<<XYOXW\ OPTK
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MM5@E*T3D.--9]GA9@#(;Z4S2$XX+EUB*VC'!DV Z<)&$-]ZE ,\1"R.:IX@
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M6Z +5"B;0K2<22":205?@I4LY:(+I=<7P:Q@1'$: P^!:*$,CPFGZ",UE)=
M7[XWR;1QU(.K#VVG=(+QGK/ &34^!>Y9L"IYKZV#O[!FK,SIGI\3S%P1E+G1
M$A.]9CZ:) BWQ9H-F22)+A"%62A#-KG$6E*6' (5#!-)A=3"<$^IB91PJC3C
M"H@D+D-NLA2DH-P>AVF!%>8R[_G+'?<Z$9D(X\1(RK M.Y84B_-*)Q1-&0V$
MY7KKE$MK'#',B&BT)HXY$Y^54"H*<).&6"Z))B)B'SC!QB86)!$J&(8E%V4
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MYRDO+A':>D:\$%A[[,JT-\+TDK@_?.1P, *WVAOV.^U@\R8,Z_#D*VYW Z0
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M+?\5;6>T]QH"Z8W!KNVUSXK!HG,AM.S)>7Q9 >-]@+%]C9>QO).HMQ9Q)C@
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M#=JC=AQ")PSA4!V^]G;?0R_TP[BZ4<N>5/[\/OZ\?2U6H((10PA%4F1_SHU
MSHB$')54,QD5=VYI!53IFC__=7Y<>56,XYZ&/KORKY6ASXFA7R7NS"M#+<Z;
M@%F+.)!VY)B6\,E@%;&@G!@P].O3F^?(SA> /SV0LH?VERMI<)3/7R87:_&W
M>P$8SC(R!>8]&@"]B\#H:Z !T8]J_72AINR%#>:+"0GW@N&2[?"RF'RK N![
M O#I-:;E<03?*C%R20O$&<DKV0)'PF@I&'AC@=G2"KU>-O;N #Q_Z]B>NX67
MAVA5%GYO"[]*L30@N*<J(:\BR96A#7)<,20"-C0IZT4NJS/7!KX #.L[+)28
M><Q/W98=+;8LRD0JUWV=R=9%=UJ/44+4?7Q>E0&V&4<;"6#T?7^0&[@Z&@W:
M[JB81]OJO[<#X.05PMX#83>NCVR3 #"J<MG]@"%TE3XB1[1#WA%GF7))>+FT
MHJZ7C[UW$#LW5?<?8X>C1<6!QV=?%0[,! >N,BUG@W/,YU@JK]8'X2'M3$"1
MNQ0XIM9;O;1"2&EQ8 %X6%D&IR]9<57&=KIO/(<.Y"FG.=[@,2;>HG()]W$)
M6]>H83!6>\H$LI'*7+><(XL5?+4)4^><(=B#2]"TQ(4BJYJV%6X]R13*"K>F
MAEM7J6R(T9#(&&)84<0Q<<CPO(N\XLJ;X(+G>&F%D@=ON% 5N*U6YL]%WS]T
M9?[DBO.UZ?FM^:.-=!=+\K=BK $5!%"TO5/HW5JO/XK#E]>6WE]1+T['@_2'
M_6$[6_#R(';L"!#U?.7\.<Y?N/!\W3W^=HEU8+%'H]LON6JOT^D7@N_4,0U
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MN)F;N9$^0LB4(6TU+_M<]?ZH>]2QHQCJ\7  3RD6-L*5J]U<INNL^%H!V[V
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MK8>&]K?)O<>W0'G\,R*:W)O)AS4'UQ2O[]SN!K"4GB%3S_S^2OCU#@][^5'
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M_0032['SA8'CE,YH"#!<,A1)GL"ZYI0A0ZE&#&,!D,@)XV9E7<]&$=PZBJG
M8H'%1PN+MT#%H*GG6N6([-P(21C#A?%88!6(MY+.R[ N%9/OAI0[,W6M//.)
M:"2T!>N:Y$KM1 )<$@SZOB#>2UM73!:J*)+WA9@%+J]9DH>-E5;&H!-/R:G$
MJ<9&*X:I3P'T2$*Q*5BY'%@Y<WSL84\C$BQMK\#2YD$;9"GU2 =*!1 2U/^Z
MK84R_+>#9:D@6$:6TA%E9&& ,K(P0!E9&*",+ Q01A8&*",+ Y21A0'*R,(
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M#/[Q+]?_Y_H?'[IV%-K#&/YQ&P2\:0^&Y8/&G:.853XP:7+-F&]@<\3!LYM
MR"]W<?F=]WBT[2RVX[!JURU([]+?\C$5]GI$M;LD XLK<IDB_#38&.L]XS+
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MH\$Z9V@Z7>F?QYK.,.L#VQ%N$.9Z^777K6J]DS1[P:E><Q/U+ _*>F9[>-S
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MK>,#/_O.>384554)E86CQE(<H*K0Z]5#7+5&?5- /\[O?DU2CT%@="Z\64)
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M32&RM0WR0C_^E,+B'="L(:R&L!&$38+6!*1Y?](Y:6>KM_0B7#H1LA'T9P2
MBKOV>PU&#P.CR8,&6D?J/':(ZY00ISP@K9E#\&<IHF>",P%@5 -1#40U$$T
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M4F DE-2)ZNAU!#N)O<!F7CUU9F.M!2\M7R-BC8AUAYY%P[8)!90$7-(N4A@
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M0%Q 7,(7BP+Q;/@B*N:M<A9$*1<0, +<!$,8DMXH'2G7BKBUS64ZSJF >)E
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M%_QY::C>E@@LM#N>F-]A7C(A#68LHQ>_"/1$E-5\,V<V84%Y\B(BD9)$7+F
MC"(1!6?!?.)$"A?7-LFZ8LM4TK#D?[PDM%^R/PK2%X;T6>,D*B92E!KYY #I
M7BODB#5(X0 2X#75+F]J69?RP?M:EB]C9)G-DPMKY-Q &<;N ^R3EUMGZ5D8
M*_/4A+)V8_<Z^Z00T^V)Z9H"IC@)2YQ'(+48<<,(LB!FB&FFJ0W840U>$UO8
M=KLEBMP4."\%G$L Y)Y0GK,QI+64!XN,XQ%QS?/):8(C[+4PRI&0= (HXQ(
M>5(+XV'F1'& %LH_Q89X,/&TYFP(*8/SQDLD63X5#>?JR3Y2Y D8$$I;351<
MVQ3JP4<VEB!&P? %AHOA<$_\SAH.3D6F(\%(,!?S$BY!SA*#C!?*ZJ# K%"
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MTQ1PKS2X)S;+Z4(07KR)90?Y;(0?&THCT1@1&L&98)X@(ST@'5-P'Z/0-D@
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M,&<7,/=L!RQUF@OL$HY FAWB3@5DA;?YST#S1>9(/NM94T)_+5@O6'\.<[U
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MH.WFP6=F HY>$I1KKB%NB4%:.8*\,2F(D*QS(#C$S*?9GPO."?P[IM^:!WO
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M';Y"?.,:A^7IE_P;/XX#K5^* $V.&BC%B%Y<*0\ML4L*2XXMY]$:IYBCTNI
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M-DE)%CBL.W!\D$M#=#"9 ^8,VLP?<FZ"P'(M5^K2KC5HJC]V$PK>VQ3LM1%
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M)?.63VP[UJ#?9MQN]OL#CD>EW.:P-_2;7L_T;=^R3=_LOGAC6G6J\G/CRO;
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MB-S-(3*L(@ 1/4#D28>[^$/6)D8^1VG8<;CCN^; [UEN=V":3K?/A]SMN/8
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M_EX'\W$RQW?@V]>M67&IZ$T\%"-+9.O@;*F2=#8#$$B3S#_?@+F.4L!'4;R
M/_^3!C&-GT"D,X>?9FQ!MD#D -I1#XG)S9"N!7*$R8/\3+"_O!AQ!/_BG,;B
MIWCM1I.A&ASXGH]@3A^0KCB"]J2*'(AMI,<9^@.B]E*P#19&D, V.U^X2S04
MHA"-@!(F[%H(6[G71'= 0C[WT,)HP*"!-,6N@O:#^8^B*QZ'1 @M$-'3V20
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M%E<2H<A?&&"\)@'*6\"R248P$^(#+X.XI"N-D*/:A+G05\<,1@N0&@ :"("
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MA"$8Z/.1](,KH( >3-!M\(5\XS4>UCZK./%8Z>\R+ZL!'5P<7:@!E410/LD
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M%  9U(!@GXR)Q+,>DT&<S%4#%'R%V&3A$@6A)7L[WZ:4?:?_&$Z")W,)[.P
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M+7AYK=8NB;\+.MIF201Z :**"'^'KU( ,K%P$OZ#/?$(C#'PV_^\^*^;4>@
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M_'$DDV0;B/80CM/"S,<8'VYD+" >3]($89J*C6"R2Y[RP"F,#ZL\%Y8(&KI
M\,+?@A'%8=OP0!7*P,@!P*Y)-H&6D4].7AGL-C68"7V%A6(&ZFN4M8 ^Q EF
M[J/!CF.7N0AB*/], ?N9/?6]-)Q@(%*]O4)LL-E#EX/77!(LT$L@?_72.*=_
MA"@>NE6%]96'K:X!]L?X"I4AA39GA/]:&&#.47*(^,A$_B.'RH2Q%<\E2SPG
M-F8F>6Y9;*Z5C[GG14K6ZF18[RB9SC)U4)D9W!(9'H4Q: D*NN(6J03C<^'P
MWX?9P1R^H=\.Z:K@'":20Z_*-Q <Y&/YD (_1<9YX$:"0SP4.]$5D/.@UV[
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MQ^4S/9-)E21%7VZ@Q%  G#C/,XQ6KUEQJ>A-7/AFTJ1L>LE,$IJDKN9 @*8
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M12 :<<@(LY3J6H31*!+9EC16$N>Y(-=3)XN_X5W\/VBV8%BW5$EH&H1I(@K
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M:3?TO8@2XR>Z5T!@"V(SBFEH<B!&&]HCR).D:+DB.(I8[#4ID_V*ZW+#F$5
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M'0A"'&@)+(L>\J,+JR\2!K&*X:QY9<MXFX62$CP[ILO8(N%$Z1P :39V48@
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MW 0&$ )LQ:]4O*^T_%5??2Q.U$)XQ6-+X14>J$;UN1)SB['\%/,7QOJ Y0Z
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MW@/]9I@"%U)!@1DW5];4O.A^%4T8GXL;A*+69JZ8)X?5-KKC4&$0A3:Q!3:
MI&[IB%&%#])>-&MHDR=+0SAUORPWKG(1&J(1];<+J*<M@7J*B8KQ1:-)8PDE
M&2RQ!'L,R[2Q4BO09I<WD)U'U28U'RD;OC(RQW01[3_Y*JW$+,B*<5<5XRJ[
M*<:M[+,85]Q*B3,XIU0&./I+WCTIGLI'JM0-#5)_'1D/AO/Y2,/:>_ENU(I\
M3E1-;^NVJ?X@_3NB_KAN?6GU>P=6CW!Z"1U;$E_I2>5.*C#9V[34LRK)\GJU
M>)L6#F[WU*5EJ56I4KA(R6"+5:FL%'=9Y7@$KU-UK<.^RE0FKT8RI5B7Z4%K
M@PXV_;[AC ]7@):,.=_HSLA$S,,K@UY]"DU_56Q@ _?.JIG3AQS4%T[%=K<K
M'4N,[2@1BX.RX5:]#CEV8%P==E3<MAHYSNPRGW]Y>9'HV*0G\^]\G9K<T"XC
MKP^?-"L_U!PM+\L7M9I2R].UX"_IF8;^*=4\GX9<D']I$\0=9"?=B2Z-'"J'
M=?@0D:^H@*C\TC2 ')PC  *'UMJ')M30SV.6*P*R$0#!L:^;\Z+K4_+-M#-"
MZ;,1N9'(_UUZ.'/L9T:AF!-DQ"$@5:IJUYI;5B!YWABS"FANK!!0Y>"SL/0G
MPW; X>0!P^)INWK^'8%K(UA4BJ#N;FVX V]K17G7VUJV>>U)U4S,D?Q;47[I
MKQ :1=W08T#SI%A0",!&8G,9@83=0)1KU4/!OF,HU_O2$<GF<Z8$ (887-L2
MV<1J3?;,J 0KF02G3H*5M278APO.)/@T)5C)]N#T2;#"]^!U]UTR<RW;A=9O
MU/24J^1>ZDD-B0@%(!?+A1Q8J=K0G$$$-'B[N*E6J(AF$SW->M"FNGU^]SK6
MW[!W @9P"\K>3@')EJ*3U@_9#I\^_: LU0\+NWJF'S+]L*UK6I9:M[WHC,M3
M7M(6!D_)CR_=-NEKK^;4G$ N$#1E'.BD:0Y<]+V>HT 8XO.A^'QH<GQ\;39C
M[=SP1NRDH[%62$W-T2#.H9,'?:"YT"+1L=D/.MH3:^&H3Q[TX3#<BL@(C$S\
MWG&#8YFT[5#:>HWK3-I0VM171Y]B@X_>8*1/-$_J,FX_&6YOU-L9M\]Q>T,;
M#]PQL^G:QO09FWQFO']RO-]4KS+>G^/])K2>-#+6/W'6;]>_9*P_Q_IM[4$?
M9UQ_PES?Z:H?:3%7\'O'TFW*WS%VSD<BU"ES?>DC+60#&_=VM*<(3P^VJSYC
M!5 .2QH*"@AD7LU[>_RDHD"?C@] QCEY6!2'546FT14G<A([-T86SJ2S@JRX
MFPJRVCXKR))6)':J]6")*OWJM;[>UOOWW12U-/3";]A>6/_M&A9KYNW%X+S^
MQG2;8%WO12!.KA5+.?Y%D85*1G2_&;K0N!A"#<-@AV/>D]>FZH9>H,88Q"%8
MFT3(FH8'(>?P&Z"45W>G]$OX/,UU1J9%9S=<MZ%N DK;:C6I6BYN4]E6EHHE
M9?<U:$6I6MJNT]X1!DLO5M8;[.X[[>WGUL1"+]W<M5NW=7*MUMO]ZT:]J]+-
M^+8181)E1-Z>R&==3T]^BJ+LG%THEY9 Z>R2A)7EMVY_,DP(G!,]%^G#RWC@
MWA2Q4'UF&6.B5)E=?#)EF^M-/F_GR;>[GMJYQFJB^R]=M=_[_C-52FK;\M&D
M=&[\9MKSU5RIHG^0Q"6I>)%,*L?6O:24T@EEYK..94P'QDP;+](ZVZ&S'3K;
MH;?8H6_JW>^D+9'O:NLF50HK[5OSC68](^%U8Y(JPJ> MG$)[Q!.Z5NZ9KM6
MMCWO<7M>H'S$]AP;K<E ^5:%5$KQ(97\@SE\H_]&SF3\WW\ 4$L#!!0    (
M &9@G%2*P(&.VPX  !.>   0    ;6]H+3(P,C(P,S,Q+GAS9.U=6W/B.!9^
M[U_AY65FJX8&@W.M3D\10J:I30(+]/3LTY2P9="V;=&6G$[FUZ\DV]C$MGR!
M=+QCJKH38NM\1])W='1TY<.O3[:E/$*7(.Q<M=3WW98"'1T;R%E=M3XO;MOG
MK5\_OGOWX1_M]A_7LSOE!NN>#1VJ#%T(*#24[XBNE2\&)%\5T\6V\@6[7]$C
M:+<_"J$AWCR[:+6F2J_;Z[U\ZUZ>=B].5:VOMY<0=-N:<:JUSX%VVH9+V(6]
MLU/S[.+LE]5ES^SVNF<7W7;76)IMK7M^T3XWP'G[G*4[ 9J^/#D_%:!/Y)+H
M:V@#A17,(9=/Y*JUIG1SV>E\__[]_??^>^RN.KUN5^W\<7\W%TE;05H+.5]W
M4C\M72M,W^_PUTM 8)C<QNN=U#9F*< : HNN=>#"]SJV.[S4W7Y?#84X))(H
M00ZAP-&W2@SJMNGS!I)T&?:ZPU]S/:QRU'9O1Y-!MV)Q-2<=_V5+ 92Z:.E1
M>(M=^P::P+.8B.=\\X"%3 0-9@X6Y(3O)(B]IL!=0?H ;$@V0(<E:N3C.T7A
M?"%[@UVJ. D($Y"ER#)Q*1=3>0%Y5?H,WV$=4&&V/#T)RYB0ZD"+$OY7.\)X
M_T2,5J=X#CS27@&PJ9"+N*2?D^!)^=S$#%B]N+CH/'&+3,]'JFV)]&W^L:WV
MRJG-,M+BNME?[5#N$'F(6F.Y/(1R>^8AM>%E642>I/B;%,Q&>D,N6 FA "_]
M21F%!.KO5_BQ8T D3/F;EM, D@+\8]O_N*L9. ZF H,_"9YM-L@QL?^ />*T
M78;<S: 9.KF$STYI(.+7)7!U%ULYK:FS<?$&NA1!$O?W F#M0O.JQ;Q^.W1A
M?UI@^9YE)$R1P-^U/_ZZPT2@=1<5))3E)G#5(HP%"_I54^-R;Y@O+UEN)D)8
M-R)H_G\OO@ZLLL5G(KIG_2U*;T"S;.F9"')0A<)SZ05[KR#CJC7$+%"=@A7+
M''_^>3;.CS:$^D@P1 _QHXQ][+*8D/U3VE&,VU:$I,)%/W1>"KR \@@T)LY'
M\?FEL0?"01*)X LS*2RW6\&I8L'#L$9E]3QYF$_NQC>#Q>AFOF _[T</B_GD
M=OPPG-R/2E>^'$W"B"H8Z3$:YJPJ84A)#$^) )7)K>)#'IFZ9=4PG8T^C1[F
MX]]'AZ4M#5K.(7<#Q3G<P6\VH]>#N\'#<#3_-!HMYOOPMPLD9ZO?[6HRM@(L
MQ0<[,K.83UF].W0-*6+Y/!A-NZARSC06S!?G3/EY!_N?#>4P[M3FB\GP7Y\F
M=S>CV7ST[\_CQ7\.Y2Y3D.5<GG2[I\6]91S^)\57<.3S=CB8?[J]FWS9RVNF
M \K9.^UVSTKT=0Q5$; -XFSBKH"#_A*Y (YQ#0@BV)S&RE26M *($M9Z:E=5
M_;@?$=W"Q',A^R,.JC!41< JV%3BP$?>8F6Z@10@BQR>OA!8QJ+69?\JLJC\
M'&AH4E\X1RL'F2P"<.A U['G4.2LIHPE'<'2',K!Y*VOKXHQW@YO,3PE E1"
MQ"--?CV\"EV%:.MUM5ZRN>70QB+/X-.QH045L0!+Z\#\!9 R]OK=DWX%]GSD
M(W=!A0P!6?/_HV\>>@06*R5A7<P,$NHBG4*#OZO8)QY,K[S+/-5*NUX>T3+\
M7\1/)9:%7T3_&N7"3W#L65^0-X,Z9%7&&])KV$8*O-P$SC0Q.U?2!&)JCA2_
MY&!@\P?DQH,+_!M?0'#X4'"P@@Y_^QJL%],H-X1S34S\E32$0+/"5"L+K$3*
ME5#[T3Y>LO4 7)?E[Q&^ABDDP.6L7VABZK DZULEC23W =*QP]B 4^C.UXR:
ML@0F :0C)+6K)GTTPU!\$(6A* *FR1Q4"Z2S8*3!LZKVDV%3&A]-C)@3-5K1
MR67B2/V9RH/:8M0TT'%=>P0YD) AMI>LVCEJ:5Y2,>3NJZ\F(XL01HGC-)R*
MBBU%!B5O+)HF5BORB6ED:[D%R/T=6!Z\AX!7#H]J2Y.3#B)O+R=J,B;C.(H
M4N)(3:>C6J\O@Y+W_*?]9"2604T3.__4BKUE++"1(+#&#J&NV%E'L -F4/=<
MEPTLQ)),1=^WOT*YASQCX^*B?+,WH6(EIEGA*T_*5GFP G5TJ$&U[3L8+@8J
M9_F<C8.+L]SLP6]J?=]A9[6 _(#0DAZ2QS1<.947FMHM3B7';W,%"M?02#['
MSB,DM%)L$Q>51C2]KIH<E<6DFUG=U6*7)( T8NFI_>3@*X;1Q"@E5ORY9]O
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M<>5^L7KD$PU47R&LBH/7,[(J2O@=<@0]9%_+B0&]<2P5'[*7G>8K)EN/>;Z
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MV)R^1B92 \YC:X?E5QOKM\Q8:.+\, MF66!O/ $2N<7XMQ!'\7,P194S)5!
MOJY;F(9@@_RC*G[HFK=2EIF^IK'N%!#"UQ-*."&I2 V<4)2OG'XS)6$-LC_H
MGY<9?62DKD-!I!M9BZY92F1KVJ2*[<LZ8+>1 E:+>7-DY,6MNZEJ8+/\A"9V
MQ%P?GP9=0\M8X#FDU((C>V/A9PA9KS59LK&#R$CV *0"4EW[P,,>^8LL.FG/
M/^C4H3P+=:5!>+UB44A:TIIZ2Y'5PMNCLU+7P'5$&V[S?5ZM3I:%9X:*F59&
MZC>W+G&PG.AK:(./[_X'4$L#!!0    ( &9@G%04[A)$@1X   $F 0 4
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M&\^F'^![6;DO/3Q"Z,Y27*$!:F2TFBNBDZ*8+F!("(XJXK-6*=F0 FVSS?(
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MZE\G?S7,&ZYDA)"1@4I&@4-E((?,LK"F6&__]X>_BL($LYX!2Z& 8LZ#2^C
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MS($7VX0P'8$_;(KM4ZLW2:EZV:'>YH_S23PA2:5?YQ/:-]_DR7"<EMOI0)$
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M@R;;P#U0R*2!WF^C5C.E'9QI0:L2,DTZJZKQ$5,U9H,#F;GG):@<?9NVAD?
ML/OB),=&L&UTU9)8ST<?Y[/I0@+\(A<B>9E$B1!]]8EJC17T/-%Z;IDMM+BS
MU7+??=/H)J@#NAS]J_,VXG3418MKHFN@B7-H1G'&N)90 H_D.HL 3K, TB4E
M)"]9B/W11'R?--E%%WM:3>1%K0<7N+2^WFRFU51EK)E50H,-.EIG>41L%+Z_
M'=3W1I-==-$FW6AM@1I/+D$.D8&+-4KM5(80DJL> Q$X,Z=]F\9X1U+\[,A\
ML!ZT=.S%T389RX_B:#L51]N*)DVK3>V@XV,OCF;(&-2U=BGCWI)_PCR@I'E=
MK_)YJ[URCGVG?-VQ.-K1T'4;U3:@Z=/QY.-X@K/\=6+ 1<>^$((FBP2$(U$I
M%3QX$00P^J7.F"PVRCF_$]8W7EAM*XV/6ZFK@=?X='QV1E8/#?KE>#+[@!_R
M$XQ_K*D#)YFWLG;S93F2!(RIQ7AU!L(OM>:.FVP:T6HSA-\UPQHHL<'"M;"5
M;X&&H3@,Y <'R^OXD>8!2@[:69H=QB1?>!-^W0'J.Z947ZIJX%W\_N[]9.%@
M?5GT)K\!SX1Z0U0)L*E6K'2&# 9?$ACNLJR9L<6U"8?? ^P[9E.?*NNYRL_+
M^8C$\A%/;X"R:',VL4"*]2)&*0R"H>VY!(?>6"%UO"_W_,X7?(=\Z$_@/;<8
M6W2_7@,H^$3\ _(R!*A 7USQ&83&DK6,NIB-^X7_T'Y/@KZUP=C^;JSTT%U\
ML^>VOGFR53=Q(86QDLF<F5=<)E?H;]EP<K^+"IFM/SCOJ8OXS> PGA(W\[N3
MG&=_GXSG'XG,EWQ]-R-WJ[[^*7Y<7"=^<9FTA0ZU39Q!Y+6JG%DD;=7;P\4H
MY-(7&=H<RW1%WKG\)TW;%^/I]/7H*I:1TX=<6U^//XR&_U.O#CS#R8C@3 >F
M)&6YD."-"*"0UF(4Y#-$'4/VF%59;:#95QG0;6 >,#BT#_[=J W:3(4-3A9V
M2?$V$570)8-4H;8_T!+0V02"]A0;"^-,M2D^^VVE[Q^">ZW5>= +)(]ICZ+?
M+C:LM_6[U^7U?$9[9YZ>!WT_G R2B=)+#+6-=JB%94APCEFH[HG.)<FPZ@_L
MG9R;C.,';_=%@@9G'V_P2\7WVWARW^1;-O5=7 LDZVMA; ^"%*K$[,$B^=HJ
M.@\^Y@"1C'FCF3(NMTD#Z@3[.R/L_E3<X%++YN#/Q?@5>*VMLK8$0%_!:UL
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M$R-@](EP%5N"EQ(U;J"OXTNQW%5A'66T;8KE^:_KEX#3_+=_^?]02P,$%
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MP0$EJB(3XO30*7>'IR8(;4I?"-N\'$P,>[H(=.;FU+'OB0C+2@9\4^;-E&L
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M/4M1B3U5<X_--YS0MYI=<) 5$7BD1OD6Q\AWC>_LHK/GA[J]N\HR4GWD3D7
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MC3MFQ=,7C5N)76_XN^PQXV+#F[%O'H0^T-S<KF3@1VIM1D JF ZN8Q' $4H
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M)?1,YRNOUMK3:_A&<T^K;ONV[L?=].WM#,UYWN:C@!SPCC>"9^0[OU_&S#Z
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MK4YW3MB\->@NF/RBTMREZX<'-1_.BJX?2;;6QT<?\N(K68M?-X4@:UV97[M
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M^ZP%T(W\57UO]9:E6LONLK%U0M\J"=)8R#@&#/LI@$DH )&^6F\&4222E-+
M-RZI:2]^:0RKM :[$E+U#F_#I&ME&%#R[RVJK@R<C\NKU&E1GI@AM?) :^]I
M!5_T%-,KM(X1WKYR@S9C4MS-U[W3XC_3@GB2>;!:, ^'L6<E/6#0V9;8PPWN
MKKU'C#(B'5M[EH6X$YLR>Q2':)Q:[#?R_7-#E==5561T6^\(?,L_$ZW9*J0L
MC$08 QGX&$#$B?+E=>_<Q">,X5A&@MK$38[4Q^J-,T-L9)-]S+KVJ-=-J9:\
M&_48ZJ!]\GU %O>("2,D4*Z ((!#'8_@QQ#@-(C4CVD84"HP#I!U<OU,$S9;
MYOV9"9MWILR653/B/['ST$#_S!3O691J\^Y2#XTR2>\9-0Y<URJ=8-O8Y3B?
M?SS [I/]1^@T?R6 \0">+!/@8-@),W8/06 4H30(8@#3E +(4 )00#F <1A1
M'(44)E;EZZRD+XUBS=-*!P:,V<V-&<U.AOC$I.H2[&DR>"<-0[/38'GYNY<"
MUH8-,E=7U%T?A8Q_+K*\^$]!BC)828&B*$U"0$,$ 81< AHQ'\@(I6F8!&&,
MPVG[HY[4:VDT6:OF/6G=IFZ2>GJ>S(CQ%="?>A-K:./4JT/S%5W KIG _^R=
MP!EZJ/;"_<K=5$_KMO"^JKV CN^PVC^\ZV*J7[+R]X,*2BOE'5?O]&_U489Z
MF:P"A"7VHQ"D/@T!)%("++ ^0@@YB0A-:6H4I^% EZ51M%;-(P<>T.R@=?;>
M>87^4]FH[:IJZ.6YNGR\,.,,3$S3W6JBU9EJHO4$72]H@ER5>G4Z4:]0_G6J
M"7-8%M88XL&E8B]+6$CY6&,HS$O*F@]I]\;C(ENU$=]/04B_9=5:K"2$<1H'
M(0AX&@,8!"D@.(7 CZ,H\AFC06"TXC@U^-+>2;52>I,T"'^@?]ZE5SR94=Q)
M]/I?*F,QF?@M80N',8'TV7W"JRX%^_$V?_Q)W58[U/^ ^B-H/M9\<7+ 60B@
MSY3=$]U[S=CPP>.TNX\;M?*ZKU]';Y[:/]91-"L&PQ0E$.N"T#Z /(0Z_9Z"
M$ <4^RG'L;1*NA^@P](>^&Y4VLM$THX95QY]VE_11*;99N(.F#&S782)YV%B
MDIEF"D9$!%J#.%$TH+D>KQ0): W4^2A ^Z&&T6;;ES"41 ;$%R",=?J$SU*
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M=C!IU_)LW90WJ<WR]G;-.E'.^M YGK EM:<;/7$N&]=9X#R\GYV)D(6<4]@
M8M']SF;4X=&D^::NE-V4U+[>5G=YH7,]5C*@@22ZP:DD L!$!(! B$%$6!+K
MEN@!,:H18R!K:6^L1E6OU+I>M?T,/+)7U_O!MLN!"=YFJP%'*$[\+FH!_-H
MV/:1.&CJ-M+S AS.XSK/R9L]BO."X:=B-B_=,O!$9?OPL!;UJW+=V7Y4KOSG
M(G\01?7TEI1;LM:N>[DMB++PUXT:_H\BTX_S/M[H4HC2"O(8^X0C$/':T<88
M$!&&0,"(!0FG$O-PI7B4YL8',3.I;O-P=@V8<#U>APFVC5M8K?65)\EC7M09
M+5S7J,T?S M S?YE"&@4R33P@9]0]8+"(0,H%@CX.&$,!SZ*H%4WLB5^%18=
M\#O;3!N>Y2UP_J;>4]N'^AH%"CL\\IL9:[?GA',I/^_AXLQ3\N)$<F[YPWR5
MDT535CB*992F$*0HC@'T$0,D#B/ 2 JEQ)(Q&=N\2TY*61KQZZS6MFV.FI]F
M1>.!MIR07N/P?+U6;X7#7RV7.Z>Q-F/ST0A.3+UG"S&Y(]E>")PRXFE)L])7
MK[''7--_L?,S@'KW1>=%Y+<%N=]G<)( )31-A:YJI%8C40P!22,,:(*BB(F0
MA-0HNW:P!DLCE)V:WD.CYU^<;2.?F8'16_SC<5W"KOX.]M8,ZP3FX1/@;.M^
M_$0L:;=^P(2XW)_O!W/XEOR9<9>R"]]OML7&^X6!ACF>A\Z4G080AUI+JX23
M*,5)")CT)8!Q(@'F"05<PD"YICQ)L-5VQ@5Y2WMW=+JK9D,;9%R"V,SS= C<
MQ"^'#F8=5;MEU]PYHX:H.'5++\F<U4$U!.#8536];4!G\WT(\.="W&?;^R_B
M46RVXLW3WX1:9M]]5M^5;VK8)AX>P9ABGTD@(JK[FLL4($1C0#E#42J4)YL8
M5^2TDKPTHMD'S=](KU7?:_7WWCQYC06>-L'3-MAE+-C/RV47=C*T)V:G;G;"
M,=!T?J M.IE/!?A<?<P[P#^TP!<'X.\:X!\T\%KXCXXZF ]!K:]_N=5X\W4O
M'V+FL][E@P:PST9]UW[9]%@KGS#L2TJ 3)@N?8\(0%$<Z=-3%"/(& Z-(A2/
M!UX:N>]TJQG%//?T&5;]C#P&@8D)U\QXJTS34Y8.SC)]-MAL&::G3.AFEY[\
M^]C,4OOR*RN*9)CPF /.=&(5BE- (@P!9"3PA7IX:8J'I9C:*[.TQ[K[1AM<
M)FEHSNF N30\L)YIAF;T\P9/SDPM*X8#/5&FZ@"%7BEE=3ATYW-71XPYM".N
M<HA95CO@2LAU4]F\61(@PE$8QU3OO?D 2NH#+#$%7#&O9"&F<6I5++5'UM+X
MM:MJ_9R2CK*V36K/(VQ&BXYPF]K9ZFAYY:F?UF*/7E?E>C?NH<CYEO6".: _
M[$68'/=[/2]OYOZM%PU_V8_U\BW#6VQ_W)154?N0'S?J:15E]854XJM:Y@O^
M6:COFUKQWXH51Y'/(M\'82B0<NMT#9& )B!(0\P(#*(XYG;!J^;";1Z<><)/
MZ]X?V5[Y*_6Y4=\KE.I77EE;H$-/6A/L>V4;S@N*_8# A /B)W5G MU*0OT(
ML5 ^><PIB:P[F[N?E5DB0?>::5]./8[UN=>6K)]/CJ=H;I-;-Y.TF!+3%\44
M0$_^WE#?^X^=[_U.;YW)I;[WC>K>Y\O?^T$=Q>WP<MXPW%#\[/W [6 YU>[;
M<H2Q&PS7K.["4_ZBG\-/.=EHG_E#MB$;EFUNOP@FLL?GW1*%3S"*=-_;.!
MTC0"5,?,RSCP0Q8@&!.[</GANBR-][HKV(.ZMM'P(^;&=K]@4L1GW"[8V:&=
MY+HA;VU+[4/OK>G,R$R;!(/1G6B/P%Z?5]HB& S<^1V"X4/:'ZCK:A/Y.N.[
M94)-Y-E]*^U95'O3,+KY]_ 81R*5D$$"4H25AX_"%!"9,A GF##?%U3ZQG4@
MQBJS-(Y]9D_]A+<6>7N3NA7KS$^!1\_:Y1/X.>=B8O9]/@W7EZ9A4(MT]U-D
M?G8_YU3-=)P_QY19G?2[PKCG\'^TB-GB 5R!T0T1<#;FP$J/CR1;ZY?JA[SX
M2M:BK;^K>_NHA<[/I&I_NI9*K9N-^'97Y-O;NP_9HZB[1ESO^H6^S<MJQ2+,
MN?01".O0 Y'H;77U*6)10&)?*KRMVNXXU6YI;TD=54ZTXEZ^$75.KE<U^GM2
M]R4<D*7K=C;-5BJO-D=S;-X<C+GR]H8"]40";>J5MU?>T]KKVCVUN4_J+^N:
M6-5?M/_S53FP:C&S^[/WKM[_:6:_3NE5P'@M,IZ&QF%9SBGFQVUU3Z<:SELD
M= IP7]0:G43(P)*E31Q;J;/R!/]%*,XGA#+D,R EPP R/P%((@K2- HP950(
M;E4[Z(6$I?'VY^=AEI951%_@9\:RHU"9F"EWNGF-<G4+78?5.\]9[K8BYPLI
M\U;9/&?DB\J99R\<]CR_V9;91I3EV_R>*I=3NYF72G*NB ]I+$((? ZE]O(8
M('[* :-A(B77M5JL&B0,T&%IG- I<LN>%;E=MQKW%;1U-C%F5#(QW!.3S4Y[
MKZ/^U=DBPU>'*#5WC#0"0*><-42/65EM!%#'O#=F*/O=X5^VNC[XC:R/],J_
M9]7=(7/TZX->L1>"-R'\C!2B31XM5T%,9.0G*: B5+Y0[/L D8  $H6$PI#P
M-#$*+QBAP]*8L3%#'P#541ZE]T>F$U):;<WW%8=.R>4=WQF GI@36XQO9!-1
M4'K:B$ZZ.MB;X1WLV"6LSS 'YENZ,\S%3#NY$\V)U>;M2#1[]FR'CCS;5NU(
MT[L[M&.'&EI"X#%?/ZKWVULU>E9](*Q^J?U<=ZY8T91*1J(8A$)G^/J! %A"
M#F0 &84!Q&%L64"@1]K27BF-CMY.2=NZ 7VXFGG0SM":^+VPU],[@LS[K='5
M84B%$2:.*P;T29RY7H"!\2^K!9C<-(P]/I"L^ ^RWHIW6<G6>;DMQ,=*W.]J
MH>3W)-NL8()3&20$1+ZORP3$D?)6&0,<)0GR!82!64TK&Z%+XQ*MLU<K[?TL
MB%:YZ9O7:&O9N] (=3.*<8WEQ$PS%$9KFK'!Q2G;& F>E71LH#CF'JM[!\:O
M9K>;3&:,;*HVL$M177UXG8FR$ZJ:1#&.! 1)R'Q%0E214"@A@+H:I\ \CGQD
M%:IJ)'9I--31VCNH[>WTMHQ.-4/>C(C<XSDQ%5V TOMMFHA2*YC<!H^:B9XW
M3M0*CA<AH79W3U,#M'C1B45WD"]RF55M^_A#5R,1A9(B#$$DN:*N.)6 0 8!
M)A)3PA,*A:NF8+:Z+8WI.AW"ZLB(AUKKNN2P4MMM#4N;*;R\3_B*$S,Q99K7
MN2Q.MZ32@8J-E5YKYM4$_<6LY]1MQ=*)YG9QM4R=SK'S4J<#9F%D$50;B8LJ
MCSH *MO"J4-$#%M._"*JMZ2\4V,_9ESP-T^_EKK,XLU#?>SWK-<N1$(BS!"@
M/E5+"A)B@!$4 "511!#C+ IBF[;EYJ*M7K8SM#;75?^94EV_96O==4VX?*>W
M1RXWVQT[%V:+C&D0GOK438&KM?8^=\#]06ON99L_>WOE)^EI;(^8TS6'A?A9
MUQWVL!RO/0:,,##ROIOMIEBS3G@[)+E]RC;UEDRY2@(9TU@&@#'U#XQ9"!"-
M$D 0C (JTS"QZ_-N*GAI*P?K!%)MB5>;8KF/:SPU9NPV!>!3KPBFP-H^=-T2
M.+=1Z:;"YPTXMX3D12RY[?WVFRNM1[BO[O5&;(3R!\O/Y$F+.)3Y*M_>J>^<
M^+AIR;98H03%J:]<-9RR1%=#1 #)% ,N420$PXBEOND^RG UED9\C7[*J? V
M^0846?E[_2#FU9TH=IZ=^M#891'.,V*B+N^6S /_Q#2X6P;O2ADJU'=V>*TA
M5YT"AXHGV[GZN-EYA<4L\V&^TS'/O,RTJ7$T/\1X?C*#^;':NA@/:\\NQ8C!
M9]N0& ] =^_!P6CV+ZX3,<;UJ*7Z\"P1]^-&+0#(^G V\5%WUM-5 3N:73!A
M11'! <(I\'&J"Y"E,<!QX /ET%/$$A(2%IB^ZV;5?&FOQQT)L ,)T!T)M"]%
M<PZ>]SMP^36ZV)F=^,U[.LVC8_KS,@BM]=T#WX/]W5? 86N[YYVQU*^+^5M^
ML5^;F1R#97Y]K#R*5YG"'B=D7GUF\UM>!>:NJ_,Z"HP,*[TN2U'5^P>'_,8V
M\(_?;+[H!'5]^*,N^"7?%+L?=>O6LFU1E02,<(A B!,!H)]00 .( 0ZB!"7,
M#Y" @V)/QVJV-._F=&2E6LGL3:DYJ&N,77<E]W-KMBOZ*C,VL==RF*Q1\S,\
M*M85EM.$SH[6[G7B:UV!>C8(UYD %W7-VPYJ/H\H1 Q@#F, &0T!"9-$[\3"
M* XY3H@5/Y^0L32F?=;;)-_< B7TWCNJX5P.(]=3$)O1Y$C@)B8\1YB-+&\]
M'76=DO.*!:M[Z:3OTHF+PW4+#.W[A:<QY#@-?!#S)  0!3% +(" Q5S]12IO
M+R:3%(,[I<W2R.9YX;")JKR=G!;#,^NYP)Z8H"Y4<2M/5G'[D)5ZB5\79MN7
M;'/9U]TIRJ]3B^VD1LNLO=8'WN!::[V#CNT:KR.0=%\L];_W_]AFCTH1]1I=
M,1JQ(.0"$!^K1;.B5* &HD#$R$\"&DJ2QG9=92Z)M'F2Y^DET^F#7D<VZL55
M_4$<M![:2?X,[&:,Z1+*B4FQ@^';'8;UA_<&&([H)M\/S$3MY,\(?:5^\OT0
MG&\H?^&^883S=Y'=WJG!K]6C2V[%OM#%'5'?MIMM55;JF]&N--DJ# 24?@)!
M"I,4P" F "L?#DA.I)!^((E=H4<KZ4OSW]Z)37ZOMVOSHFY_2;62WD;H/E<L
MOQ>ZF56=U"2\'[)-\ZG\LQTQV4V/&4M-!OK$E+73VVL5]PYUI1K=O8[R5UZM
MOCL*&X2:4SZSTV!6<AL$SC'3#1MD&.WIVIEJJ/*S*.KQWV7KK1*]BGT40A9%
M@$%. 4RY(C@_$6I*($ZC*"'8MVS:=T;2\KRJ7TX1%_!:?6L*X_EZ38KR\'=+
M-CN'NAEO.4!R8H;:::C;N36<=+7#SQT178#!*>6<DS4KN5PP^)A&+ET^L)2%
MN-5;:FT!%TPYC%B$ (IQ"* ,0D!3)D&22$H$9S%D5EOCST9?FI_3*E<.K(CS
M'#FS1WTP'E/O=1M#85\]XI3);HM$/),P;RV(4\:]*/EP\J*A^RC[MGXZFVM;
M%&KD%0PC*&"0@$@$"$ , T!"$0 >A1+'),10,KN2>2>D+.WQ'=SA\#2&** )
M1\HOXD+W3M>9M2CP$6 R8A3Y/(VDM-V &HGB//[1-YVLZQ5NT33=5QJ)T.2;
M27O]ZLK_5UZKH\L=I!X('&\;G9(T\UY1C[$O-XCZ+G;9$N!08/M;03:E%$H4
M#U91FA*"2*18E0CM# E 8NJ#(! I%"G"E%FQJHWPI9%M0Q(/:K@[4JJ%5)$Q
MR^X@5M";T<=4@$[,*F?+_'=Z*W14G[JX?S]>,U3U/Z/  LKY]T-C5L?_PACV
MJ3P?-ZP0ZB%\)YK_?]RT@;%M_Y1]DX"ZNDE=T^1I%:0\2?2A&@^%5%PF"<"!
MSX%NFAW'/J,4&VUP#U5@:7RV*QG$M\*[/=0+(FT%&/,LB4&ST4]O<V \,<7M
MU/=^V!GP9YTWNDLPV+69VENQ*]W4&#(Q^N:I)E//PDP9(Z=F([LT&]7%V;!*
M^1@#94_FQJ!A9TO &&-T-X]BU#@#2DA*F6W4:$WA_\_JNZ04:*O(AX)&R&<A
M".(@KBO9 H35FYXRD42![ZM%M#0N!WE>SN+>%ZVJ;4,+3RNK<ZO.'\19H7KY
MA> (JXEY_RQ,EZOR6^%E4?W0#6YS53*T_IK9%2&\#$9?0<&>N^<K#GC9A&>%
M_@PN'[:5H+S\AT+<">7@/XHZ74W\(JH;^8U\7V&(N2]Q J)8^  &)%;>=DH!
M9T$4\30AH5V5OAY95D0Y0UF^9ZJVYZYV&P5]P)KM"SB":V*N?(Y4HZ;W@RXV
M^>=ZLU''?RB-K[SKJBHRNJWJ:E3*+?M,W&Y!&L#E=!>@3]ZLBWX#PX_7^":W
M#$Q(J!.E3C0O6&&?A"$B!(1)'"@VB0B@B*4@18QA+&04D<"&3<Y*6AJ7-)N.
MI%;7,HW@+)AF#.($HJE]K5K'*Z^317O0TV$<_R4HW,;HGY4V;_S]):-?Q-9?
MO&%D5OK'S<.V*C^)1[$.6B<X$BD1!(8@UF>]D*E_*(P2P%*92C_$"8Z-EF(&
MLI:V'/NA5LX++..T^M T(P9'&$U,#=U<[4;1*Z]%;(+V: :83)-S?4+>ZV11
MGS?\;%YTSRU.BXA_W#R*\GEQWWVZG PH1DCW\HAUI\4HC12!< P"3D@04@0A
M,VKI.UR%I?'*7M5._?"_."D@WC</9M0S+;H3,]*%@N('W ]63)*5.!S$.6J,
M]ZFQA%KC!C 9UAPW&<DI#^Y+.W<*^$<LIB+V8Y 2&:F%E=!!\2D#5"8)]6/(
MPR1QT$SAA.BEK;3VS12VS1/IR7TE;,>-%$[-PRC^&XGNZ_+>H>#XC(T4>A";
M@^1.B5\"N?7 8DAJ?2,,([,;70?[1'\&+?W#.O^C[MNMSR56+/9)C&FL8WZ9
M\N5(!(B?8)# .)&2\1!#*U_.6/+27+A:\2N=KFC'5^90F]'5) !.S%:USB>[
MNUPU+*85]_::NV,J:["<$I6Y]%EYRAJ48YJR'V!(-)IVY.KDD3:_<5=5Y+,H
MLIRO6"1Y'%$.@D2?A:$D ,C',?"IE((PGQ%NW/?@DK"E<=$NH?=^5VCEH5;3
M^V&MPS^K.[(QW, R0KJ?EUSC-S$5=52]VB=&[PO6-.HZQ,XF)LP=AK/%?XW
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MG+ UZJ)B__F#+B).&':X:#AU2;^)^7$ZUY_,VZ56]B6#6#(EK2.AI',IC-2
M:29!5>9(F[*@&GF5)CGU\+%Y$[</KD_0BUX13]956V8SO5XW&V^R5CQLSK[
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M-AIG<Z=R8(NI"_CZ^>$144O,][]]V<%5ZQI4\S&\OY0?,'$[3%V0.6R/*3\
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MWVQFBS]#JPM<]1;X>7.#C6WJU6,]H.Z_V4_[ [K3O?FE&\S#?]N[(6*!@AC
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MG ZW%;&WQ-OL0[Q?+-TNQ$_?Y>Q)U;GY<OFDU8>YI0"]6D]8SDB!80FJLE0
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MC:GGL>:U2"7^G/0!*?S0L@N$N$>3)R4->P#99>S1,6/GQ3TI8*G5=/V>RSI
MHSZZ$H9BR+CU<D4E -:F J(HL/6!*UE1E&.EO?I[G!<QNLE?:YAM5.QU+G@"
M2,])?Q4\J6=\&#+AD_VL\7%G^K&88:?Y63./YOCY*U-TU7#=P:?SI\73:M=W
MT:7'?5ZLILX?<5U<[^[YO( _VROO[8J8:R&%)$!2;,D!4PX$+#A 4!45$;)
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MZ#00;@?VZB2EQ=E\O7H?OM>;T9J 36EY1G3<D]Y$R:2M%@S(G"-9>!_!2>U
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M/;1WH6Y< SP^AA:-%=H!2.\'@J\N"#F7\J?P!ZXFZ!-GO&1(MI9J6),AL!"
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M^5+\QMR,>D7P!6?YT^(CKM<S?'WZ=;;XCC5#^R[.II\WJEQ-; [H%.TYEU@
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MU>/&.T>"\='4V@&$'Y\O\M?YDD[.VA>DM@UYOSAOL'@5Z]UA/7*%ND2$Y*(
M5<N* H6"@,YZF65$EMK$ @,R,6Z._D@ 'TOIS\AK_7AV>AJ6WQ?EEDKV?9RZ
MXP>W\F]W9N;X3F]F66FK%&CN:S<NU!"5BY!8%JAT)%2UN;@[GM/[^&Z[F(;F
M:F6 JC7D2(Y/20B^=C4NRC LIBB=VS1\VX&X9^.Z/@5+3S.)3U=2!T?[EJF2
MFT(LI1G3GLX+N6F6P5P@#\4KB*PDKJ64IK09J?4 0>/7\@^J^+O7BP-HH0,P
M#3K4M'"=L\<Z@713"I@5.)<D6!YMKK-KK6_SIFA(+D:^>1P"5HM.=-P!OE\N
MEE\72PKG;MN#R](IP8)7DH$E7Y><;<XA.NG QFRCX,8+V>8B_%&RQD7@>&BY
M6P<WF.HZP.&OB^7Z<_B,+T+Z.^9[W&1!5#M,$+&^3*Z!5C2*US^R&+CV);2Y
M,GJ<KG'30MT@<4#E=0#%S4W5 ZR8&N,[YB&FHNI8\@S.* M&H:[/RT0*;4J
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M>'Y>TI-Q<_5;N,)M([A\JRG#)5X4>KVQ+D.22-LBI7IE*18HAN(^I14+,9T
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MVJ$M5=S4<CA0B=*=K0;].\*1:L3',IEU7G>UY,EKSX#QJT9H&;EA(_\K  F
MHLNI [H/LQ.9BA*XWT2H_3_.!F\'0];R:SZ[#W1YOUS?P):MRCK^ >A=@AR
MC87^J9A[_:OAX-V@UQT.+B\@,J^N/W8OAFQXN1;_K\5[]?%]_YKY+5[UV]M\
MY]56>__(WPW=U3/%_/'BM'_%AF=]=MWO?;P:# >PA?X?O;/NQ>_]9XJYVQNR
MRW?,/VRU/=:]9MWS/NSB=).H/LQ^5-JU5T(=>.P?0()9S,YK[-_Y2 MK;F<>
M"X2V,IHQ&W/[:FOWX&@3\'ME1LHT!*MWFFVBI)^Z(;_&!BSF$\&TF$@Q!>*V
M,5YD2ENF4O9.Z3'S&]5_LDAI&LM@)14R :!#=LYU$+_:\O<:1RW?(U;WF(K8
MN8*U.#L3/+%QP+7PV" -:F";PQ=CFV:-O>4&-@EF&,_8;:JFB0AO8"M+)@J5
M,"Q54/= 'Y<IX^F,Y:G5N0"44 FI*()%.!O#%:)B$0_@)\W46%IFE9-[))"*
M0!C#]8R!5J5#H5%VS&\%K3]7;N"W$$"!5$*E%19#@4!J**4@EH(>@(0*IK$,
M8F9R_%C,GPHM"B6XD[$T"=1<+-]3:6/8J<E$0$B7_!^H"4P+V6BV9(X7Y=_6
M9_T;0?RF 7IC82D/O OB,*R7QF4*J0&^@S8*O@=)CHD!WEB8Q0./2IW,6 :V
MQ'C .$F2A<,+$YL'*T-,A=2>>2B1)R  SE7@ 5K-$)R FYA%B9J:TO-:W$AC
MH;>SC../#C: ])8<:$HP#\&^*!^V:VQX;\>O3>&?@I(QBE442;ATYAHP8",R
M.!A0CA)!Q"; R:-$FACE46P,N8SYC->A-$&B3 [S,,NU2IRJ3*M A/"S8=M@
MZ%" YYPUKW+02YW#[K;8(6'J'.BJ\-*U"'(-WH79_;L@YNF-8-V TM>50E#)
MQT2S.\Z#$DMSZN("43!,P:5P<?Y#Q"O@F!)/= ]/])5XRFJP'&N@%4O)5Q?
M]F'M9\</='+L5!CH?,!2Q(M/.]M#[@YX;C:?@MPY$N"28B7'QBK7H #2<2(-
M)3E(B93T8".QH(=EAM$BX>3C@HX7#O *]L%!"50!6 R4X9".8R8?&1E*KB5N
M0+JB09R7HJ;<()%3YAAB?:($:'4 D*6@\%C&(;B"/.'(9+ M K$H"!@1KK[
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M\!$00&[73UGWHL/:]WV*3_?V$;T'=?(_4$L#!!0    ( &9@G%3?SG.W/0@
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MV>U3MKTSL/75F?S3O<A#KQ2=_@]02P,$%     @ 9F"<5-3]5V^H!   2!$
M !$   !M;V@Q<3(R7V5X,S(Q+FAT;=58;6_:2!#^?K]B2G1I*N%73 !#(A$@
M"J<FY(*KM/?EM'C7817C]:V7$.[7W^P:MR0IUTC7]%(^6-BS,_/,LS,[8_?>
M#">#Z-/E".9JD<+EAY/WXP'4+,>Y;@P<9Q@-X2PZ?P^![7H029(57'&1D=1Q
M1A<UJ,V5RD/'6:U6]JIA"WGC1%>.-A4XJ1 %LZFBM>.>?H)71NCQ+[TWE@5#
M$2\7+%,02T84H[ L>'8#UY05MV!9FU4#D:\EOYDK\%W?AVLA;_D=*>6*JY0=
M5W9Z3GG?<XR3WDS0]7&/\CO@]*C&O>#0;3 O:#+*@F8S:7O--J')8<MM-Y(&
M:_[I(4@'EY<ZA5JG[*BVX)DU9]I_&/AVJYFK[HI3-0\]U_VU9I8>]Q*1*?0G
M4;_\6YIY8DRQ>V61E-]DH0FI5JI6XEBD0H9[KOEUM<1*R(*GZ_!M7W*2OJT7
M2+Y5,,F34ESPOQDB05#F=E4";:%VRC-6 ?=\#77T\6Q\,HZ@X=L>/ 2Z'2^1
M-QBR$GGHM='N%N08.6;RAV(>C*ZB\>EXT(]&F)=7TP_]BPBBR4[T_R]:KPT?
M[*D]L&$Z&D3CR05XC:9;?Z5H^U/H#R>7T6CX$U!;$=IQ#V%R"M'9"*;]JY/^
MQ6AJ33Z^'WV"_B#2$M]U_><D=Z?*;9Y1#"?T U/<+Q14\-6@QAG$(LM8K(]3
M6'$U!S5G(%DNI *1P+E )0)GC*1J'A/)ZC#.8AL.]++]O;;ON]V!6.0D6YL[
MK_L.T-*ID OP7.MW2(0T)G,$*"@PC)7".9'Q?'_/.W2[#:]>'JO;%J^,_\H@
MNJS#;WB,YW,XM^&/Y4PR5=RNZS"8<Y; Z)[%2\7O&$R2A,=,:N#:V@98'?"9
MX@G^R9>R6!)D5PG8JI4R_A*0*1@@!1 J<MT3MG4>K-29L/$T)7)&,E98D_N4
MK:$?&_)T)M113C"49KO[G*0X?)040<?^T3EQX+V#"&,J-P&299JN,4L6><I9
ML9TC?RVY9+KM%3K81R0>$$P$"5[S@+[[S!+ND\3.C69&]_&<9#>LHLKK-(*2
M]85)$22LTP62T9^%-+\DC6>8\ MBR@DK2Q%<2?&IB;]BE'")E.:2%9J\NA:3
M- 548QH)4EODR&91-UH)%F 6Z^=HD)K!1Q.C5RW3DGN!U65\%H]2WW[.85H-
M HK,4E;)9T)2)BUD+25YP<+J3Y?R(D_).N298<$H=3>;,1-*B46H1Y0[77(Q
M23<^C+M2O)E>.AV[Y;;T *-P:E&T<KR9;6PSVSB*/I4%#?O0]W:*77NW[-_,
M=NR@V?KN5@U8_UEF'4.$K!9L\JO1,:F,BK@%!6[J4:U1J];DA%*<6$,7/+.J
M\O$"2S?HOJ7CY_=::WMJ2UGR)!_*5/A1)6H&Y:&>\,U!#/U<\A3\=MEZ/M?(
M=R7O]1*QOQ>TNH6Y?JVM/J#C&[N^.27,K)XC?)P6*%2X7R8YG^7R-9#_9(PT
MY/]'PE^VX%\O;3LFO3I<8AODNNN;GCC$B2160CZEU#&-:JL1[GQGWFJ2CUZ[
M<U%^=P@E2XF&\>1%_$N2FD;H?E$A,\S4I=JMLNOM9N=;_>9:?F,P7SN._P%0
M2P,$%     @ 9F"<5/2I8>RS!   F!0  !$   !M;V@Q<3(R7V5X,S(R+FAT
M;>U875/;1A1][Z^X,5,",]:G96S)AAECF\%3P"E6)LE39RVM\!99JZ[6&/?7
M]^[*2@S40#L-(9WX06/I?NRY9\^NKK;[9C#NAY_>#6$FYRF\>W]\-NI#S;"L
M#XV^90W" 9R&YV?@F;8#H2!9P23C&4DM:WA1@]I,RCRPK.5R:2X;)A=75GAI
MJ52>E7)>4#.6<>VHJY[@E9+XZ*?N&\.  8\6<YI)B 0EDL:P*%AV!1]B6ER#
M8:R]^CQ?"78UD^#:K@L?N+AF-Z2T2R93>E3EZ5KE?=?2@W2G/%X==6-V RP^
MK#'_8.HGC39-?-+P7#MIMZ.F3UROY38/$K=-?W,0I(7N94PA5RD]K,U99LRH
M&C_P7+/5S&5GR6(Y"QS;_KFF78^Z"<\DCB<POOQ;IGF03-);:9"4766!+JE6
MAE;FB*=<!#NV_G64Q4C(G*6KX&U/,)*^K1=(OE%0P9+27+ _*2)!4/IV60)M
M873*,EH!=UP%=?CQ='0\"J'AFB[<!;I9+Q%76++D>>"T,>\&Y @YIN)%,?>'
ME^'H9-3OA4/4Y>7D?>\BA'"\%?VW1>NTX;TY,?LF3(;]<#2^ *?1M.NO%&UO
M KW!^%TX''P'U%:$^O8!C$\@/!W"I'=YW+L83HSQQ[/A)^CU0V5Q;=M]CKC]
M2MLLB[&<P/7TXOY*17E_6]0H@XAG&8W4=@I+)F<@9Q0$S;F0P!,XYQA$X)22
M5,XB(F@=1EEDPIYRV]UINZ[=Z?-Y3K*5OG,Z^X"93KB8@V,;OT+"A4Z9(T >
M \5:8S@G(IKM[C@'=J?AU,MM=3/CI1Z_2HA#UE7(-9R9\ ME\SKT9XPF<(+0
ML@A)@'&2L(@*A5BE62.J SZ3+,$_^4(4"X*T2@X;BZ0LO$2B5PJ0 DC,<_4R
MV(RYXZDDL!YI0L249+0PQK<I74$OTJPI"=313K"&9KOS'#4<W%.#YYLO+88]
M9Q]"K*ED'Y)%FJY0'O,\9;38%,<?"R:H>M\5JMA[).X15(  I[D7[W]FB48+
M@:]L3#.\C68DNZ(558[?\$K6YUH;2)C? 9+%WPMI;DD:RU#I<Z+7$2XI2= S
MQJ>Z_HI1P@12F@M:*/+JRDS2%#",*B1(;9$CFT5=1R6?Y8T)8]WQ*&*4UR(M
MN>>XK/28Q3WIF_]H%Y5DFM+*8<I%3(6!M*4D+VA0_>G$K,A3L@I8IFG009WU
M;$RYE'P>J.;D1JVYB*3K0?1XI7G=M_B^V;);JG61V*_(N!IXW=68NJNQ9/S0
MYC7, ]?9:K;-[;;'TOJFUVS]YUDU6/=9:2U-A*@<U@)K^%K+&(A34."L'M8:
MM<HG)W&,O6I@@Z.]JC&^@NL:W5,Q;GZKHC;[M90F#_102N&EUJAND0>JM]<[
M,?1RP5)PV^5+Y_,B>9J1;U"=]ZSBRGWW=5?RS'G:W?%:G4)?[[SO[Q3WA!K7
MNY?^>L@1-_8O,52 ?TSFZZODM4[8TY\%NLY_J]/_SP3^J.3EU+;MNT>UA:&@
MI%@(*A[*T-*]VN/-X.^+0GTJU;:>)3UVSO2$[5YC4QUCY;P\QPL$3;&+O:$/
M#K:^;!*ZO;2_A) I[A0+N3UDVVG!UE.R];4\L].GAT=_ 5!+ 0(4 Q0    (
M &9@G%3X?;T6PJH! "A5$P 0              "  0    !M;V@M,C R,C S
M,S$N:'1M4$L! A0#%     @ 9F"<5(K @8[;#@  $YX  !
M ( !\*H! &UO:"TR,#(R,#,S,2YX<V102P$"% ,4    " !F8)Q4%.X21($>
M   !)@$ %               @ 'YN0$ ;6]H+3(P,C(P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    " !F8)Q4S8OA=NPU    20( %               @ &LV $
M;6]H+3(P,C(P,S,Q7V1E9BYX;6Q02P$"% ,4    " !F8)Q48L@D&D\W   W
M5P  $P              @ '*#@( ;6]H+3(P,C(P,S,Q7V<Q+FIP9U!+ 0(4
M Q0    ( &9@G%29SW&5(ZL  %0:!P 4              "  4I& @!M;V@M
M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( &9@G%3>B=:[N&D  #"T!  4
M              "  9_Q @!M;V@M,C R,C S,S%?<')E+GAM;%!+ 0(4 Q0
M   ( &9@G%1!C6*B8@@  &(E   1              "  8E; P!M;V@Q<3(R
M7V5X,S$Q+FAT;5!+ 0(4 Q0    ( &9@G%3?SG.W/0@  *TD   1
M      "  1ID P!M;V@Q<3(R7V5X,S$R+FAT;5!+ 0(4 Q0    ( &9@G%34
M_5=OJ 0  $@1   1              "  89L P!M;V@Q<3(R7V5X,S(Q+FAT
M;5!+ 0(4 Q0    ( &9@G%3TJ6'LLP0  )@4   1              "  5UQ
I P!M;V@Q<3(R7V5X,S(R+FAT;5!+!08     "P + ,$"   _=@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
